68th ASH® Annual Meeting and Exposition

DECEMBER 12-15, 2026
NEW ORLEANS, LOUISIANA

PROGRAM-AT-A-GLANCE

#ASH26
hematology.org/annualmeeting





DARZALEX *Faspro*®
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

Land on the latest data with DARZALEX *FASPRO*®

See current data in the treatment space at the 2026 ASH® Annual Meeting

December 12-15 • Visit Booth #2913



Scan the QR code to visit DARZALEXHCP.com

© Johnson & Johnson and its affiliates 2026 10/26 cp-546182v2

Johnson&Johnson

PROGRAM OF THE 68TH ANNUAL MEETING OF

AMERICAN SOCIETY OF HEMATOLOGY

December 12 - 15, 2026

Printed in the USA
Copyright © 2026 by the American Society of Hematology, Washington, DC
All rights reserved.



Greetings from the President

Welcome to #ASH26!

On behalf of the American Society of Hematology, I am delighted to welcome you to the 68th ASH Annual Meeting and Exposition.

Over the years, the ASH annual meeting has grown in size and scope, but one thing remains constant: It is the place where clinicians and researchers come to learn about the latest advances in hematology, collaborate, and celebrate our professional achievements in a spirit of camaraderie and community.

Every year I attend the ASH annual meeting, I leave feeling energized and enthused about the work we do and grateful for the friendships that it generates. However, in recent years given the challenges we are all facing I notice that I NEED to attend this meeting more than ever. Personally, I so value the energy of our community, the collaborative spirit and enthusiasm about the data and perspectives that are presented and discussed.

A record-breaking number of abstracts were submitted for this meeting, and more than 6,300 abstracts were accepted for presentation. As always, the education and scientific programs are robust, covering an array of exciting developments in hematology. The comprehensive programs make it a challenge for any attendee — whether virtual or in person, and no matter one's career level — to choose among the riches. The good news is that all attendees will have access to the virtual platform until January 1, so there will be time to catch up on sessions after the meeting. We also hope that the new AI-powered tools we will be using will make it easier to navigate the meeting and meet colleagues.

I want to extend my thanks to the Scientific Program co-chairs — Saar Gill, MD, PhD, and Ami Bhatt, MD, PhD — and the Education Program co-chairs — Maureen Achebe, MD, MPH, and Robert Zeiser, MD — for their superlative work in curating sessions that will enlighten, challenge, and inspire both clinicians and scientists.

I'm also looking forward to the always-engaging marquee sessions and lectures, which include the ASH-EHA Joint Symposium (a collaboration with the European Hematology Association), the Best of ASH talks, and the E. Donnall Thomas, Ernest Beutler, and Ham-Wasserman lectures.

Tuesday's Presidential Symposium, which I had the privilege of designing, will focus on the role of immune function in treating diseases, including hematologic malignancies.

What I've covered here is simply a taste of what's in store for our time in New Orleans. Within this program book, you will find details on the many other sessions, presentations, and events that promise to make this meeting a success. What you won't find in the book, though, are those unexpected moments that await us, whether it's catching up with an old friend, making a new professional connection, or discovering a fresh source of inspiration for what we do.

Finding and holding onto that inspiration can be especially meaningful and powerful at a time when we face ongoing political threats to medical research and science. More than anything, the ASH annual meeting reminds us that hematology remains a field full of fulfillment, discovery, and life-changing wonder.

Robert Negrin, MD

President

If you're interested in making a donation to support ASH's hematology research award and training programs, please visit the ASH Foundation. To learn about ASH's efforts to protect medical research, please visit the Fight4Hematology Action Hub and see what you can do. The QR codes for both are below.

Fight4Hematology Action Hub

ASH Foundation

Table of Contents

About ASH

ASH Executive and Program Committees	5
Reviewers of Abstracts and *Hematology 2026*	9
Corporate Acknowledgements	13
Recipients of Awards	17

Guide to Navigating the Meeting

General Information	29
Advancing Excellence and Addressing Health Equity at ASH	41
Non-CME Sessions	45

Meeting Schedule

Schedule-At-A-Glance	47

Browse by Session Type

Marquee Sessions	69
Scientific Sessions	71
Education Sessions	85
Special Interest Sessions and Studios	95
Trainee Activities	107
Scientific Categories	113
Oral and Poster Abstract Sessions	115

continued on next page

Table of Contents
continued

Interact with Industry

Satellite Symposia	129
Clinical Trial Showcases	141
Company Showcases	143
Industry Forums	144
Industry Theaters	145
Product Theaters	147
Exhibitor Directory	151

Browse by Disease

Browse By Disease Introduction	159
Bleeding and Clotting	161
Bone Marrow Failure Syndrome	165
Genetic Disorders	167
Hemoglobinopathies	169
Immunology	171
Lymphoid Malignancies	175
Metabolic Disorders	184
Myeloid Malignancies	185

AMERICAN SOCIETY OF HEMATOLOGY EXECUTIVE COMMITTEE

STAFF LIAISONS:

Martha Liggett, Esq., *mliggett@hematology.org*
Matthew Gertzog, MBA, CAE, *mgertzog@hematology.org*
LaFaundra Neville Ingram, CAP, *lneville@hematology.org*

OFFICERS:

President: Robert Negrin, MD
President-Elect: Cindy E. Dunbar, MD
Vice President: Alison Loren, MD, MSCE
Secretary: Jennifer R. Brown, MD, PhD
Treasurer: Joseph R. Mikhael, MD

COUNCILLORS:

Adam Cuker, MD, MS ('29)
Chancellor E. Donald, MD ('28)
Christopher R. Flowers, MD, MSc ('26)
H. Leighton Grimes, PhD ('27)
Jennifer Holter Chakrabarty, MD ('28)
Mary M. Horowitz, MD ('27)
Charlotte Marie Niemeyer, MD ('26)
Mikkael A. Sekeres, MD, MS ('29)

PROGRAM COMMITTEE

STAFF LIAISON:

Ana Velarde
E-mail: *avelarde@hematology.org*

Robert Negrin, MD ('26) - Chairperson, President
Cindy E. Dunbar, MD ('26) - President-Elect
Alison Loren, MD, MSCE ('27) - Vice President
Jennifer R. Brown, MD, PhD ('28) - Secretary
Joseph R. Mikhael, MD ('26) - Treasurer
Catherine M. Bollard, MD ('29) - Liaison, Editor-in-Chief, *Blood Advances*
Hetty Eileen Carraway, MD, MBA ('26) - Liaison, Chair, Committee on Training
Jorge Cortes, MD ('29) - Liaison, Editor-in-Chief, *Blood Global Hematology*
Amy E. DeZern, MD ('28) - Liaison, Chair, Committee on Educational Affairs
Willem E. Fibbe, MD, PhD ('29) - Liaison, Editor-in-Chief, *Blood Immunology & Cellular Therapy*
Patrick G. Gallagher, MD ('29) - Liaison, Editor-in-Chief, *Blood Red Cells & Iron*
Phoebe Joy Ho, MBBS, DPhil ('27) - Liaison, Chair, International Members Committee
Margaret Kasner, MD, MSc ('27) - Liaison, Chair, CME Accreditation Committee
Jonathan D. Licht, MD ('28) - Liaison, Editor-in-Chief, *Blood Neoplasia*
Keith R. McCrae, MD ('28) - Liaison, Editor-in-Chief, *Blood Vessels, Thrombosis & Hemostasis*
Menaka Pai, MD, BSc, FRCPC, MSc ('27) - Liaison, Chair, Committee on Quality
Mary-Elizabeth M. Percival, MD ('27) - Liaison, Chair, Committee on Practice
Andrew W. Roberts, MBBS, PhD ('29) - Liaison, Editor-in-Chief, *Blood*
Bethany Samuelson Bannow, MD ('28) - Liaison, Editor-in-Chief, *ASH Clinical News*
Surbhi Sidana, MD ('28) - Liaison, Chair, Committee on Communications
Alison R. Walker, MD, MBA, MPH ('26) - Liaison, Chair, Committee on Advancing Excellence and Population Health
Andrew S. Weyrich, PhD ('26) - Liaison, Deputy Editor, *Blood Advances*
Alisa S. Wolberg, PhD ('26) - Liaison, Chair, Committee on Scientific Affairs

ANNUAL MEETING ACCREDITED EDUCATION COMMITTEE

STAFF LIAISON:

Ana Velarde
E-mail: *avelarde@hematology.org*

Maureen Okam Achebe, MD, MPH ('26) - Co-Chairperson, 2026 Education Program Co-Chair
Robert Zeiser, MD, PhD ('26) - Co-Chairperson, 2026 Education Program Co-Chair

Ami S. Bhatt, MD ('26) - 2026 Scientific Program Co-Chair
Saar Gill, MD, PhD ('26) - 2026 Scientific Program Co-Chair
Michael Auerbach, MD ('26) - Appointed Member
Franziska Blaeschke, MD, PhD ('26) - Appointed Member
Robert A. Campbell, PhD ('27) - 2027 Scientific Program Co-Chair
Nelson J. Chao, MD ('26) - Appointed Member
Jana M Ellegast, MD ('26) - Appointed Member
Patrick G. Gallagher, MD ('26) - Appointed Member
Stephanie Halene, MD ('26) - Appointed Member
Margaret Kasner, MD, MSc ('27) - Chair, CME Accreditation Committee
Jane A. Little, MD ('26) - Appointed Member
Lori S. Muffly, MD, MS ('27) - Executive Editor, Hematology
Jyoti Nangalia, MBBChir ('27) - 2027 Scientific Program Co-Chair
Peter E. Newburger, MD ('26) - Appointed Member
Obiageli Eunice Nnodu, MD ('26) - Appointed Member
Florian Perner, MD ('26) - Appointed Member
Michal Rose, MD ('26) - Appointed Member
Nirali N. Shah, MD ('26) - 2027 Education Program Co-Chair
Sean Stowell, MD ('26) - Appointed Member
Raymond Thertulien, MD, PhD ('26) - Appointed Member
Tzu-Fei Wang, MD, MPH ('26) - Appointed Member
Julia Zhe Xu, MD, MScHG ('26) - 2027 Education Program Co-Chair

ASH'S LEGACY OF LEADERSHIP CONTINUES



Martha "Marty" Liggett, Esq.
ASH Executive Director
through December 31, 2026



Matthew Gertzog, FASAE, MBA
ASH Chief Executive Officer,
starting January 1, 2027

#ASH26

2026 REVIEWERS

The Society gratefully acknowledges the time and effort of the following individuals who served as reviewers of abstracts for this meeting and of *Hematology* 2026, the ASH Education Program.

ASH ABSTRACTS COORDINATING REVIEWERS

Nadine Abdallah
Lionel Ades
Othman Akhtar
Juan Alderuccio
Fumio Arai
Susan Bal
Rahul Banerjee
Stefan Barta
Spero Cataland
Marta Chesi
Lori Crosby
Mattia D'Agostino
Aleksandra Dain
Blachy Davila Saldana
Nirav Dhanesha
Maria Diez-Campelo
Christen Ebens
Hany Elmariah
Andrew Evens
Zachary Frosch
Gabriel Ghiaur
Jahnavi Gollamudi
Mahasweta Gooptu
Claudia Haferlach
Cynthia Hahn
Patrick Hayden
Caroline Heckman
Florian Heidel
Eldad Hod
Hitomi Hosoya
Boyu Hu
Sandra Huber
Scott F. Huntington
Eric Huselton
Gloria Iacoboni
Ryan Jacobs
Amanda Jacobson-Kelly
Laure Joseph
Theodosia Kalfa
Gurbakhash Kaur
Robert Kridel
Curtis Lachowiez
Daniel Landsburg
Hugo Lara-Martinez
Avi Leader
Emily Liang
Camille Lobry
Kah Poh (Melissa) Loh
Kellie Machlus
Abhishek Maiti
Florent Malard
Punam Malik
Olufunke Martin
Francesco Maura
Thomas Mercher
Michele Merli
Ruben Mesa
Marcus Messmer
Klaus Metzeler
Roberto Mina
Coraline Mlynarczyk
Scott Moerdler
Riccardo Moia
Peter Mollee
Lori Muffly
Ann Mullally
Ariela Noy
Kristen O'Dwyer
Carolyn Owen
Margareth Ozelo
Manu Pandey
Jens Panse
Helen Papadaki
Rushad Patell
Scott Peslak
Yana Pikman
Thomas Pincez
Sandra Pinho
Olga Pozdnyakova
Keith Pratz
Susan Prockop
Sarwish Rafiq
Daniel Richardson
Kerry Rogers
Mark Roschewski
Richard Rosenquist
Sandrine Roulland
Bipin Savani
Kelly Schoenbeck
Michelle Schoettler
Naranie Shanmuganathan
Patricia Shi
Akiko Shimamura
Sarah Skuli
Meera Sridharan
Evi Stavrou
Koichi Takahashi
Justin Taylor
Sigrun Thorsteinsdottir
Antiopi Varelias
Elvin Wagenblast
Shannon Walker
Justin Watts
Amanda Winters

ASH ABSTRACTS REVIEWERS

Maya Abdallah
Oussama Abla
Pau Abrisqueta
Melissa Acquazzino
Amber Afzal
Luis E. Aguirre
Ana Alfonso-Pierola
Stefan Alig
Lapo Alinari
David Allan
Hanny Al-Samkari
Othman Al-Sawaf
Aseel Alsouqi
Jessica Altman
Ana Antun
Tomohiro Aoki
Sally Arai
Mutlu Arat
Donald Arnold
Alberto Arribas
Frida Bugge Askeland
Shebli Atrash
Emily Ayers
Roberta Azbell
Melissa Azul
Maria Baer
Juhi Bagaitkar
Nizar Bahlis
Amneet Bajwa
Alessandra Balduini
Somedeb Ball
Ramesh Balusu
Versha Banerji
Noffar Bar
Allison Barraclough
Taha Bat
Linda Baughn
Ali Bazarbachi
Roelof Bekendam
Marina Beltrami Moreira
Christy Bemrich-Stolz
Lina Benajiba
Markus Bender
P. Leif Bergsagel
Callie Berkowitz
Jonathan Berry
Luca Bertamini
Alison Bertuch
Neel Bhatt
Vijaya Bhatt
Xia Bi
Poorva Bindal
Adam Binder
James Blachly
Allison Bock
Stephan Bohl
Côme Bommier
Claire Booth
Aaron Boothby
Arndt Borkhardt
Azra Borogovac
Wallace Bourgeois
Robert Bowman
Terrence Bradley
Marc Braunstein
Annamaria Brioli
Gabriel Brisou
Rena Buckstein
Gesine Bug
Lars Bullinger
Cathy Burton
Craig Byersdorfer
Ja Min Byun
Teresa Calmieri
Vincent Camus
Jose Cancelas
Felicia Cao
Rohini Chakravarthy
Namrata Chandhok
Sharat Chandra
Yi-Bin Chen
Carol Yuk-Man Cheung
Mark Chiang
Thita Chiasakul
May Chien
Kuo-Kai Chin
Timothy Chlon
Jaehyung Cho
Hannah Choe
Edward Cliff
Alexander Coltoff
Nichola Cooper
Matthew Cortese
Susan Creary
Stacy Croteau
Frederik Damm
Alexey Danilov
Michael Daunov
Matthew S Davids
Marta Davidson
Pavel Davizon-Castillo
Ann De Becker
Lucia De Franceschi
Javier De La Rubia
Marcos De lima
Marta Derecka
Ani Deshpande
Susan DeWolf
Bhagirathbhai Dholaria
Mengyang Di
Danai Dima
Shira Dinner
Martin Dreyling
Wei Du
Matthieu Duchmann
Amylou Dueck
Andrew Dunbar
Urshila Durani
Jibran Durrani
Fabio Efficace
Dimitar Efremov
Sigrun Einarsdottir
Fuad El Rassi
Ola Elgamal
Areej El-Jawahri
Daisuke Ennishi
Narendranath Epperla
Bita Fakhri

2026 REVIEWERS

Rawan Faramand
Carmen Fava
Joshua Fein
Pierre Fenaux
Anna Ferrari
Tobias Feuchtinger
Charles Foucar
Ellen Fraint
Mathew Frank
Jason Freed
Fateeha Furqan
Felipe Furtado
Manila Gaddh
Nico Gagelmann
Federico Gaiti
Paolo Gallipoli
Maher Gandhi
Juan-Jose Garces
Jessica Garcia
Guillermo Garcia-Manero
Valter Gattei
Evripidis Gavathiotis
Eleni Gavriilaki
Oluwabukola Gbotosho
Biju George
Gemlyn George
Aaron Gerds
Irene Ghobrial
Helene Gleitz
Ingrid Glimelius
David Gomez-Almaguer
Lukasz Gondek
Inna Gong
Jesus Gonzalez-Lugo
Max Gordon
Sasidhar Goteti
Katharina Götze
Doriana Gramenga
Philipp Greif
Emma Groarke
Zhaohui Gu
Elizabeth Gunn
Ashish Gupta
Guru Subramanian Guru Murthy
Anna Halpern
Betty Hamilton
Paul Hampel
Emily Harris
Daniel Herranz
Erin Hertlein
Kyle Hewitt
Aimee Hildenbrand
Kirsty Hillier
Laura Hilton
Andreas Hochhaus
Craig Hofmeister
Sanghee Hong
Brett Houston
Chi-Joan How
Matthew Hsieh
Li-Wen Huang
Anne Hubben
Anthony Hunter
Chibuzo Ilonze
Ho Wan Ip
Raphael Itzykson
Julie Jaffray
Akriti Jain
Nitin Jain
Andrew Jallouk
Omer Jamy
Jelena Jelicic
Christopher Jensen
Anand Devaprasath Jeyasekharan
Antonio Jimenez Jimenez
Carlos Jimenez-Vicente
Victor Jimenez-Zepeda
Tami John
Nathalie Johnson
Patrick Johnson
Anna Johnston
Brian Jonas
Nisha Joseph
Jakrawadee Julamanee
Eric Jurgens
Martin Kaiser
Jennifer Kanakry
Elizabeth Kang
Yogendra Kanthi
Rick Kapur
Theodoros Karantanos
Motohiro Kato
Gina Keiffer
Michael Keng
Michael Kent
Bryce Kerlin
Irum Khan
Eugene Khandros
Rathana KIM
Tae Kon Kim
Ashwin Kishtagari
Amy Kiskaddon
Adam Kittai
Emre Kocakavuk
Jean Koff
Valery Kogler
Rachel Koldej
Rami Komrokji
Mika Kontro
Neha Korde
Laura Korin
Taxiarchis Kourelis
Jakub Krejcik
Florian Kuchenbauer
Mi Kwon
Barbara Lam
Jeffrey Lancet
Gabrielle Lapping-Carr
Thomas Larsen
Kang Le
Gregoire Le Gal
Andrew Leavitt
Thomas LeBlanc
Michelle Lee
Karin Leiderman
Alexander Lesokhin
Jianping Li
Loretta Li
Ye Ethan Li
Christopher Liam
Jane Liesveld
Kim Linton
Daniel Lipka
Richard Little
Maja Ludvigsen
Selina Luger
Thomas Lund
Marlise Luskin
Meng Lv
Jaroslaw Maciejewski
Nicola Maciocia
Yazan Madanat
Rafael Madero-Marroquin
Kris Mahadeo
Nadim Mahmud
Sham Mailankody
Rinku Majumder
Maksim Mamonkin
Abhishek Mangaonkar
Salomon Manier
Gabriel Mannis
Kate Manos
Maria Maryanovich
John Mascarenhas
Camila Masias
Emily F. Mason
Melissa Mavers
Georgia McCaughan
Catherine McGuinn
Morgan McLemore
Robert Means
Erin Meermeier
Johanna Melo-Cardenas
Megan Melody
Cheryl Mensah
Reid Merryman
Maximilian Merz
Lekha Mikkilineni
Paolo Milani
Alice Mims
Alain Mina
Simone Minnie
Bassem Mohammed
Meera Mohan
Mohamad Mohty
Patrizia Mondello
Barbara Mora
Jerome Moreaux
Adrian Mosquera
Marek Mraz
Lutz Mueller
Erin Mulvey
Pashna Munshi
Hemant Murthy
Khaled Musallam
Neel Nabar
Omar Nadeem
Antonella Nai
Swati Naik
Lalitha Nayak
Sergei Nekhai
Natalia Neparidze
Alexander Ngwube
Yuki Nishida
Lisa Niswander
Alex Niu
Hanne Norseth
Nneka Nwachukwu
Oreofe Odejide
Olatoyosi Odenike
Elizabeth O'Donnell
Steven Okoli
Rebecca Olin
Thomas Ollila
Joseph Opferman
Jamie O'Sullivan
Jad Othman
Katia Pagnano
Dimitrios Papaioannou
Sunmin Park
Erin Parry
Oren Pasvolsky
Krish Patel
Seema Patel
Shyam Patel
Barry Paul
Katerina Pavenski
Rafal Pawlinski
Regis Peffault De Latour
Ari Pelcovits
Dan Peltier
Ariel Perez
Juliana Perez Botero
Andrew Peseski
Tycel Phillips
Armin P. Piehler
Valeria Pinto
Maria Pirosa
Christina Poh
Mortimer Poncz
Priyanka Pophali
Gizelle Popradi
Tirthadipa Pradhan-Sundd
Alexandre Puissant
Kevin Quann
Lynn Quek
Minke Rab
Mahvish Rahim
Ruyan Rahnama
Herleen (Sofi) Rai
Sunil Raikar
Anita Rajasekhar
Hari Raman
Archana Ramgopal
Parvathi Ranganathan
Leo Rasche
Katya Ravid
Suravi Raychaudhuri
Delphine Rea
Hans Christian Reinhardt
Andreas Reiter
Kehan Ren
Joanna Rhodes
Eloisa Riva
Marta Riva
Aldo Roccaro
Claire Roddie
Lindsey Roeker
Alexandra Rojek
Gregory Roloff
Rizwan Romee
David Ross
Jennifer Rothman
Giovanni Roti
Kevin Rouault-Pierre
Leo Ruhnke
Tarinee Rungjirajittranon
David Russler-Germain
Christine Ryan
Justine Ryu
Giuseppe Saglio
Aditi Saha
Kieran Sahasrabudhe
Sujith Samarasinghe
Deepa Sampath
Luisanna Sanchez
Valeria Santini
Santosh Saraf
Joshua Sasine
Andromachi Scaradavou
Eric Schafer
Jonathan Schatz
Joe Schroers-Martin
Christian Schultze-Florey
Marie Scully
Craig Seaman
Marie Sébert
Pierre Sesques
Harsh Shah
Mansi Shah
Neil Shah
Nirav Shah
Nishi Shah
Urvi Shah
Anjali Sharathkumar
Deva Sharma

Bo Shen
Polina Shindiapina
Robert Sidonio
Audrey Sigmund
Maria Silva
Haley Simpson
Sharon Singh
Andrea Sitlinger
Portia Smallbone
Erica Sparkenbaugh
Henri Spronk
Claudia Stege
Eytan Stein
Nickolas Steinauer
Jessica Stempel
Alexandra Stevens
John Storring
Charlotte Story
Paolo Strati
Kaitlin Strumph
Ryan Stubbins
Christopher Sturgeon
Pamela Sung
Ingigerdur Sverrisdottir
Jakub Svoboda
Thota Swapna
Kaoru Takasaki
Hannah Tamary
Francesco Paolo Tambaro
Ishan Tatake
Benoit Tessoulin
Cristina Tognon
Daisuke Tomizawa
Pallawi Torka
Asaad Trabolsi
Venee Tubman
Ashwin Unnikrishnan
Aysegul Unuvar
Tiziana Vaisitti
Niels van de Donk
Carrie van der Weyden
Layla Van Doren
Francisco Vega
Sangeetha Venugopal
Carlos Villa
Pierre Villeneuve
Carlo Visco
Valeria Visconte
Phuong Vo
Franziska Wachter
Moneeza Walji
Sarah Wall
Eric Wang
Trent Wang
Yucai Wang
YunZu Wang
Alan Warren
Jennifer Webb
Jonathan Webster
Megan Weivoda
Rob Welner
William Wierda
Tanya Wildes
Jennifer Wilkes
Basem William
Matthew Witkowski
Char Witmer
Marcin Wlodarski
Anne Wofford
Janghee Woo
Kitsada Wudhikarn
Joanne Yacobovich
Chao-Yie Yang
Marianne Yee
Agnes Yong
Gian Maria Zaccaria
Sara Zarnegar-Lumley
Christine Zhang
Yumeng Zhang
Yanmin Zhao
Bachisio Ziccheddu
Marc Zumberg

ASH ABSTRACTS TRAINEE REVIEWERS

Aldo Acosta Medina
Biplov Adhikari
Damilola Akani
Joanne Alfred
Cecily Allen
Charyguly Annageldiyev
Nicole Arellano
Sankalp Arora
Michael Austin
Giuliano Banco
Suraj Bansal
Luiz Bazzo Catto
Tanushree Bhatt
Stefan Bjelosevic
Leora Boussi
Sara Bowman
Peter-Martin Bruch
Luca Vincenzo Cappelli
Bria Carrithers
Yu-Sung Chang
Aaron Cheng
Karan Chohan
Stefano Crippa
Katia Crisler
Brandon Dasilva
Jonathan Day
Nidhi Desai
Saarang Deshpande
Daisy Diaz Rohena
Venkatasai Rahul Dogiparthi
Katherine J. Feder
Emma Fink
Sofiane Fodil
Violeta Garcia-Hernandez
Kriti Gera
Jason Gilbert
Utkarsh Goel
Julian Guetta-Weiss
Taha Bartu Hayal
Umar Iqbal
Salman Khan
Dimitrios Kotsos
Tessa Lavorgna
Nicholas Lee
Maria Leon-Camarena
Lisa Liu
Yoshito Nishimura
Giorgio Orofino
Isabel Sandner
Nora Rebecca Schwingen
Kexin Shen
Koki Shimizu
Sayantani Sinha
Jackson Smith
Abigail Sneider
Shreya Srivastava
Patrick Stelmach
Alexander Streuer
Charles Sukin
Arvind Suresh
Toshiki Terao
Vasil Toskov
Serhan Unlu
Betül Ünlü
Dhvani Vora
Helen Wang
Annie Xiao
Xi Yang
Chen Zhang
Simon Zhen
Kevin Zhu
Shicong Zhu

HEMATOLOGY 2026 REVIEWERS

Sameem M. Abedin
Elisabetta Abruzzese
Denise M. Adams
Hanny Al-Samkari
Juan Pablo Alderuccio
Ibrahim Aldoss
Elysia Alvarez
Jennifer Effie Amengual
Jane F. Apperley
Kenneth I. Ataga
Ehab L. Atallah
Michael Auerbach
Karen Ballen
Rahul Banerjee
Noffar Bar
Geoffrey D. Barnes
Nancy L. Bartlett
Lisa Baumann Kreuziger
J. Scott Beeler
Ashley E. Benson
Jesus G. Berdeja
Neil Blumberg
Alexandra Borst
Jennifer R. Brown
Andrew M. Brunner
Tyler W. Buckner
Sophie Gabrielle Carlson
Hetty E. Carraway
Carla Casulo
Yi-Bin Chen
Satheesh Chonat
Stella T. Chou
Robert D. Christensen
Thomas D. Coates
James A. Connelly
Stacey Cooper
Paolo Corradini
Jennifer L. Crombie
Susanna A. Curtis
Kate Cwynarski
Christin B. DeStefano
Robert Diep
Donna M. DiMichele
Stephanie B. Dixon
Talib Dosani
Carlo Dufour
Ritika Dutta
Daniel A. Ermann
Steven M. Frank
Anat Gafter-Gvili
Patrick G. Gallagher
Jacqueline S. Garcia
Eleni Gavriilaki
Mark B. Geyer
Andreas Glenthøj
Rachael F. Grace
Natalie S. Grover
Claire N. Harrison
Jennifer L. Herrick
Gabriela S Hobbs
Billy Holcombe
Shernan G Holtan
Monica Hulbert
Zalaya K. Ivy
Ryan Jacobs
Nitin Jain
Siddhartha Jaiswal
Cassandra D. Josephson
Seth E. Karol
Leon D. Kaulen
Prabhakar Kedar
Shannon Kelly
Vanessa E. Kennedy
Adam S. Kittai
Youngil Koh
E. Anders Kolb
Rami S. Komrokji
Kevin H.M. Kuo
Ann S. LaCasce
Curtis A. Lachowiez
Arielle L. Langer
Sarah Larson
Tasha L. Lin
Andrew H. Lipsky
Jane A. Little
Julie Ma
James Malone
John P. Manis
John O. Mascarenhas
Michael J. Mauro
Matthew G. Mei
Joseph R. Mikhael
Samin Mohsenian
Alfonso Molina
John C. Molina
Alison J. Moskowitz
Khaled M. Musallam
Kasiani C. Myers
Diane Nugent
Francesca Palandri

2026 REVIEWERS

Jan Palmblad
Helen A. Papadaki
Anand A. Patel
Krish Patel
Andrew C. Perkins
Antonio Giulio Piga
Andrew Jay Portuguese
Anca Prica
Benjamin R. Puliafito
Rachel E. Rau
Kiersten W. Ricci
Kerry A. Rogers
Mark Roschewski
Noemi Roy
Roberta Russo
Kristen Sanfilippo
Farzana A. Sayani
Levanto Schachter
Elisabeth Schorb
Joseph G. Schroers-Martin
Brian C. Shaffer
Harsh R. Shah
Urvi A. Shah
Michelle Sholzberg
William Shomali
Joshua I. Siner
Bryan A. Sisk
Melody Smith
Cynthia So-Osman
Richard M. Stone
Paolo Strati
John J. Strouse
Hannah Tamary
Sarah K. Tasian
Swee Lay Thein
Suzanne Thibodeaux
Swapna Thota
Suresh Vedantham
M. Paulina Velasquez
Umberto Vitolo
Eunice S. Wang
William G. Wierda
Samuel R. Wilson
Erica M. Wood
Ted Wun
Andrew J. Yee
Marianne E.M. Yee
Roger Yusen
Joshua F. Zeidner
Jeffrey I. Zwicker
Catherine Lai
Michele P Lambert
Saskia M.C. Langemeijer
Sarah Larson
Jessica T. Leonard
Nelson Leung
Mark J. Levis
Emily C. Liang
Ming Y Lim
Tasha L Lin
Aaron C Logan
Hannah Lust
Alice Ma
Gabriel N. Mannis
Karlyn Martin
Shannon L. Maude
Jori Ellen May
Kenneth L McClain
Patrick T. McGann
Lauren E Merz
Joseph R. Mikhael
Narla Mohandas
Philippe Moreau
Johann Morelle
Khaled M. Musallam
Igor Novitzky-Basso
David O'Connor
Caspian Oliai
Sandhya Ramanathan Panch
Sameer A Parikh
Anand A Patel
Christopher J Patriquin
Christopher Jordan Patriquin
Giulia Petrone
Antonio Pierini
Rob Pieters
Steven W. Pipe
Rajiv K Pruthi
Parul Rai
Noopur S. Raje
Patrick M. Reagan
Michael Recht
Josep-Maria Ribera
Annalisa Ruggeri
Sarah C. Rutherford
Jesús F. San-Miguel
Kristen Sanfilippo
Yazeed Sawalha
Natalia Scaramellini
Marie Scully
Tulika Seth
Mazyar Shadman
Kenneth H Shain
Amy D. Shapiro
Akshay Sharma
Aditi Shastri
Sujit Sheth
Andrew Shih
Kristin A Shimano
Nicholas J. Short
Sonali M. Smith
Senthil R Sukumar
Julie-An M. Talano
David Trent Teachey
William Temple
Will Thomas
Tzu-Fei Wang
Jonathan Allen Webster
Ted Wun
Patricia Young

2026 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 21, 2026.

2026 ASH Annual Meeting Foundation Run/Walk Supporters

PREMIER

Acrotech Biopharma
AstraZeneca
Gilead and Kite Oncology
GSK
Johnson & Johnson
PharmaEssentia

LEAD

AbbVie
Autolus
BeOne Medicines USA, Inc.

SUPPORTING

Astellas
NeoGenomics

2026 ASH Annual Meeting Education Supporters

ASH would like to acknowledge the following companies for the educational grants provided in support of the 2026 ASH Annual Meeting:

General Education Grant

AbbVie
AstraZeneca
GSK
Janssen Scientific Affairs, LLC
Merck Sharp & Dohme Corp
Novartis Pharmaceuticals Corporation

Hematology 2026: The Education Program

AstraZeneca
GSK
Eli Lilly and Company
Merck Sharp & Dohme Corp
Novartis Pharmaceuticals Corporation

2026 ASH Independent Medical Education Supporters

ASH would like to acknowledge the following companies for their support:

Janssen Scientific Affairs, LLC
GSK

2026 ASH Scientific Workshops Supporters

ASH would like to acknowledge the following companies for their support of the 2026 Scientific Workshops:

Agios
Sanofi

2026 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 21, 2026.

2026 ASH Award Supporters

ASH would like to acknowledge and thank the following companies for supporting the ASH Award for Research Careers in Hematology, Hematology Inclusion Pathway and Scholar Award programs:

AbbVie

AstraZeneca

Janssen Scientific Affairs, LLC

Regeneron Pharmaceuticals

2026 Annual Meeting Corporate Supporters

ASH would like to acknowledge the following companies for their support of the 2026 ASH Annual Meeting:

AbbVie
Sponsored Lounges

AstraZeneca
Exhibit Hall Aisle Signs

Bristol Myers Squibb
ASH Park @ the Plaza – Table Clings

Eli Lilly and Company
Photo Zone
Social Media Wall

GSK
ASH Hotel Door Drop Bag
Mobile Device Charging Stations

Johnson & Johnson
Headshot Alley
Mobile Device Charging Stations

NMDP
ASH-a-Palooza – Gold Level Supporter

PharmaEssentia
Mobile Device Charging Stations

Sanofi
Sponsored Lounge

SOBI, Inc.
Mobile Device Charging Stations

Syndax Pharmaceuticals
Mobile App

2026 ASH Global Initiatives

ASH would like to acknowledge and thank the following companies and foundation for supporting ASH's international consortia:

Children's International Consortium on Acute Leukemia

Direct Relief

Servier

Consortium on Newborn Screening in Africa

Bristol Myers Squibb

Novartis

Novo

Revvity

International Consortium on Acute Leukemia

Illumina

Torsten Haferlach Leukemia Diagnostics Foundation

2026 CORPORATE ACKNOWLEDGMENTS

These acknowledgments reflect contributions made prior to October 21, 2026.

2026 ASH Corporate Friends

ASH Corporate Friends are dedicated partners of the Society and their support to advance hematology research, education, training, and advocacy throughout the year is sincerely appreciated. ASH is grateful for the generous support of the following companies:

Premier Circle	Partner Circle	Advocate Circle	Insider Circle	Signature Circle
BeOne	AstraZeneca	AbbVie	Autolus	Nurix
GSK	Bristol Myers Squibb	Agios Pharmaceuticals	Genetix	
Janssen Scientific Affairs, LLC	Eli Lilly and Company	Amgen	Geron	
Novartis Oncology	Genentech	Genmab	Orca Bio	
Pfizer, Inc.	Gilead and Kite Oncology	Merck Sharp & Dohme Corp	Secura Bio	
Regeneron Pharmaceuticals	Vertex Pharmaceuticals	Sanofi		
		Summitomo		
		Syndax		
		Takeda		

2026 Health Impact Collective

The Health Impact Collective represents a cooperative enterprise of support opportunity areas for organizations seeking to help stop the trajectory and minimize the impact of health care inequality. Building on ASH's work over the last 20 years to combat health inequity, and through the support of partnering organizations, participating members of the Collective have taken tangible steps to dismantle inequitable practices within the health care community. ASH is grateful for the support and recognizes the members for their laudable work:

Genentech

Gilead and Kite Oncology

GSK

Janssen Scientific Affairs, LLC

Merck Sharp & Dohme Corp

ASH Foundation
Moving Hematology Forward

Progress in **Hematology** Powered by **Philanthropy**

The ASH Foundation fuels the future of hematology through your generous contributions.

Every dollar you donate directly supports the groundbreaking programs and initiatives led by the American Society of Hematology.

Your donation helps to advance progress in hematology and patient care worldwide.

With 100% of your donation going to critical programs, you're helping shape a brighter future for patients and professionals.

> ***A gift to the ASH Foundation is an investment in the continued growth of every facet of hematology, especially in translating advances to patients with blood disorders worldwide.***



James LaBelle, MD, PhD, Chair, ASH Foundation Committee, 2024–2026

Donate now.

Visit ***hematology.org/foundation*** to learn more and contribute today.

Moving hematology forward

RECIPIENTS OF AWARDS

WALLACE H. COULTER AWARD FOR LIFETIME ACHIEVEMENT IN HEMATOLOGY

2026 Elliott Vichinsky
2025 Rainer Storb
2024 Éliane Gluckman
2023 Blanche P. Alter
2022 Irving Weissman
2021 Harvey Lodish
2020 Mohandas Narla
2019 Richard H. Aster
2018 Victor Hoffbrand
2017 Marshall A. Lichtman
2016 Thalia Papayannopoulou
2015 Aaron Marcus
2014 Kanti Rai
2013 Sir David John Weatherall
2012 James George
2011 David G. Nathan
2010 Volker Diehl
2009 H. Franklin Bunn
2008 Robert Kyle
2007 Ernest Beutler

ERNEST BEUTLER LECTURE AND PRIZE

2026 Suzanne Cory and Marina Konopleva
2025 Radek Skoda and Ruben Mesa
2024 Stuart Orkin and John Tisdale
2023 Johnny Mahlangu and Takehisa Kitazawa
2022 John Atkinson and Peter Hillmen
2021 Margaret Shipp and Stephen Ansell
2020 Courtney DiNardo and Ari Melnick
2019 Sriram Krishnaswamy and Jeffrey I. Weitz
2018 Alan D'Andrea and Neal Young
2017 Luigi Naldini and Marina Cavazzana
2016 Hugues de Thé and Zhu Chen
2015 Alfred Goldberg and Paul Richardson
2014 Michael R. DeBaun and Robert P. Hebbel
2013 Kenneth Kaushansky and David J. Kuter
2012 Bruce R. Blazar and Carl H. June
2011 Janet D. Rowley and Brian J. Druker
2010 Barry S. Coller and Joel S. Bennett
2009 Yuet Wai Kan and Thomas Maniatis

E. DONNALL THOMAS LECTURE AND PRIZE

2026 Scott Armstrong
2025 Nancy Speck
2024 Sean J. Morrison
2023 Katy Rezvani
2022 Bruce Blazar
2021 Connie Westhoff
2020 Toshio Suda
2019 Philip D. Greenberg
2018 Connie J. Eaves
2017 James R. Downing
2016 David Scadden
2015 Barbara C. Furie and Bruce Furie
2014 Tomas Ganz
2013 Katherine A. High
2012 Timothy J. Ley
2011 George Q. Daley
2010 Leonard I. Zon
2009 John E. Dick
2008 Neal S. Young
2007 Hal Broxmeyer
2006 E. Richard Stanley
2005 Rainer Storb
2004 Donald Metcalf
2003 Ernest Beutler
2002 Kenneth Mann
2001 Samuel E. Lux, IV
2000 David Ginsburg
1999 Irving Weissman
1998 Stuart H. Orkin
1997 Robert Rosenberg
1996 Stanley Korsmeyer
1995 Charles Esmon
1994 Thomas P. Maniatis
1993 Thomas P. Stossel
1992 Stuart Kornfeld

WILLIAM DAMESHEK PRIZE

2026 Stella Chou
2025 Mark Dawson
2024 Ami Bhatt
2023 Omar Abdel-Wahab
2022 Irene Ghobrial
2021 Elizabeta Nemeth
2020 Adolfo Ferrando
2019 Emmanuelle Passegué
2018 Ross L. Levine
2017 Benjamin L. Ebert
2016 Charles Mullighan
2015 John Byrd
2014 Scott Armstrong
2013 Andrew Weyrich
2012 Margaret A. Goodell
2011 Christoph Klein
2010 David T. Scadden
2009 Louis M. Staudt
2008 Kenneth Anderson
2007 William Vainchenker
2006 Riccardo Dalla-Favera
2005 John Dick
2004 Ronald Levy
2003 Gary Gilliland
2002 Catherine Verfaillie
2001 Brian Druker
2000 David A. Williams
1999 Salvador Moncada
1998 J. Evan Sadler
1997 Björn Dahlbäck
1996 Kenneth Kaushansky
1995 James Ihle
1994 George J. Broze, Jr.
1993 Owen Witte
1992 Richard D. Klausner
1991 Makio Ogawa
1990 Thalia Papayannopoulou and George Stamatoyannopoulos
1989 Samuel E. Lux IV
1988 Theodore S. Zimmerman
1987 Charles Sherr
1986 Stuart Orkin
1985 Thomas F. Deuel
1984 Barbara C. and Bruce Furie
1983 Thomas P. Stossel
1982 Janet D. Rowley
1981 Philip W. Majerus
1979 Yuet Wai Kan
1978 Robert D. Rosenberg
1977 Yale Nemerson
1976 Robert I. Weed
1975 Charlotte Friend
1974 Robert C. Gallo

ROLAND B. SCOTT-CHARLES DREW EXCELLENCE IN EQUITY AWARD

2026 Leon Bernal-Mizrachi

ASH ADVANCING INCLUSIVE EXCELLENCE AWARD (2017-2025)

2025 Diane Krause
2024 James George
2023 Alexis A. Thompson
2022 James Gavin and David Wilkes
2021 Deepika Darbari
2020 Edward J. Benz Jr.
2019 Griffin P. Rodgers
2018 Cage S. Johnson and José A. López
2017 Betty Pace

JANET ROWLEY BASIC SCIENCE MEDAL (1992-2025)

2026 Benjamin Levine Ebert

HELEN M. RANNEY CLINICAL AND TRANSLATIONAL SCIENCE MEDAL

2026 Andrew Roberts

HENRY M. STRATTON MEDAL (1992-2025)

2025 Karina Yazdanbakhsh and David A. Williams
2024 Douglas Cines and Katherine High
2023 Rodger McEver and James B. Bussel
2022 Timothy Ley and Robert Montgomery
2021 Denisa Wagner and Kwaku Ohene-Frempong
2020 Michelle Le Beau and Maria Domenica Cappellini
2019 William Allen Eaton and Richard A. Larson
2018 Freda K. Stevenson and Brunangelo Falini
2017 Josef Tomas Prchal and Sherrill J. Slichter
2016 J. Evan Sadler and Ayalew Tefferi
2015 Nancy Speck and Karl Welte
2014 Timothy Springer and Geraldine Schechter
2013 Nancy Andrews and Elaine Jaffe
2012 David Ginsburg and Richard Aster
2011 Ching-Hon Pui
2010 Sanford Shattil
2009 Connie Eaves
2008 Clara Bloomfield
2007 Carlo Croce
2006 Jack Hirsh
2005 Barry Coller
2004 Stanley Korsmeyer
2003 Janet Rowley
2002 George Stamatoyannopoulos
2001 Harold R. Roberts
2000 H. Franklin Bunn
1999 Helen Ranney
1998 Arthur W. Nienhuis
1997 Rainer Storb
1996 Bernard Forget
1995 David Nathan
1994 Titus H.J. Huisman
1993 Earl W. Davie
1992 Kenneth G. Mann

HENRY M. STRATTON LECTURE (1970-1991)

1991 Ralph L. Nachman
1990 Malcolm Moore
1989 Aaron J. Marcus
1988 Robert S. Schwartz
1987 Robert C. Gallo
1986 Bernard Babior
1985 Vincent DeVita
1984 Samuel Rapaport
1983 Eugene P. Cronkite
1982 Ernest A. McCulloch
1981 Clement A. Finch
1980 Yuet Wai Kan
1979 Henry S. Kaplan
1978 William N. Valentine
1977 Thomas A. Waldmann
1976 Wendell F. Rosse
1975 E. Donnall Thomas
1974 Ernest Beutler
1973 Albert S. Gordon
1972 Oscar D. Ratnoff
1971 H.G. Kunkel
1970 W.R. Bruce

J. EVAN SADLER AWARD FOR MENTORSHIP

2026 Roy Silverstein

BERNARD FORGET AWARD FOR MENTORSHIP

2026 Laura De Castro

ASH MENTOR AWARD (2006-2025)

2025 Jorge Di Paola and Sophie Lanzkron
2024 Stephen D. Nimer and Charles A. Schiffer
2023 Stephen Sallan and Helen Heslop
2022 Michael Caligiuri and Christopher Flowers
2021 Jonathan Licht and Anthony Goldstone
2020 Judith Gasson and Wendy Stock
2019 Leonard I. Zon and Michael R. DeBaun
2018 John E. Dick and Reed E. Drews

2017 Ronald Hoffman and Oliver W. Press
2016 Laurence Boxer and Ralph L. Nachman
2015 Curt Civin and Craig Kitchens
2014 Grover C. Bagby Jr. and John F. DiPersio
2013 John Adamson and Stanley Schrier
2012 Beverly S. Mitchell and Rainer F. Storb
2011 Nancy C. Andrews and Malcolm K. Brenner
2010 Mary M. Horowitz and Harvey F. Lodish
2009 Arthur Nienhuis and Stuart H. Orkin
2008 George R. Buchanan and Timothy J. Ley
2007 Edward J. Benz Jr and Harold R. Roberts
2006 Samuel E. Lux and Deane F. Mosher

ASH OUTSTANDING ABSTRACT ACHIEVEMENT AWARDS

The American Society of Hematology is pleased to recognize the following abstract presenters who received the highest ranking in their categories of undergraduate student, medical student, graduate student, resident physician, and post-doctoral fellow.

UNDERGRADUATE STUDENT

Elyad Babaei
University of Calgary

MEDICAL STUDENT

Wimeth Dissanayake
New York University Grossman School of Medicine

GRADUATE STUDENT

Komal Mandleywala
Rutgers Cancer Institute

RESIDENT PHYSICIAN

Julius Michel
Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH)

POST-DOCTORAL FELLOW

Sen Zhang
University of Illinois Chicago

ASH-BRITISH SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the British Society of Haematology (BSH) is granted to up to three British trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first-or-senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of BSH and reside in the United Kingdom.

Matthew Carter
University College London

Angus Hodder
Great Ormond Street Hospital for Children

Felix Radtke
University of Oxford

ASH-HEMATOLOGY SOCIETY OF AUSTRALIA AND NEW ZEALAND ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Haematology Society of Australia and New Zealand (HSANZ) is granted to up to two Australian or New Zealander trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of HSANZ and reside in Australia or New Zealand.

Phillip Nguyen
Peter MacCallum Cancer Centre

ASH-JAPANESE SOCIETY OF HEMATOLOGY ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Japanese Society of Hematology (JSH) is granted to up to three Japanese trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be members of JSH and reside in Japan.

Kazuki Mitani
Kyoto University Graduate School of Medicine

Yuri Tsuboi
University of Tsukuba

Naokazu Nakamura
Graduate School of Medicine, Kyoto University

ASH-SOCIETY ITALIANA DI EMATOLOGIA ABSTRACT ACHIEVEMENT AWARD

This annual award in partnership with the Society Italiana di Ematologia (SIE) is granted to up to two Italian trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must be a member of SIE and reside in Italy.

Luca Guarnera
University of Rome Tor Vergata

Martina Sarchi
University of Pavia

ASH-IPIG ABSTRACT ACHIEVEMENT AWARD FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

This annual award in partnership with International Paroxysmal Nocturnal Hemoglobinuria (PNH) Interest Group (IPIG) is granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious PNH focused abstracts submitted in the fields of Red Cells and Erythropoiesis or Bone Marrow Failure.

Akram Abushamma
Cleveland Clinic Akron General

Camille Malbrun
Université de Lorraine

JOANNE LEVY, MD, MEMORIAL AWARD FOR OUTSTANDING ACHIEVEMENT

This award was established in 2006 to recognize the current ASH Scholar with the highest scoring abstract for the ASH annual meeting. This award is given in honor of a past Scholar Award recipient and distinguished member of ASH, Joanne Levy, who passed away in 2004. This annual award is made possible by the Levy family to continue her legacy and promote excellence in hematology research.

Andri Leo Lemarquis
Karolinska Institute

MARY RODES GIBSON MEMORIAL AWARD IN HEMOSTASIS AND THROMBOSIS

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of hemostasis and thrombosis. This annual award is made possible by the Mary Rodes Gibson Hemostasis-Thrombosis Foundation to continue the legacy of Mary Rodes Gibson who suffered from severe, type 3 von Willebrand's disease.

Hui Xiao Chao
University of Washington

ASH DAVID M. GOLDENBERG CLINICAL RESEARCH TRAINING INSTITUTE AWARD

This annual award in partnership with the Goldenberg Family Foundation is granted to four trainees from the CRTI cohort (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious submitted abstract.

Access Representation and Population Health
Alfonso Molina
University of California – San Francisco

Classical
Pedro Prata
University of Limoges

International
Angela Consagra
USL Toscana Centro

Malignant
Yannis Valtis
Memorial Sloan Kettering Cancer Center

ASH-FRANK TOOHEY ABSTRACT ACHIEVEMENT AWARD FOR MYELODYSPLASTIC SYNDROMES

This award was established to recognize the trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral fellow) who is the first author and presenter of the highest-scoring abstract submitted in the field of MDS, with a preference for highly rated abstracts related to older populations. This annual award is made possible by donations from Mary McGrane in memory of Frank Toohey.

Mingjun Liu
New York University Grossman School of Medicine

ASH-LATIN AMERICA ABSTRACT ACHIEVEMENT AWARD

This award is granted to one trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who is the first or senior author and presenter of the most meritorious submitted abstract. Recipients of this award must reside in Latin America.

Victor Gabriel de Faria Pastre
University of Campinas - UNICAMP

ASH-BERTHA BOURONCLE, MD HIP GRADUATE STUDENT ABSTRACT ACHIEVEMENT AWARD

This annual award is granted to one trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who is the first or senior author and presenter of the most meritorious abstract submitted for the HIP Graduate Student Abstract Achievement Award.

Alicia Matthews
Case Western Reserve University

ASH-RICHARD T. SILVER, MD ABSTRACT ACHIEVEMENT AWARD FOR MYELOPROLIFERATIVE NEOPLASMS

This annual award is granted to one trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who is the first or senior author and presenter of the most meritorious abstract in the area of Myeloproliferative Neoplasms (MPNs).

Jingliao Zhang
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

ASH-SHIU Y. KWOK, MD, PHD FAMILY DISTINGUISHED ABSTRACT ACHIEVEMENT AWARD

This annual award is granted to up to two trainees (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who are the first or senior author and presenter of the most meritorious abstracts in the area of Hemophagocytic Lymphohistiocytosis and Cytokine Storm.

Kamilia Moalem
National Institutes of Health

Luocheng Zhang
West China Hospital, Sichuan University

ASH–SWEE LAY THEIN, MD ABSTRACT ACHIEVEMENT AWARD IN HEMOGLOBINOPATHY RESEARCH

This annual award is granted to one trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who is the first or senior author and presenter of a most meritorious abstract in the area of Hemoglobinopathy Research.Nicole Arellano The University of Utah.

Suruchi Salgar
Baylor College of Medicine

ASH-CRAIG TENDLER, MD ABSTRACT ACHIEVEMENT AWARD FOR MULTIPLE MYELOMA

This annual award is granted to one trainee (undergraduate student, medical student, graduate student, resident physician, or post-doctoral (MD or PhD) fellow) who is the first or senior author and presenter of a most meritorious abstract in the area of Multiple Myeloma.

Julius Michel
Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH

HIP GRADUATE STUDENT ABSTRACT ACHIEVEMENT AWARD

Each year, the American Society of Hematology offers merit-based HIP (Hematology Inclusion Pathway) Graduate Student Abstract Achievement Awards to select graduate students to acknowledge accomplishments in the field of hematology.

Justice Ameyi
The Ohio State University

Nicole Arellano
The University of Utah

Briandy Fernandez Marrero
University of Texas at El Paso

Clarissa Garcia
University of Colorado Anschutz Medical Campus

Kiana Guillermo
University of California – Irvine

Kartik Lakhotiya
Cleveland Clinic

Ariel Leyte-Vidal
University of Miami

Shuyang Lin
Washington University

Jannaldo Nieves-Salva
Rackham Graduate School

Amara Pang
Oregon Health & Science University

ASH ABSTRACT ACHIEVEMENT AWARDS

Each year, the American Society of Hematology offers merit-based Abstract Achievement Awards to select individuals to acknowledge the accomplishments of hematologists-in-training. This year's Abstract Achievement Awards recognize undergraduate students, medical students, graduate students, resident physicians, and post-doctoral fellows who are both first author and presenter of an abstract.

Jayachitra Aadi
Aya Abdoh
Mohammad Abdulla
Sheikh Abdullah
Yoshiaki ABE
Parisa Abedi
Deanna Abid
Nazanin Abolghasemi Taree
Stork Abruda
Abdel Azez Abu Samak
Rohan Achar
Vera Adema
Aakriti Adhikari
Biplov Adhikari
Seyram Adzraku
Nowah Afangbedji
Anton Agana
Ayush Agarwal
Jeff Justin Aguilar
Mashal Ahmed
Manal Ahmidouch
Sungwoo Ahn
Katya Ahr
Louise Ainley
Marisa Aitken
Amir Akbari
Batool Al Qanber
Ahmed Al Sharie
Adekunle Alagbe
Rasha Al-Ali
Nil Albiol
Moath Albliwi
Mahmood Aldapt
Ana Aldaz
Kim Abbegail Aldecoa
Federico Mario Aletti
Ariceli Alfaro
Amani Alghamdi
Zachrieh Alhaj
Abdulrahman Alhajahjeh
Bakr Alhayek
Maryam Ali
Elrazi Ali
Mohammad Ali
Shaya Alimoghadam
Mir Alishah
Jessica Allen
Cecily Allen
Majed Al-Nazer
Judy Al-Sayyad
Samar Alshammasi
Alecia Alto
Johnathan Altom
Akshay Aluri
Nuria Alvarez-Pizarosso
Noor Alzraikat
Muhammad Kashif Amin
Fnu Amisha
Joseph An
Shankara Anand
Lucas Anastacio
Felicia Andresen
Zhiwei Ang
Ghada Araji
Naszrin Arani
Ashok Arasu
Janeth Araujo Cardenas
Christopher Arends
Abul Ariza-Manzano
Adrian Arnaiz-Leche
Kirti Arora
Ruby Arora
Nancy Arthur
Emmanuel Aryee
Kazuya Asano
Kazuki Asazuma
Majid Asgari
Amirsaman Ashtari
Rafal Asmaro
Eleftheria Atalla
Katherine Atkinson
Enrico Attardi
Elizabeth Aughey
Kalil Auzier Martins Costa
Valerie Awad
Carmel A R Awadallah
Inci Aydemir
Syed Ahmad Ayyubi
Nahal Azimi
Corbin Azucenas
Hidekazu Azumi
Leena Babiker
Martin Bablok
Cameron Bader
Diva Baggio
Shifali Bagmare
Jie Bai
Lauryn Bailey
Palak Bajaj
Chrissy Baker
Iris Bakker
Nora Balas
Ramya Balasubramanian
Nithya Balasundaram
Ferran Balbastre-Ubeda
Tommaso Balestra
Noah Balestra
Maya Ball-Burack
Gbolahan Bamgbose
Sariya Banday
Mohammad Bani Amer
Allison Banuelos
Laura Baquero Galvis
Taylor Barbieri
Chloe Baron
Mauricio Barreto
Kimberly Basalyga
Gaetan Basile
Hemavathi Baskarane
Suhana Basnyat
Carter Bass
David Bastos
Jackson Bauer
Luiz Bazzo Catto
Bianca Bean
Samantha Beck
J. Scott Beeler
Sina Beer
Malte Behrendt
Andreas Beilhack
Roni Ben Ami
Chokri Ben Lamine
Sacha Benaoudia
Samon Benrashid
Alador Bereketab
Jonas Berger
Michael Bern
Philipp Berning
Heather Betz
Vidhi Bhanushali
Vedha Bharanidharan
Ishan Bhatia
Shubhmita Bhatnagar
Ukti Bhatt
Meha Bhatt
Tanushree Bhatt
Satyaki Bhowmik
Irin Bhuiya
Kunzangla Bhutia
Nayda Bidikian
Aavani Biju Sindhu
Nayanthara Bijukumar
Daniel Bilek
Marta Biondi
Sophie Bislev
Nikoleta Bizymi
Stefan Bjelosevic
John Bliamptis
Arwa Bohra
Abiola Bolarinwa
Jyothsna Bolleddula
Megan Bones
Davide Bonometti
Cristina Borin
Oscar Borja Montes
Carla Isabel Borre
Marc Bosch Schips
Jonas Bouhlal
Kevin Boumeghar
Wallace Bourgeois
Sean Bowden
Antonio Brandao
Willem Brandt
Dominic Brauer
Daniela Carolina Bravo Solarte
Carlos Bravo-Perez
Christoph Brey
Kelsey Bria
Matteo Brindisi
Tonio Brinkschmidt
Lincoln Brown
Roshana Brown
Andrew Brown
Kari Brown
Camille Brzechffa
Francisco Buendia-Pelaez
Samuel Burciaga
John Burke
Jee Hyuk Byun
Lilia Cabrera-Cosme
Shannon Cahalan
Nating Cai
Wenjie Cai
Jacopo Calabrese De Feo
Daphne Campbell
Edoardo Campodonico
Leticia Campoverde
Ruoqiong Cao
Valentina Cardenas Castro
Jake Carrion
Alberto Carturan
Giulia Carvalhal
Gabriele Casirati
Henry Castellani
Mistral Castellanos Mares
Brenda Castillo
Juliana Castro
Melanie Castro Mollo
Chloe Caudrelier
Alexis Caulier
Kyle Cavanagh
Pietro Centorrino
Enise Ceran
Ela Cerovska
Okan Cetin
Zhirong Chai
Derek Chan
Breanna Chandler
Iyra Chandra
Isabela Chang
Guanghui Chang
Shing Chao
Reece Charles
Poornima Charpuria
Saran Chattopadhyaya
Sophia Chaudhry
Tuba Shahid Chaudhry
Mahija Cheekati
Asfand Yar Cheema
Kasey Chelemedos
Hongru Chen
Yingjie Chen
Zhangjie Chen
Chia-Jo Chen
Ying Chen
Jie Chen
Yi Chen
Bing-Yi Chen
Binzhen Chen
George Chen
Zhangliang Cheng
Xianjing Cheng
HeeJin Cheon
Karthik Chetlapalli

Jennifer Wing Lam Cheung
Tak Kit Cheung
Tanishq Chhabra
Giulia Chianella
Cho Han Chiang
Jessica Chicola
Davide Chizzoniti
Youbeen Cho
Hyeon Gyu Cho
Sikander Chohan
Karan Chohan
Rachel Choi
Daniel Sungchul Choi
Michael Choi
Yoonhee Choi
George Cholack
Joanna Chorazeczewski
Nicholas Chornenki
Pavlina Chrysafi
Michele Ciboddo
Bryan Ciccarelli
Nicoletta Cieri
Luke Ciminera
Fanny-Mei Cloarec-Ung
Daniele Colazzo
Anthony Colombo
Maria Florencia Comelles
Lisett Contreras
David Cordas Dos Santos
Elizabeth Corley
Luis Correa-Medero
Kadriye Nehir Cosgun
Iliana Cosio
Ronin Joshua Cosiquien
Samantha Covey
Kira Cozzolino
Alessandro Criscimanna
Gabrielle Croston
Samuel Crow
Francesca Crupi
Clifford Csizmar
Victor Cury
Elijah Dahunsi
Zhenyu Dai
Mehndi Dandwani
Nicolo Danesin
Nana Adjoa Dankyi
Alessia D'Anna
Melinda Dantec
Van-Thao Dao
Isha Darbari
Jared Darcy
Sameeran Das
Saurav Das
Ronak Dave
Gemma Davies
Jonathan Day
Felipe de Almeida Sartori
Janneke De Boer
Eduardo de Camargo Magalhaes
Anna de Daniel
A. Vera De Jonge
Diana Laura De la Torre-Torres
Gustavo de Oliveira Canedo
Elisa De Togni
Jonathan de Wilde
Sonia Debek
Joseph deBettencourt
Celine Debou
Danielle DeCicco
Vaishali Deenandayalan
Thomas Deere
Grace DeFranco
Lina Degenfeld-Schonburg
Maria Victoria del Rosal
Nicholas Demetriou
Rongjia Deng
Ella Derkzen
Eva Desbrousses
Alok Deshane
Vismay Deshani
Saarang Deshpande
Isaure Dewitte
Sai Anoop Dhamera
Vikram Dhillon
Benedetta Elena Di Majo
Maria Dias
Marthinus Dicks
Bingjie Ding
Joel Dzidzorvi Kwame Disu
Elizabeth Do
Brian Do
Catherine Nicole Domingo
Morgan Donahoe
Xiaxin Dong
Yetian Dong
Ruoyu Dong
Yanhua Dong
Huan Dong
Jiaxin Dong
Ruochen Dong
Sharlene Dong
Davide D'Onghia
Kieran Doran
Paymon Doroodian
Pedro Antonio dos Santos
Krishna Doshi
Krishna Doshi
Daniel Drangenstein
David Drum
Claire Drysdale
Jeevitha D'Souza
Chenxiao Du
Mengbao Du
Simo Du
Adam Duca
Francesca Duca
Kaleigh Ducas-Mowchun
Julia Dudkiewicz-Garbicz
Henry Dumke
Michael Durante
Gaelen Dwyer
Neela Easton
Harris Ebrahim
Alexandria Eiken
Alex Eishingdrelo
Omar Elghawy
Khaled Elhusseiny
Habib El-Khoury
Aura Enache
Jessica Encinas Mayoral
Caroline Ennis
Daniel Enriquez-Vera
Julius Enssle
Ozgur Can Eren
Maite Erguin
Leo Escano
Silvia Escribano Serrat
Arvin Eslami
Jether Amos Espinosa
Christina Estes
Jesse Fajnzylber
Ayo Falade
Zhong Fan
Hui Fang
Karen Fang
Lauren Fang
Saubia Fathima
Susheel Fatima
Joshua Faust
Katherine J. Feder
Jennifer Feigin
Erin Feliciano
Nadia Linxi Feng
Zidan Feng
Shi Feng
Justin Ferdinandus
Juncal Fernandez Orth
Maria Fernandez-Turizo
Grace Ferri
Caroline Fileni
Giuliano Filippini Velazquez
William Fischer
Julianna Fisher
Jacquelyn Fitzgerald
Madison Fitzsimmons
Sofiane Fodil
Anna Katharina Foerster
Amos Fong
Luiza Fonseca
Katrina Fordwor-Hepburn
Dorian Forte
Jodi Forward
Kwadwo Fosu
Thomas Fox
Valentina Fragliasso
Alana Franceski
Madeline Franke
William Tyler Frantz
Marisa Frausto Alejos
Allyson Freedy
Tyler Freeland
Benjamin Frost
Callie Fry
Patrycja Fryzik
Manabu Fujisawa
Thomas Fusillo
Maria Gabarros-Subira
Kathrin Gabriel
Mrunanjali Gaddam
Saivaroon Gajagowni
Nikolai Gajic
Dona Hasini Vathsalya Gammune
Margery Gang
Daniel Gao
Xiaoyue Gao
Hongye Gao
Filip Garbicz
Juan-Jose Garces
Joaquin Garcia-Solorio
Roberto Garcia-Vicente
Eline Gaucher
Tarang Gaur
Gunjan Gaur
Janamejey Gaur
Shuaishuai Ge
Shiliang Ge
Meenal Gehlawat
Kriti Gera
Drew Gerber
Hila Ghersin
Subash Ghimire
Anushka Ghosh
Salome Ghvinephadze
Mariateresa Giaimo
Madison Gil
Odil Giladi
Jason Gilbert
Yugal Goel
Utkarsh Goel
Krista Goerger
Alexander Goglia
Krutika Gohil
Aharon Golod
Simon Golowin
Marina Gomez-Llobell
Andrew Gontko
Carmen Gonzalez
Keishla Gonzalez
Adrian Gottschlich
Patrick Gould
Rachel Granberg
Ivonne Kriss Grande
Betty Gration
Emma Gray
Matthew Gromowsky
Eva Gruden
Alexander Grullon Espinal
Steven Grzegorski
Baokun Gu
Xinyuan Gu
Nehemias Guevara Rodriguez
Alberto Guijosa
Laibing Guo
Saurabh Kumar Gupta
Ravi Kumar Gupta
Smriti Gurung
Omar Gutierrez-Ruiz
Lukas Haaksma
Ashley Hadjis
Sanya Haiaty
Ann-Sophie Hainold
Trent Hall
Omar Hamdan
Anne Sofie Borg Hammer
Xiao Han
Sarah Hanache
Shaniza Haniff
John Hanna
Justine Hanotaux
Annika Hanrieder
Sune Hansen
Aishwarya Hanspal
Nishi Arun Harwani
Masataka Hasegawa
Kazuki Hashimoto
Tatsuya Hashizume
Eman Hassan

Ryo Hasunuma
Dunia Hatabah
Euan Haynes
Pranay Hegde
Konstantin Helmsauer
Amanda Henderson
Sophie Hendrickson
Carina Hernandez
Alejandra Hernandez-Galicia
Elizabeth Herrity
Jacob Herstein
Julia Heymann
Emil Hiitola
Dalton Hill
Oscar Hinojosa Castro
Tatsuro Hirao
Sam Hirniak
Matthew Ho
Bao Duy An Hoang
Fieke Hoff
Shaniah Holder
Matthew Holt
Anna Homeniuk
Cih-Li Hong
Ruby Honjol
Ruida Hou
Shenda Hou
Lara Hovel
Jacquelyn Hovey
Jennifer Hsu
Aye Myat Htun
Thura Htut
Jing Hu
Jeremy Hu
Yu Hu
Yuanlu Huang
David Huang
Jingtao Huang
Rong Huang
Xin Huang
Sixia Huang
Yue Huang
Qianqian Huang
Yiming Huang
Jiayu Huang
Bethan Hudson-Lund
Natalia Huerga Trevino
Chiara Hummel
Zachary Hunzeker
Zi-Qi Huo
Henri C. Hupe
Samantha Hurwitz
Anastasia Iatrou
Ombeni Idassi
Taha Iftikhar
Takashi Ikeda
Nosakhare Ilerhunmwuwa
Seohyeon Im
Antonio Imparato
Yusuke Inoue
Umar Iqbal
Eric Irons
Danielle Isakov
Jonathan Isenberg
Ibtida Tabassum Ishmam
Rubia Isler Mancuso
Sapir Israeli
Shino Iwata
Varun Iyengar
Sidharth Iyer
Nandhini Iyer
Yamna Jadoon
Kim Jae-Sung
Hedieh Jafari
Baqir Jafry
Karishma Jalapu
Manu Jamwal
Ankit Jana
Guneet Janda
Maela Jan-Kronborg
Mohan Jauhar
Billy Jebaraj
Hanzala Jehangir
Madeline Jenkin
Amy Ji
Yuanyuan Ji
Qi Ji
Qizhen Jia
Yuting Jiang
Yuan Jiang
Yanan Jiang
Karina Jimenez Camacho
Zhen Jin
Julia Jones
Sally Jones
Daniel Thomas Jones
Colton Jones
Sandra Jones
Asha Jose
Gaurav Joshi
Subhashini Joshi
Manu Juneja
David Jung
Christina Jurotich
Marie Juzans
Stephan Kadauke
Justin Kahla
Bailee Kain
Satoshi Kaito
Brandon Kale
Ecem Kalemoglu
Zeguela Kamagate
Dinisha Kamble
Josette Kamel
Tomasz Kaminski
Yui Kano
Nicole Kantor
Ruhi Kanwar
Wissam Karam
Zuena Karim
Gabriel Karin
Sadik Karma
Imke Karsten
Emiko Kashima
Monisha Kashyap
Joshua Kassner
Shota Kato
Alvin Katumba
Anuj Kaul
Sukhmani Kaur
Padmavathi Kavadipula
Hiroki Kawahara
Shunto Kawamura
Hayato Kawashima
Nozomu Kawashima
Sarah Kayser
David Kegyes
Niklas Kehl
Max Kelsten
Angelina Kendi
Josh Kent
Akhil Kesaraju
Geetha Keshav
Jordan S. Kesner
Sarada Ketharnathan
Samuel Keyes
Elmira Khabusheva
Imaz Khalid
Muhammad Ali Khan
Taha Khan
Hufsa Khan
Muhammad Waqas Khan
Fayaz Khan
Abat Khan
Israr Khan
Rahul Khandekar
Somya Khare
Hargunpreet Kharoud
Chander Perkash Khatri
Sami Khaznadar
Junichiro Kida
Evan Kidder
Sujin Kim
So Jeong Kim
Ye Jun Kim
Kyung Lock Kim
Yejin Andrea Kim
Jowon Laura Kim
Shintaro Kinoshita
Charles Kinzig
Keisuke Kirito
Maria Kislova
Sakura Kito
Musa Kiyani
George Kladis
Miriam Klahr
Tabea Klaus
Tesa Klenovsek
Sun-Hye Ko
Satoshi Koi
Abhishek Vallabhbhai Koladiya
Vladimir Kolyadko
Mayuresh Konde
Tim Kong
Mark Korst
Dimitrios Kotsos
Khouloud Kouidri
Josh Koyyana
Jason Krastein
Sarah Kricheff
Kushal Kriplani
Aishwarya Krishnan
Jayasree Krishnan
Linus Kruk
Bomin Ku
Tomoyo Kubo
Julia Kuehn
Marius Kuelp
Charles Kuhlmann
Monika Kulasekaran
Narender Kumar
Anurag Kumar
Love Kumar
Rupayan Kundu
Cheng-Fu Kuo
Jacob Kurek
Marcel Kusy?
Norberto Kzan
Madeline Labott
Husayn Ladha
Alessandro Lagana
Pedro Luiz Lage Bodour Danielian
Yingjie Lai
Annabel Laidler
Olivia Lambertson
Erica Lamkin
Maria Landwehr
Andrea Lang Goldgewicht
Cara Lange
Tom Lapidus
Audrey Lasry
Rina Latscha
Lisa Latzko
I-Jun Lau
Kire Lau
Madeline Lauener
Lauren Laufer
Henrik Marius Laukli
Anouchka P. Laurent
Patrick Lawrence
John Lazar
Jonathon Le
Catherine Le
Davide Leardini
Marie-Helene Lebel
Hannah Lebensburger
Noemie Leblay
Stella Lee
Wan Hsuan Lee
Lucia Lee
Yoonkyu Lee
Daniel K.C. Lee
Yuan Yee Lee
Julianna Lee
Dana Lee
Nicholas Lee
Ying Lei
Frederick Lemaistre
Mackenzie Lemieux
Jean Lemoine
Ariel Lerner
Etienne Leveille
Julia Lew
Sebastian Leyes Porello
Yan Leyfman
Yiqi Li
Will Li
Yun Li
Wenyu Li
Yaqi Li
Yue Li
Wantong Li
Zeyang Li
Katherine Li
Ruixin Li
Luyuan Li
Chenying Li
Allison Li

Amy Li
Shuning Li
Dong Liang
Ruiqi Liao
Michael Lim
Zhouning Lin
Meiyin Lin
Rick Y. Lin
Cindy Hsin-Ti Lin
Jonathan Lindgren
Lorenzo Lindo
Elizabeth Linton
Frederico Lisboa Nogueira
Rafaella Litvin
Qianlin Liu
Yin Liu
Yingying Liu
Lianxuan Liu
Tengyuan Liu
Qianqian Liu
Fuguo Liu
Jianlin Liu
Vivian Liu
Meng Liu
Yu Liu
Lisa Liu
Anusree Lohithakshan
Iris Lommerse
Paolo Lopedote
Judith Lopez
Naty Lopez Cordova
Alejandra Lorenzen
Feiteng Lu
Michelle Lu
Danny Luan
Brandon Lucari
Kana Lucero
Katia Luciani
Jacob Ludington
Johannes Luebke
Jerry Luo
Owen Luo
Amanda Lussier
Ann Ly
Faye Lynch Williams
Lutfi M.J.
Sirui Ma
Karla Machlab
Ryan Mack
Sandhya Maddali
Masaya Maegaki
Syed Mahamad
Giuseppe Maiocco
Sarah Makhani
Theodore Makler
Panagiotis Malandrakis
Nina Malburg
Aikaterini Mallou
Michael Malloy
Paola Manara
Alessandro Mancini
Pranay Maniar
Fnu Manikanta
Nicholas Manini
Muhammad Shaheer Mannan
Meenakkshy Manoharan
Kirsi Manz
Xinjian Mao
Shahzaib Maqbool
Monia Marchetti
Christian Marinaccio
Sarah Marion
Maxim Maron
Paola Marra
Mariana Marrero Castillo
Antoine Martin
Stephen Martindale
Melanie Martinsen
Alexey Martyanov
Atsushi Marumo
Kevin Marzotto
Michal Masar
Kiyomi Mashima
Ramon Massoni-Badosa
Sahra Mateen
Peyton Mathisen
Abhinav Mathur
Konstantin Matjusinski
Christina Mayerhofer
Rebecca Maynard
Francesca Mazzocco
Federico Mazzon
Abigail McCann
Ellie McCracken
Dustin McCurry
Rabea Mecklenbrauck
Georgio Medawar
Elisa Meddi
Luisa Medeiros
Mariana Medeiros
Muluken Megiso
Vahid Mehrtash
Romy Meier
Juliet Meir
Mark Mendoza
Yamin Meng
Zhe Meng
Tara Menon
Anagha Menon
Ami Merker
Svatava Merkle
David Mery
Rebecca Metellus
Thomas Meyer
Zhimin Miao
Jorne Migchelbrink
Bret Miller
Taylor Mills
Lang Min
Hyder Mir
Abdul Rouf Mir
Avijeet Mishra
Brianna Mitchell
Aminatta Mitchell
Katherine Mnuskin
Reagan Mogire
Safa Mohamad
Mostafa Mohamed
Ayman Mohammad
Ivan Mohammed
Rafael Moisan
Magda Molenda
Jorge Montemayor Mora
Maryam Mooghali
Jessica Moore
Katharine Moosic
Michail Mordvintsev
Yael Morgenstern
Lyra Morina
Johnathan Morris
Joseph Mort
Kristy Moss
Paul Mueller
Roger Mulet-Lazaro
Ryanne Mulligan
Umair Munawar
Ashlie Munoz
Aarya Murali
Nat Murren
Ali Mushtaq
Rohini Muthukumar
Samira Naderinezhad
Kazuki Nagao
Kira Nagoshi
Nikhil Nagpal
Mohamad Ali Najia
Rishi Nanda
Drew Nannini
Sri Harsha Narayana
Saharsh Narayanam
Saad Nasir
Kristina Nasr
Dany Nassar
Aneesha Nath
Vindhya Nawaratne
Vivianne Nelson
Karun Neupane
Carl Jannes Neuse
Rhiannon Newman
Kimberly Newman
Ding Quan Ng
Lay She Ng
Wern Lynn NG
Anh Ngo
Winnie Nguy
Matthew Nguyen
Stefan Niedermeier
Subbaiah Chary Nimmagadda
Hakuei Nishihara
Shunsuke Nishino
Satyavardhan Rao Nittu
Ziyu Niu
Michidai Nobe
Hanne Norseth
Joseph Novak
Tereza Novakova
Aneta Nowicka
Ioannis Ntanasis-Stathopoulos
Jessica Nunes
Jordan Nunnelee
Steve Nwokeocha
Modesty Obasohan
Mario Ochoa Rodriguez
Ivan Odak
Anas Odeh
Afua Ofori-Darko
Olisaemeka Ogbue
Oluwadara Ogunwale
Denis Ohlstrom
Chinenye Okafor
Yoshio Okamoto
Koji Okazaki
Izel Okcu
Yuki Oku
Temiloluwa Okusolubo
Diego Olavarria-Bernal
Ashlyn O'Leary
Olga Oleshko
Elyse Olesinski
Aina Oliver-Caldes
David Orccosupa Quispe
Ysaith Orellana Ascencio
Mark Orland
Angel Luis OROSCO-TTAMINA
Daniela Ortiz Chavez
Matthew Osborn
Jude Ossai
Lena Osswald
Aleksandra Oszer
Albert Owusu-Ansah
Oladayo Oyebanji
Ildem Ozluk
Chioma Ozoalor
Hasan Ozpolat
Emely Pacheco
Daniel Packard
Nilesh Pandey
Arjun Pandey
Kareena Pansuria
Gvantsa Pantsulaia
Marios Papadimitriou
Aayushi Pareek
Jaeyoung Park
Jimin Park
Hyun Sung Park
Chanjun Syd Park
Alexander Parks
Luca Paruzzo
Parina Patel
Zil Patel
Heta Patel
Jeet Patel
Anika Patel
Shivam Patel
Kishan Patel
Ana Patino
Bonell Patino-Escobar
Jeddeo Paul
Allan Pavy
Giacinto Luca Pedone
Joe Pelt
Julia Pennell
Pedro Perez
Claudia Perez Carretero
Olivia Perez De Acha Lopez
Eric Perkey
Chiara Perni
Noe Perron
Luiza Perruso
Holly Pertile
Mareike Peters
Daniel Petersheim
Sarah Peterson
Kirsten Pfeffer
Tuan Phan
Witsanu Phetsai
Benjamin Philipson
Nick Phillips

Daniel Phillips
Marie Piatski
Jonah Pierce
William Pilcher
Kelly Pimenta
Alfredo Pinedo Rodriguez
Elisha Pinker
Sandro Pino-Ascencio
Ted Piorczynski
Chiara Pirillo
Tom Podolsky
Petri Polonen
Lauren Pomerantz
Alexandra Pommier
Harshitha Popuri
Robert Power
Aishwarya Pradeep
Debolina Pramanik
Neha Prasad
Elexis Price
Jacey Pridgen
Shalini Pullarkat
Priyanka Pullarkat
Neha Puttagunta
Zihe Qi
Jiaqian Qi
Hu Qian
Xinmiao Qu
Dan Qu
Bonyan Qudah
Laura Quevedo
Miguel Quijada-Alamo
Haris Qureshi
Ruyan Rahnama
Sandhya Rai
Vincenzo Raimondi
Sabrina Rainey
Nandini Rajaram Siva
Anshul Raman
Veronica Ramirez
Andres Ramirez-Gamero
Nikhil Ranjan
Tabitha Ranson
Fizza Rasheed
Asha Ravichandran
Vishvaas Ravikumar
Arjun Ravishankar
Yazmin Reategui Almonacid
Daniel Rebibo
Faith Reid
Simon Renders
Moritz Renner
Valeria Renola
Matthew Repp
Valentina Restrepo
Laura Reyes-Uribe
Rhys Richmond
Tiff Ricketts
Kristina Rinaldi
Joshua Rivera
Macarena Roa
Mark Robinson
Yara Rodriguez
Martin Rodriguez
Daiana Rodriguez
Sergio Rodriguez-Rodriguez
Hannah Rohdjess
Francesca Romano
Alessandra Romano
Marco Roncador
Rasmus Rønnemoes
Lukas Ronner
Maria Ros
Robert Rosen
Marco Rosichini
Sophia Roush
Justine Roy
Renat Roytenberg
Yuhua Ru
Michelle Rudshteyn Korostin
Federico Ruiz Moreno
Le'Mark Russell
Mysa Saad
Ariana Sabzevari
Rafeh Safdar
Siri Sagedahl
Subhra kamal Saha
Ranjit Sahoo
Wataru Saika
Chiranjeevi Sainatham
Hajime Sakuma
Kiarash Salafian
Ana Salazar
Ruth Salim
Gabriel Salzman
Ravand Samaeekia
Pranav Samineni
Nikhila Sampath Kumar
Noelia Sandoval-Hellin
Chandan Sanghera
Dhruvi Reddy Sanikommu
Alexander Sanjurjo
Uday Aditya Sarkar
Akshat Sarkari
Larissa Sarri Binelli
Yuya Sasaki
Samuel Sassine
Katherine Scarton
Christoph Schaefers
Robert Scheel
Lukas Scheller
Laura Schmalbrock
Tina Schnoeder
Hanna Scholze
Christopher Schorr
Freya Schulze
Anna Schwartz
Elizabeth Schweighart
Viviana Scoca
Amelia Seabold
Tara Sebastian
Emma Self
Murugan Selvam
Sushil Selvarajan
Stephanie Sendker
Abhinav Sengupta
Adi Seri Kanot
Tahereh Setayesh
Zuha Shabbir
Ariel Shaddaie
Veer Shah
Divyash Shah
Tishira Shah
Orthi Shahzad
Farhaz Shaikh
Yue Shang
Morgan Shannon
Jason Shapiro
Mohamed Sharaf
Shikhar Sharma
Toral Shastri
Muhammad Talha Shaukat
Nina Shaver
Jaclyn Shaw
Yifei Sheng
Steven Sher
Ankith Sherapura
Pranay Shettywarangale
Shuyu Shi
Kayleen Shi
Vivian Shim
Young Jun Shim
Koki Shimizu
Michiho Shindo
Sumito Shingaki
Yuto Shioiri
Haruki Shirozu
Samuel Short
Isabel Shrestha
Asmita Shukla
Evgenii Shumilov
Shaheen Siddiqui
Ronald Siebenaler
Ariel Siegel
Byron Sigel
Ruth Sikora
Rodrigo Silva-Aguiar
Alexander Silver
Martha Sim
Giulia Simini
Daniel Simpson
Ilias Sinanidis
Rhea Singh
Varsha Singh
Upendra Singh
Amritpal Singh
Jivtesh Singh
Pranav Singh
Krissana Singh
Gunin Singhal
Adit Singhal
Maria Sirenko
Ayyanar Sivanantham
Barath Sivasubramanian
Dominic Skeele
Emilie-Charlot Skerbek
Jackson Smith
Matthew Smith
Arianna Smith
Abigail Sneider
Ingridy Sodre da Costa Bonfim
Haris Sohail
Zeeshan Solangi
Eirini Solia
Majeela Solomon
Mahfuza Afroz Soma
Shivapriya Somasundaram
Alba Sommerschield
Anya Sondhi
Minjae Song
Qingxiao Song
Anushri Soni
Pavan Sonnenahalli Rudramurthy
Dhriti Sood
Mohammad Ahsen Soomro
Eli Soyfer
Manuela Spadea
Penny Sparkes
Nikolaos Spyrou
Ramaditya Srinivasmurthy
Harshini Sriram
Ananta Manjula Hasini Sriram
Sooraj Srirangadhamu Gopu
Noura Srour
Laurenz Steiner
Sophia Stock
Jonathan St-Onge
Charlotte Story
Jack Stover
Alexander Streuer
Jack Stylli
Shengqin Su
Sofie Subiaur
Kumar Subramani
Arjun Surya Subrramanya
Takeshi Sugio
Sujata
Paula Sulikowski
Mamta Sumi
Ruifeng Sun
Hao Sun
Ryan Sun
Arvind Suresh
James Swann
Farzeen Fatma Syed
Farzeen Syed
Katarzyna Szoltysek
Jason Ta
Areya Tabatabai
Aniketh Tadepalli
Lauren Tagliaferro Epler
Amy Tai
Honoka Takahashi
Kensuke Takaoka
Reina Takeda
Nana Talvard-Balland
Yoko Tamamushi
Melody Tan
He Tan
Kiyoto Tanaka
Xinzhu Tang
Adarsh Vardhan Tangella
Carmela Tangredi
Misbah Tariq
QI Tatarata
Samantha Tauchmann
Urbain Tauveron-Jalenques
Samuel Taylor
Toshiki Terao
Steven Tessier
Sabrina Testa
Jesse Tettero
Mohamad Ali Tfaily
Rahul Thakur
Alexandra Thalberg
Rohit Thalla
Serena Tharakan
Hishan Tharmaseelan

Apoorva Thatavarty
Foteini Theodorakakou
Haley Thigpen
Anna Thommen
Zanshe Thompson
Helen Tian
Bernadette Tiberi
Natalia Timofeeva
Joyce Tiong
Tanatuch Tiratrakoonseree
Tobias Tix
An To
Joshua Tobin
Yusuke Toda
Rosa Toenges
Masanori Toho
Chiara Tomasoni
Emily Tomlinson
Connor Tompkins
Mariya Tomy
Gigi Nu Hoang Quy Ton
Peter Tonzi
Esteban Toro Velez
Astrid Hundeboell Torpe
Aimee Tran
Rashmi Tresa Philpose
Emily Tsai
Daniel Tsai
Nicole Tseng
Ioanna Tsialta
Princess Della Tsivor
Nolan Tucker
Gurcan Tunali
Lauren Turecki
Ekrem Turk
Eno-obong Udoh
Chidiebube Ugwu
Fahd Umar
Julia Unglaub
Serhan Unlu
Amog Urs
Daniela Urueta Portillo
Kanishka Uttam Chandani
Lukas Vacek
Daniel Vail
Lizbeth Valdez Jacobo
Maithri Vallabhaneni
Isabel Vallecillo-Viejo
Anne van Kuijk
Vandana
Aida Vanderpuye
Nikhil Vasudeva
Ishaan Vaswani
Alessandra Vatteroni
Akhil Deepak Vatvani
Jorge Vazquez-Urrutia
Charan Vegivinti
Lakshmi Chandana Velaga
Pilar Velarde
Vanessa Velazquez
Ivo Veletic
Carolina Velez-Mejia
Venu Venkatarame Gowda Saralamma
Federica Vento
Christina Verbruggen
Nikki Verma
Jennifer Vidler
Heidi Vieira
Claudia Villa Celi
Elena Vivona
Manjuprasanna Voddarahalli Nagaraju
Nikhil Vojjala
Jan Vorwerk
Aikaterini Voulgaridou
Laure Vreux
Meesha Vullikanti
Sireesha Vutukuri
Morgan Walcheck
Anushka Walia
Kamalpreet Walia
Yishan Wang
Yidan Wang
Qi Wang
Steven Wang
Alice Wang
Hua Wang
Guangqi Wang
Tiantian Wang
Jie Wang
Shuyang Wang
Yizhen Wang
Leyu Wang
Shijing Wang
Hanyu Wang
Zhe Wang
Ao Wang
Luxiang Wang
Rong Wang
Xu WANG
Jacqueline Wang
Zhe Wang
Bret Wankel
Emily Ward
Fiona Watt
Samuel Weeks
Kristin Weeks
Graham Wehmeyer
Yujun Wei
Ruowen Wei
Joshua Weinreb
Chloe Wells
Jing Wen
Diguang Wen
Frank Wen
Xuan Wen
Annika Werly
Justin Wheat
Rikki Williams
Thomas Wiseman
Marcin Wlodarski
Sophie Wollnitza
Marta Wolosowicz
Caroline Wong
Daniel Wronski
Jieya Wu
Xiya Wu
Kefei Wu
Xiancheng Wu
Christine Wu
Rebecca Wurm-Kuczera
Naomi Xiao
Michael Xiao
Min Xiao
Yankai Xiao
Alexander Xiao
Jiayi Xie
Xinyi Xiong
Barbara Xiong
Jingyu Xu
Yiyang Xu
Jia Xu
Ran Xu
Jane Xu
Xiyue Xu
Yaqun Xu
Chengyang Xu
Miao Xu
Changwen Xue
Tomohiro Yabushita
Tara Chand Yadav
Umesh Yadav
Zak Yaffe
Alexandra Yakusheva
Yuta Yamada
Yoh Yamaguchi
Akira Yamamoto
Ikumi Yamanaka
Yusuke Yamashita
Nusrat Jahan Yamim
Qi Yan
Wenqiang Yan
Kensuke Yanashima
Sizhe Yang
Wenbin Yang
Xingcheng Yang
Mengya Yang
Yichan Yang
Zining Yang
Zhe Yang
Xuejing Yang
Yihan Yang
Yuan Yao
Farah Yassine
Yingying Ye
Yao Yu Yeo
Joshua Yi
Tiankai Yin
Tianhao Yin
Jie Yin
Wu Yixuan
Taishi Yonezawa
Jihye Yoon
Futoshi Yoshino
Deyan Yosifov
Aijing You
Muhammad Yousaf
Ayman Youssef
Youssef Youssef
Heye Yu
Jinglei Yu
Hongyin Yu
Mengyao Yuan
Kyle Yuan
Abdel Rahem Yusuf
Eesha Zaheer
Fahad Zamir
Diana Zamora Quintanilla
Tanja Zamrik
Michael Zargari
Chandan Zha
Dewen Zhan
Senlin Zhang
Beatrice Zhang
Wanying Zhang
Xiaoxu Zhang
Xuan Zhang
Xiaoshuai Zhang
Runqing Zhang
Jie Zhang
Ruoxuan Zhang
Cindy Zhang
Xiaoyan Zhang
Chunyi Zhang
Pu Zhang
Zixuan Zhang
Yinqiang Zhang
Qiongdi Zhang
Chaowei Zhang
Jing Zhang
Zishan Zhang
Yongping Zhang
Qiqi Zhang
Mingying Zhang
Zilu Zhang
Michelle Zhang
Bihuan Zhao
Yanmin Zhao
Huanbin Zhao
Xintong Zheng
Yiqiu Zheng
Hannah Zhong
Ling Zhong
Lu Zhou
Jieqiong Zhou
Yile Zhou
Kehua Zhou
Xiaoqin Zhu
Yiyan Zhu
Shicong Zhu
Jintao Zhu
Qilin Zhuang
Rebecca Zhuang
Tony Zhuang
Katherine Zhuo
Victor Zibara
Klaudia Zielonka
Markie Zimmer
Jan Zlamal
Julian Zoller
Ken Zou
Yingling Zu
Angela Theresa Zuffo Yabrude
Hadil Zureigat
Maud Zwolsman

SAVE THE DATE

#ASH27

69th ASH® Annual Meeting and Exposition

DECEMBER 4–7, 2027 | SAN DIEGO, CA

View key dates and plan early:
hematology.org/annualmeeting



AMERICAN SOCIETY OF HEMATOLOGY 68TH ASH® ANNUAL MEETING AND EXPOSITION

MEETING DATES: DECEMBER 12-15, 2026

GENERAL INFORMATION

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

PURPOSE OF ASH SCIENTIFIC AND EDUCATIONAL MEETINGS

The mission of the American Society of Hematology (ASH) is to foster high-quality, equitable care, transformative research, and innovative education to improve the lives of patients with blood and bone marrow disorders. In accordance with this mission, the primary purpose of scientific meetings organized by ASH, including the Society's annual meeting, is to facilitate the global exchange of scientific information and clinical results related to the field of hematology. Another important goal of ASH-organized meetings is to assist physicians and scientists in developing and maintaining academic collaborations that will generate new knowledge, ultimately benefiting patients.

At this year's annual meeting, ASH will continue to offer an inclusive environment for all participants, including a focus on making the in-person meeting in New Orleans and the virtual platform as accessible as possible for attendees with disabilities. ASH will offer mobility, vision, hearing, and other resources as needed. For more information or for questions regarding these services, please contact *accessibility@hematology.org*.

TWO WAYS TO ATTEND THE 68TH ASH ANNUAL MEETING

ASH is pleased to continue to offer the 68th ASH Annual Meeting and Exposition as a hybrid experience where participants can decide to attend in person in New Orleans or participate using ASH's virtual platform. All participants, regardless of location, will have access to the virtual platform built for learning, collaboration, and networking. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual platform, and attendees will have the ability to ask questions and participate in real time.

REGISTRATION

ASH is offering multiple registration options for the annual meeting. Both in-person and virtual registration packages include access to sessions, Q&A, networking, CME/MOC, exhibit halls, and more. If an attendee chooses to participate in person, they will also receive complimentary access to the virtual platform through January 1, 2027.

Registration is available now at *hematology.org/meetings/annual-meeting/registration-information*. Those who have previously registered may upgrade their subscription to extend their access to the meeting's virtual platform at any time by contacting the Registration Center.

IN-PERSON MEETING

When you register for the in-person meeting, you will receive complimentary access to the virtual platform through January 1, 2027. In-person registrants have the option to extend their access to the virtual platform for an additional fee.

VIRTUAL REGISTRATION ACCESS OPTIONS

The virtual meeting packages were designed to give attendees maximum flexibility. Most sessions offered at the in-person meeting will be broadcast simultaneously on the virtual platform, and attendees will have the ability to ask questions and participate in real time. The platform will also include on-demand recordings of all sessions (unless otherwise noted), as well as access to networking opportunities, exhibits, and more.

- **Real-Time Experience: Access through January 1, 2027**

  Provides access during peak dates and hours of the meeting with the largest number of participants at a given time, maximizing opportunities for interactions and networking. CME/MOC credits can be claimed through April 9, 2027 by viewing the qualifying sessions on the virtual platform.

- **Extended Flexibility: Access through February 1, 2027**

  Provides ongoing access to continue watching on-demand sessions after the meeting ends. CME/MOC credits can be claimed through April 9, 2027 by viewing qualifying sessions on the virtual platform.

- **Best Value: Access through March 1, 2027**

  Provides maximum flexibility to continue accessing on-demand sessions at the best price per day of access. CME/MOC credits can be claimed through April 9, 2027 by viewing qualifying sessions on the virtual platform.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

LATE PURCHASE REGISTRATION FEES (BEGINNING OCTOBER 23)

Registration Category	In-Person or Real-Time Experience (Virtual access through January 1, 2027)	In-Person or Virtual Extended Flexibility: (Virtual access through February 1, 2027)	In-Person or Virtual Best Value: (Virtual access through March 1, 2027)
Member (Active and International)	$1,000	$1,100	$1,200
Non-Member	$1,900	$2,000	$2,100
Associate or International Member	$175	$200	$225
Medical Student, Graduate Student, or Resident Member	$175	$200	$225
Non-Member in Training*	$275	$300	$325
Allied Health Professional	$900	$1,000	$1,100
Spouse/Guest (in person only)	$175	NA	NA
Honorary/Emeritus (before 1/1/15)	$0	$50	$100
Honorary/Emeritus (after 1/1/15)	$175	$200	$225
Non-Profit Patient Advocacy Organization Representative **(Application for approval is required in advance)**	$0	$0	$0

* Advance registration rates for Non-Members in Training are available through December 1, 2026.

BADGE COLORS

Each badge holder at the ASH annual meeting is color-coded for easy identification of participants:

Member .....Red
Non-Member .....Green
Associate Member.....Blue
International Associate Member .....Blue
Non-Member in Training .....Blue
Graduate/Medical Student Member .....Blue
Resident Member.....Blue
Honorary/Emeritus Member .....White
Allied Health Professional.....Purple
Exhibitor Booth Personnel .....Black
Spouses/Guest.....Yellow
Media.....Orange

BADGES

Badges will be mailed in advance of the meeting to North American attendees who have registered by October 21. International attendees may pick up their badge at either the Louis Armstrong International Airport or the Ernest N. Morial Convention Center Great Hall Foyer. Your name badge contains a barcode that stores your name and address provided at the time of registration. It can be used by the exhibitors, with your consent, to register your visit to their booths and to send you additional information on their products and services. Your name badge also provides the information you require to access CME stations or receipt stations.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

OVERVIEW OF THE MEETING SCHEDULE
PREVIEW DAYS: DECEMBER 9-10, 2026

Beginning December 9, 2026, the ASH annual meeting virtual platform will be available to all registered participants at *annualmeeting.hematology.org.*

All registered attendees are encouraged to log in early to get acquainted with the site's navigation.
To log into the platform, you will need your ASH username and password used to register for the meeting.

WHO TO CONTACT

If you are having difficulty accessing the meeting's virtual platform, please contact the ASH Customer Service department by emailing *customerservice@hematology.org* or calling 866-828-1231 (U.S. toll free) or 001-202-776-0544 (for International callers), Monday through Friday, from 8:30 a.m. to 5:00 p.m. Eastern time.

Over the dates of the meeting, extended customer service hours will be offered; please visit *hematology.org/contact-us* for specific hours. If you have successfully accessed the meeting's virtual platform but are having difficulty with one of its features, please use the online support form feature within the platform for technical assistance.

FRIDAY-ONLY PROGRAMMING: DECEMBER 11, 2026

There are pre-meeting activities scheduled on Friday, December 11, 2026.

- Friday Satellite Symposia
- ASH-a-Palooza
- Scientific Workshops

Refer to schedule at-a-glance or the mobile app for specific session times.

OFFICIAL MEETING DAYS: DECEMBER 12-15, 2026

The 68th ASH Annual Meeting and Exposition will take place December 12-15, 2026, in New Orleans, Louisiana, and on the meeting's virtual platform. All times listed reflect the Central time zone.

Saturday, December 12	Refer to schedule-at-a-glance or the mobile app for specific session times.
Sunday, December 13	Refer to schedule-at-a-glance or the mobile app for specific session times.
Monday, December 14	Refer to schedule-at-a-glance or the mobile app for specific session times.
Tuesday, December 15	All sessions will occur in the Marquee Session Room beginning at 7:30 a.m. The meeting concludes at 1:00 p.m.

All sessions will be presented at the in-person meeting in New Orleans and, unless otherwise noted, all events will stream simultaneously on the virtual platform. Session recordings will be available on demand on the virtual platform for the duration of your registration package. Scientific Workshops will be available until January 1, 2027.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

CATCH UP DAYS: DECEMBER 16-18, 2026

After the official dates of the annual meeting, ASH Poster Walks will be held on Wednesday, December 16, on the meeting's virtual platform.

BINGE WATCHING—CATCH UP ON CONTENT

Participants will also be able to watch presentation recordings on demand for sessions and posters that were presented earlier in the meeting through the end of their virtual meeting registration package.

NETWORKING

ASH understands that connecting with colleagues is one of the most important reasons that people love attending the ASH annual meeting. In New Orleans, small gathering and seating areas will be available indoors and outdoors to informally meet with colleagues. ASH's virtual platform makes connecting with colleagues in New Orleans and all around the world easy. On the meeting's virtual platform click on Networking to connect with your peers.

ASH SOCIAL MEDIA WALLS

Take a break from the science and visit the ASH Social Media Walls located on the meeting's virtual platform and throughout the center to view and contribute to a real-time scientific conversation and engage with colleagues on a variety of topics.

SPEAKER INFORMATION

SPEAKER READY ROOM

The Speaker Ready Room will be located in ASH Central in Hall D at the Ernest N. Morial Convention Center. All times are in Central time

Speaker Ready Room Hours

Thursday, December 10 . . . . 3:00 p.m. – 6:00 p.m.
Friday, December 11 . . . . . 7:00 a.m. – 6:00 p.m.
Saturday, December 12 . . . . 7:00 a.m. – 6:00 p.m.
Sunday, December 13. . . . . 7:00 a.m. – 6:00 p.m.
Monday, December 14 . . . . . 7:00 a.m. – 6:00 p.m.
Tuesday, December 15 . . . . . 7:00 a.m. – 11:00 a.m.

All speakers should bring a copy of their presentation to the Speaker Ready Room on a CD-R, DVD-R, or USB flash drive (memory stick, jump drive, etc.). A professional audio-visual (AV) technician will be available to consult with you on any of the guidelines and to make certain your slides are properly identified for your specific session. Please turn in your presentation to the Speaker Ready Room according to the following guidelines:

24 hours before your presentation if you would like the AV technician to assist you in formatting your presentation to ensure clear and readable images.

24 hours before your presentation, if your PowerPoint presentation was prepared on an Apple computer.

At least 6 hours before your presentation if your presentation contains movies or other videos.

At least 4 hours before your presentation if your presentation is final and requires no modifications.

CONFLICT-OF-INTEREST POLICY

ASH is committed to providing quality, objective, balanced, and scientifically rigorous continuing medical education activities that are free from commercial and non-commercial bias. In accordance with the rules of the Accreditation Council for Continuing Medical Education (ACCME), all meeting session chairs, speakers, and moderators are required to disclose in writing any financial relationships they may have prior to the meeting. All poster presenters are required to disclose in writing any financial relationships they may have prior to the meeting and display their disclosures as a part of their poster presentation. If bias, actual or perceived, occurs during the presentations, session attendees are encouraged to address such bias during the question-and-answer periods following the presentations.

All ASH annual meeting presenters (including chairs, speakers, and moderators) are asked to disclose any relationships of the following types: Employment, Consultancy, Equity Ownership, Research Funding, Honoraria, Patents & Royalties, Speakers Bureau, Membership on an entity's Board of Directors or advisory committee, and any other financial relationship.

Any questions about this policy or concerns regarding disclosures should be directed to *CME@hematology.org*.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

CONTINUING MEDICAL EDUCATION INFORMATION

EDUCATIONAL OBJECTIVES

Upon completion of this educational activity, participants should be able to:

- Employ the knowledge gained regarding the diagnosis and treatment of classical and malignant hematologic disorders to improve patient care;
- Discuss state-of-the-art research in hematology; and
- Analyze the potential contribution of novel, not-yet-approved modalities of therapy to current evidence-based management of hematologic disorders.

ACCREDITATION

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Hematology designates this Other [blended live and on-demand content] activity for a maximum of **90 *AMA PRA Category 1 Credits***™. Physicians should claim only the credit commensurate with their participation in the live activity.

CME CERTIFICATE ELIGIBILITY

ASH is accredited to provide ***AMA PRA Category 1 Credits***™ to physicians only. The American Medical Association (AMA) defines physicians as those individuals who have obtained an MD, DO, or equivalent medical degree from another country.

Physicians not licensed in the United States who participate in this CME activity are also eligible for ***AMA PRA Category 1 Credits***™.

HOW TO OBTAIN A CME CERTIFICATE

A processing fee of $50 will be charged for CME certificates. Attendees must complete the Annual Meeting Evaluation Surveys to claim their CME credits and print their CME certificates through the ASH website (*www.hematology.org*) by clicking the CME link on the homepage. **The online process for claiming CME credits and printing a CME certificate for the 68th ASH Annual Meeting must be completed no later than April 9, 2027.**

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **90** MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Attendees will earn MOC points equivalent to the amount of CME credits claimed for the activity. In addition to completing the evaluation survey, attendees must submit a reflective statement on how they intend to change their practice based on the knowledge gained from participation in the meeting. Attendees must also provide their ABIM number and date of birth. Upon review and approval of the reflective statement, points will be submitted to the ACCME by ASH and will appear in the ABIM Physician Portal within 48 hours. Points will only be submitted if all the steps are completed. **To receive ABIM MOC points for the 68th ASH Annual Meeting, the online process for claiming CME/ABIM MOC credits must be completed by April 9, 2027.** By requesting MOC points through ASH's CME Portal, learners agree to allow ASH to share completion/participation information with ABIM via ACCME's program and reporting system.

CERTIFICATE OF PARTICIPATION

Non-physicians and other health-care professionals attending the meeting may print a Certificate of Participation **after** completing the Annual Meeting Evaluation Surveys through the ASH website *(hematology.org)* beginning Saturday, December 12, 2026. The online process of **filling out the annual meeting survey and printing the certificate must be completed no later than April 9, 2027.**

There is no charge to meeting registrants for this service.

EUROPEAN BOARD OF ACCREDITATION IN HEMATOLOGY CME CREDIT

ASH is applying for accreditation with the European Board of Accreditation in Hematology (EBAH). If you plan to claim EBAH-CME credit for attending the meeting, please check the appropriate box during the registration process or after the meeting in the online evaluation site. There is no fee required in order to be eligible for EBAH-CME Credit Points. For additional information about EBAH-CME Credit points, visit the EBAH website *(ebah.org)*. For information about claiming EBAH CME for the 68th ASH Annual Meeting email *cme@hematology.org*.

QUALIFYING ACCREDITED SESSIONS

Attendees can claim CME for viewing qualifying sessions as they are broadcast in-person and on the virtual platform. Credit can also be claimed for viewing qualifying sessions on the platform after they have concluded.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

ATTENDEE SERVICES

ASH CENTRAL

ASH Central, a place where hematologists can gather to collaborate, is located in Hall D at the Ernest N. Morial Convention Center. Within ASH Central, you can learn about ASH membership, purchase ASH products at the ASH Store, or donate to the ASH Foundation. The following resources are also offered at ASH Central: the ASH Studio, fASHion boutique for the hematologist with style, smASH Pickleball, ASH Store, Collaboration Rooms, Headshot Alley, Photo Zone, Power Nap @ ASH, Trainee Lounge, and the ASH Wellness Studio. Additional seating and charging areas are also offered in ASH Central.

ASH Studio

The ASH Studio hosts brief, targeted talks that focus on removing barriers to high-quality care, principles of medical education, and cutting-edge teaching techniques. These sessions will include short presentations by an in-person speaker followed by an interactive discussion. These micro-sessions will also be available on the virtual platform.

ASH Store

ASH offers a variety of products to aid hematologists in their professional development. Stop by to peruse the latest ASH educational products, which will be available for a discounted on-site rate. These items will also be available for purchase in the online ASH Store at *hematology.org/Store.*

ASH Wellness Studio

In between sessions and throughout the day, ASH will feature informal micro-learning workshops on various aspects of resiliency and wellness in the ASH Wellness Studio, where there will be short presentations and stand-up audience participation. Topics in the studio will be geared towards helping professionals attain a balanced, productive, and healthy work life balance through wellness.

Collaboration Rooms

Small conference rooms will be available for attendees to meet and collaborate in a more private setting. These small conference rooms, equipped with a table, chairs, flat screen monitor, and a cable to connect your own laptop to the monitor, can accommodate groups of up to 20 people and are free to reserve for up to 45 minutes. Each reservation starts at the top of the hour and lasts 45 minutes and each attendee will be limited to one 45-minute reservation per day. For the courtesy of all attendees, multiple back-to-back reservations cannot be accommodated. Outside food and beverage and/ or additional audiovisual equipment may not be brought into a Collaboration Room. Visit the ASH website *(hematology.org)* via the mobile application or the Collaboration Room Help Desk in Hall D to reserve a Collaboration Room..

Collaboration Room Hours

Friday, December 11 . . . . . 7:00 a.m. – 5:45 p.m.
Saturday, December 12 . . 7:00 a.m. – 5:45 p.m.
Sunday, December 13 . . . 7:00 a.m. – 5:45 p.m.
Monday, December 14 . . . 7:00 a.m. – 5:45 p.m.
Tuesday, December 15 . . 7:00 a.m. – 12:45 p.m.

fASHion

For the hematologist with style! Visit the fASHion boutique for ASH-branded apparel, ranging from outerwear, athletic wear, golf polos, hematology specialty socks, bow ties, neck ties, scarves, and kids' apparel, too. Items will be available for purchase in an array of sizes while supplies last.

Headshot Alley

Need a new professional headshot? Get one for free at Headshot Alley in ASH Central. Your headshot will be sent to you via email for immediate download.

Photo Zone

Capture the excitement of the annual meeting with your friends and colleagues by taking a photo in the ASH photo zone, located in ASH Central. Various props and backdrops will be available and will change daily.

Trainee Lounge

Attendees with a blue badge are invited to visit the Trainee Lounge in ASH Central, a relaxing place for trainees to meet with colleagues and recharge with complimentary refreshments.

ASH ATTENDEE TECHNOLOGY TO ENHANCE YOUR EXPERIENCE

Meeting Wi-Fi

To increase the protection and security of Wi-Fi for users, ASH will require users to enter a password to gain access to the exclusive Wi-Fi network.

The Wi-Fi network name (SSID) is **ASHMEETING** and the password is **hematology**. The password is all lower-case letters. After entering this password once, the Wi-Fi network should recognize your device without having to enter the password again—however, if you switch devices, you will need to enter the password again.

ASH Meeting Navigator

New this year ASH has built a personalized online tool to help attendees navigate content presented at this year's meeting. Features will include session recommendations based upon your clinical and research interests, the ability to ask specific questions about the program, and a schedule planner that integrates with the ASH Mobile App. Visit *navigator.hematology.org* for a personalized ASH meeting experience.

Mobile App

ASH's mobile application will provide program and exhibitor information, messaging capability, and general information happening with the 2026 annual meeting. The application includes the full text of the abstracts and the articles available in *Hematology 2026* (the ASH Education Program). The application will allow users to add a session to their device's calendar which will build their itinerary for the meeting. A login is no longer required to view application content; a login is only required to contact other attendees and view Education Program articles.

ASH FOUNDATION DONOR LOUNGE

Gifts of all amounts to the ASH Foundation are always helpful and appreciated. With cumulative annual giving of $250 or more, you can access the ASH Foundation Donor Lounge during the annual meeting. Please visit the ASH Foundation page for more

information. The Donor Lounge will be located in Ma Maison located above the Hall C Lobby Atrium Food Court in the Ernest N. Morial Convention Center.

ASH MANAGEMENT OFFICE

The ASH Staff Office is located in Room 238-239 on the second level of the Ernest N. Morial Convention Center.

ASH PARK @ THE PLAZA

ASH Park @ the Plaza will be located in three distinct locations: Magnolia Porch, Heritage Porch, and Live Oak Porch along Convention Center Boulevard in front of the Ernest N. Morial Convention Center. These areas will feature early morning yoga, lunchtime entertainment, life-sized games, and lounge furniture. There will also be ample seating and tables outdoors for those who wish to take a break and enjoy the New Orleans sunshine.

BUSINESS CENTER

The Ernest N. Morial Convention Center has a UPS Store that provides full-service business needs for your convenience located in Lobby F of the convention center. UPS provides attendees with photocopying, faxing, computer workstations, and printing services. Office supplies are also available for purchase.

CHILD CARE ROOM

ASH has once again made arrangements with KiddieCorp to provide child-care services for children ranging in age from 6 months to 12 years at the meeting. KiddieCorp has been caring for children at the ASH annual meeting for over 25 years and offers a wide range of activities to keep children entertained while you attend the ASH sessions. KiddieCorp staff come prepared with age-appropriate games, souvenir arts and crafts projects, toys, and entertainment. KiddieCorp staff members are bonded and trained childcare specialists. Additionally, KiddieCorp utilizes a photo identification system to check your child in and out of the room. There will also be a refrigerator in this room for nursing mothers to store milk after using the nursing mothers' rooms. The deadline for reserving space for your child is November 13.

The cost for child-care service is completely free and is subsidized by ASH, however a cancellation penalty will be assessed if you cancel after the November 13 pre-registration deadline. Snacks, light meals, and beverages will be provided each day. Pre-registration is recommended to ensure participation. This service will be available from Friday, December 11, through Tuesday, December 15.

The child-care room is located in Rooms 397-399 of the Ernest N. Morial Convention Center.

Child Care Room Hours

Friday, December 11 . . . . . 6:30 a.m. – 7:30 p.m.
Saturday, December 12 . . 6:30 a.m. – 7:30 p.m.
Sunday, December 13 . . . 6:30 a.m. – 8:00 p.m.
Monday, December 14 . . . 6:30 a.m. – 8:00 p.m.
Tuesday, December15 . . . 7:30 a.m. – 1:30 p.m.

COAT/BAG CHECK

Complimentary coat and bag check is available in the Rivergate Room and Hall G Lobby of the Ernest N. Morial Convention Center. Electronic items will not be accepted.

Coat/Bag Check Hours

Friday, December 11 . . . . . 7:00 a.m.* – 6:30 p.m.
Saturday, December 12 . . 7:00 a.m. – 8:00 p.m.
Sunday, December 13 . . . 7:00 a.m. – 8:30 p.m.
Monday, December 14 . . . 7:00 a.m. – 8:30 p.m.
Tuesday, December 15 . . 7:00 a.m. – 2:00 p.m.
*(Rivergate Room location opens at 1:00 p.m. on Friday)

FRIENDS OF BILL W.

A meeting room for the Friends of Bill W. is located in Room 203 at the Ernest N. Morial Convention Center.

HEMATOLOGY MEETUPS

To encourage interaction among attendees, Hematology MeetUp areas consisting of public meeting spaces with chairs and tables will be placed throughout the convention center.

Where possible and permissible, portable concession carts will be located nearby offering coffee and quick grab-and-go food. These locations will be indicated on the campus maps so that attendees can coordinate meeting up with each other at a specific location.

INTERNET STATIONS

Internet Stations are placed throughout the Ernest N. Morial Convention Center. Attendees can utilize the Internet and do any of the following at all Internet Stations:

- Check email
- Print a boarding pass
- Print a registration receipt
- Access ASH Job Center
- View the Annual Meeting Program online
- Complete the Meeting Evaluation
- Obtain a Certificate of Attendance
- Register for the ASH Foundation Run/Walk (up to 6:00 p.m. on Saturday night)

LOST AND FOUND

Contact the ASH Security Main Office for all lost items and inquiries. The ASH Security Main Office is located in Room 206 of the Ernest N. Morial Convention Center.

NURSING MOTHERS' LOUNGES

Dedicated lounges will be available for nursing mothers in safe, accessible areas throughout the Ernest N. Morial Convention Center and Hilton New Orleans Riverside. Each nursing mothers' lounge will provide a private, comfortable area equipped with lockable doors, furniture, and power outlets to use for pumping sessions during the ASH annual meeting.

There is also a complimentary refrigerator located in the Child Care Room, Rooms 397-399 at the Ernest N. Morial Convention Center.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Nursing Mothers' Lounges Locations

Ernest N. Morial Convention Center:

- Hall B Lobby existing Nursing Room
- Hall H Lobby existing Nursing Room
- Built Office Outside of Room 257

Hilton New Orleans Riverside

- Built Office on Level 1 near Grand Salon

QUIET ROOMS

Two quiet rooms are located in the Ernest N. Morial Convention Center. Room 232 is designated as the Female Quiet Room and Room 231 is designated as the Male Quiet Room.

PRESS COMPLEX

The Press Complex, open to registered members of the media, is located in Rooms 356-357 at the Ernest N. Morial Convention Center.

Press Room Hours

Friday, December 11 . . . . . 9:00 a.m. – 5:00 p.m.
Saturday, December 12 . . . . 7:00 a.m. – 6:00 p.m.
Sunday, December 13. . . . . 7:00 a.m. – 6:00 p.m.
Monday, December 14 . . . . . 7:00 a.m. – 6:00 p.m.
Tuesday, December 15. . . . . 7:00 a.m. – 1:00 p.m.

RESTAURANTS/CONCESSIONS

Consult the ASH Campus Map and ASH Food Guide for detailed information regarding concessions and dining options throughout the Ernest N. Morial Convention Center. The map will provide information on what type of food is available where so that you can easily find meals and snacks throughout the ASH campus.

TRAVEL INFORMATION AND OFFICIAL SHUTTLE SERVICE

VISITOR SAFETY

To stay safe during your visit to New Orleans, please follow the tips provided below:

Never hand your phone to someone else (i.e. handing to an Uber or Taxi driver to show them directions or asking a stranger to take your photo).

Always lock your front and/or patio doors in your hotel room. Use the safety chain/lock for security.

Never open your room door unless you know who is there. If you did not call for the hotel service offered by the person at the door, call hotel security or the front desk to see if they have sent someone to your room.

Place valuables in a safety deposit box in your room or at the hotel office. Do not leave valuables in your car.

When checking into a hotel, consult the floor plan on the back of your room door to familiarize yourself with fire and emergency exits.

When driving, keep all car doors locked.

SHUTTLE SERVICE

ASH will provide complimentary shuttle service between most hotels in the ASH housing block and the Ernest N. Morial Convention Center; additionally, 13 hotels are within walking distance of the Ernest N. Morial Convention Center.

Shuttle Boarding Locations

- Routes 1–8 Convention Center Transportation Hub across from Hall G
- Routes 9–14 Convention Center Parking Lot G across from Halls I-J

Shuttle Hours

Thursday, December 10 . . . . No shuttle service
Friday, December 11 . . . . . 6:30 a.m. – 10:30 p.m.
Saturday, December 12 . . . . 6:30 a.m. – 9:30 p.m.
Sunday, December 13. . . . . 6:30 a.m. – 9:30 p.m.
Monday, December 14 . . . . . 6:30 a.m. – 9:30 p.m.
Tuesday, December 15. . . . . 6:30 a.m. – 2:00 p.m.

Service frequency will vary throughout the day. Look for detailed shuttle bus schedules in each hotel lobby.

Service will not be provided for the following hotels, located within walking distance of the Ernest N. Morial Convention Center:

- Cambria New Orleans Downtown Warehouse District
- Courtyard New Orleans Warehouse Arts District
- Embassy Suites New Orleans Convention Center
- Hampton Inn & Suites New Orleans Convention Center
- Higgins Hotel New Orleans
- Hilton Garden Inn New Orleans Convention Center
- Hyatt Place New Orleans Convention Center
- Marriott New Orleans Warehouse Arts District
- Mercantile Hotel New Orleans
- Renaissance New Orleans Arts Warehouse District
- Riverfront Hotel New Orleans
- Sonesta ES Suites New Orleans Convention Center
- SpringHill Suites New Orleans Warehouse Arts District

AIRPORT SHUTTLE INFORMATION

The official shuttle provider, Kushner & Associates, will offer one-way direct shuttle service every 30 minutes from the Ernest N. Morial Convention Center to the New Orleans International Airport during the days and times indicated below.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Tickets are sold on site at the ASH Airport Shuttle Desk in the Hall G Lobby of the Ernest N. Morial Convention Center. Tickets cost $20 (credit card only).

Tickets Sales Hours

Monday, December 14 . . . . . 9:00 a.m. - 7:00 p.m.
Tuesday, December 15 . . . . . 7:00 a.m. - 1:45 p.m.

Shuttle Hours

Monday, December 14 . . . . . 12:00 noon - 6:00 p.m.
Tuesday, December 15 . . . . . 9:00 a.m. - 2:00 p.m.

Departure Location: Ernest N. Morial Convention Center, buses load in the transportation hub outside of Hall G.

PARKING

On-site private vehicle parking is available at the Ernest N. Morial Convention Center as well as nearby parking options that serve the Downtown New Orleans area. For detailed parking information, visit *mccno.com/gettinghere*.

GETTING AROUND

The area's public transportation system, New Orleans Regional Transit Authority Bus Service, has routes servicing the New Orleans Convention Center with connections to the New Orleans International Airport and downtown New Orleans. To plan your journey and obtain the latest fares, visit *norta.com*.

Taxis in New Orleans are billed using a base fare of $3.50 with a $2.40 per mile charge.

EXPOSITION

Nearly 300 pharmaceutical companies, medical suppliers, clinical diagnostic and research-based companies, publishers, and nonprofit organizations will be participating in the 68th ASH Annual Meeting and Exposition. The state-of-the-art exhibit hall will feature the latest technology and research as well as a wide range of products and services. The exposition will be held in Halls G-J in the Ernest N. Morial Convention Center. Badges will be required for entrance. For safety and liability reasons, ASH does not permit children 12 years of age or younger at any time in the exhibit areas. During move-in or move-out, **no one** under the age of 18 will be permitted within the exhibit areas.

Exhibit Hours

Saturday, December 12 . . . . 11:00 a.m. – 5:00 p.m.
Sunday, December 13. . . . . 10:00 a.m. – 5:00 p.m.
Monday, December 14 . . . . . 10:00 a.m. – 2:00 p.m.

LUNCH AVAILABLE SUNDAY AND MONDAY

Your "ticket" for lunch is encoded in your badge, which will be scanned for entry into the "ticketed" event. Simply present your badge to access the complimentary light lunch offered on Sunday and Monday in the Hall J Lobby. Lunch seating and live music will also be available on the Live Oak Porch.

Lunch Hours

Sunday, December 13. . . . . 11:00 a.m. – 12:30 p.m.
Monday, December 14 . . . . . 12:00 noon – 1:30 p.m.

ASH BOOTH (#1429) – YOUR GATEWAY TO ALL ASH HAS TO OFFER

ASH is more than just an annual meeting; it is the premier hematology organization in the world. ASH is proud to offer its members many valuable resources. Come say hello and see what the Society has to offer at the ASH Booth (#1429). Get the latest information on grants and awards, publications, educational materials, and ASH meetings and find out how you can help move hematology forward with a contribution to ASH Foundation programs. Be sure to pick up the most recent issues of *Blood*, see what materials are available to hematologists around the world, and discover free online ASH resources. Our friendly staff will be glad to answer any questions and hear your feedback about the annual meeting or the Society. Consider this an open invitation to visit the booth Saturday, Sunday, and Monday to see how ASH can do more for you. Be sure to pick up a small giveaway as a token of our appreciation for attending the annual meeting.

CORPORATE PRESENTATIONS

Corporate Presentations include Product Theaters, Industry Theaters, Industry Forums, Clinical Trial Showcases, and Company Showcases, which feature new research findings, clinical trial and company overviews, and products presented to small groups of annual meeting attendees (no more than 150). All corporate presentations will take place in built rooms in Exhibit Hall J and in meeting rooms on Level 2 of the Ernest N. Morial Convention Center. Check the mobile app for the specific room number of the presentation you wish to attend. The sessions offered at the times listed below will be solely promotional in nature; therefore, continuing medical education credits will not be offered.

Corporate Presentation Theater Hours

Saturday, December 12	8:00 a.m. – 9:00 a.m.
	11:30 a.m. – 12:30 p.m.
	1:30 p.m. – 2:00 p.m.
	3:30 p.m. – 4:00 p.m.
Sunday, December 13	8:00 a.m. – 9:00 a.m.,
	11:30 a.m. – 12:30 p.m.
	4:15 p.m. – 4:30 p.m.
Monday, December 14	8:00 a.m. – 9:00 a.m.
	10:00 a.m. – 10:30 a.m.
	12:15 p.m. – 1:15 p.m.

Please see pages 141-150 for detailed Corporate Presentation program information.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

POSTER SESSIONS

Poster sessions are held in Hall F of the Ernest N. Morial Convention Center. Receptions are scheduled for Saturday, Sunday, and Monday evening during the poster sessions, and badges will be required for entrance.

Saturday, December 12

8:00 a.m. – 7:30 p.m. . . . . Poster Session I – Viewing
5:30 p.m. – 7:30 p.m. . . . . Poster Session I – Presentations

Sunday, December 13

8:00 a.m. – 8:00 p.m. . . . . Poster Session II – Viewing
6:00 p.m. – 8:00 p.m. . . . . Poster Session II – Presentations

Monday, December14

8:00 a.m. – 8:00 p.m. . . . . Poster Session III – Viewing
6:00 p.m. – 8:00 p.m. . . . . Poster Session III – Presentations

SOCIAL EVENTS

POSTER HALL RECEPTIONS

Saturday, December 12. . . . . 5:30 p.m. – 7:30 p.m.
Sunday, December 13 . . . . . 6:00 p.m. – 8:00 p.m.
Monday, December 14. . . . . 6:00 p.m. – 8:00 p.m.

Abstracts selected for poster presentations feature new advancements in hematologic research and are considered among the best of the thousands submitted for the 2026 ASH Annual Meeting. ASH invites meeting attendees to take advantage of these special opportunities to meet the abstract authors, discuss their research, and ask them questions. Light snacks and beverages will be provided.

ASH FOUNDATION RUN/WALK

Sunday, December 13, 2026, 7:00 a.m. – 9:00 a.m.

Outside of the Julia Street Entrance

Begin your day in a fun, healthy, and philanthropic way by participating in the 13th annual ASH Foundation Run/Walk before attending the sessions on Sunday, December 13.

Participants may run or walk through the designated event course, choosing either a 3K or 5K route. Not attending in person this year? Don't worry! You can still support the Foundation by choosing your own virtual 3K or 5K route.

Proceeds from all individual and group registration fees as well as additional individual donations will benefit the ASH Greatest Needs Fund. ASH and the ASH Foundation may opt to designate a portion, or all, of corporate sponsorship revenues associated with the run/walk to help support the cost of administering the event. Learn more and register at h*ematology.org/foundation/run-walk.*

MEETING RULES AND REGULATIONS

CODE OF CONDUCT

As a registered meeting participant, you have agreed to:

- Treat everyone with respect and professionalism
- Help maintain a safe, inclusive, harassment-free environment
- Communicate constructively and collegially

If you or anyone you know is being treated inappropriately, feels unsafe, and/or witnesses any unacceptable behavior, please contact *codeofconduct@hematology.org* as soon as possible. ASH will do its best to respond in a timely manner and determine the appropriate next steps.

MEETING AND SESSION PARTICIPATION

Admission to all official ASH events will require a proper display of registration badges. Badges should always be worn and are non-transferable. False certification of individuals as paid ASH meeting attendees, misuse of badges, any method of assisting unauthorized persons to gain access to any in-person or virtual meeting event, or inappropriate conduct, including but not limited to harassment, threatening physical or verbal actions, or disorderly or disruptive conduct, will not be tolerated and will be just cause for repossessing badges of any individuals involved and/or revoking access to the meeting or virtual platform. As a result, ASH reserves the right to expel all parties involved and has no obligation to refund registration fees paid.

Below are the policies that all in-person participants of the annual meeting will be required to acknowledge and agree to as part of the badge pick-up process at the Ernest N. Morial Convention Center:

1. **I AM AN ADULT OVER THE AGE OF 18, AND I KNOWINGLY AND VOLUNTARILY ASSUME ANY AND ALL RISKS AND DANGERS THAT MAY OCCUR PURSUANT TO MY ATTENDANCE AND PARTICIPATION IN THE ASH ANNUAL MEETING, INCLUDING THE RISK OF ILLNESS, INJURY, DEATH, OR PROPERTY DAMAGE AND I RELEASE ASH AND THE ERNEST N. MORIAL CONVENTION CENTER FROM ANY AND ALL SUCH LIABILITY.** I agree, for myself and any heirs, not to sue ASH or the Ernest N. Morial Convention Center or otherwise assert any claim for damages arising out of any illness (including COVID-19 or other communicable disease or illness), personal injury, temporary or permanent disability, death, damages, liabilities, or expenses I or they may sustain arising out of my attendance and participation in the ASH Annual Meeting.
2. I agree that I will not pass my registration badge to another individual or otherwise allow anyone else to use my badge. I understand that violating this requirement will result in immediate revocation of my access to the meeting, and possibly future meetings.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

FINANCIAL PROFESSIONALS

Financial professionals and other individuals whose principal reason for attending the meeting is to seek business opportunities or obtain information affecting investment positions are welcome to register for the meeting. However, the educational and scientific aspects of the meeting are always top priorities. Financial professionals are required to identify themselves when speaking with presenters, particularly when asking questions for which the answers may have implications for corporate valuation or positions in equity markets. Speakers and moderators are also asked to give preference to questioners with scientific or clinical inquiries.

CHILDREN

For safety reasons, children under the age of 12 (including infants in carriers and strollers, or hand-carried infants and toddlers) are not permitted in the exhibit hall or poster sessions. Additionally, ASH prohibits all children and infants from the sessions, as they may distract the speakers and disrupt other attendees. Attendees should contact ASH for assistance with childcare options in advance of the meeting.

PROHIBITED BEHAVIOR

In crowded sessions, please honor the instructions provided by ASH staff. You may be told not to stand against the walls in these rooms or not to block the aisles. Please note that if a room reaches full capacity, you may be denied entry, as ASH must obey the guidelines established by the Fire Marshal.

MATERIAL DISTRIBUTION

No literature may be distributed in the convention center, hotels, or public areas without ASH's permission in advance.

REGISTRATION DATA COLLECTION

As a participant of the meeting, you have read and agreed to ASH's Privacy Policy and ASH's Terms of Service that are available on the ASH website. Attendees who have questions or concerns can contact *ashregistration@spargoinc.com*.

TECHNOLOGY

RADIO FREQUENCY IDENTIFICATION (RFID) BADGE SCANNING IN USE

As part of ASH's ongoing efforts to improve the member experience, RFID-enabled badges will be used at the ASH annual meeting. This technology allows ASH to better understand which sessions and topics generate the most interest and will inform how future meeting are structured. No identifying personal information will be stored in the RFID badge, only an ID number. Badge scanning will only be utilized at entrances to session rooms and select ASH events. Data collected will only be used for program planning purposes and will not be shared or sold to other entities. Attendees who have questions or concerns can contact *ashregistration@spargoinc.com*.

PHOTOGRAPHY AND RECORDING OF COPYRIGHTED MATERIAL AT THE ASH ANNUAL MEETING

A. General

Abstracts and materials presented at the ASH annual meeting, including all slides, written and oral presentations (including visual/audio recordings), posters, and other materials displayed, shown, or otherwise published during the ASH annual meeting (the "Presentation and Meeting Materials"), are protected by copyright and may not be publicly displayed or republished without the express written consent of ASH. For a full description of Presentation and Meeting Materials, please review the Annual Meeting Copyright and Reuse Policy. Attendees of the annual meeting may share a limited number of photographs or audio recordings for personal, non-commercial use, including on social media (as outlined below).

B. Photographs and Audio Recording

1. **Limited Right to Share:** Except as provided in Sections A and B.2 of this Policy, attendees of the ASH meeting may take photographs and make audio recordings (but no video recordings) of Presentation and Meeting Materials for personal, non-commercial use, which are licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license (available in its entirety at creativecommons.org/licenses/by-nc-nd/4.0/legalcode). This means that, except as provided in Sections A and B.2 of this Policy, attendees may share a limited number of photographs or short audio recordings of the Presentation and Meeting Materials in a reasonable manner, as determined by ASH, in any medium or format subject to the following terms:

a. Attribution: An attendee must give appropriate credit to the original author, and may not in any way suggest that the original author endorses the attendee or their use;;

b. An attendee may not use the Presentation and Meeting Materials for commercial purposes; and

c. No Derivatives: if an attendee remixes, transforms, or builds upon the meeting material, he or she may not distribute or publish the modified material.

2. **Poster and Exhibit Hall Presentations:** Attendees of the ASH meeting may take photographs and make recordings of Presentation and Meeting Materials associated with Poster and Exhibit Hall presentations and displays for personal, non-commercial, use only. Attendees are strictly prohibited from sharing Presentation and Meeting Materials associated with poster presentations or exhibit hall displays without the express consent of the presenter or exhibitor, respectively, and the copyright owner of such Presentation and Meeting Materials.

3. **Commercial Filming or Photography:** Any requests for commercial filming or photography within public spaces of the convention center must be approved by ASH. Commercial filming of Presentation and Meeting Materials is strictly prohibited. For filming permission, please contact *ASH@Springer.com*.

C. No Disruptive Recordings or Photos

Attendees taking photos or audio recording of Presentation and Meeting Materials must do so in a non-disruptive manner so as not to disturb the presenter and other attendees.

D. No Video Recording, Live Audio, or Video Streaming

Sharing any recordings of Presentation Meeting Materials, including live streaming audio or video recordings, is strictly prohibited.

E. Violators

Violators of this Policy may be asked to leave the room or session and may be escorted and barred from the ASH meeting. Repeat violators may have their ASH meeting badges and/or virtual meeting access revoked and not be allowed to return to attend the remainder of the ASH meeting.

F. Disclaimer

ASH will have professional photographers present at the meeting, and portions of the meeting will be recorded. Any photographs or recordings taken during the meeting may be used in future ASH publications, online, or in other ASH materials. Attendance or participation in the meeting constitutes an agreement with ASH by the registrant for the Society to digitally store, use, and distribute the registrant's image or voice in photographs, audiotapes, or other electronic media pertaining to the ASH meeting events and activities, or other work of the Society.

Credentialed media/press will also attend the meeting and have permission to capture photos, video, and audio in public areas of the convention center. Registered media attendees are required to always display their press badge and camera tags while on site at the meeting.

COPYRIGHT AND REUSE POLICY FOR MEETING MATERIALS

The ASH Annual Meeting Copyright and Reuse Policy for Abstracts, Presentations, and Presentation Materials can be found at *hematology.org/meetings/annual-meeting/abstracts/copyright-and-reuse-policy.*

ADVANCING EXCELLENCE AND ADDRESSING HEALTH EQUITY AT ASH

As a global hematology community, ASH understands the importance of having individuals with diverse perspectives and experiences in all areas of the field. Through various ASH programs and committees, ASH continues its long-standing commitment to combating inequities in hematology, supporting scientists and clinicians from backgrounds underrepresented in medicine, and embracing diverse voices across the patient and health care communities. ASH's efforts to foster excellence and improve health outcomes for all apply to everyone, regardless of race, ethnicity, religion, age, sexual orientation, gender identity or expression, ability, national origin, or other attributes. Join us for the following events at the 68th ASH Annual Meeting to help advance the highest quality outcomes across all segments of the population through advancing medical research on hematologic diseases and disorders and in the practice of hematology.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

THE ASH STUDIO non-CME

Saturday, Sunday, Monday **Hall D**

The ASH Studio hosts brief, targeted talks that focus on removing barriers to high-quality care, principles of medical education, and cutting-edge teaching techniques.

ASH Treating Fairly Talks: This inclusive space is designed to help attendees recognize the drivers of differing outcomes for various populations as viewed through the hematology lens and provide tools to make changes in their institutions. These sessions will include a short expert commentary followed by facilitated conversations about actions that can be taken to drive change at your institution.

Med Ed Talks @ the ASH Studio: These sessions focus on best practices within medical education, including tips and strategies for overcoming common challenges.

ANNUAL MEETING SESSIONS THAT HIGHLIGHT ACCESS, REPRESENTATION, AND POPULATION HEALTH

Day	Time	Session Title	Program	Location	CME
Friday	3:00–6:00 p.m.	Immune Therapy for Myeloma: From CAR T and T-Cell Engagers to Community Care	Interact with Industry	343-345	CME
Friday	7:00–10:00 p.m.	From Evidence to Action in MPN: Transforming Challenges to Opportunities in PV and ET Patients	Interact with Industry	208-210	CME
Saturday	8:00–8:25 a.m.	Treating Fairly Talks: Building Infrastructure for Systemic Change in Maternal Health Outcomes	Treating Fairly Talks	Hall D ASH Studio	
Saturday	8:00–9:00 a.m.	Who Wants to Design a Better Sickle Cell Trial	Interact with Industry	293-294	
Saturday	9:05–9:30 a.m.	Meet the Journal Editors: Blood Immunology & Cellular Therapy	Blood Journals Studio	Hall F Blood Journals Studio	
Saturday	9:30–10:45 a.m.	Optimizing Patient Care: Practicing Bloodless Medicine	Education Program	391-392	CME
Saturday	9:30–10:45 a.m.	Ancestry Origins in Personalized Medicine: Advancing Biological Discovery, Population-Representative Research Design, and Translational Validity in Hematology	Special-Interest Sessions	220-222	CME
Saturday	9:30–11:00 a.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Beyond Efficacy - Quality of Life, Patient Reported Outcomes and Social Determinants of Health	Oral Abstract Session	271-273	
Saturday	9:30–11:00 a.m.	907. Outcomes Research: Plasma Cell Disorders - Beyond Disease Control: Supportive Care, Survivorship, and Patient-Centered Outcomes in Multiple Myeloma	Oral Abstract Session	La Nouvelle C	

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Day	Time	Session Title	Program	Location	CME
Saturday	11:00–11:25 a.m.	Treating Fairly Talks: Engaging American Indians and Alaska Native Populations in Community Interventions/Research	Treating Fairly Talks	Hall D ASH Studio	
Saturday	12:00–1:30 p.m.	904. Outcomes Research: Hemoglobinopathies: Health Systems, Care Delivery, and Real-World Outcomes in Sickle Cell Disease	Oral Abstract Session	243-245	
Saturday	1:30–1:55 p.m.	Treating Fairly Talks: Leveraging AI on Our Path to More Inclusive Clinical Outcomes	Treating Fairly Talks	Hall D ASH Studio	
Saturday	2:00–3:15 p.m.	Classical Hematology: Innovation and Technology to Match Supply and Demand	Education Program	293-294	CME
Saturday	2:00–3:15 p.m.	The Unusual Bleed: Cracking the Code of Platelet and Rare Bleeding Disorders	Education Program	220-222	CME
Saturday	2:00–3:15 p.m.	Lab-Grown Red Blood Cells: From Scalable Manufacturing to Clinical Translation	Scientific Symposia	391-392	CME
Saturday	2:00–3:15 p.m.	Single-Cell and Spatial Genomics Redefining the Immune Cell Landscape in AML/MDS	Scientific Symposia	288-290	CME
Saturday	2:00–3:30 p.m.	900. Health Services and Quality Improvement: Hemoglobinopathies - Emerging Clinical, Treatment, and Health Services Considerations Across Different Stages of Sickle Cell Care	Oral Abstract Session	252-254	
Saturday	2:00–3:30 p.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: CAR-T Cell Therapy	Oral Abstract Session	260-262	
Saturday	2:00–3:30 p.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders - Beyond Response: Toxicity, Infection, and Late Events After Novel Therapies	Oral Abstract Session	New Orleans Theatre C	
Saturday	2:00–3:30 p.m.	908. Outcomes Research: Myeloid Malignancies: Beyond Biology: Social, Environment, and Healthcare Determinants of Outcomes in Myeloid Malignancies	Oral Abstract Session	Great Hall AD	
Saturday	3:30–3:55 p.m.	Treating Fairly Talks: Iron Deficiency Interventions in Low Resource Settings	Treating Fairly Talks	Hall D ASH Studio	
Saturday	4:00–5:15 p.m.	T Resident Memory Cells (Trm) in Health, Disease, and Therapeutics	Scientific Program	275-277	CME
Saturday	4:00–5:30 p.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: Geriatrics, Palliative, and End of Life Care	Oral Abstract Session	260-262	
Sunday	8:00–8:25 a.m.	Treating Fairly Talks: Leveraging AI on Our Path to More Inclusive Clinical Outcomes	Treating Fairly Talks	Hall D ASH Studio	
Sunday	8:00–9:00 a.m.	How I Treat: MPN	How I Treat	Hilton - Jackson	CME
Sunday	9:30–10:45 a.m.	Power Sharing: Transplantation and Cellular Therapy in Autoimmunity	Scientific Program	Hall E	
Sunday	9:30–10:45 a.m.	Designing Microbiome-Directed Interventional Trials in Hematologic Malignancies	Scientific Symposia	288-290	CME
Sunday	9:30–11:00 a.m.	900. Health Services and Quality Improvement: Hemoglobinopathies: Improving How Sickle Cell Care is Organized, Implemented, and Delivered Across Healthcare Settings	Oral Abstract Session	243-245	
Sunday	9:30–11:00 a.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: Monitoring, Demographics, and Access to Care	Oral Abstract Session	271-273	
Sunday	9:30–11:00 a.m.	Early Faculty Career Development Session	Special-Interest Sessions	293-294	CME

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Day	Time	Session Title	Program	Location	CME
Sunday	11:00 a.m.–12:30 p.m.	LBGTQIA+ Community Networking Brunch	Special-Interest Sessions	Marriott Warehouse - Cypress I-II	CME
Sunday	11:30 a.m.–12:30 p.m.	Treating Fairly Rounds Lunch	Special-Interest Sessions	Marriott Warehouse - Gravier AB	CME
Sunday	12:00–1:30 p.m.	629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: Clinical Trials in Untreated and Relapsed/Refractory LBCL, Including CNS Lymphoma	Oral Abstract Session	New Orleans Theatre B	
Sunday	12:00–1:30 p.m.	901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Decoding Cytopenias	Oral Abstract Session	208-210	
Sunday	1:30–1:55 p.m.	Treating Fairly Talks: What is "Normal?" Updating Absolute Neutrophil Count Reference Ranges by Duffy Status	Treating Fairly Talks	Hall D ASH Studio	
Sunday	4:00–4:25 p.m.	Treating Fairly Talks: Building Infrastructure for Systemic Change in Maternal Health Outcomes	Treating Fairly Talks	Hall D ASH Studio	
Sunday	4:30–5:45 p.m.	A New Treatment Paradigm for Follicular Lymphoma	Education Program	New Orleans Theatre A	CME
Sunday	4:30–5:45 p.m.	Building Hematology Capacity Globally	Education Program	293-294	CME
Sunday	4:30–5:45 p.m.	Innovations in the Treatment of Pediatric AML	Education Program	Hall E	CME
Sunday	4:30–5:45 p.m.	Sticky Situations: Glycans in Classical and Malignant Hematopoiesis	Scientific Spotlight Sessions	288-290	CME
Sunday	4:30–6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: From Iron to Immunity: Real-World Outcomes in Classical Hematology	Oral Abstract Session	252-254	
Monday	8:00–8:25 a.m.	Treating Fairly Talks: What is "Normal?" Updating Absolute Neutrophil Count Reference Ranges by Duffy Status	Treating Fairly Talks	Hall D ASH Studio	
Monday	10:00–10:25 a.m.	Treating Fairly Talks: Engaging American Indians and Alaska Native Populations in Community Interventions/Research	Treating Fairly Talks	Hall D ASH Studio	
Monday	10:30–11:45 a.m.	Advances in Management of Vascular Anomalies	Education Program	220-222	CME
Monday	10:30–11:45 a.m.	Managing Iron Status Before and During Pregnancy: Protecting Mother and Fetus	Education Program	Hall E	CME
Monday	10:30–11:45 a.m.	The Golden Era of ALL Management: Rapid Advances Across the Age Spectrum	Education Program	278-282	
Monday	10:30–11:45 a.m.	The Heart and Brain in Older Patients with Sickle Cell Disease	Education Program	243-245	
Monday	10:30–11:45 a.m.	Public Health & Hematology: Results and Lessons from the PEN-Plus Model of Care for Severe, Chronic Non-Communicable Diseases like Sickle Cell Disease in Resource-Poor Areas	Education Spotlight Sessions	295-296	CME
Monday	10:30 a.m.–12:00 p.m.	907. Outcomes Research: Plasma Cell Disorders: Real-World Efficacy of Immunotherapy	Oral Abstract Session	La Nouvelle C	
Monday	12:00–1:30 p.m.	Celebrating Diverse Voices: Enriching Hematology Lunch	Special-Interest Sessions	Marriott Warehouse - Cypress I-II	CME

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Day	Time	Session Title	Program	Location	CME
Monday	12:15–1:15 p.m.	ASH Poster Walk on Leukemia in Latin America: Outcomes and Access to Diagnostics and Therapies Hosted by Blood Global Hematology	ASH Poster Walks	Hall F Blood Journals Studio	
Monday	2:45–4:00 p.m.	Improving Care of Patients with Sickle Cell Disease via Complement, Pain Control, and Trial Design	Education Program	Hall E	CME
Monday	2:45–4:00 p.m.	Balancing the Blood: Immune Control of Stem Cell Fidelity	Scientific Program	275-277	CME
Monday	2:45–4:00 p.m.	CAR-T Manufacturing Across Nations: From Low-to-Middle-Income Academic Platforms to Frontier Innovations in Global Access	Scientific Spotlight Sessions	391-392	CME
Monday	2:45–4:15 p.m.	908. Outcomes Research: Myeloid Malignancies: Mind the (Molecular) Gap: From Testing to Trials, Across Race and Place	Oral Abstract Session	Hall C	
Monday	2:45–4:15 p.m.	Clinical Practice Guidelines on the Treatment of Iron Deficiency with or without Anemia	Special-Interest Sessions	293-294	CME
Monday	2:45–4:15 p.m.	The Predicament of Patients in Prison: A Hematology Perspective	Special-Interest Sessions	295-296	CME
Monday	4:30–5:45 p.m.	Battle-Scarred Blood Cells: Hematologic Malignancies in Military Service Members	Education Program	278-282	CME
Monday	4:30–5:45 p.m.	Bispecific Antibody Therapy vs CAR T Therapy in Lymphoid Malignancies	Education Spotlight Sessions	271-273	CME
Monday	4:30–5:45 p.m.	Iron Homeostasis Across the Lifespan in Health and Disease	Scientific Program	288-290	CME
Monday	4:30–6:00 p.m.	901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: A World of Bleeding and Clotting	Oral Abstract Session	217-219	
Monday	4:30–6:00 p.m.	903. Health Services and Quality Improvement: Myeloid Malignancies: JAKPOT! Improving Care Quality from Pre-hab, Sleep, and Home Transfusions to Pall-care, Costs, and JAK Testing	Oral Abstract Session	R02-R05	
Monday	4:30–6:00 p.m.	904. Outcomes Research: Hemoglobinopathies: Therapeutic Innovation and Clinical Outcomes in Hemoglobinopathies	Oral Abstract Session	252-254	
Monday	7:30–9:00 p.m.	Women in Hematology Networking Dinner Event	Special-Interest Sessions	Hilton - St. Charles Ballroom	CME
Tuesday	11:30 a.m.–1:00 p.m.	Best of ASH	Marquee Sessions	Hall E	
Wednesday	10:00–11:00 a.m.	ASH Poster Walk on Population Health and Access to Care	ASH Poster Walks	ASH Virtual Platform	

NON-CME SESSIONS

ASH is committed to continuously re-evaluating our policies and processes to ensure that they align with the Accreditation Council for Continuing Medical Education's (ACCME) increasingly stringent standards. The ACCME defines Ineligible Companies (IC), also known as commercial interests, as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Pharmaceutical and biotechnology companies, including biomedical startups and diagnostic laboratories with proprietary products, are classified as ineligible companies and, per ACCME, any presentation given by employees of industry is considered to be promotional in nature and therefore ineligible to be accredited.

There are a number of programs and sessions in the program that are not accredited for CME. Please note that oral and poster abstracts are no longer included in the accredited programming.

The final list of Non-CME sessions is subject to change. Accredited sessions will be labeled on the virtual platform, and an up-to-date list of sessions will also be available.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Non-CME Programs

***All** sessions in the following programs are not accredited for CME credit:*

ASH Poster Walks
ASH Wellness Studio
ASH-a-Palooza Events
Blood Journals Studio
Clinical Trial Showcases
Company Showcases
Corporate Poster Walks
Industry Forums
Industry Theaters
MedEd Talks at ASH Studio (formerly known as Health Equity Studio)
Oral and Poster Abstracts
Product Theaters
Scientific Workshops
Trainee Activities
Treating Fairly Talks at ASH Studio (formerly known as Health Equity Studio)

Due to stricter ACCME guidelines regarding who may be allowed to control/present accredited content, the following sessions will not be certified for CME credit.

Education Program

Driving CARs Safely- Preventing and Managing Intermediate and Long-Term CAR-T Toxicity

From Mutations to Manifestations: Connecting Clonal Hematopoiesis (CH) and Thrombosis

The Golden Era of ALL Management: Rapid Advances Across the Age Spectrum

The Heart and Brain in Older Patients with Sickle Cell Disease

Marquee Sessions

Best of ASH Session

Late-Breaking Abstracts Session

Plenary Scientific Session

Presidential Symposium

Meet the Scientist Sessions

Engineering Tolerance: CAR-Tregs and the New Era of Cell Therapy for Autoimmunity

From Splicing Mutations to Cancer Neoantigens: A Decade of Targeting RNA Biology in Leukemia

αIIbβ3: One Receptor, Two Drugs, and the Long Road of Translational Platelet Biology

Scientific Program

Cutting-Edge Insights into Pro-Thrombotic Anti-Platelet Factor 4-Associated Disorders

How Clots Form and Fall Apart: From Engineered Vessels to Targeted Therapies

JOINT SESSION - New Horizons in RNA Biology in Myeloid Development and Malignancy

Power Sharing: Transplantation and Cellular Therapy in Autoimmunity

Rethinking Antiplatelet Strategies: Selective Blockade, Broad-Acting Drugs, and Beyond

T Resident Memory Cells (Trm) in Health, Disease, and Therapeutics

Unlocking Blood Disorders: Targeting Genetics to Identify Early Phenotypes

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Scientific Symposia

AI Models of Cell State for the Design of Next-Generation T Cell Therapies

In Vivo Gene Modification Approaches for Classical and Malignant Hematologic Disorders

Special-Interest Sessions

Back to Business Breakfast

***Blood* Presents: How to Get Published in a Peer Review Journal**

Fireside Chats on Innovation in a Changing Regulatory Landscape

From Real-World Evidence to Real-World Impact: Translating Multiple Myeloma Data into Clinical Practice

Real-World Data Applications in Sickle Cell Disease Trial Design

Showcasing a Decade of Discoveries in *Blood Advances*

The AI Colleague: Promise, Peril, and Practice in Hematology

The Future of Clinical Endpoints in Sickle Cell Disease

AMERICAN SOCIETY OF HEMATOLOGY 68TH ASH® ANNUAL MEETING AND EXPOSITION

SCHEDULE-AT-A-GLANCE

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

WEDNESDAY, DECEMBER 9, 2026

Beginning at 9:00 a.m. — **Preview Day on the Virtual Platform**

ASH Virtual Platform: annualmeeting.hematology.org

THURSDAY, DECEMBER 10, 2026

All Day — **Preview Day on the Virtual Platform**

ASH Virtual Platform: annualmeeting.hematology.org

10:00 a.m. – 10:00 p.m. — **Registration at the Airport (for in-person participants)**

Louis Armstrong New Orleans International Airport

3:00 p.m. – 7:00 p.m. — **Registration at the Convention Center (for in-person participants)**

Great Hall Foyer

FRIDAY, DECEMBER 11, 2026

7:00 a.m. – 6:00 p.m. — **Registration at the Convention Center (for in-person participants)**

Great Hall Foyer

8:30 a.m. – 9:30 p.m. — **Registration at the Airport (for in-person participants)**

Louis Armstrong New Orleans International Airport

7:00 a.m. – 6:00 p.m. — **Learn, Engage, and Relax in ASH Central (for in-person participants)**

Hall D

7:00 a.m. – 10:00 a.m. — **Satellite Symposia**

A Hematologist's Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond
Hall C

Anti-BCMA Bispecific Antibodies in Multiple Myeloma: From Biology to Real-World Implementation
Great Hall AD

B-Cell–Directed Therapies in Immune Thrombocytopenia: Real-World Practice
R06-R09

Breaking News: Launching Bispecific Antibodies for Multiple Myeloma in Community Practice
Hall B

Consensus or Controversy? Documenting And Discussing Investigators' Approaches to the Management of Patients with Chronic Lymphocytic Leukemia
Sheraton - Napoleon Ballroom CD

Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review
Sheraton - Napoleon Ballroom AB

From Controversies to Consensus in Paroxysmal Nocturnal Hemoglobinuria: Developing IPIG Guidelines
R02-R05

MDS in Practice: Navigating Complex Decisions Across the Disease Spectrum
208-210

Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs
Hilton - Grand Ballroom CD

9:00 a.m. – 12:00 p.m. — **Training Program Directors' Workshop**

Hilton Garden Inn - Magnolia

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

11:00 a.m. – 2:00 p.m. Satellite Symposia

A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We're Going
Sheraton - Napoleon Ballroom AB

Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together
Hall C

Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation
Hilton - Grand Ballroom CD

Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review
Sheraton - Napoleon Ballroom CD

Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum
R02-R05

CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation
243-245

Cases and Conversations: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways with Current and Emerging CD123-Directed Therapies
La Nouvelle A-B

CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies
208-210

CML Treatment Continuum: Optimizing Therapy Selection, Molecular Monitoring, And Long-Term Quality of Life
Great Hall BC

Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making
343-345

Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease
265-268

Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care
Great Hall AD

Medical Crossfire®: Redefining DLBCL — How Biomarker- and Mechanism-Driven Strategies Are Reshaping Management Across the Disease Continuum
La Nouvelle C

Medical Crossfire®: Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies
393-396

Realigning Modern Care in MCL: Guidance on the Next Wave of Advances with BTK Inhibitor Options and New Targeted Strategies
Hilton - Grand Ballroom AB

Show Me the Data™: Emerging Evidence and Evolving Clinical Practice in Essential Thrombocythemia and Polycythemia Vera
R06-R09

The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care
217-219

Transforming Care for Newly-Diagnosed Multiple Myeloma: Integrating Evidence-Based Innovation into Community Practice
Hall B

12:00 p.m. – 5:00 p.m. ASH-a-Palooza (Open to Trainees Only)

Generations Hall (located at 310 Andrew Higgins Blvd, within walking distance to convention center)

2:00 p.m. – 6:00 p.m. Scientific Workshops

Scientific Workshop on Myeloid Development
220-222

3:00 p.m. – 6:00 p.m. Scientific Workshops

Scientific Workshop on Clonal Evolution in Chronic Lymphocytic Leukemia: Mechanisms of Resistance, Disease Progression and Measurable Residual Disease-Based Monitoring
288-290

Scientific Workshop on Emerging Technologies and Innovations in Diagnostic Hematology
252-254

Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure
278-282

Scientific Workshop on Interplay between Coagulation and Malignancy
295-296

Scientific Workshop on Mechanism-Driven Biomarkers in Sickle Cell Disease
293-294

Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Discovery to Patients
275-277

Scientific Workshop on New Frontiers in T-Cell Acute Lymphoblastic Leukemia Biology: Metabolism, Genomics, and Microenvironment
260-262

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies
291-292

Scientific Workshop on TP53: A Moving Target
271-273

3:00 p.m. – 6:00 p.m. Satellite Symposia

A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We're Going
Sheraton - Napoleon Ballroom CD

Acknowledging the Rare: Navigating Diagnostic and Therapeutic Complexities in Rare Hematologic Disorders
Hall B

Cases and Conversations: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms
R06-R09

Evidence at Every Step: Applying the Latest CAR T-Cell Data Across the NHL Care Continuum
R02-R05

FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances with BTK Inhibitors as New STandards for Frontline Treatment
Hilton - Grand Ballroom CD

Hemophilia at the Crossroads: New Evidence for Individualized Care
Great Hall BC

Immune Therapy for Myeloma: From CAR T and T-Cell Engagers to Community Care
343-345

ITP at a Crossroads: Closing Knowledge Gaps in Pathophysiology, Treatment Selection, and Patient-Centered Care
217-219

Live Hot Seat™: Advancing Precision Care in Acute Myeloid Leukemia with the Integration of Menin Inhibitors
393-396

Live Tumor Board: Advancing Clinical Competence in Primary CNS Lymphoma — Navigating Molecular Pathways and Emerging Therapies
La Nouvelle C

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

MDS in the Modern Era: Getting Ahead of the 8-Ball
Hall C

Medical Crossfire®: Strategic Sequencing in ALL — From Asparaginase to Cellular Therapy in an MRD-Driven Era
La Nouvelle A-B

Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice
243-245

Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions
265-268

Quadruplet Therapy in NDMM: Interpreting the Data, Applying the Evidence
208-210

The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities from Later-Line to Frontline Care
Hilton - Grand Ballroom AB

5:00 p.m. – 7:00 p.m. Trainee Welcome Reception (Open to Trainees Only)

Generations Hall

7:00 p.m. – 10:00 p.m. Satellite Symposia

Accelerating CARs for Lymphoma: Expert Workshops on CAR-T Standards, Sequencing, and Emerging Cellular Therapy Platforms
Hilton - Grand Ballroom AB

Addressing Community Oncologists' Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies in Multiple Myeloma – What Clinicians Want To Know
Sheraton - Napoleon Ballroom CD

Addressing Community Oncologists' Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want to Know
Sheraton - Napoleon Ballroom AB

Advancing the DLBCL Paradigm: Sequencing Bispecifics in Optimizing Patient Care
Great Hall BC

Cases and Conversations: Endothelial Injury, Complement, and TA-TMA After Allogeneic Stem Cell Transplant
La Nouvelle C

Cases and Conversations: Sequencing Strategies in Relapsed and Refractory CLL
La Nouvelle A-B

Clinical Turning Points: Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis
Hall C

From Evidence to Action in MPN: Transforming Challenges to Opportunities in PV and ET Patients
208-210

Overcoming the Challenges of Managing Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia
343-345

SATURDAY, DECEMBER 12, 2026

7:00 a.m. – 6:00 p.m. Registration at the Convention Center (for in-person participants)

Great Hall Foyer

7:00 a.m. – 6:00 p.m. Learn, Engage, and Relax in ASH Central (for in-person participants)

Hall D

7:00 a.m. – 7:45 a.m. ASH Yoga (for in-person participants)

Magnolia Porch

8:00 a.m. – 7:30 p.m. Poster Session I - Viewing

Hall F

8:00 a.m. – 8:25 a.m. Treating Fairly Talks at ASH Studio

Building Infrastructure for Systemic Change in Maternal Health Outcomes
Hall D ASH Studio

8:00 a.m. – 9:00 a.m. ASH Poster Walks

ASH Poster Walk on Emerging Toxicities and Predictors in T-Cell–Redirecting Therapies Hosted by Blood Immunology & Cellular Therapy
Hall F Blood Journals Studio

8:00 a.m. – 9:00 a.m. Coffee and Collaboration in ASH Central (for in-person participants)

Hall D

8:00 a.m. – 9:00 a.m. How I Treat (Ticketed Session)

How I Treat: ALL
Hilton - Camp

How I Treat: Follicular Lymphoma
Hilton - Ascot/Newberry

How I Treat: Heavy Menstrual Bleeding in Women with Bleeding Disorders
Hilton - Canal

How I Treat: HLH and Related Hyperinflammatory Syndromes
Hilton - Royal

How I Treat: Refractory ITP Unresponsive to Steroids and Thrombopoietin Agonists
Hilton - Commerce

8:00 a.m. – 9:00 a.m. Industry Forums

Myth vs Mast Cell: Would You Recognize Systemic Mastocytosis? Patient and Clinician Perspectives on Diagnosis, Disease Burden, and Unmet Need
295-296

Navigating PV with MIMRYLO: A Patient-Centered Clinical Conversation
288-290

Who Wants to Design a Better Sickle Cell Trial
293-294

8:00 a.m. – 9:00 a.m. Meet the Scientist (Ticketed Session)

aIIbß3: One Receptor, Two Drugs, and the Long Road of Translational Platelet Biology
Hilton - Parish

Chemoresistance in Acute Myeloid Leukemia
Hilton - Magazine

From GATA2 to SAMD9: Discovering the Genetic Architecture of Pediatric Myelodysplastic Syndrome and Bone Marrow Failure
Hilton - Windsor

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

From Splicing Mutations to Cancer Neoantigens: A Decade of Targeting RNA Biology in Leukemia
Hilton - Fulton

Reading the Epigenetic History of Lymphoma: From Cell of Origin to Mitotic Clocks and Clinical Outcome
Hilton - Jackson

9:00 a.m. – 9:25 a.m. Treating Fairly Talks at ASH Studio

Expanding Access to Therapies for Underserved Populations
Hall D ASH Studio

9:00 a.m. – 9:30 a.m. Coffee Break in the Poster Hall (for in-person participants)

Hall F

9:05 a.m. – 9:15 a.m. ASH Wellness Studio

The Instant Calm
Hall D Wellness Studio

9:05 a.m. – 9:30 a.m. Blood Journals Studio

Meet the Journal Editors: Blood Immunology & Cellular Therapy
Hall F Blood Journals Studio

9:15 a.m. – 9:25 a.m. ASH Wellness Studio

Sip Yourself Sharp
Hall D Wellness Studio

9:30 a.m. – 10:45 a.m. Ancestry Origins in Personalized Medicine: Advancing Biological Discovery, Population-Representative Research Design, and Translational Validity in Hematology

220-222

9:30 a.m. – 10:45 a.m. Education Program

Addressing Resistance and Progression in Myeloproliferative Diseases
R06-R09

Navigating the Treatment Landscape of CNS Lymphomas
278-282

Optimizing Patient Care: Practicing Bloodless Medicine
391-392

9:30 a.m. – 10:45 a.m. Scientific Program

Scientific Committee on Plasma Cell Neoplasia: Back to the Future: Using Old and New Tools to Move the Field of Plasma Cell Research Forward
288-290

9:30 a.m. – 11:00 a.m. Oral Abstract Sessions

112. Thalassemia and Globin Gene Regulation: Advances Across the Thalassemia Spectrum: Novel Targets and Therapeutics
243-245

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological - Natural History
252-254

201. Granulocytes, Monocytes, and Macrophages: Novel Therapeutic Targets in Histiocytosis and Hyperinflammation
291-292

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Bench to Bedside: Practical Applications in ITP
217-219

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Refining Risk in Cancer-Associated Thrombosis: From Circulating Biomarkers to Population Outcomes
208-210

508. Bone Marrow Failure: Acquired: The Science Behind the Clinic
295-296

603. Lymphoid Oncogenesis: Basic: Epigenetic and Transcriptional Deregulation
275-277

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Integrated Omics Approaches for Precision Medicine in Acute Lymphoblastic Leukemia
265-268

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Novel Combination Regimens for Fit and Less-fit AML Patients
Great Hall BC

617. Acute Myeloid Leukemias: Commercially Available Therapies: Rewriting the AML Playbook: Precision, Intensification, and New Therapeutic Frontiers
Great Hall AD

621. Lymphomas: Translational – Molecular and Genetic: Genomics and Liquid Biopsy in Lymphoma: Tumor Biology to Clinical Monitoring
New Orleans Theatre A

627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Novel Combinations Move Beyond Chemotherapy
New Orleans Theatre C

629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: Response-Adapted Strategies in Aggressive Lymphomas
New Orleans Theatre B

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: CALR and Friends: Adventures in MPN!
R02-R05

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Biomarkers, Resistance, and the Molecular Frontier
Hall B

636. Myelodysplastic Syndromes: Basic and Translational: Multi-Modal Mapping of Clonal Evolution and Microenvironmental Remodeling in MDS and Leukemic Progression
Hall C

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches for Patients with Relapsed/Refractory CLL, Richter Transformation, and Hypogammaglobulinemia
260-262

654. Multiple Myeloma: Pharmacologic Therapies
La Nouvelle A-B

655. Multiple Myeloma: Cellular Therapies: CART in Myeloma: Racing Towards a Cure
Hall E

701. Experimental Transplantation: Basic and Translational: Emerging Biology to Translational Innovation II
353-355

702. CAR-T Cell Therapies: Basic and Translational
343-345

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Conditioning the Outcome: Optimizing Transplantation in Acute Leukemia
388-390

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: From Cells to Code: AI and the Next Generation of Hematologic Diagnostics
393-396

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Beyond Efficacy - Quality of Life, Patient Reported Outcomes and Social Determinants of Health
271-273

907. Outcomes Research: Plasma Cell Disorders - Beyond Disease Control: Supportive Care, Survivorship, and Patient-Centered Outcomes in Multiple Myeloma
La Nouvelle C

9:30 a.m. – 11:00 a.m. **QI Intensive - A Practical Guide to Quality Improvement in Hematology**

293-294

11:00 a.m. – 5:00 p.m. **Exhibits Open**

Halls G-J

11:00 a.m. – 11:25 a.m. **Treating Fairly Talks at ASH Studio**

Engaging American Indians and Alaska Native Populations in Community Interventions/Research
Hall D ASH Studio

11:00 a.m. – 12:30 p.m. **Live Music and Outdoor Lunch Seating (for in-person participants)**

Heritage Porch

11:05 a.m. – 11:15 a.m. **ASH Wellness Studio**

Quiet the Noise
Hall D Wellness Studio

11:15 a.m. – 12:15 p.m. **ASH Advocacy Network Lunch**

Marriott Warehouse - Gravier A-F

11:15 a.m. – 12:15 p.m. ***Blood* Presents: How to Get Published in a Peer Review Journal**

252-254

11:15 a.m. – 12:15 p.m. **Career Development Lunch (Open to Trainees Only)**

Hilton - St. Charles Ballroom

11:20 a.m. – 11:30 a.m. **ASH Wellness Studio**

Reclaim Your Spark
Hall D Wellness Studio

11:30 a.m. – 12:30 p.m. **Product Theaters**

A Therapy for Adults with RRMM After a PI and an Immunomodulatory Agent
Hall J Theater 1

Discover A New Oral-Based Regimen for First Relapse Myeloma
Hall J Theater 6

Insights into a RRMM Patient and Care Partner Journey: Clinical Evidence for a BCMA-Directed Therapy
Hall J Theater 3

The Only BTKi Approved in 1L CLL/SLL and 1L MCL
Hall J Theater 5

Understanding Time off Treatment with an All-Oral, Fixed-Duration Regimen: Perspective of a Patient with Previously Untreated CLL
Hall J Theater 2

WAYRILZ Real World Cases & Patient Experience
Hall J Theater 4

11:35 a.m. – 11:45 a.m. **ASH Wellness Studio**

Own Your Time
Hall D Wellness Studio

12:00 p.m. – 1:30 p.m. **Oral Abstract Sessions**

401. Blood Transfusion: Advancing Transfusion Medicine - From Precision Blood Component Therapy to Blood Substitutes
220-222

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Is Chemo-immunotherapy Ready for Retirement? Bispecific and CELMoD-Based Frontline Regimens in Follicular Lymphoma
278-282

904. Outcomes Research: Hemoglobinopathies: Health Systems, Care Delivery, and Real-World Outcomes in Sickle Cell Disease
243-245

12:30 p.m. – 1:30 p.m. **Ham-Wasserman Lecture: CD7 CAR-T Therapy in T-cell Acute Leukemia/Lymphoma: Past, Present and Future**

Hall E

1:30 p.m. – 1:45 p.m. **Clinical Trial Showcases**

Advancing Research in Hemophilia A and von Willebrand Disease
Hall J Theater 1

HARBOR: A Global Phase 2/3 Clinical Trial Evaluating Elenestinib in Patients with Indolent Systemic Mastocytosis
Hall J Theater 3

1:30 p.m. – 1:45 p.m. **Company Showcases**

From Subjectivity to Precision: Hybrid AI-Powered Bone Marrow Smear Analysis in Myelodysplastic Syndrome
Hall J Theater 5

1:30 p.m. – 1:55 p.m. **Treating Fairly Talks at ASH Studio**

Leveraging AI on Our Path to More Inclusive Clinical Outcomes
Hall D ASH Studio

1:30 p.m. – 2:00 p.m. **Blood Journals Studio**

Inside Peer Review at Blood Advances
Hall F Blood Journals Studio

1:30 p.m. – 2:00 p.m. **Coffee Break in the Exhibit Hall (for in-person participants)**

Halls G-J

1:35 p.m. – 1:45 p.m. **ASH Wellness Studio**

Eat for Energy
Hall D Wellness Studio

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

1:45 p.m. – 1:55 p.m. ASH Wellness Studio

Shake it Off
Hall D Wellness Studio

1:45 p.m. – 2:00 p.m. Clinical Trial Showcases

Fitusiran ATLAS-KIDS Clinical Trial
Hall J Theater 3

2:00 p.m. – 3:00 p.m. Distinguished Abstract Achievement Award Ceremony

346-347

2:00 p.m. – 3:15 p.m. Education Program

Classical Hematology: Innovation and Technology to Match Supply and Demand
293-294

Targeted Therapies for AML: Bulls Eye!
R02-R05

The Unusual Bleed: Cracking the Code of Platelet and Rare Bleeding Disorders
220-222

2:00 p.m. – 3:15 p.m. Scientific Symposia

In Vivo Gene Modification Approaches for Classical and Malignant Hematologic Disorders
275-277

Lab-Grown Red Blood Cells: From Scalable Manufacturing to Clinical Translation
391-392

Single-Cell and Spatial Genomics Redefining the Immune Cell Landscape in AML/MDS
288-290

2:00 p.m. – 3:30 p.m. Oral Abstract Sessions

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: The Tip of the Iceberg - How Do We Spot and Stop Organ Damage in Sickle Cell Disease?
243-245

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological
208-210

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: New Frontiers in Thrombosis: FXI Inhibition, Intervention, and Long-term Outcomes
217-219

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Mechanisms in Hematopoietic Stem Cell Regulation, Development, and Regeneration
291-292

503. Clonal Hematopoiesis, Aging, and Inflammation: Evolution, Interactions, and Interception
Hall E

506. Bone Marrow Microenvironment
295-296

602. Myeloid Oncogenesis: Basic
R06-R09

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Integrating Genomic and Functional Approaches to Uncover Mechanisms of Pathogenesis and Treatment Resistance in B-ALL
265-268

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis
Hall C

622. Lymphomas: Translational: Non-Genetic – Lymphoma Landscapes: Spatial Biology of Tumor States and Immune Niches
New Orleans Theatre B

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Mapping the Post-BTK Inhibitor Landscape: Cellular Therapy, Novel Combinations, and Genomic Insights in B-Cell Lymphomas
New Orleans Theatre A

634. Blood Syndromes: Clinical and Epidemiological: Emerging Therapies and Approaches in MPN
Hall B

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Novel Therapeutic Strategies and Prognostic Stratification in MDS and MDS/MPN
Great Hall BC

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Improving Outcomes for Relapsed/Refractory CLL/SLL
271-273

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Clinical Trials for Plasma Cell Dyscrasias and Related Disorders
278-282

654. Multiple Myeloma: Pharmacologic Therapies: Novel Approaches in Relapsed Myeloma: Immunotherapies and Small Molecules
La Nouvelle A-B

655. Multiple Myeloma: Cellular Therapies: Efficacy Meets Safety: Optimizing CART in MM
La Nouvelle C

702. CAR-T Cell Therapies: Basic and Translational: Engineering CAR T-cells for Improved Persistence, Activity, and Tumor Control
343-345

703. Cellular Immunotherapies Other Than CAR-T Cells: Basic and Translational: Expanding the Garage: Advancements in Non-T Cell CAR Platforms and Optimization Strategies
353-355

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Building a Better Transplant: Refining the PTCy Platform and Beyond
388-390

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: From Algorithms to the Clinic: AI and Molecular Innovation in Hematology
393-396

900. Health Services and Quality Improvement: Hemoglobinopathies - Emerging Clinical, Treatment, and Health Services Considerations Across Different Stages of Sickle Cell Care
252-254

902. Health Services and Quality Improvement: Lymphoid Malignancies: CAR-T Cell Therapy
260-262

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders - Beyond Response: Toxicity, Infection, and Late Events After Novel Therapies
New Orleans Theatre C

908. Outcomes Research: Myeloid Malignancies: Beyond Biology: Social, Environment, and Healthcare Determinants of Outcomes in Myeloid Malignancies
Great Hall AD

3:30 p.m. – 3:45 p.m. Clinical Trial Showcases

LUNA 4 - Early Multi-Immune Modulation with Rilzabrutinib in Patients with Primary ITP After First-Line Treatment Failure: A Phase 3b Study
Hall J Theater 3

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

3:30 p.m. – 3:45 p.m. Company Showcases

Discover the Organization of Cell Surface Proteins to Uncover Mechanisms Behind Hematological Disease
Hall J Theater 5

3:30 p.m. – 3:55 p.m. Treating Fairly Talks at ASH Studio

Iron Deficiency Interventions in Low Resource Settings
Hall D ASH Studio

3:30 p.m. – 4:00 p.m. Coffee Break in the Exhibit Hall (for in-person participants)

Halls G-J

3:30 p.m. – 4:30 p.m. Blood Journals Studio

Blood Journals Club: Characteristics of Donor and Recipient Clonal Hematopoiesis in Non-myeloablative Transplant for Sickle Cell Disease
Hall F Blood Journals Studio

3:35 p.m. – 3:45 p.m. ASH Wellness Studio

Find Your Tribe
Hall D Wellness Studio

3:45 p.m. – 3:55 p.m. ASH Wellness Studio

The Instant Calm
Hall D Wellness Studio

3:45 p.m. – 4:00 p.m. Clinical Trial Showcases

LUMINA 3 – A Phase 3, Two Arm Study, Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Warm Autoimmune Hemolytic Anemia (wAIHA)
Hall J Theater 3

4:00 p.m. – 5:15 p.m. Education Program

Longer Lives, New Challenges: Managing Thalassemia in 2026
252-254

Persistent Challenges in Managing Chronic Myelogenous Leukemia
R06-R09

The Big Clot Problem
Hall E

4:00 p.m. – 5:15 p.m. Scientific Program

Scientific Committee on Transfusion Medicine: Cutting-Edge Insights into Pro-Thrombotic Anti-Platelet Factor 4-Associated Disorders
220-222

Scientific Committee on Immunology and Host Defense: T Resident Memory Cells (Trm) in Health, Disease, and Therapeutics
275-277

4:00 p.m. – 5:30 p.m. Fireside Chats on Innovation in a Changing Regulatory Landscape

293-294

4:00 p.m. – 5:30 p.m. Oral Abstract Sessions

101. Red Cells and Erythropoiesis, Excluding Iron: Internal and External Drivers of Erythroid Development
291-292

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological - Therapeutics
243-245

322. Hemophilia A and B: Clinical and Epidemiological: Transforming Hemophilia Care: Long-term Outcomes, Treatment Transitions, and Innovation
208-210

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational
217-219

508. Bone Marrow Failure: Acquired: Clinical Data on PNH and SAA Therapeutics
295-296

602. Myeloid Oncogenesis: Basic: Transcriptional and Epigenetic Dependencies
R02-R05

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms - Resistance Mechanisms and New Therapeutic Vulnerabilities in AML
Hall B

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Molecular Vulnerabilities and Therapeutic Resistance
271-273

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Relapsed/Refractory Acute Lymphoblastic Leukemia: From Novel CAR T-cell Constructs to Real-World Experience in B-ALL, and an Investigational Agent in T-cell ALL
265-268

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Decoding AML Resistance: Cell States, Immune Niches, and Therapeutic Vulnerabilities
Great Hall BC

619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Measures for Measures: New Tools and New Uses for MRD in AML
Great Hall AD

621. Lymphomas: Translational – Molecular and Genetic: From Tumor Evolution to Therapeutic Targets: Integrated Genomic and Microenvironmental Insights in B-Cell Lymphomas
New Orleans Theatre B

622. Lymphomas: Translational – Non-Genetic: Shaping Lymphoma Fate: Oncogenic Programs, Stromal Support, and Immune Failure
New Orleans Theatre A

627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Novel Study Designs and New Immunotherapy Approaches
New Orleans Theatre C

634. Myeloproliferative Syndromes: Clinical and Epidemiological: MF and SM: Emerging Targets and Treatment Strategies
Hall C

653. Multiple Myeloma: Clinical and Epidemiological: Optimizing Outcomes for Multiple Myeloma, Young and Old
La Nouvelle A-B

654. Multiple Myeloma: Pharmacologic Therapies: The March of Immunotherapy
La Nouvelle C

702. CAR-T Cell Therapies: Basic and Translational: Overcoming Resistance and Escape in CAR-T Cell Therapy
343-345

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations from Bench to Bedside
391-392

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: HCT Under Stress: Acute Toxicities and Organ Injury
388-390

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Allogeneic Transplantation Outcomes: Lymphoid Malignancies, Pediatric Malignancies, and Donor Factors
278-282

802. Chemical Biology and Experimental Therapeutics: Leveraging Chemical Biology for Therapeutic Discovery
353-355

902. Health Services and Quality Improvement: Lymphoid Malignancies: Geriatrics, Palliative, and End of Life Care
260-262

4:00 p.m. – 5:35 p.m. Scientific Program

Scientific Committee on Epigenetics and Genomics & Scientific Committee on Myeloid Biology: JOINT SESSION - New Horizons in RNA Biology in Myeloid Development and Malignancy
288-290

5:30 p.m. – 7:30 p.m. Welcome Reception in the Poster Hall (for in-person participants)

Hall F

5:30 p.m. – 7:30 p.m. Poster Session I - Presentations (for in-person participants)

Hall F

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I (1099–1121)

102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster I (1122–1134)

112. Thalassemia and Globin Gene Regulation: Poster I (1135–1139)

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I (1140–1155)

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I (1156–1194)

201. Granulocytes, Monocytes, and Macrophages: Poster I (1195–1215)

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I (1216–1229)

301. Platelets and Megakaryocytes: Basic and Translational: Poster I (1230–1238)

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I (1239–1264)

321. Coagulation and Fibrinolysis: Basic and Translational: Poster I (1265–1271)

322. Hemophilia A and B: Clinical and Epidemiological: Poster I (1272–1287)

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster I (1288–1301)

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster I (1302–1312)

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster I (1313–1324)

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I (1325–1345)

401. Blood Transfusion: Poster I (1346–1353)

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I (1354–1366)

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I (1367–1380)

506. Bone Marrow Microenvironment: Poster I (1381–1389)

508. Bone Marrow Failure: Acquired: Poster I (1390–1412)

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I (1413–1427)

602. Myeloid Oncogenesis: Basic: Poster I (1428–1453)

603. Lymphoid Oncogenesis: Basic: Poster I (1454–1466)

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I (1467–1498)

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I (1499–1516)

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I (1517–1536)

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I (1537–1560)

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster I (1561–1575)

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I (1576–1624)

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I (1625–1641)

617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I (1642–1670)

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I (1671–1718)

619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster I (1719–1726)

621. Lymphomas: Translational: Molecular and Genetic: Poster I (1727–1755)

622. Lymphomas: Translational – Non-Genetic: Poster I (1756–1774)

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I (1775–1817)

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I (1818–1829)

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I (1830–1856)

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster I (1857–1884)

627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster I (1885–1910)

628. Aggressive Lymphomas: Cellular Therapies: Poster I (1911–1930)

629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: Poster I (1931–1957)

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I (1958–1979)

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I (1980–1998)

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I (1999–2052)

636. Myelodysplastic Syndromes: Basic and Translational: Poster I (2053–2064)

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I (2065–2097)

641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I (2098–2108)

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I (2109–2147)

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I (2148–2183)

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I (2184–2202)

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

653. Multiple Myeloma: Clinical and Epidemiological: Poster I (2203–2240)

654. Multiple Myeloma: Pharmacologic Therapies: Poster I (2241–2267)

655. Multiple Myeloma: Cellular Therapies: Poster I (2268–2287)

656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: Poster I (2288–2315)

701. Experimental Transplantation: Basic and Translational: Poster I (2316–2331)

702. CAR-T Cell Therapies: Basic and Translational: Poster I (2332–2376)

703. Cellular Immunotherapies Other Than CAR-T Cells: Basic and Translational: Poster I (2377–2388)

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I (2389–2416)

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I (2417–2427)

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I (2428–2460)

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I (2461–2491)

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I (2492–2516)

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I (2517–2539)

801. Gene Therapies: Poster I (2540–2552)

802. Chemical Biology and Experimental Therapeutics: Harnessing Chemical Biology to Reveal Therapeutic Vulnerabilities: Poster I (2553–2559)

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I (2560–2591)

900. Health Services and Quality Improvement: Hemoglobinopathies: Poster I (2592–2605)

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I (2606–2623)

902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I (2624–2652)

903. Health Services and Quality Improvement: Myeloid Malignancies: Poster I (2653–2664)

904. Outcomes Research: Hemoglobinopathies: Poster I (2665–2679)

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I (2680–2707)

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I (2708–2774)

907. Outcomes Research: Plasma Cell Disorders: Poster I (2775–2808)

908. Outcomes Research: Myeloid Malignancies: Poster I (2809–2846)

909. Medical Education and Workforce Development: Poster I (2847–2858)

6:00 p.m. – 8:00 p.m. Hematology Inclusion Pathway (HIP) Oral Presentations

Classical Hematology
Hilton - Grand Ballroom C

Health Outcomes
Hilton - Grand Ballroom D

Malignant Hematology I
Hilton - Grand Ballroom A

Malignant Hematology II
Hilton - Grand Ballroom B

8:00 p.m. – 9:00 p.m. Hematology Inclusion Pathway (HIP) Reception

Hilton - Chemin Royale

SUNDAY, DECEMBER 13, 2026

7:00 a.m. – 5:00 p.m. Registration at the Convention Center (for in-person participants)

Great Hall Foyer

7:00 a.m. – 6:00 p.m. Learn, Engage, and Relax in ASH Central (for in-person participants)

Hall D

7:00 a.m. – 9:00 a.m. ASH Foundation Run/Walk

Julia Street & Convention Center Boulevard

7:00 a.m. – 9:00 a.m. Medical Educators' Symposium

Marriott Warehouse - Cypress I-II

8:00 a.m. – 8:00 p.m. Poster Session II - Viewing

Hall F

8:00 a.m. – 8:25 a.m. Treating Fairly Talks at ASH Studio

Leveraging AI on Our Path to More Inclusive Clinical Outcomes
Hall D ASH Studio

8:00 a.m. – 9:00 a.m. ASH Poster Walks

ASH Poster Walk on New Developments in Targeted Therapies for Myeloid Malignancies Hosted by Blood Neoplasia

Hall F Blood Journals Studio

8:00 a.m. – 9:00 a.m. Coffee and Collaboration in ASH Central (for in-person participants)

Hall D

8:00 a.m. – 9:00 a.m. How I Treat (Ticketed Session)

How I Treat: Cold Agglutinin Disease and Related Complement-Mediated Hemolytic Anemia
Hilton - Canal

How I Treat: Large B-Cell Lymphoma
Hilton - Camp

How I Treat: MPN
Hilton - Jackson

How I Treat: Pediatric AML
Hilton - Ascot/Newberry

How I Treat: TTP in the Caplacizumab Era
Hilton - Commerce

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

8:00 a.m. – 9:00 a.m. Industry Theaters

Beyond Bone Marrow: Integrating Circulating Plasma Cell Enumeration and Genomic Profiling into Multiple Myeloma Disease Assessment
Hall J Theater 5

When Pediatric Care Ends, What Comes Next for Patients with PROS and Lymphatic Malformations?
Hall J Theater 1

8:00 a.m. – 9:00 a.m. Meet the Scientist (Ticketed Session)

Beyond the Niche: Systemic Regulation of Hematopoietic Stem Cell Numbers in Health and Disease
Hilton - Royal

Building Bone Marrow in a Dish: Bioengineered Niches for Understanding and Treating Platelet Disorders
Hilton - Windsor

Engineering Tolerance: CAR-Tregs and the New Era of Cell Therapy for Autoimmunity
Hilton - Fulton

From Ribosomes to Risk Stratification: Decoding Inherited Bone Marrow Failure and Its Path to Leukemia
Hilton - Magazine

Why the Mouse Matters: Building Faithful Models of Multiple Myeloma
Hilton - Parish

8:00 a.m. – 9:00 a.m. Product Theaters

Changing the ET Conversation: A New Paradigm in ET Management
Hall J Theater 4

DARZALEX FASPRO® + VRd: A Clinical Foundation from the CEPHEUS and PERSEUS Trials
291-292

Gene Addition Therapy in Sickle Cell Disease: Connecting Clinical Outcomes with the Patient Journey
Hall J Theater 3

Learn About A Frontline Treatment Option in Peripheral T-Cell Lymphoma
288-290

Let's Talk About Hemophilia Management Today
Hall J Theater 2

Ph+ CML-CP: A Nilotinib Treatment Option
Hall J Theater 6

9:00 a.m. – 9:25 a.m. MedEd Talks at ASH Studio

Interactive Teaching Methods
Hall D ASH Studio

9:00 a.m. – 9:30 a.m. Coffee Break in the Poster Hall (for in-person participants)

Hall F

9:05 a.m. – 9:15 a.m. ASH Wellness Studio

Sip Yourself Sharp
Hall D Wellness Studio

9:05 a.m. – 9:30 a.m. Blood Journals Studio

Meet the Journal Editors: Blood Neoplasia
Hall F Blood Journals Studio

9:15 a.m. – 9:25 a.m. ASH Wellness Studio

Reclaim Your Spark
Hall D Wellness Studio

9:30 a.m. – 10:45 a.m. Education Program

Advancing Personalized Care in Classic Hodgkin Lymphoma
278-282

9:30 a.m. – 10:45 a.m. Scientific Program

Scientific Committee on Myeloid Neoplasia: Innovations in the Detection and Characterization of Chemoresistant Cells in AML: From Molecular MRD to Molecular Resistance Mechanisms
R06-R09

Scientific Committee on Transplant Biology and Cellular Therapies: Power Sharing: Transplantation and Cellular Therapy in Autoimmunity
Hall E

Scientific Committee on Hematopoiesis: Through Space and Time: Spatiotemporal Organization of Haematopoiesis in Health and Disease
295-296

9:30 a.m. – 10:45 a.m. Scientific Symposia

AI Models of Cell State for the Design of Next-Generation T Cell Therapies
393-396

Designing Microbiome-Directed Interventional Trials in Hematologic Malignancies
288-290

9:30 a.m. – 11:00 a.m. Early Faculty Career Development Session

293-294

9:30 a.m. – 11:00 a.m. From Real-World Evidence to Real-World Impact: Translating Multiple Myeloma Data into Clinical Practice

265-268

9:30 a.m. – 11:00 a.m. Oral Abstract Sessions

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advancing Sickle Cell Disease Care on All Fronts
252-254

301. Platelets and Megakaryocytes: Basic and Translational: Megakaryocytes and Platelets from Development to Defense
208-210

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis and Hemorrhage in Hematologic Malignancy: From CAR T-Cells to Clonal Hematopoiesis
217-219

503. Clonal Hematopoiesis, Aging, and Inflammation: Forces Shaping Clonal Selection
291-292

603. Lymphoid Oncogenesis: Basic: Metabolic and Immune Mechanisms
260-262

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Prognostic and Predictive Factors in AML and BPDCN
Hall B

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Emerging Clinically Relevant Biomarkers in AML
Great Hall BC

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

621. Lymphomas: Translational – Molecular and Genetic
275-277

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Emerging Targeted Therapies in NK/T-Cell Lymphomas and HLH: From Epigenetic Modulation to JAK Signaling
New Orleans Theatre C

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Evaluation of Newly-Diagnosed DLBCL Patients
New Orleans Theatre B

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Combining Forces Against Myelofibrosis
R02-R05

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Novel Targeted Agents and Combination Regimens in CMML, MDS, and MDS/MPN Overlap Neoplasms: Emerging Clinical Trial Data
Hall C

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Studies in Previously Untreated CLL/SLL
New Orleans Theatre A

653. Multiple Myeloma: Clinical and Epidemiological: Optimizing Sequencing and Toxicity Management with Novel Myeloma Therapies
La Nouvelle A-B

656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: The Evolving Landscape of Risk Definition in Multiple Myeloma
La Nouvelle C

702. CAR-T Cell Therapies: Basic and Translational: Next-Generation CAR T-cell Therapy Strategies for AML
Great Hall AD

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities
343-345

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Advances in GVHD Prophylaxis and Immune Reconstitution after Allogeneic HCT
388-390

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Predicting and Preventing Post-transplant Relapse and GvHD: Minimal Residual Disease, Immune Dynamics, and Biomarkers
353-355

900. Health Services and Quality Improvement: Hemoglobinopathies: Improving How Sickle Cell Care is Organized, Implemented, and Delivered Across Healthcare Settings
243-245

902. Health Services and Quality Improvement: Lymphoid Malignancies: Monitoring, Demographics, and Access to Care
271-273

9:30 a.m. – 11:00 a.m. Scientific Program

Scientific Committee on Thrombosis & Vascular Biology: How Clots Form and Fall Apart: From Engineered Vessels to Targeted Therapies
220-222

9:30 a.m. – 11:05 a.m. Scientific Program

Scientific Committee on Hematopathology and Clinical Laboratory Hematology & Scientific Committee on Lymphoid Neoplasia: JOINT SESSION - Bridging the Gap: Research and Clinical Implications of Emerging Technologies in Hematology
391-392

10:00 a.m. – 5:00 p.m. Exhibits Open

Halls G-J

11:00 a.m. – 11:25 a.m. Treating Fairly Talks at ASH Studio

Expanding Access to Therapies for Underserved Populations
Hall D ASH Studio

11:00 a.m. – 12:30 p.m. Complimentary Light Lunch at ASH Cafe (for in-person participants)

Hall J Foyer-ASH Cafe

11:00 a.m. – 12:30 p.m. LBGTQIA+ Community Networking Brunch

Marriott Warehouse - Cypress I-II

11:00 a.m. – 12:30 p.m. Live Music and Outdoor Lunch Seating (for in-person participants)

Heritage Porch

11:05 a.m. – 11:15 a.m. ASH Wellness Studio

Own Your Time
Hall D Wellness Studio

11:15 a.m. – 12:15 p.m. ASH Poster Walks

ASH Poster Walk on Innovations in Hemostasis and Thrombosis Clinical Research Design Hosted by Blood Vessels, Thrombosis & Hemostasis
Hall F Blood Journals Studio

11:15 a.m. – 12:15 p.m. Showcasing a Decade of Discoveries in *Blood Advances*

252-254

11:15 a.m. – 12:15 p.m. Trainee Didactic Sessions (Open to Trainees Only)

Giving a Scientific Presentation
260-262

How to Transition from Academia to Industry or Community Practice
265-268

11:15 a.m. – 12:30 p.m. ASH Clinicians in Practice Lunch - Beyond Bandwidth: Improving Workflow Efficiency in Clinical Practice through Clinical Collaborations and Artificial Intelligence

Marriott Warehouse - Gravier C-F

11:20 a.m. – 11:30 a.m. ASH Wellness Studio

Quiet the Noise
Hall D Wellness Studio

11:30 a.m. – 12:30 p.m. Product Theaters

A BCMA-Directed Bispecific for the Treatment of Patients with R/R Multiple Myeloma After At Least 4 Prior Lines of Treatment
Hall J Theater 1

Challenging the Status Quo in Thalassemia Management: Hear Patient Perspectives and Discover an Oral Treatment Option from Agios Pharmaceuticals
Hall J Theater 4

First-in-Class Treatment for Patients with Relapsed or Refractory Multiple Myeloma
Hall J Theater 5

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

From Data to Decisions: Advancing Patient Care in 2L+ Follicular Lymphoma and R/R DLBCL
Hall J Theater 6

Real-World Management of Hemophilia A and B: Clinical Cases with Rebalancing and Factor Replacement Therapies
Hall J Theater 3

See How Jaypirca® (pirtobrutinib) is Sparking More Possibilities
Hall J Theater 2

11:30 a.m. – 12:30 p.m. Treating Fairly Rounds Lunch

Marriott Warehouse - Gravier AB

11:35 a.m. – 11:45 a.m. ASH Wellness Studio

Shake it Off
Hall D Wellness Studio

12:00 p.m. – 12:25 p.m. MedEd Talks at ASH Studio

Leadership Skills and Styles in Medical Education
Hall D ASH Studio

12:00 p.m. – 1:30 p.m. Oral Abstract Sessions

101. Red Cells and Erythropoiesis, Excluding Iron: Programming Erythropoiesis: From Chromatin Architecture to Red Cell Fate
291-292

321. Coagulation and Fibrinolysis: Basic and Translational: Right Protein, Right Place: Compartmentalized Coagulation in Development, Vasculature, and Organ Injury
220-222

322. Hemophilia A and B: Clinical and Epidemiological: Precision Hemophilia Care: Bleeding Prediction and Overcoming Inhibitors
217-219

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Mechanistic Insights and Therapeutic Strategies
295-296

628. Aggressive Lymphomas: Cellular Therapies: Optimizing Every Step of the CAR T-Cell Journey in Large B-Cell Lymphoma
New Orleans Theatre C

629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: Clinical Trials in Untreated and Relapsed/Refractory LBCL, Including CNS Lymphoma
New Orleans Theatre B

656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: Tracking MRD in Blood and Marrow of Multiple Myeloma Patients
La Nouvelle A-B

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Hemoglobinopathies, Fungus, and Deceased Donor HPCs, Oh My!
243-245

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Decoding Cytopenias
208-210

907. Outcomes Research: Plasma Cell Disorders: T-Cell–Redirecting Therapies in Multiple Myeloma: Treatment Optimization and Emerging Toxicities
La Nouvelle C

909. Medical Education and Workforce Development: Shaping the Future: From AI to Wellbeing and the Hematology Workforce
293-294

12:30 p.m. – 1:30 p.m. ASH-EHA Joint Symposium: Novel Approaches to Cell Engineering in Hematopoietic Cell Transplantation

Hall E

1:30 p.m. – 1:55 p.m. Treating Fairly Talks at ASH Studio

What is "Normal?" Updating Absolute Neutrophil Count Reference Ranges by Duffy Status
Hall D ASH Studio

1:30 p.m. – 2:00 p.m. Announcement of Awards: Outstanding Service Award, Roland B. Scott-Charles Drew Excellence in Equity Award and Wallace H. Coulter Award for Lifetime Achievement in Hematology

Hall E

1:30 p.m. – 4:00 p.m. Simulcast of Awards and Plenary Scientific Session

208-210 & New Orleans Theatre C

2:00 p.m. – 4:00 p.m. Plenary Scientific Session

Hall E

4:00 p.m. – 4:25 p.m. Treating Fairly Talks at ASH Studio

Building Infrastructure for Systemic Change in Maternal Health Outcomes
Hall D ASH Studio

4:00 p.m. – 4:30 p.m. Blood Journals Studio

Meet the Journal Editors: Blood Vessels, Thrombosis & Hemostasis
Hall F Blood Journals Studio

4:00 p.m. – 4:30 p.m. Coffee Break in the Exhibit Hall (for in-person participants)

Halls G-J

4:05 p.m. – 4:15 p.m. ASH Wellness Studio

Eat for Energy
Hall D Wellness Studio

4:15 p.m. – 4:25 p.m. ASH Wellness Studio

The Instant Calm
Hall D Wellness Studio

4:15 p.m. – 4:30 p.m. Clinical Trial Showcases

Evaluating Osivelotor in Sickle Cell Disease: The Phase 3 DREAM Trial
Hall J Theater 5

4:15 p.m. – 4:30 p.m. Company Showcases

A New Standard in MRD Assessment: ARUP CLARISPECT(TM) Supports Highly Sensitive Detection for Rare Residual Malignant Populations
Hall J Theater 3

AbbVie In Oncology
Hall J Theater 1

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Eilean Therapeutics. Targeting Escape Mutations in Hematological Cancers with First and Best in Class Medicines
Hall J Theater 4

4:30 p.m. – 5:45 p.m. Education Program

A New Treatment Paradigm for Follicular Lymphoma
New Orleans Theatre A

Are We There Yet? Improving Outcomes in MDS
R02-R05

Building Hematology Capacity Globally
293-294

Driving CARs Safely- Preventing and Managing Intermediate and Long-Term CAR-T Toxicity
New Orleans Theatre C

From Mutations to Manifestations: Connecting Clonal Hematopoiesis (CH) and Thrombosis
208-210

Hemolysis Beyond Globin: Managing Inherited RBC Membrane and Enzyme Disorders
275-277

Innovations in the Treatment of Pediatric AML
Hall E

Tailored Transfusion Strategies for Alloimmunized Patients
353-355

4:30 p.m. – 5:45 p.m. Education Spotlight Sessions

Current Perspectives on Evolving Classification of Myeloid and Lymphoid Neoplasms
391-392

4:30 p.m. – 5:45 p.m. Scientific Program

Scientific Committee on Hemostasis: Built to Clot, Built to Break: Structural Control of Hemostasis and Fibrinolysis
220-222

Scientific Committee on Megakaryocytes and Platelets: Rethinking Antiplatelet Strategies: Selective Blockade, Broad-Acting Drugs, and Beyond
217-219

Scientific Committee on Red Cell Biology: Understanding and Targeting Metabolism in Erythrocyte Development and Disorders
291-292

4:30 p.m. – 5:45 p.m. Scientific Spotlight Sessions

Decoding Macrophage Diversity in Lymphomas: Spatial Insights and Immunotherapeutic Implications
271-273

Sticky Situations: Glycans in Classical and Malignant Hematopoiesis
288-290

4:30 p.m. – 6:00 p.m. Oral Abstract Sessions

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Strategies and Modulation of Anti-Tumor Responses
260-262

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies - Novel Combinations with Menin, FLT3 and BCL2 Inhibitors
Hall B

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Genetic Heterogeneity and Functional Vulnerabilities in AML
Great Hall BC

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Triple S: MPN Goes Spatial, Selective and to the Cell Surface!
Hall C

641. Chronic Lymphocytic Leukemia: Basic and Translational: Resolving Complexity of CLL and Richter Transformation
265-268

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Optimizing T-cell Redirected Therapy for Myeloma and Related Conditions
La Nouvelle C

656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: Immune and Microenvironment Drivers of Treatment Outcomes in Multiple Myeloma
La Nouvelle A-B

701. Experimental Transplantation: Basic and Translational: Emerging Biology to Translational Innovation I
343-345

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Next-Generation CAR T-Cell Therapy in Lymphoma: In Vivo Engineering and Beyond
New Orleans Theatre B

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Long-term Follow-up After Allogeneic Hematopoietic Cell Transplantation
388-390

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Allogeneic Transplantation for Myeloid Malignancies: Timing, Donors, and Disease Control
Great Hall AD

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: From Iron to Immunity: Real-World Outcomes in Classical Hematology
252-254

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders - Outcomes Across the Age Spectrum: Assessment, Tolerability, and Survivorship
278-282

908. Outcomes Research: Myeloid Malignancies: From Patient Voice to Clinical Impact: PROs and Real-World Outcomes in an Evolving Digital Era
R06-R09

4:30 p.m. – 6:00 p.m. Real-World Data Applications in Sickle Cell Disease Trial Design

243-245

4:30 p.m. – 6:00 p.m. The AI Colleague: Promise, Peril, and Practice in Hematology

393-396

6:00 p.m. – 8:00 p.m. Poster Hall Reception (for in-person participants)

Hall F

6:00 p.m. – 8:00 p.m. Poster Session II – Presentations (for in-person participants)

Hall F

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II (2859–2880)

102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster II (2881–2894)

112. Thalassemia and Globin Gene Regulation: Poster II (2895–2899)

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II (2900–2915)

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II (2916–2956)

201. Granulocytes, Monocytes, and Macrophages: Poster II (2957–2976)

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II (2977–2991)

301. Platelets and Megakaryocytes: Basic and Translational: Poster II (2992–2999)

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II (3000–3026)

321. Coagulation and Fibrinolysis: Basic and Translational: Poster II (3027–3033)

322. Hemophilia A and B: Clinical and Epidemiological: Poster II (3034–3049)

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II (3050–3062)

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster II (3063–3074)

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster II (3075–3085)

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II (3086–3110)

401. Blood Transfusion: Poster II (3111–3119)

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II (3120–3130)

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II (3131–3146)

506. Bone Marrow Microenvironment: Poster II (3147–3155)

508. Bone Marrow Failure: Acquired: Poster II (3156–3178)

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II (3179–3192)

602. Myeloid Oncogenesis: Basic: Poster II (3193–3218)

603. Lymphoid Oncogenesis: Basic: Poster II (3219–3232)

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II (3233–3263)

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II (3264–3280)

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II (3281–3300)

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II (3301–3322)

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster II (3323–3337)

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II (3338–3384)

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II (3385–3402)

617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II (3403–3431)

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II (3432–3479)

619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster II (3480–3487)

621. Lymphomas: Translational – Molecular and Genetic: Poster II (3488–3516)

622. Lymphomas: Translational – Non-Genetic: Poster II (3517–3534)

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II (3535–3580)

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II (3581–3592)

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II (3593–3619)

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster II (3620–3647)

627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster II (3648–3673)

628. Aggressive Lymphomas: Cellular Therapies: Poster II (3674–3693)

629. Aggressive Lymphomas, Non-Cellular Immunotherapy including Bispecific Antibodies: Poster II (3694–3720)

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II (3721–3742)

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II (3743–3761)

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II (3762–3816)

636. Myelodysplastic Syndromes: Basic and Translational: Poster II (3817–3828)

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II (3829–3861)

641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II (3862–3872)

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II (3873–3912)

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II (3913–3949)

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II (3950–3968)

653. Multiple Myeloma: Clinical and Epidemiological: Poster II (3969–4007)

654. Multiple Myeloma: Pharmacologic Therapies: Poster II (4008–4034)

655. Multiple Myeloma: Cellular Therapies: Poster II (4035–4054)

656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, including Minimal Residual Disease: Poster II (4055–4081)

701. Experimental Transplantation: Basic and Translational: Poster II (4082–4097)

702. CAR-T Cell Therapies: Basic and Translational: Poster II (4098–4142)

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster II (4143–4153)

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II (4154–4182)

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II (4183–4192)

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II (4193–4226)

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II (4227–4255)

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II (4256–4279)

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II (4280–4302)

801. Gene Therapies: Poster II (4303–4316)

802. Chemical Biology and Experimental Therapeutics: Poster II (4317–4322)

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II (4323–4356)

900. Health Services and Quality Improvement: Hemoglobinopathies: Poster II (4357–4370)

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II (4371–4388)

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II (4389–4417)

903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II (4418–4431)

904. Outcomes Research: Hemoglobinopathies: Poster II (4432–4445)

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II (4446–4473)

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II (4474–4534)

907. Outcomes Research: Plasma Cell Disorders: Poster II (4535–4568)

908. Outcomes Research: Myeloid Malignancies: Poster II (4569–4607)

909. Medical Education and Workforce Development: Poster II (4608–4618)

MONDAY, DECEMBER 14, 2026

7:00 a.m. – 5:00 p.m. **Registration at the Convention Center (for in-person participants)**

Great Hall Foyer

7:00 a.m. – 6:00 p.m. **Learn, Engage, and Relax in ASH Central (for in-person participants)**

Hall D

7:00 a.m. – 7:45 a.m. **ASH Yoga (for in-person participants)**

Magnolia Porch

7:30 a.m. – 9:00 a.m. **Back to Business Breakfast**

Marriott Warehouse - Gravier ABC

8:00 a.m. – 8:00 p.m. **Poster Session III - Viewing**

Hall F

8:00 a.m. – 8:25 a.m. **Treating Fairly Talks at ASH Studio**

What is "Normal?" Updating Absolute Neutrophil Count Reference Ranges by Duffy Status
Hall D ASH Studio

8:00 a.m. – 9:00 a.m. **ASH Poster Walks**

ASH Poster Walk on Beyond Acute Vaso-Occlusion: Emerging Mechanisms and Phenotypes of Chronic Pain in Sickle Cell Disease Hosted by Blood Red Cells & Iron
Hall F Blood Journals Studio

8:00 a.m. – 9:00 a.m. **Coffee and Collaboration in ASH Central (for in-person participants)**

Hall D

8:00 a.m. – 9:00 a.m. **Industry Theaters**

Advancing Care in Primary Central Nervous System Lymphoma: Evolving Treatment Approaches
288-290

Beyond BCMA: Investigating GPRC5D CAR T Therapy in RRMM
Hall J Theater 5

Hemolysis in Sickle Cell Disease (SCD): Connecting Biology, Clinical Outcomes, and the Lived Experience
Hall J Theater 6

Integrated Innovation in Cell Therapy: From Manufacturing to Clinical Development
Hall J Theater 4

8:00 a.m. – 9:00 a.m. **Product Theaters**

7-Year Follow-up of the POLARIX Study
Hall J Theater 3

HYMPAVZI (marstacimab-hncq): Expanding Possibilities in Hemophilia Management and Case-Based Treatment Considerations
Hall J Theater 2

The APP Perspective: Building Confidence With DARZALEX Faspro®
291-292

Understanding the Evolving Treatment Landscape of Relapsed/Refractory NPM1-mutated AML
Hall J Theater 1

9:00 a.m. – 10:00 a.m. **Announcement of Awards: J. Evan Sadler Award for Mentorship, Bernard Forget Award for Mentorship, and E. Donnall Thomas Lecture and Prize**

Leveraging the Biology of the MLL (KMT2A) Complex to Discover New Therapies for Leukemia
Hall E

10:00 a.m. – 2:00 p.m. **Exhibits Open**

Halls G-J

10:00 a.m. – 10:15 a.m. **Clinical Trial Showcases**

Closing the Evidence Gap in Hemophilia: Marstacimab Phase 3 Clinical Trial in Mild to Moderate Hemophilia and the MARVL-US Real-World Study
Hall J Theater 5

Phase 2 and 3 Placebo-Controlled and Long-Term Extension Study of Rilzabrutinib in Adults with iCVID to Evaluate Efficacy, Safety, and Tolerability
Hall J Theater 3

Sutimlimab in Adults with Chronic ITP: An Upcoming Phase 3 Clinical Trial
Hall J Theater 1

10:00 a.m. – 10:25 a.m. **Treating Fairly Talks at ASH Studio**

Engaging American Indians and Alaska Native Populations in Community Interventions/Research
Hall D ASH Studio

10:00 a.m. – 10:30 a.m. **Blood Journals Studio**

Meet the Journal Editors: Blood Red Cells & Iron
Hall F Blood Journals Studio

10:00 a.m. – 10:30 a.m. **Coffee Break in the Exhibit Hall (for in-person participants)**

Halls G-J

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

10:05 a.m. – 10:15 a.m. ASH Wellness Studio

Sip Yourself Sharp
Hall D Wellness Studio

10:15 a.m. – 10:25 a.m. ASH Wellness Studio

Own Your Time
Hall D Wellness Studio

10:15 a.m. – 10:30 a.m. Clinical Trial Showcases

LIBRA – A Randomized Placebo-Controlled Study Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Sickle-Cell Disease (SCD)
Hall J Theater 3

10:30 a.m. – 11:45 a.m. Education Program

Advances in Management of Vascular Anomalies
220-222

Managing Iron Status Before and During Pregnancy: Protecting Mother and Fetus
Hall E

The Golden Era of ALL Management: Rapid Advances Across the Age Spectrum
278-282

The Heart and Brain in Older Patients with Sickle Cell Disease
243-245

10:30 a.m. – 11:45 a.m. Education Spotlight Sessions

Public Health & Hematology: Results and Lessons from the PEN-Plus Model of Care for Severe, Chronic Non-Communicable Diseases like Sickle Cell Disease in Resource-Poor Areas
295-296

Rebooting the Immune System with Cellular Therapies
275-277

Splenectomy in Membrane Disorders and Enzymopathies: Who, When and How?
391-392

10:30 a.m. – 11:45 a.m. Scientific Program

Scientific Committee on Blood Disorders in Childhood: Unlocking Blood Disorders: Targeting Genetics to Identify Early Phenotypes
208-210

10:30 a.m. – 11:45 a.m. Scientific Spotlight Sessions

Illuminating the Dark Corners in the Genomes of Lymphoid Neoplasms
288-290

10:30 a.m. – 12:00 p.m. ASH-FDA Joint Symposium on Newly Approved Therapies 1

343-345

10:30 a.m. – 12:00 p.m. Clinical Practice Guidelines on the Treatment of Light-Chain Amyloidosis

293-294

10:30 a.m. – 12:00 p.m. Oral Abstract Sessions

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: End-organ Dysfunction in Sickle Cell Disease: From Risk Prediction to Therapeutic Innovation
252-254

201. Granulocytes, Monocytes, and Macrophages: Decoding Neutrophil and Macrophage Biology: Novel Insights into Congenital Neutropenia Defects, Inflammation, and Leukemia Immunology
291-292

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Reshaping the Research Frontier in ITP: Targeted Therapeutics and Validation of the ITP Diagnosis
217-219

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Cell-Intrinsic and Niche-Mediated Mechanisms of Drug Resistance in AML
Great Hall BC

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: New Genomic and Immunologic Insights
265-268

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Optimizing Treatment Decisions for Acute Myeloid Leukemia in Pediatric and AYA Patients
R02-R05

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Novel Immunotherapeutic Approaches to AML
Hall C

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Finite vs. Forever: Redefining Treatment Duration in Relapsed/Refractory Waldenstrom's Macroglobulinemia and Marginal Zone Lymphoma
New Orleans Theatre B

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Precision Approaches in NK/T-Cell Lymphoma and CTCL: Optimizing Therapy and Predicting Outcomes
New Orleans Theatre A

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials
New Orleans Theatre C

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: New Drugs, New Paradigms in CML
R06-R09

637. Myelodysplastic Syndromes: Clinical and Epidemiological
Great Hall AD

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Initial CLL Treatment Strategies with Targeted Agent Combinations and MRD-guidance
271-273

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Transcriptional and Epigenetic Control of MM
La Nouvelle A-B

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Advancing Treatment Strategies in AL Amyloidosis
260-262

702. CAR T-cell Therapies: Basic and Translational: Engineering CAR-T Cell Fitness, Persistence, and Safety
353-355

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution
388-390

907. Outcomes Research: Plasma Cell Disorders: Real-World Efficacy of Immunotherapy
La Nouvelle C

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

908. Outcomes Research: Myeloid Malignancies: Advancing Precision and Value-Based Care in AML: Real-World Evidence Across the Disease Continuum
Hall B

12:00 p.m. – 12:25 p.m. MedEd Talks at ASH Studio

Giving Feedback and Remediation for UME/GME
Hall D ASH Studio

12:00 p.m. – 1:30 p.m. Celebrating Diverse Voices: Enriching Hematology Lunch

Marriott Warehouse - Cypress I-II

12:00 p.m. – 1:30 p.m. Complimentary Light Lunch at ASH Cafe (for in-person participants)

Hall J Foyer-ASH Cafe

12:00 p.m. – 1:30 p.m. Live Music and Outdoor Lunch Seating (for in-person participants)

Heritage Porch

12:05 p.m. – 12:15 p.m. ASH Wellness Studio

Eat for Energy
Hall D Wellness Studio

12:15 p.m. – 1:15 p.m. ASH Poster Walks

ASH Poster Walk on Leukemia in Latin America: Outcomes and Access to Diagnostics and Therapies Hosted by Blood Global Hematology
Hall F Blood Journals Studio

12:15 p.m. – 1:15 p.m. Industry Theaters

Building the Evidence: Novo Nordisk's Investigational Clinical Development in Sickle Cell Disease and Thalassemia
Hall J Theater 6

12:15 p.m. – 1:15 p.m. Product Theaters

Beyond a Single Biomarker: NGS Solutions for Hematologic Malignancies MRD Research
Hall J Theater 4

Expanding Community Therapy Options in Relapsed or Refractory Multiple Myeloma: A BCMA-Targeted Option
Hall J Theater 3

Indolent Mastocytosis: Evolving Perspectives on Treatment and Patient Impact
Hall J Theater 5

OMISIRGE®: Challenging Conventional Thinking About Time to Transplant and Patient Outcomes in Hematological Conditions with a Novel Cell Therapy Donor Source
Hall J Theater 1

Unlocking the Potential for a Bispecific Antibody in 2L+ FL and 3L+ DLBCL
Hall J Theater 2

12:15 p.m. – 1:15 p.m. Trainee Didactic Sessions (Open to Trainees Only)

How to Transition from Trainee to Faculty
260-262

Mentoring and Being Mentored
265-268

12:20 p.m. – 12:30 p.m. ASH Wellness Studio

Quiet the Noise
Hall D Wellness Studio

12:35 p.m. – 12:45 p.m. ASH Wellness Studio

Shake It Off
Hall D Wellness Studio

1:00 p.m. – 1:25 p.m. Treating Fairly Talks at ASH Studio

Iron Deficiency Interventions in Low Resource Settings
Hall D ASH Studio

1:15 p.m. – 1:30 p.m. Blood Journals Studio

Meet the Journal Editors: Blood Global Hematology
Hall F Blood Journals Studio

1:30 p.m. – 2:30 p.m. Ernest Beutler Lecture and Prize: How Molecular Understanding of Apoptosis Led to a New Class of Cancer Therapeutics

Hall E

2:30 p.m. – 2:45 p.m. Coffee Break in the Poster Hall (for in-person participants)

Hall F

2:35 p.m. – 2:45 p.m. ASH Wellness Studio

The Instant Calm
Hall D Wellness Studio

2:45 p.m. – 4:00 p.m. Education Program

Chronic Lymphocytic Leukemia - From Clonal Evolution to Novel Therapies
271-273

Diffuse Large B-cell Lymphoma
278-282

Improving Care of Patients with Sickle Cell Disease via Complement, Pain Control, and Trial Design
Hall E

2:45 p.m. – 4:00 p.m. Education Spotlight Sessions

Balancing Bleeding and Clotting: Extended VTE Treatment for Whom and at What Dose?
208-210

2:45 p.m. – 4:00 p.m. Scientific Program

Scientific Committee on Stem Cells and Regenerative Medicine: Balancing the Blood: Immune Control of Stem Cell Fidelity
275-277

2:45 p.m. – 4:00 p.m. Scientific Spotlight Sessions

CAR-T Manufacturing Across Nations: From Low-to-Middle-Income Academic Platforms to Frontier Innovations in Global Access
391-392

Greasy Situations: Unraveling Lipid-Mediated Therapy Resistance
288-290

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

2:45 p.m. – 4:15 p.m. ASH-FDA Joint Symposium on Newly Approved Therapies 2

343-345

2:45 p.m. – 4:15 p.m. Clinical Practice Guidelines on the Treatment of Iron Deficiency with or without Anemia

293-294

2:45 p.m. – 4:15 p.m. Oral Abstract Sessions

102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Iron at the Crossroads: Physiology, Pathology, Including Pregnancy
291-292

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Red Cell Rescue: Novel Approaches in Sickle Cell Disease
243-245

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Immune Dysregulation and Clinical Translation
R06-R09

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: New Therapeutics in ITP and Chemotherapy-Induced Thrombocytopenia
217-219

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological
220-222

602. Myeloid Oncogenesis: Basic: Rewiring Chromatin, Metabolism, and Immunity in Myeloid Neoplasms
R02-R05

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Clinical, Genomic, and Social Predictors of Outcomes
265-268

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Venetoclax-based Therapy and AML Risk
Great Hall AD

617. Acute Myeloid Leukemias: Commercially Available Therapies: Molecularly Targeted Combinations in AML
Great Hall BC

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Cellular and Immune Therapies in T-Cell and NK-Cell Malignancies
New Orleans Theatre B

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: From Trials to Reality: Real-World Evidence in Large B-cell Lymphoma
New Orleans Theatre C

629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: T-cell Engagers and ADC Combinations and Long-Term Outcomes of Trials in Relapsed/Refractory LBCL
New Orleans Theatre A

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Molecular Insights and New Approaches in MPNs
Hall B

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myeloma Genomics
La Nouvelle A-B

653. Multiple Myeloma: Clinical and Epidemiological: Evolving Population-Level Outcomes and Trends
La Nouvelle C

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence
353-355

801. Gene Therapies: Beyond Transplant: The Expanding Role of Gene Therapy in Hematology
388-390

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: AI at the Bedside: From Prediction to Therapeutic Decisions
393-396

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: H and T on the Rocks: Real-World Hemostasis and Thrombosis
252-254

907. Outcomes Research: Plasma Cell Disorders: Beyond Response Rates: T-cell Engagement in the Real World
260-262

908. Outcomes Research: Myeloid Malignancies: Mind the (Molecular) Gap: From Testing to Trials, Across Race and Place
Hall C

2:45 p.m. – 4:15 p.m. The Predicament of Patients in Prison: A Hematology Perspective

295-296

4:30 p.m. – 5:45 p.m. Education Program

A Decade of Progress Towards Safer and More Broadly Applicable Allogeneic Stem Cell Transplantation
343-345

Battle-Scarred Blood Cells: Hematologic Malignancies in Military Service Members
278-282

Don't Miss It! Methemoglobinemia: Inherited and Acquired
293-294

Multiple Myeloma: The Future is Now
Hall E

Neutropenia: Updates in Diagnosis, Treatment, and Supportive Care.
275-277

4:30 p.m. – 5:45 p.m. Education Spotlight Sessions

Bispecific Antibody Therapy vs CAR T Therapy in Lymphoid Malignancies
271-273

4:30 p.m. – 5:45 p.m. Scientific Program

Scientific Committee on Iron and Heme: Iron Homeostasis Across the Lifespan in Health and Disease
288-290

Scientific Committee on Bone Marrow Failure: The Great Escape- Immune Evasions in Bone Marrow Failure
295-296

4:30 p.m. – 6:00 p.m. Oral Abstract Sessions

101. Red Cells and Erythropoiesis, Excluding Iron: How to Make a Red Cell: Remodeling, Enucleation, Signaling, and Resilience
291-292

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: T and NK Cell Development and Anti-Tumor Functions
R06-R09

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms
Hall B

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Frontline Therapy in Acute Lymphoblastic Leukemia: At the Crossroads of Chemotherapy, Immunotherapy, and Targeted Therapy Across the Age Spectrum
265-268

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Chemotherapy and Transplantation
Great Hall BC

617. Acute Myeloid Leukemias: Commercially Available Therapies
Great Hall AD

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - From Cytotoxic to Selective: The BTK Inhibitor Revolution in The Frontline Treatment of Mantle Cell Lymphoma
New Orleans Theatre B

624. Hodgkin Lymphomas: Clinical and Epidemiological: Precision, Prognostication, and Paradigm Shifts
New Orleans Theatre C

628. Aggressive Lymphomas: Cellular Therapies: Novel CAR-T Constructs, Durability, and Long-Term Outcomes
New Orleans Theatre A

634. Myeloproliferative Syndromes: Clinical and Epidemiological: ET and PV: Moving Beyond Conventional Therapy
Hall C

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myeloma Basic and Translational Research
La Nouvelle C

653. Multiple Myeloma: Clinical and Epidemiological: Differentiating Multiple Myeloma(s): A Path to Cure
La Nouvelle A-B

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Early Innovation of Immune Effector Cell Therapies
388-390

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prophylaxis-Clinical and Translational Aspects
353-355

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Emerging Technologies for Molecular Classification, Monitoring, and Modelling
393-396

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: A World of Bleeding and Clotting
217-219

903. Health Services and Quality Improvement: Myeloid Malignancies: JAKPOT! Improving Care Quality from Pre-hab, Sleep, and Home Transfusions to Pall-care, Costs, and JAK Testing
R02-R05

904. Outcomes Research: Hemoglobinopathies: Therapeutic Innovation and Clinical Outcomes in Hemoglobinopathies
252-254

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Platelets in Practice: Outcomes Across ITP, TTP, and TMA
243-245

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Assessing Real World Effectiveness and Toxicity of Immune and Cellular Therapies
260-262

4:30 p.m. – 6:00 p.m. Scientific Symposia

Special Symposium on the Basic Science of Hemostasis and Thrombosis (SSBSHT)
208-210

4:30 p.m. – 6:00 p.m. The Future of Clinical Endpoints in Sickle Cell Disease

220-222

6:00 p.m. – 7:30 p.m. ASH Networking Reception for the Hemostasis and Thrombosis Community

Rivergate Terrace

6:00 p.m. – 8:00 p.m. ASH Networking Reception for the Sickle Cell Disease Community

215-216

6:00 p.m. – 8:00 p.m. Poster Hall Reception (for in-person participants)

Hall F

6:00 p.m. – 8:00 p.m. Poster Session III – Presentations (for in-person participants)

Hall F

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III (4619–4640)

102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster III (4641–4653)

112. Thalassemia and Globin Gene Regulation: Poster III (4654–4658)

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III (4659–4674)

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III (4675–4717)

201. Granulocytes, Monocytes, and Macrophages: Poster III (4718–4738)

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III (4739–4752)

301. Platelets and Megakaryocytes: Basic and Translational: Poster III (4753–4761)

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III (4762–4787)

321. Coagulation and Fibrinolysis: Basic and Translational: Poster III (4788–4795)

322. Hemophilia A and B: Clinical and Epidemiological: Poster III (4796–4811)

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster III (4812–4824)

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster III (4825–4836)

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster III (4837–4847)

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III (4848–4870)

401. Blood Transfusion: Poster III (4871–4878)

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III (4879–4891)

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster III (4892–4906)

506. Bone Marrow Microenvironment: Poster III (4907–4915)

508. Bone Marrow Failure: Acquired: Poster III (4916–4938)

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III (4939–4952)

602. Myeloid Oncogenesis: Basic: Poster III (4953–4978)

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

603. Lymphoid Oncogenesis: Basic: Poster III (4979–4992)

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III (4993–5023)

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III (5024–5041)

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III (5042–5061)

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III (5062–5082)

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster III (5083–5098)

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III (5099–5145)

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III (5146–5163)

617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III (5164–5192)

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III (5193–5240)

619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster III (5241–5247)

621. Lymphomas: Translational – Molecular and Genetic: Poster III (5248–5277)

622. Lymphomas: Translational – Non-Genetic: Poster III (5278–5295)

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III (5296–5340)

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster III (5341–5351)

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III (5352–5378)

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster III (5379–5406)

627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster III (5407–5432)

628. Aggressive Lymphomas: Cellular Therapies: Poster III (5433–5453)

629. Aggressive Lymphomas, Non-Cellular Immunotherapy including Bispecific Antibodies: Poster III (5454–5480)

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III (5481–5503)

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III (5504–5522)

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III (5523–5576)

636. Myelodysplastic Syndromes: Basic and Translational: Poster III (5577–5588)

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III (5589–5622)

641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster III (5623–5632)

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III (5633–5674)

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III (5675–5710)

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III (5711–5729)

653. Multiple Myeloma: Clinical and Epidemiological: Poster III (5730–5767)

654. Multiple Myeloma: Pharmacologic Therapies: Poster III (5768–5795)

655. Multiple Myeloma: Cellular Therapies: Poster III (5796–5814)

656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, including Minimal Residual Disease : Poster III (5815–5842)

701. Experimental Transplantation: Basic and Translational: Poster III (5843–5858)

702. CAR-T Cell Therapies: Basic and Translational: Poster III (5859–5904)

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster III (5905–5915)

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III (5916–5944)

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III (5945–5954)

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III (5955–5988)

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III (5989–6017)

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III (6018–6040)

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III (6041–6063)

801. Gene Therapies: Poster III (6064–6078)

802. Chemical Biology and Experimental Therapeutics: Poster III (6079–6085)

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III (6086–6120)

900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III (6121–6134)

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III (6135–6151)

902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III (6152–6180)

903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III (6181–6193)

904. Outcomes Research: Hemoglobinopathies: Poster III (6194–6207)

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III (6208–6235)

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III (6236–6291)

907. Outcomes Research: Plasma Cell Disorders: Poster III (6292–6325)

908. Outcomes Research: Myeloid Malignancies: Poster III (6326–6365)

909. Medical Education and Workforce Development: Poster III (6366–6377)

7:30 p.m. – 9:00 p.m. **Women in Hematology Networking Dinner Event**

Hilton - St. Charles Ballroom

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

TUESDAY, DECEMBER 15, 2026

7:00 a.m. – 1:30 p.m. **Registration at the Convention Center (for in-person participants)**

Great Hall Foyer

7:00 a.m. – 1:30 p.m. **Learn, Engage, and Relax in ASH Central (for in-person participants)**

Hall D

7:00 a.m. – 9:30 a.m. **Morning Coffee and Tuesday Marquee Sessions (for in-person participants)**

Hall E

7:30 a.m. – 9:00 a.m. **Late-Breaking Abstracts Session**

Hall E

9:30 a.m. – 9:45 a.m. **Announcement of Awards: William Dameshek Prize, Janet Rowley Basic Science Medal, and Helen M. Ranney Clinical and Translational Science Medal**

Hall E

9:45 a.m. – 11:15 a.m. **Presidential Symposium: New Horizons in Immune Function and Treatment**

Hall E

11:15 a.m. – 11:30 a.m. **Business Meeting and Ceremonial Passing of the ASH President's Gavel**

Hall E

11:30 a.m. – 1:00 p.m. **Best of ASH**

Hall E

WEDNESDAY, DECEMBER 16, 2026

All Day **Binge-Watch Content on the Virtual Platform**

ASH Virtual Platform: annualmeeting.hematology.org

10:00 a.m. – 11:00 a.m. **ASH Poster Walks**

ASH Poster Walk on Population Health and Access to Care

ASH Virtual Platform: annualmeeting.hematology.org

5:00 p.m. – 6:00 p.m. **ASH Poster Walks**

ASH Poster Walk on Beyond the Algorithm: The Next Era of Artificial Intelligence in Hematology

ASH Virtual Platform: annualmeeting.hematology.org

THURSDAY, DECEMBER 17, 2026

All Day **Binge-Watch Content on the Virtual Platform**

ASH Virtual Platform: annualmeeting.hematology.org

FRIDAY, DECEMBER 18, 2026

All Day **Binge-Watch Content on the Virtual Platform**

ASH Virtual Platform: annualmeeting.hematology.org


“THE FUTURE OF BLOOD CANCER TREATMENT IS TAKING SHAPE HERE.”
City of Hope
Alex Herrera, M.D.
Chief of Lymphoma, Hematologist-Oncologist
Leading the evolution of blood cancer treatment for over 50 years, from transplantation to cellular immunotherapy.
As one of the nation’s largest and most advanced cancer research and treatment organizations, City of Hope® has performed more than 20,000 bone marrow and stem cell transplants with exceptional survival outcomes and treated 2,500 patients through our pioneering CAR T cell program. From developing our own CAR T products to contributing to pivotal clinical trials leading to FDA approvals, we continue to advance innovative treatments for patients with blood cancers.
NCI Designated Comprehensive Cancer Center
National Comprehensive Cancer Network Member Institution
Magnet Recognition
BEST HOSPITALS U.S.News CANCER 2026-2027
City of Hope®
Ending cancer starts with Hope
Meet the minds advancing blood cancer treatment.
Visit City of Hope at Booth #3423.
CityofHope.org/ASH26
© 2026 City of Hope

MARQUEE SESSIONS

These signature sessions are designed to be of interest to a broad and diverse audience and include the prestigious Plenary Scientific Session, Best of ASH, and the Presidential Symposium. Many of the Marquee Sessions also honor distinguished leaders in the field through awards and special lectures.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

Ham-Wasserman Lecture

Saturday **12:30 p.m. – 1:30 p.m.**
Hall E

Chair:
Robert Negrin, MD, President, American Society of Hematology, Stanford University, Stanford, CA

Speaker:
Peihua (Peggy) Lu, MD, Beijing Lu Daopei Hospital, Beijing, China

CD7 CAR-T Therapy in T-cell Acute Leukemia/Lymphoma: Past, Present and Future

SUNDAY

ASH-EHA Joint Symposium: Novel Approaches to Cell Engineering in Hematopoietic Cell Transplantation

Sunday **12:30 p.m. – 1:30 p.m.**
Hall E

Co-Chairs:
Robert Negrin, MD, President, American Society of Hematology, Stanford University, Stanford, CA

Konstanze Döhner, MD, President, European Hematology Association, Ulm University, Ulm, Germany

Speakers:
Everett Meyer, MD, PhD, University of Colorado, Aurora, CO

Immune Regulatory Mechanisms to Improve Outcomes following HSCT

Antonio Pierini, MD/PhD, University of Perugia, Perugia, Italy

Strategies to Improve Outcomes following Haploidentical Transplantation

Announcement of Awards: Outstanding Service Award, Roland B. Scott-Charles Drew Excellence in Equity Award and Wallace H. Coulter Award for Lifetime Achievement in Hematology

Sunday **1:30 p.m. – 2:00 p.m.**
Hall E

Chair:
Robert Negrin, MD, President, American Society of Hematology, Stanford University, Stanford, CA

Plenary Scientific Session non-CME

Sunday **2:00 p.m. – 4:00 p.m.**
Hall E

Chair:
Robert Negrin, MD, President, American Society of Hematology, Stanford University, Stanford, CA

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

MONDAY

Announcement of Awards: J. Evan Sadler Award for Mentorship, Bernard Forget Award for Mentorship, and E. Donnall Thomas Lecture and Prize

Monday **9:00 a.m. – 10:00 a.m.**
Hall E

Chair:
Robert Negrin, MD, President, American Society of Hematology, Stanford University, Stanford, CA

Speaker:
Scott Armstrong, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Leveraging the Biology of the MLL (KMT2A) Complex to Discover New Therapies for Leukemia

Ernest Beutler Lecture and Prize

Monday **1:30 p.m. – 2:30 p.m.**
Hall E

Chair:
Robert Negrin, MD, President, American Society of Hematology, Stanford University, Stanford, CA

How Molecular Understanding of Apoptosis Led to a New Class of Cancer Therapeutics

Speakers:
Suzanne Cory, PhD, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

Basic Science Speaker

Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, Bronx, NY

Clinical/Translational Science Speaker

TUESDAY

Late-Breaking Abstracts Session non-CME

Tuesday **7:30 a.m. – 9:00 a.m.**
Hall E

Co-Chairs:
Maureen Okam Achebe, MD, MPH, Brigham and Women's Hospital, Boston, MA

Robert Zeiser, MD, PhD, Universitatsklinikum Freiburg, Freiburg, Germany

Announcement of Awards: William Dameshek Prize, Janet Rowley Basic Science Medal, and Helen M. Ranney Clinical and Translational Science Medal

Tuesday **9:30 a.m. – 9:45 a.m.**
Hall E

Chair:
Robert Negrin, MD, President, American Society of Hematology, Stanford University, Stanford, CA

Presidential Symposium non-CME

Tuesday **9:45 a.m. – 11:15 a.m.**
Hall E

New Horizons in Immune Function and Treatment

Chair:
Robert Negrin, MD, President, American Society of Hematology, Stanford University, Stanford, CA

Speakers:
Edgar Engleman, MD, PhD, Stanford University School of Medicine, Palo Alto, CA

Role of EPO/EPOR in Tolerance Induction

David Scadden, MD, Harvard Stem Cell Institute, Cambridge / Massachusetts General Hospital, Boston, MA

Role of the Adult Thymus in Health and Disease

Fyodor Urnov, University of California—Berkeley, Berkeley, CA

Novel Approaches to in vivo Therapy

Business Meeting and Ceremonial Passing of the ASH President's Gavel

Tuesday **11:15 a.m. – 11:30 a.m.**
Hall E

Best of ASH non-CME

Tuesday **11:30 a.m. – 1:00 p.m.**
Hall E

Co-Chairs:
Ami Bhatt, MD, Stanford University, Stanford, CA

Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA

Scientific Program Co-Chairs:
Ami Bhatt, MD, Stanford University, Stanford, CA
Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA

Scientific Program

Scientific Program Sessions were developed by the Society's 18 Scientific Committees. They highlight emerging areas of science in the field of hematology and address topics referenced in ASH's Agenda for Hematology Research. Following the didactic lectures, there will be a panel discussion at the end of the session, during which questions from the audience will be entertained.

Scientific Symposia

Scientific Symposia are developed from proposals submitted by the hematology community and feature transformative basic, translational, and clinical research poised to advance the field. There will be a panel discussion at the end of each session, during which questions from the audience will be entertained.

Scientific Spotlight Sessions

Scientific Spotlight Sessions are developed from proposals submitted by the hematology community and cover niche topic areas that are of interest to specific communities. Following the didactic lectures, there will be a panel discussion at the end of the session, during which questions from the audience will be entertained.

Scientific Workshops

The Scientific Workshops are interactive discussions of the latest science developments in a particular field of hematology. All registered ASH annual meeting attendees are welcome to attend these workshops. There is no additional fee to attend.

ASH Scientific Workshops are not offered for CME credit.

ASH Poster Walk

ASH Poster Walk highlight posters selected for the Annual Meeting that showcase emerging science in hematology. Five poster walks will take place as in-person sessions in the Blood Journals Studio during the Annual Meeting, and two will take place virtually following the Annual Meeting.

ASH Poster Walk are not offered for CME credit.

Meet the Scientist (Ticketed)

Meet the Scientist sessions will provide an opportunity for a small number of attendees to meet with a scientific expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives. A boxed breakfast will be provided.

Tickets are restricted to research and medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 10, at the Ticketed Sessions Counter in the Ernest N. Morial Convention Center.

Ticket Prices (per session)

Active or International Members and Non-Members $90

Associate, International Associate, Resident, Graduate/Medical Student, Non-Member in Training, Allied Health Professional, or Honorary/Emeritus Members $50

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

FRIDAY

Scientific Workshop on Myeloid Development

non-CME

Friday 2:00 p.m. – 6:00 p.m.
220-222

Co-Chairs:
Ulrich Steidl, MD, PhD, Albert Einstein College of Medicine, Bronx, NY

Patricia Ernst, PhD, University of Colorado Anschutz Medical Campus, Aurora, CO

2:00 p.m. – 2:05 p.m.	Opening Remarks
2:05 p.m. – 2:55 p.m.	Stem Cells
2:55 p.m. – 3:45 p.m.	Transcription and Epigenetics
3:45 p.m. – 4:15 p.m.	Break
4:15 p.m. – 5:05 p.m.	Signaling and Developmental Hematopoiesis
5:05 p.m. – 5:55 p.m.	Myeloid Malignancies
5:55 p.m. – 6:00 p.m.	Closing Remarks

Scientific Workshop on Clonal Evolution in Chronic Lymphocytic Leukemia: Mechanisms of Resistance, Disease Progression and Measurable Residual Disease-Based Monitoring

non-CME

Friday 3:00 p.m. – 6:00 p.m.
288-290

Co-Chairs:
Martin Cabero-Becerra, MD, PhD, Hospital Universitario Mancha Centro, Alcazar de San Juan, Spain

Paolo Ghia, MD, PhD, IRCCS Ospedale San Raffaele, Milan, Italy

3:00 p.m. – 3:05 p.m.	Opening Remarks
3:05 p.m. – 4:00 p.m.	Molecular Mechanisms of Resistance to Targeted Agents
4:00 p.m. – 4:55 p.m.	Biology of Clonal Evolution
4:55 p.m. – 5:00 p.m.	Break
5:00 p.m. – 5:55 p.m.	MRD Assessment as a Tool for Detecting and Monitoring Clonal Evolution
5:55 p.m. – 6:00 p.m.	Closing Remarks

Scientific Workshop on Emerging Technologies and Innovations in Diagnostic Hematology

non-CME

Friday 3:00 p.m. – 6:00 p.m.
252-254

Co-Chairs:
Christopher Park, MD, PhD, NYU Grossman School of Medicine, New York

Gerlinde Wernig, MD, Stanford Hospital and Clinics, Stanford

Sanjay Patel, MD, PhD, Weill-Cornell Medicine, New York

3:00 p.m. – 3:03 p.m.	Opening Remarks
3:03 p.m. – 3:43 p.m.	Translating Spatial Biology into the Diagnostic Lab
3:43 p.m. – 4:23 p.m.	New Frontiers in Flow Cytometry
4:23 p.m. – 4:38 p.m.	Break
4:38 p.m. – 5:18 p.m.	Novel Approaches in Molecular Diagnostics
5:18 p.m. – 5:58 p.m.	Digital Pathology in Diagnostic Hematology
5:58 p.m. – 6:00 p.m.	Closing Remarks

Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure

non-CME

Friday 3:00 p.m. – 6:00 p.m.
278-282

Co-Chairs:
Lucy Fox, MBBS, BCom/BSc, DmedSci, FRACP, FRCPA, Peter Mac Cancer Centre, Melbourne, Australia

Marcin Wlodarski, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

3:00 p.m. – 3:02 p.m.	Opening Remarks
3:02 p.m. – 3:44 p.m.	Diseases and Mechanisms
3:44 p.m. – 4:28 p.m.	Therapeutic Advancements
4:28 p.m. – 4:33 p.m.	Break
4:33 p.m. – 5:15 p.m.	Novel Insights in Diagnostics and Molecular Surveillance
5:15 p.m. – 5:57 p.m.	New Discoveries
5:57 p.m. – 6:00 p.m.	Closing Remarks

Scientific Workshop on Interplay between Coagulation and Malignancy

non-CME

Friday 3:00 p.m. – 6:00 p.m.
295-296

Co-Chairs:
Lisa Baumann Kreuziger, MD, MS, Medical College of Wisconsin & Versiti, Milwaukee, WI

Jeffrey Zwicker, MD, Memorial Sloan Kettering Cancer Center, New York, NY

3:00 p.m. – 3:04 p.m.	Opening Remarks
3:04 p.m. – 4:25 p.m.	Translational Studies in Cancer-Associated Thrombosis
4:15 p.m. – 4:24 p.m.	Break
4:24 p.m. – 5:23 p.m.	Coagulation and Cancer Progression
5:23 p.m. – 5:28 p.m.	Closing Remarks

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

Scientific Workshop on Mechanism-Driven Biomarkers in Sickle Cell Disease non-CME

Friday 3:00 p.m. – 6:00 p.m.
293-294

Co-Chairs:
Karina Yazdanbakhsh, PhD, New York Blood Center, New York, NY

Thomas D. Coates, MD, Children's Hospital Los Angeles, Los Angeles, CA

3:00 p.m. – 3:10 p.m.	Opening Remarks
3:10 p.m. – 3:55 p.m.	Mechanistic Cell-Based Biomarkers of Disease Severity in Sickle Cell Disease
3:55 p.m. – 3:59 p.m.	Break
3:59 p.m. – 4:46 p.m.	Thrombo-inflammatory Biomarkers as Predictors of Disease Severity in Sickle Cell Disease
4:46 p.m. – 4:50 p.m.	Break
4:50 p.m. – 5:35 p.m.	Multi-omic Biomarkers of Disease Severity in Sickle Cell Disease
5:35 p.m. – 5:39 p.m.	Break
5:39 p.m. – 5:54 p.m.	Where Do We Go from Here: Stakeholder Discussion
5:55 p.m. – 6:00 p.m.	Closing Remarks

Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Discovery to Patients non-CME

Friday 3:00 p.m. – 6:00 p.m.
275-277

Co-Chairs:
Sarah Skuli, MD, PhD, University of Cincinnati, Cincinnati, OH

Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, Bronx, NY

Jean-Emmanuel Sarry, PhD, Cancer Research Center of Toulouse, Toulouse, France

3:00 p.m. – 3:05 p.m.	Opening Remarks
3:05 p.m. – 3:45 p.m.	Mitochondria and Metabolism – Fundamental Discovery
3:45 p.m. – 4:25 p.m.	Translational Research – Targeting Mitochondria and Metabolism in Cancer
4:25 p.m. – 4:30 p.m.	Break/Networking/Interaction
4:30 p.m. – 5:20 p.m.	Metabolism in the Tumor Microenvironment of Blood Cancers
5:20 p.m. – 5:55 p.m.	Mitochondria and Metabolism – Clinical Trials
5:55 p.m. – 6:00 p.m.	Closing Remarks

Scientific Workshop on New Frontiers in T-Cell Acute Lymphoblastic Leukemia Biology: Metabolism, Genomics, and Microenvironment non-CME

Friday 3:00 p.m. – 6:00 p.m.
260-262

Co-Chairs:
Ksenia Matlawska-Wasowska, PhD, University of Alabama at Birmingham, Birmingham

Daniel Herranz, PharmD, PhD, Rutgers Cancer Institute, New Brunswick, NJ

3:00 p.m. – 3:05 p.m.	Opening Remarks
3:05 p.m. – 3:45 p.m.	Genomic Architecture of T-ALL
3:45 p.m. – 4:25 p.m.	Epigenetic and Transcriptional Regulation of T-ALL
4:25 p.m. – 4:35 p.m.	Break
4:35 p.m. – 5:15 p.m.	Metabolic Reprogramming and Therapeutic Vulnerabilities
5:15 p.m. – 5:55 p.m.	Leukemia-Microenvironment Interactions and CNS Disease
5:55 p.m. – 6:00 p.m.	Closing Remarks

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies non-CME

Friday 3:00 p.m. – 6:00 p.m.
291-292

Co-Chairs:
Panagiotis Ntziachristos, PhD, Ghent University, Ghent, Belgium

Christina Glytsou, PhD, Rutgers University, Piscataway, NJ

Daniel Starczynowski, PhD, Cincinnati Children's Hospital, Cincinnati, OH

Aristotelis Tsirigos, PhD, New York University, New York City, NY

3:00 p.m. – 3:01 p.m.	Opening Remarks
3:01 p.m. – 3:55 p.m.	Chromatin and Transcription in Therapy-Resistant Clonal Evolution
3:55 p.m. – 4:50 p.m.	RNA Regulation and Therapeutic Vulnerabilities in Therapy-Resistant Hematologic Malignancies
4:50 p.m. – 5:00 p.m.	Break
5:00 p.m. – 5:55 p.m.	Targeting Protein-Level Vulnerabilities and the Inflammatory Niche in Therapy Resistance
5:55 p.m. – 6:00 p.m.	Closing Remarks

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

Scientific Workshop on TP53: A Moving Target

non-CME

Friday **3:00 p.m. – 6:00 p.m.**
271-273

Co-Chairs:
Jonathan Gerber, MD, University of Massachusetts Chan Medical School, Worcester, MA

Ann-Kathrin Eisfeld, MD, Ohio State University, Columbus, OH

3:00 p.m. – 3:05 p.m.	Opening Remarks
3:05 p.m. – 3:55 p.m.	Risk Factors of Clonal Hematopoiesis
3:55 p.m. – 4:00 p.m.	Break
4:00 p.m. – 4:50 p.m.	Identifying Biological Vulnerabilities in TP53 mutations
4:50 p.m. – 4:55 p.m.	Break
4:55 p.m. – 5:55 p.m.	Discovering Novel Therapeutics & Future Research
5:55 p.m. – 6:00 p.m.	Closing Remarks

SATURDAY

ASH Poster Walk on Emerging Toxicities and Predictors in T-Cell–Redirecting Therapies Hosted by *Blood Immunology & Cellular Therapy*

non-CME

Saturday **8:00 a.m. – 9:00 a.m.**
Hall F, Blood Journals Studio

Co-Chairs:
Mirko Farina, MD, PhD, University of Brescia, Brescia, Italy

Willem Fibbe, MD, PhD, Editor-in-Chief, Blood Immunology & Cellular Therapy & Leiden University Medical Center, Leiden, Netherlands

Meet the Scientist: αIIbß3: One Receptor, Two Drugs, and the Long Road of Translational Platelet Biology (ticketed session for in-person participants)

non-CME

Saturday **8:00 a.m. – 9:00 a.m.**
Hilton - Parish

Speaker:
Barry Coller, MD, Rockefeller University, New York, NY

Meet the Scientist: Chemoresistance in Acute Myeloid Leukemia (ticketed session for in-person participants)

Saturday **8:00 a.m. – 9:00 a.m.**
Hilton - Magazine

Speaker:
Jean-Emmanuel Sarry, PhD, Cancer Research Center of Toulouse, Toulouse, France

Meet the Scientist: From GATA2 to SAMD9: Discovering the Genetic Architecture of Pediatric Myelodysplastic Syndrome and Bone Marrow Failure (ticketed session for in-person participants)

Saturday **8:00 a.m. – 9:00 a.m.**
Hilton - Windsor

Speaker:
Marcin Wlodarski, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

Meet the Scientist: From Splicing Mutations to Cancer Neoantigens: A Decade of Targeting RNA Biology in Leukemia (ticketed session for in-person participants)

non-CME

Saturday **8:00 a.m. – 9:00 a.m.**
Hilton - Fulton

Speaker:
Omar Abdel-Wahab, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Meet the Scientist: Reading the Epigenetic History of Lymphoma: From Cell of Origin to Mitotic Clocks and Clinical Outcome (ticketed session for in-person participants)

Saturday **8:00 a.m. – 9:00 a.m.**
Hilton - Jackson

Speaker:
Jose Martin-Subero, MD, Hospital Clinic Barcelona & Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

Scientific Program: Back to the Future: Using Old and New Tools to Move the Field of Plasma Cell Research Forward

Saturday 9:30 a.m. – 10:45 a.m.
288-290

Scientific Committee on Plasma Cell Neoplasia

Chair:
Giada Bianchi, MD, Dana-Farber Cancer Institute, Boston, MA

Speakers:
Xin Gu, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Show Me Your Face and I Will Understand Your Purpose: How Protein Structure Informs Function

Marta Chesi, PhD, Mayo Clinic Arizona, Scottsdale, AZ

Running on Wheels: How Mouse Models Inform the Study of Plasma Cell Biology

Mirco Friedrich, MD, PhD, German Cancer Research Center (DKFZ), Heidelberg, Germany

Getting by with a Little Help from Friends: Novel Approaches to Study Myeloma Microenvironment

Scientific Symposia: In Vivo Gene Modification Approaches for Classical and Malignant Hematologic Disorders non-CME

Saturday 2:00 p.m. – 3:15 p.m.
275-277

Chair:
Annarita Miccio, PhD, Imagine Institut, Inserm, Universite' Paris Cite', Paris, France

Speakers:
Hans-Peter Kiem, PhD, Fred Hutchinson Cancer Center & University of Washington, Seattle, WA

Viral Vector-Mediated In Vivo Hematopoietic Stem Cell Gene Therapy: Targets, Delivery, and Selection

William Peranteau, MD, Children's Hospital of Philadelphia, Philadelphia, PA

Lipid Nanoparticle (LNP) Delivery to Hematopoietic Stem Cells in Vivo

Michael Birnbaum, PhD, Massachusetts Institute of Technology, Cambridge, MA

In Vivo Car T Cell Generation to Treat Cancer and Autoimmune Disorders

Scientific Symposia: Lab-Grown Red Blood Cells: From Scalable Manufacturing to Clinical Translation

Saturday 2:00 p.m. – 3:15 p.m.
391-392

Chair:
Eric Bouhassira, PhD, Albert Einstein College of Medicine, Bronx, NY

Speakers:
Eric Bouhassira, PhD, Albert Einstein College of Medicine, Bronx, NY

Scalable Manufacturing of Lab-Grown Red Blood Cells: Overcoming Metabolic and Bioprocess Constraints

Stella Chou, MD, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA

Unmet Needs in Transfusion Medicine: Alloimmunization, Rare Blood Types, and the Case for Lab-Grown Red Cells

Joanne Mountford, PhD, Scottish National Blood Transfusion Service, Edinburgh, United Kingdom

Clinical Translation of Lab-Grown Red Blood Cells: First-in-Human Studies and Early Outcomes

Scientific Symposia: Single-Cell and Spatial Genomics Redefining the Immune Cell Landscape in AML/MDS

Saturday 2:00 p.m. – 3:15 p.m.
288-290

Chair:
Catherine Wu, MD, Dana-Farber Cancer Institute, Boston, MA

Speakers:
Livius Penter, MD, Charité - Universitätsmedizin Berlin, Berlin, Germany

AML Immune Escape Mechanisms Driving Post-Therapy Relapse

Susan DeWolf, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Spatial Niches within the AML/MDS Bone Marrow Immune Microenvironment

Hussein Abbas, MD, PhD, M D Anderson Cancer Center, Houston, TX

Phenotypes and Specificities of AML/MDS-Associated T Cell Populations

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

Scientific Program: Cutting-Edge Insights into Pro-Thrombotic Anti-Platelet Factor 4-Associated Disorders non-CME

Saturday 4:00 p.m. – 5:15 p.m.
220-222

Scientific Committee on Transfusion Medicine

Chair:
Rick Kapur, MD PhD MSc, Sanquin Blood Supply Foundation, Amsterdam, Netherlands

Speakers:
Anand Pabmanabhan, MBBS, PhD, Mayo Clinic, Phoenix, AZ

The Clone Wars: Monoclonal Gammopathy of Thrombotic Significance (MGTS)

Jing-Jing Wang, PhD, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia

Pulling the Antibody Trigger in Vaccine-Induced Thrombotic Thrombocytopenia (VITT)

Lubica Rauova, MD, PhD, The Childrens Hospital of Philadelphia, Philadelphia, PA

Heparin-Induced Thrombocytopenia (HIT): How Heparin Sparks Thrombosis

Scientific Program: JOINT SESSION - New Horizons in RNA Biology in Myeloid Development and Malignancy non-CME

Saturday 4:00 p.m. – 5:35 p.m.
288-290

Scientific Committee on Epigenetics and Genomics & Scientific Committee on Myeloid Biology

Co-Chairs:
Vikram Paralkar, MD, PhD, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Julia Maxson, PhD, Oregon Health & Science University, Portland, OR

Speakers:
Ryan Flynn, MD, PhD, Boston Children's Hospital, Boston, MA

New Frontiers in RNA Biology

Kristin Hope, PhD, Princess Margaret Cancer Centre & University Health Network, Toronto, Canada

RNA Binding Proteins in Hematopoiesis & Leukemia

Konstantinos Tzelepis, PhD, University of Cambridge, Cambridge, United Kingdom

Targeting RNA Modifications in the Clinic

Omar Abdel-Wahab, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Novel Uses of RNA as Therapeutics

Scientific Program: T Resident Memory Cells (Trm) in Health, Disease, and Therapeutics non-CME

Saturday 4:00 p.m. – 5:15 p.m.
275-277

Scientific Committee on Immunology and Host Defense

Chair:
Asha Pillai, MD, Columbia Transplant Institute (CTI), New York, NY & Regeneron Therapeutics, Tarrytown, NY

Speakers:
Jason Schenkel, MD, PhD, MD Anderson Cancer Center, Houston, TX

Trm Phenotype and Functions

Nicholas Jarjour, PhD, Medical College of Wisconsin & Versiti Blood Research Institute, Milwaukee, WI

Molecular Mechanisms of Trm Maintenance, Activation, and Proliferation

Defu Zeng, MD, PhD, The Beckman Research Institute of City of Hope, Duarte, CA

Coming to Trms with GVHD

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

SUNDAY

ASH Poster Walk on New Developments in Targeted Therapies for Myeloid Malignancies Hosted by *Blood Neoplasia* non-CME

Sunday **8:00 a.m. – 9:00 a.m.**
Hall F, Blood Journals Studio

Co-Chairs:

Steven Gore, MD, National Institutes of Health, Bethesda, MD

Jonathan Licht, MD, Editor-in-Chief, *Blood Neoplasia* & Van Andel Institute, Grand Rapids, MI

Meet the Scientist: Beyond the Niche: Systemic Regulation of Hematopoietic Stem Cell Numbers in Health and Disease (ticketed session for in-person participants)

Sunday **8:00 a.m. – 9:00 a.m.**
Hilton - Royal

Speaker:

Kira Gritsman, MD, PhD, Albert Einstein College of Medicine, Bronx, NY

Meet the Scientist: Building Bone Marrow in a Dish: Bioengineered Niches for Understanding and Treating Platelet Disorders (ticketed session for in-person participants)

Sunday **8:00 a.m. – 9:00 a.m.**
Hilton - Windsor

Speaker:

Alessandra Balduini, MD, Tufts University, Medford, MA

Meet the Scientist: Engineering Tolerance: CAR-Tregs and the New Era of Cell Therapy for Autoimmunity (ticketed session for in-person participants) non-CME

Sunday **8:00 a.m. – 9:00 a.m.**
Hilton - Fulton

Speaker:

Jeffrey Bluestone, PhD, University of California San Francisco, San Francisco, CA

Meet the Scientist: From Ribosomes to Risk Stratification: Decoding Inherited Bone Marrow Failure and Its Path to Leukemia (ticketed session for in-person participants)

Sunday **8:00 a.m. – 9:00 a.m.**
Hilton - Magazine

Speaker:

Akiko Shimamura, MD PhD, Boston Children's Hospital & Dana Farber Cancer Institute, Boston, MA

Meet the Scientist: Why the Mouse Matters: Building Faithful Models of Multiple Myeloma (ticketed session for in-person participants)

Sunday **8:00 a.m. – 9:00 a.m.**
Hilton - Parish

Speaker:

Marta Chesi, PhD, Mayo Clinic Arizona, Scottsdale, AZ

Scientific Program: How Clots Form and Fall Apart: From Engineered Vessels to Targeted Therapies non-CME

Sunday **9:30 a.m. – 11:00 a.m.**
220-222

Scientific Committee on Thrombosis & Vascular Biology

Chair:

Vivien Chen, MBBS, PhD, The University of Sydney School of Medicine, Sydney, Australia

Speakers:

Wilbur Lam, MD, PhD, Emory University, Atlanta, GA

Vessel on a Chips, Organoids and Clots: A New Era in Thrombosis Research

Pierre Mangin, PhD, INSERM, Strasbourg, France

Sticky Surfaces: Mechanistic Insights Into Macrovascular Clot Formation

Xiaowei Wang, PhD, Baker Heart and Diabetes Institute & University of Melbourne, Melbourne, Australia

Beyond Platelets and Coagulation: Novel Anti-Thrombotic Targets

Scientific Program: Innovations in the Detection and Characterization of Chemoresistant Cells in AML: From Molecular MRD to Molecular Resistance Mechanisms

Sunday **9:30 a.m. – 10:45 a.m.**
R06-R09

Scientific Committee on Myeloid Neoplasia

Chair:
Michele Redell, MD, PhD, Texas Children's Cancer and Hematology Center, Houston

Speakers:
Christopher Hourigan, DM DPhil FRCP, Virginia Tech FBRI Cancer Research Center, Washington, DC

Current Clinical Applications for Molecular MRD in Myeloid Malignancies

Felicitas R Thol, MD, Hannover Medical School, Hanover, Germany

Emerging Technologies for Molecular MRD Detection

Jean-Emmanuel Sarry, PhD, Cancer Research Center of Toulouse, Toulouse, France

Biological Insights into Resistant Cells

Scientific Program: JOINT SESSION - Bridging the Gap: Research and Clinical Implications of Emerging Technologies in Hematology

Sunday **9:30 a.m. – 11:05 a.m.**
391-392

Scientific Committee on Hematopathology and Clinical Laboratory Hematology & Scientific Committee on Lymphoid Neoplasia

Co-Chairs:
Leticia Quintanilla-Martinez, MD, University Hospital Tübingen, Tübingen, Germany

Ryan Morin, PhD, Simon Fraser University, Vancouver, Canada

Speakers:
Olga Pozdnyakova, MD, PhD, Hospital of the University of Pennsylvania, Philadelphia, PA

New Developments in AI for Flow Cytometry Diagnostics

Mina Xu, MD, Yale University School of Medicine, New Haven, CT

Spatial Transcriptomics/Multiomics in Lymphoma and Leukemia

Jose Martin-Subero, MD, Hospital Clinic Barcelona & Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Epigenome in the Classification of Lymphomas

David Scott, MD, BC Cancer & University of British Columbia, Vancouver, Canada

New Dimensions in the Classification of Aggressive B-cell Lymphomas: What Are We Missing?

Scientific Program: Power Sharing: Transplantation and Cellular Therapy in Autoimmunity non-CME

Sunday **9:30 a.m. – 10:45 a.m.**
Hall E

Scientific Committee on Transplantation Biology and Cellular Therapies

Chair:
David Ritchie, MB, ChB, PhD, Royal Melbourne Hospital, Melbourne, Australia

Speakers:
Maria Gabriella Raimondo, MD, Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nuremberg and Uniklinikum Erlangen, Erlangen, Germany

Ex Vivo or in Vivo CAR-T for Autoimmunity

Dimitrios Wagner, MD, PhD, Baylor College of Medicine, Houston, TX & Berlin Institute of Health & Charité - Universitätsmedizin Berlin, Berlin, Germany

Barrier to Feature: Immunosuppression-Resistant Off-the-Shelf CAR T Cells for Severe Autoimmune Disorders

Jeffrey Bluestone, PhD, University of California San Francisco, San Francisco, CA

Promoting the Peacekeepers: Treg Adoptive Therapies to Re-Establish Tolerance

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

Scientific Program: Through Space and Time: Spatiotemporal Organization of Haematopoiesis in Health and Disease

Sunday **9:30 a.m. – 10:45 a.m.**
295-296

Scientific Committee on Hematopoiesis

Chair:
Ingo Ringshausen, MD, University College London, London, United Kingdom

Speakers:
Ralf Adams, DPhil, Max Planck Institute for Molecular Biomedicine, Muenster, Germany

Resilience and Dynamic Expansion and Resilience of Adult Calvarial Bone Marrow

Ana Cvejic, PhD, University of Copenhagen, Copenhagen, Denmark

Time, Place, and Destiny: Fetal Liver Niches Steering HSC Fate

Kira Gritsman, MD, PhD, Albert Einstein College of Medicine, Bronx, NY

Numbers and Fates: Decoding HSC Abundance and Decisions

Scientific Symposia: AI Models of Cell State for the Design of Next-Generation T Cell Therapies

non-CME

Sunday **9:30 a.m. – 10:45 a.m.**
393-396

Chair:
Zinaida Good, PhD, Stanford University, Stanford, CA

Speakers:
Zinaida Good, PhD, Stanford University, Stanford, CA

Clinically Informed AI Models for Predicting and Engineering CAR T Cell Function

Yusuf Roohani, PhD, Arc Institute, Palo Alto, CA

State-of-the-Art Single-Cell Foundation Models for Future Cell Design

Rahul Satija, PhD, New York Genome Center, New York, NY

Scalable Frameworks for Multimodal Data Analysis and Next-Generation Cell Models

Scientific Symposia: Designing Microbiome-Directed Interventional Trials in Hematologic Malignancies

Sunday **9:30 a.m. – 10:45 a.m.**
288-290

Chair:
Urvi Shah, MD, MS, DipABLM, Memorial Sloan Kettering Cancer Center, New York, NY

Speakers:
Urvi Shah, MD, MS, DipABLM, Memorial Sloan Kettering Cancer Center, New York, NY

Dietary and Prebiotic Intervention Strategies

Doris Ponce, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Live Bacterial Therapeutic Intervention Strategies

Florent Malard, MD, PhD, Sorbonne University, Hôpital Saint-Antoine, AP-HP Paris, France, Paris, France

Fecal Microbiota Transplant Intervention Strategies

ASH Poster Walk on Innovations in Hemostasis and Thrombosis Clinical Research Design Hosted by *Blood Vessels, Thrombosis & Hemostasis*

non-CME

Sunday **11:15 a.m. – 12:15 p.m.**
Hall F, Blood Journals Studio

Co-Chairs:
Lisa Baumann Kreuziger, MD, MS, Medical College of Wisconsin & Versiti, Milwaukee, WI

Keith McCrae, MD, Editor-in-Chief**,** *Blood Vessels, Thrombosis & Hemostasis* & The Cleveland Clinic Foundation, Cleveland, OH

Sara Vesely, PhD, MPH, The University of Oklahoma, Harold Hamm Health Campus, Oklahoma City, OK

Scientific Program: Built to Clot, Built to Break: Structural Control of Hemostasis and Fibrinolysis

Sunday **4:30 p.m. – 5:45 p.m.**
220-222

Scientific Committee on Hemostasis

Chair:
Mettine Bos, PhD, Leiden University Medical Center, Leiden, Netherlands

Speakers:

Weikai Li, PhD, Washington University in St. Louis, St. Louis, MO

Structural Insights into Mechanisms

Phil Hogg, PhD, Centenary Institute & University of Technology Sydney, Sydney, Australia

Novel Regulators of Hemostasis

Valerie Tutwiler, PhD, Rutgers University, Piscataway, NJ

Novel Regulators of Fibrinolysis

Scientific Program: Rethinking Antiplatelet Strategies: Selective Blockade, Broad-Acting Drugs, and Beyond non-CME

Sunday 4:30 p.m. – 5:45 p.m.
217-219

Scientific Committee on Megakaryocytes and Platelets

Chair:

Jaehyung Cho, PhD, Washington University School of Medicine, St. Louis, MO

Speakers:

Barry Coller, MD, Rockefeller University, New York, NY

Precision Antiplatelet Therapy: Targeting Platelet-Specific Pathways for Safer and Smarter Inhibition

Xiaoping Du, MD, PhD, University of Illinois College of Medicine, Chicago, IL

The Power of Broad Inhibition: Why Pan-Platelet Blockade Remains the Gold Standard

Ingeborg Hers, PhD, University of Bristol, Bristol, United Kingdom

Striking the Balance: Selectivity vs Breadth in the Next Generation of Antiplatelet Drugs

Scientific Program: Understanding and Targeting Metabolism in Erythrocyte Development and Disorders

Sunday 4:30 p.m. – 5:45 p.m.
291-292

Scientific Committee on Red Cell Biology

Chair:

Andrew Perkins, MBBS, PhD, Monash University, Melbourne, Australia

Speakers:

Jian Xu, PhD, St. Jude Children's Research Hospital, Memphis, TN

Metabolic Switches Underpin Erythropoiesis

Marlies Rossmann, MD, PhD, University of Rochester Medical Center, Rochester, NY

The Interplay Between Pyrimidine Synthesis and Ferroptosis in Erythropoiesis

Lucia De Franceschi, MD, University of Verona, Verona, Italy

Developing Metabolism-Targeted Therapies in Red Cell Disorders

Scientific Spotlight Sessions: Decoding Macrophage Diversity in Lymphomas: Spatial Insights and Immunotherapeutic Implications

Sunday 4:30 p.m. – 5:45 p.m.
271-273

Speakers:

Anand Devaprasath Jeyasekharan, MBBS, MRCP, PhD, Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore

Dark Zone Macrophages as Mediators of T-Cell Exhaustion and Immunotherapy Response in Lymphoma

Tomohiro Aoki, MD, PhD, Princess Margaret Cancer Centre - University Health Network, Toronto, Canada

Macrophage–HRS Cell Crosstalk Driving Immune Evasion and Therapy Resistance in Hodgkin Lymphoma

Scientific Spotlight Sessions: Sticky Situations: Glycans in Classical and Malignant Hematopoiesis

Sunday 4:30 p.m. – 5:45 p.m.
288-290

Speakers:

Marie Hollenhorst, MD, PhD, Brigham and Women's Hospital & Harvard Medical School, Boston, MA

Novel Insights Into the Glycobiology of Hemostasis and Thrombosis

Anna Marneth, PhD, Radboud University Medical Center, Nijmegen, Netherlands

Glycans in the Pathogenesis and as a Therapeutic Target in Myeloid Malignancies

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

MONDAY

ASH Poster Walk on Beyond Acute Vaso-Occlusion: Emerging Mechanisms and Phenotypes of Chronic Pain in Sickle Cell Disease Hosted by *Blood Red Cells & Iron*

non-CME

Monday **8:00 a.m. – 9:00 a.m.**
Hall F, Blood Journals Studio

Co-Chairs:

Daniel Sop, PhD, Virginia Commonwealth University, Richmond, VA

Patrick Gallagher, MD, Editor-in-Chief, *Blood Red Cells & Iron* & Nationwide Children's Hospital & Ohio State University, Columbus, OH

Scientific Program: Unlocking Blood Disorders: Targeting Genetics to Identify Early Phenotypes non-CME

Monday **10:30 a.m. – 11:45 a.m.**
208-210

Scientific Committee on Blood Disorders in Childhood

Chair:

Sarah Tasian, MD, Children's Hospital of Philadelphia & University of Pennsylvania School of Medicine, Philadelphia, PA & Prinses Máxima Centrum, Utrecht, Netherlands

Speakers:

Danny Miller, MD, PhD, University of Washington, Seattle, WA

Decoding the Mysteries of the VWF Gene

Akiko Shimamura, MD PhD, Boston Children's Hospital & Dana Farber Cancer Institute, Boston, MA

Neutropenia Uncovered: The Role of Genetic Testing

Alessandra Balduini, MD, Tufts University, Medford, MA

New Insights into Inherited Thrombocytopenias

Scientific Spotlight Sessions: Illuminating the Dark Corners in the Genomes of Lymphoid Neoplasms

Monday **10:30 a.m. – 11:45 a.m.**
288-290

Speakers:

Jun Yang, PhD, St Jude Children's Research Hospital, Memphis, TN

Dissecting the Functional Consequence of Non-Coding Variants

Laura Hilton, PhD, BC Cancer, Vancouver, Canada

Clinical Relevance of Non-Coding Mutations

ASH Poster Walk on Leukemia in Latin America: Outcomes and Access to Diagnostics and Therapies Hosted by *Blood Global Hematology*

non-CME

Monday **12:15 p.m. – 1:15 p.m.**
Hall F, Blood Journals Studio

Co-Chairs:

Samuel Urrutia, MD, MS, Washington University in St. Louis, St. Louis, MO

Jorge Cortes, MD, Editor-in-Chief, *Blood Global Hematology* & University of Alabama at Birmingham, Birmingham, AL

Scientific Program: Balancing the Blood: Immune Control of Stem Cell Fidelity

Monday **2:45 p.m. – 4:00 p.m.**
275-277

Scientific Committee on Stem Cells and Regenerative Medicine

Chair:

Teresa Bowman, PhD, Albert Einstein College of Medicine, Bronx, NY

Speakers:

Anna Beaudin, PhD, University of Utah School of Medicine, Salt Lake City, UT

The Impact of Perinatal Inflammation on HSC Fitness

Masayuki Yamashita, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

Regulation of HSCs by the Adaptive Immune System

Leila Perié, PhD, IIS Biogipuzkoa, San Sebastian, Spain & Institut Curie, Paris, France

Regulation of HSCs by the Innate Immune System

Scientific Spotlight Sessions: CAR-T Manufacturing Across Nations: From Low-to-Middle-Income Academic Platforms to Frontier Innovations in Global Access

Monday 2:45 p.m. – 4:00 p.m.
391-392

Speakers:

Fernando Gibran-Nunes, MD, Hospital Sirio-Libanês, São Paulo, Brazil

Centralized and Decentralized Models of CAR-T Manufacturing: Insights from a Latin American Academic Platform on the Science of Global Access

Sarah Nikiforow, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

From Frontier to Field: Manufacturing Innovations That Could Lower Barriers to CAR-T Access in LMICs

Scientific Spotlight Sessions: Greasy Situations: Unraveling Lipid-Mediated Therapy Resistance

Monday 2:45 p.m. – 4:00 p.m.
288-290

Speakers:

Courtney Jones, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Lipids Biomarkers of Therapy Relapse in Acute Myeloid Leukemia

Mala Shanmugam, PhD, Winship Cancer Institute, Emory University, Atlanta, GA

Lipids and Therapy Resistance in Multiple Myeloma

Scientific Program: Iron Homeostasis Across the Lifespan in Health and Disease

Monday 4:30 p.m. – 5:45 p.m.
288-290

Scientific Committee on Iron and Heme

Chair:

Stefano Rivella, PhD, Children's Hospital of Philadelphia, Philadelphia, PA

Speakers:

Veena Sangkhae, PhD, UCLA David Geffen School of Medicine, Los Angeles, CA

Consequences of Maternal Abnormal Iron Delivery to the Fetus

Francesca Vinchi, PhD, Emory University School of Medicine, Atlanta, GA

The Role of Iron in Disease Progression

Laura Silvestri, PhD, San Raffaele Scientific Institute, Milan, Italy

Iron and Novel Pathologies: Beyond Erythropoiesis

Scientific Program: The Great Escape—Immune Evasions in Bone Marrow Failure

Monday 4:30 p.m. – 5:45 p.m.
295-296

Scientific Committee on Bone Marrow Failure

Chair:

Austin Kulasekararaj, MD, MBBS, FRCPath, MRCP, King's College Hospital, London, United Kingdom

Speakers:

Fernanda Gutierrez-Rodrigues, PhD, National Institutes of Health, National Heart, Lung and Blood Institutes, Bethesda, MD

Clonal Selection of Somatic Mutations in Immune Mediated BMF

Marcin Wlodarski, MD, PhD, St. Jude Children's Research Hospital, Memphis, TN

Escape Clones in Immune Mediated BMF

Mrinal Patnaik, MD, MBBS, Mayo Clinic, Rochester, NY

Clonal Dominance in VEXAS

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

Scientific Symposia: Special Symposium on the Basic Science of Hemostasis and Thrombosis (SSBSHT)

Monday 4:30 p.m. – 6:00 p.m.
208-210

Co-Chairs:

Mettine Bos, PhD, Leiden University Medical Center, Leiden, Netherlands

Jaehyung Cho, PhD, Washington University School of Medicine, St. Louis, MO

Vivien Chen, MBBS, PhD, The University of Sydney School of Medicine, Sydney, Australia

Speakers:

Oliver Borst, MD, University of Tuebingen, Tuebingen, Germany

Platelet Lipidomics and the Discovery of Novel Anti-Thrombotic Targets

Lindsey George, MD, Children's Hospital of Philadelphia & University of Pennsylvania School of Medicine, Philadelphia, PA

Rational Design of FVIII Variants for Gene Therapy: Linking Molecular Insight to Therapeutic Performance

Rosanna Asselta, PhD, Humanitas University, Milano, Italy

Precision in the Blood: Mapping Clotting Risk with Functional Genomics

WEDNESDAY

ASH Poster Walk on Population Health and Access to Care non-CME

Wednesday 10:00 a.m. – 11:00 a.m.

Chair:

Warren Fingrut, MD, MPH, MD Anderson Cancer Center, Houston, TX

ASH Poster Walk on Beyond the Algorithm: The Next Era of Artificial Intelligence in Hematology

non-CME

Wednesday 5:00 p.m. – 6:00 p.m.

Chair:

David Swoboda, MD, Tampa General Hosptal, Tampa, FL

MERCK

Visit Us at Booth #2639

Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
All rights reserved. US-BOM-00003 10/26

EDUCATION SESSIONS

Education Program Co-Chairs:

Maureen Okam Achebe, MD, MPH, Brigham and Women's Hospital, Boston, MA

Robert Zeiser, MD, PhD, Universitatsklinikum Freiburg, Freiburg, Germany

Education Program Sessions

Education Program Sessions will be held from Saturday, December 12, through Monday, December 14. A question-and-answer period will occur at the end of the final presentation. Chapters based on these sessions will be published in *Hematology 2026, the ASH Education Program.*

Education Spotlight Sessions

Education Spotlight Sessions are intended to provide an in-depth review on specific clinical topics. Speakers will discuss current challenges and controversies in exciting topics, addressing the current state of knowledge, translational and clinical applications, and future directions. Each 75-minute session will be presented once in a small-venue format on either Sunday or Monday and will include ample time for audience questions and participation. These sessions are restricted to medical and research professionals only; no businesspersons or media will be admitted.

How I Treat Sessions (Ticketed)

How I Treat Sessions will provide an opportunity for a small number of attendees to meet with a clinical expert in a setting that fosters interaction. ASH has invited experts from around the world to facilitate informal discussions, allowing participants to present their questions and gain new perspectives on specific disease topics. A boxed breakfast will be provided.

Tickets are restricted to medical professionals only and will be available on site on a first-come, first-served basis; no businesspersons or media will be admitted. Only one ticket per person is allowed. Tickets may be purchased on site during registration hours beginning Thursday, December 10, at the Ticketed Sessions Counter in the Ernest N. Morial Convention Center.

How I Treat Ticket Prices (per session)

Active or International Members and Non-Members $90

Associate, International Associate, Resident, Graduate/Medical Student, Non-Member in Training, Allied Health Professional, or Honorary/Emeritus Members $50

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

How I Treat: ALL (ticketed session for in-person participants)

Saturday 8:00 a.m. – 9:00 a.m.
Hilton - Camp

Speaker:
Rachel Rau, MD, Seattle Children's Hospital & University of Washington, Seattle, WA

How I Treat: Follicular Lymphoma (ticketed session for in-person participants)

Saturday 8:00 a.m. – 9:00 a.m.
Hilton - Ascot/Newberry

Speaker:
Alan Skarbnik, MD, Novant Health Cancer Institute, Charlotte, NC

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

How I Treat: Heavy Menstrual Bleeding in Women with Bleeding Disorders (ticketed session for in-person participants)

Saturday 8:00 a.m. – 9:00 a.m.
Hilton - Canal

Speaker:
Tyler Buckner, MD, University of Colorado School of Medicine, Aurora, CO

How I Treat: HLH and Related Hyperinflammatory Syndromes (ticketed session for in-person participants)

Saturday 8:00 a.m. – 9:00 a.m.
Hilton - Royal

Speaker:
Ashish Kumar, MD, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

How I Treat: Refractory ITP Unresponsive to Steroids and Thrombopoietin Agonists (ticketed session for in-person participants)

Saturday 8:00 a.m. – 9:00 a.m.
Hilton - Commerce

Speaker:
Elisabeth Battinelli, MD, PhD, Brigham and Women's Hospital, Boston, MA

Education Program: Addressing Resistance and Progression in Myeloproliferative Diseases

Saturday 9:30 a.m. – 10:45 a.m.
R06-R09

Chair:
Claire Harrison, DM, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Speakers:
Florian Heidel, MD, Hannover Medical School, Hannover, Germany

Mechanisms of Clonal Persistence and Progression in MPN

Francesca Palandri, MD, PhD, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

Preventing Progression and Overcoming Resistance in MPNs

Claire Harrison, DM, Guy's & St. Thomas' NHS Foundation, London, United Kingdom

Mutation-Targeted Therapies in MPN: A New Dawn?

Education Program: Navigating the Treatment Landscape of CNS Lymphomas

Saturday 9:30 a.m. – 10:45 a.m.
278-282

Chair:
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center University of Miami, Miami, FL

Speakers:
Kate Cwynarski, PhD, MD, University College London Hospital, London, United Kingdom

Management of Primary Central Nervous System Lymphoma

Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center University of Miami, Miami, FL

Management of CNS Involvement by Systemic Large B-Cell Lymphoma

Lakshmi Nayak, MD, Dana-Farber Cancer Institute, Boston, MA

The Role of CAR T-Cell Therapy, Novel Targeted Agents, and Emerging Therapies in CNS Lymphomas

Education Program: Optimizing Patient Care: Practicing Bloodless Medicine

Saturday 9:30 a.m. – 10:45 a.m.
391-392

Chair:
Erica Wood, MBBS, Monash University, Melbourne, Australia

Speakers:
Erica Wood, MBBS, Monash University, Melbourne, Australia

Blood Management and Transfusion Practice in Patients Who Need Alternatives to Blood

Patricia Locantore-Ford, MD, Pennsylvania Hospital, University of Pennsylvania Health Systems, Philadelphia, PA

Managing Autologous Bone Marrow Transplantation, CAR-T Therapy and Leukemia without Blood

Aryeh Shander, MD, Englewood Health, Englewood New Jersey, Englewood, NJ

Update on Transfusion Free Surgery

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Education Program: Classical Hematology: Innovation and Technology to Match Supply and Demand

Saturday 2:00 p.m. – 3:15 p.m.
293-294

Chair:
Talib Dosani, MD, Yale University, New Haven, CT

Speakers:
Robert Stern, MD, Dana-Farber Cancer Institute, Boston, MA

Dealing with Workforce Challenges in Classical Hematology

Talib Dosani, MD, Yale University, New Haven, CT

The Use of Virtual Care in Classical Hematology to Overcome Geographic and Resource Limitations

Sanjay Ahuja, MD, MS, Innovative Hematology & Indiana Hemophilia & Thrombosis Center, Indianapolis, IN

Harnessing Artificial Intelligence for Hematology Learning and Practice

Education Program: Targeted Therapies for AML: Bulls Eye!

Saturday 2:00 p.m. – 3:15 p.m.
R02-R05

Chair:
Joshua Zeidner, MD, University of North Carolina, Chapel Hill, NC

Speakers:
Joshua Zeidner, MD, University of North Carolina, Chapel Hill, NC

Targeted Therapy Approaches with Menin Inhibitors: Light at the End of the Tunnel?

Alexander Perl, MD, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Flt3 inhibitors in newly diagnosed and relapsed patients

Tapan Kadia, MD, MD Anderson Cancer Center, Houston, TX

Future of Targeted Therapies in AML

Education Program: The Unusual Bleed: Cracking the Code of Platelet and Rare Bleeding Disorders

Saturday 2:00 p.m. – 3:15 p.m.
220-222

Chair:
Tyler Buckner, MD, University of Colorado School of Medicine, Aurora, CO

Speakers:
Elisabeth Battinelli, MD, PhD, Brigham and Women's Hospital, Boston, MA

The Unusual Bleed: Cracking the Code of Platelet Disorders

Alessandro Casini, MD, Hôpitaux Universitaires de Genève, Genève, Switzerland

Diagnosis and Management of Fibrinogen Disorders

Tyler Buckner, MD, University of Colorado School of Medicine, Aurora, CO

Diagnosis and Management of Rare Bleeding Disorders

Education Program: Longer Lives, New Challenges: Managing Thalassemia in 2026

Saturday 4:00 p.m. – 5:15 p.m.
252-254

Chair:
Farzana Sayani, MD, MSc, University of Toronto, Toronto, Canada

Speakers:
Farzana Sayani, MD, MSc, University of Toronto, Toronto, Canada

Pregnancy in Transfusion-Dependent and Non-Transfusion Dependent Thalassemia (TDT and NTDT)

Yongshui Fu, MD, PhD, Guangzhou First People's Hospital, Guangzhou, China

Changing the Paradigm of β-Thalassemia Treatment: An Affordable, Less Toxic Gene Therapy

Gian Luca Forni, MD, IRCCS Gaslini Hospital, Genoa, Italy

An Enigma Wrapped in a Mystery: NTDT in Adults

Education Program: Persistent Challenges in Managing Chronic Myelogenous Leukemia

Saturday 4:00 p.m. – 5:15 p.m.
R06-R09

Chair:
Elisabetta Abruzzese, MD, PhD, S. Eugenio Hospital, ASL Roma2, Rome, Italy

Speakers:
Akriti Jain, MD, FACP, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH

Update on CML-CP Management: From Choice of First-Line Therapy to Treatment-Free Remission

Andreas Hochhaus, MD, Universitaetsklinikum Jena, Jena, Germany

Management of Chronic Myeloid Leukemia in Blast Phase

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Elisabetta Abruzzese, MD, PhD, S. Eugenio Hospital, ASL Roma2, Rome, Italy

Treating CML During Pregnancy

Education Program: The Big Clot Problem

Saturday **4:00 p.m. – 5:15 p.m.**
Hall E

Chair:
Lisa Baumann Kreuziger, MD, MS, Medical College of Wisconsin & Versiti, Milwaukee, WI

Speakers:
Akhilesh Sista, MD, Weill Cornell Medicine, New York, NY

Update on the Management of Intermediate Risk Pulmonary Embolism

Suresh Vedantham, MD, Washington University in St. Louis, St. Louis, MO

Update on the management of Extensive DVT

Aaron Iding, MD, PhD, Cardiovascular Research Institute Maastricht, Maastricht University & Maastricht University Medical Center, Maastricht, Netherlands

Post-Thrombotic Syndrome and the Long-Term Burden of Extensive DVT

SUNDAY

How I Treat: Cold Agglutinin Disease and Related Complement-Mediated Hemolytic Anemia (ticketed session for in-person participants)

Sunday **8:00 a.m. – 9:00 a.m.**
Hilton - Canal

Speaker:
John Manis, MD, Boston Children's Hospital, Boston, MA

How I Treat: Large B-Cell Lymphoma (ticketed session for in-person participants)

Sunday **8:00 a.m. – 9:00 a.m.**
Hilton - Camp

Speaker:
Laurie H. Sehn, MD, BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada

How I Treat: MPN (ticketed session for in-person participants)

Sunday **8:00 a.m. – 9:00 a.m.**
Hilton - Jackson

Speaker:
Florian Heidel, MD, Hannover Medical School, Hannover, Germany

How I Treat: Pediatric AML (ticketed session for in-person participants)

Sunday **8:00 a.m. – 9:00 a.m.**
Hilton - Ascot/Newberry

Speaker:
Tanja Gruber, MD, Cincinnati Children's, Cincinnati, OH & Stanford University, Palo Alto, CA

How I Treat: TTP in the Caplacizumab Era (ticketed session for in-person participants)

Sunday **8:00 a.m. – 9:00 a.m.**
Hilton - Commerce

Speaker:
Adam Cuker, MD, MS, University of Pennsylvania, Philadelphia, PA

Education Program: Advancing Personalized Care in Classic Hodgkin Lymphoma

Sunday **9:30 a.m. – 10:45 a.m.**
278-282

Chair:
Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Speakers:
Sarah Rutherford, MD, NYU Langone Health, New York, NY

Who Needs More, Who Needs Less? Risk-Adapted Frontline Care in Classic Hodgkin Lymphoma

Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Therapeutic Approaches for Relapsed/Refractory Hodgkin Lymphoma in a Rapidly Evolving Treatment Landscape

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Sharon Castellino, MD, MSc, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA

Personalized Care of Patients Cured from Hodgkin Lymphoma

Education Program: A New Treatment Paradigm for Follicular Lymphoma

Sunday **4:30 p.m. – 5:45 p.m.**
New Orleans Theatre A

Chair:
Alan Skarbnik, MD, Novant Health Cancer Institute, Charlotte, NC

Speakers:
Alan Skarbnik, MD, Novant Health Cancer Institute, Charlotte, NC

Novel Therapies for Follicular Lymphoma: Immune-Effector Cell Based

Manali Kamdar, MD, University of Colorado Cancer Center, Aurora, CO

Beyond Immune Effector Cell Therapy: Non-T-Cell Engaging Strategies in Follicular Lymphoma

Joanna Rhodes, MD, MSCE, Robert Wood Johnson Medical School & Rutgers Cancer Institute, New Brunswick, NJ

Follicular Lymphoma: Role of Molecular Disease Characterization in Diagnosis and Prognosis

Education Program: Are We There Yet? Improving Outcomes in MDS

Sunday **4:30 p.m. – 5:45 p.m.**
R02-R05

Chair:
Rami Komrokji, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Speakers:
Yazan Madanat, MD, University of Texas Southwestern Medical School, Dallas, TX

Choosing and Sequencing Anemia-Directed Treatment Options in Lower-Risk Myelodysplastic Syndromes

Sangeetha Venugopal, MD, MS, Sylvester Comprehensive Cancer Center & University of Miami, Miami, FL

High Risk MDS: Is Two Better than One?

Maximilian Stahl, MD, Yale School of Medicine and Yale Comprehensive Cancer Center, New Haven, CT

Straight to the Point: Targeted Therapies in MDS and CCUS

Education Program: Building Hematology Capacity Globally

Sunday **4:30 p.m. – 5:45 p.m.**
293-294

Chair:
Enrico Novelli, MD, University of Maryland, Baltimore, MD

Speakers:
Najibah Galadanci, PhD, MBBS, MPH, University of Alabama at Birmingham, Birmingham, AL

Showcasing ASH Resources for Continuing Medical Education for Local and International Trainees and Practitioners

Ruxandra Irimia, PhD, Emergency Clinical Hospital Prof. Dr. Agrippa Ionescu, Bucharest, Romania

Highlights of ASH's Programs to Build Hematology Capacity Around the Globe in Education Research and Clinical Practice

Eduardo Rego, PhD, University of São Paulo, São Paulo, Brazil

The Impact of Hematology Global Partnerships

Education Program: Driving CARs Safely-Preventing and Managing Intermediate and Long-Term CAR-T Toxicity non-CME

Sunday **4:30 p.m. – 5:45 p.m.**
New Orleans Theatre C

Chair:
Noffar Bar, MD, Yale University, Yale Cancer Center, New Haven, CT

Speakers:
Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA

Beyond Remission: Long-Term Hematopoietic Toxicity and Second Malignancies After CAR-T Cell Therapy

Zainab Shahid, MBBS, Memorial Sloan Kettering Cancer Center, New York, NY

Immune Determinants of Infections after CAR T- Cell Therapy: A Framework for Prevention and Management

Noffar Bar, MD, Yale University, Yale Cancer Center, New Haven, CT

A Practical Review of delayed Neurologic and Gastrointestinal Immune Toxicities After CAR-T Therapy in Multiple Myeloma

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Education Program: From Mutations to Manifestations: Connecting Clonal Hematopoiesis (CH) and Thrombosis non-CME

Sunday **4:30 p.m. – 5:45 p.m.**
208-210

Chair:
Siddhartha Jaiswal, MD, PhD, Stanford University, Stanford, CA

Speakers:
Siddhartha Jaiswal, MD, PhD, Stanford University, Stanford, CA

Clonal Hematopoiesis of Indeterminate Potential and Arterial Thrombosis: Mechanisms and Clinical Implications

Yan Xu, MD, MSc, Ottawa Hospital Research Institute, Ottawa, Canada

Clones and Clots: Clonal Hematopoiesis in the Management of Venous Thromboembolism

Abhay Singh, MD, MPH, Cleveland Clinic Lerner College of Medicine of Case Western Reserve & Cleveland Clinic, Cleveland, IL

Role of Inflammasome Inhibitors in the Intersection of CH and Thrombosis

Education Program: Hemolysis Beyond Globin: Managing Inherited RBC Membrane and Enzyme Disorders

Sunday **4:30 p.m. – 5:45 p.m.**
275-277

Chair:
Hanny Al-Samkari, MD, Mass General Brigham Cancer Institute & Massachusetts General Hospital & Harvard Medical School, Boston, MA

Speakers:
Rami Khoriaty, MD, University of Michigan, Ann Arbor, MI

Management Considerations in Inherited Hemolytic Anemias

Shalini Shenoy, MD, Washington University School of Medicine, St. Louis, MO

Hematopoietic Stem Cell Transplantation in Severe Congenital Hemolytic Anemias

Hanny Al-Samkari, MD, Mass General Brigham Cancer Institute & Massachusetts General Hospital & Harvard Medical School, Boston, MA

Emerging Therapies for Treatment of Hereditary Hemolytic Anemias

Education Program: Innovations in the Treatment of Pediatric AML

Sunday **4:30 p.m. – 5:45 p.m.**
Hall E

Chair:
Paulina Velasquez, MD, St. Jude Children's Research Hospital, Memphis, TN

Speakers:
Tanja Gruber, MD, Cincinnati Children's, Cincinnati, OH & Stanford University, Palo Alto, CA

Targeted Therapies: From Genomic Insights to Therapeutic Strategies

Paulina Velasquez, MD, St. Jude Children's Research Hospital, Memphis, TN

CAR T-Cell Therapy in Pediatric AML: Current Limitations and Emerging Opportunities

Riccardo Masetti, MD, PhD, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy

Antibody-Drug Conjugates in Pediatric AML: Delivering Targeted Payloads

Education Program: Tailored Transfusion Strategies for Alloimmunized Patients

Sunday **4:30 p.m. – 5:45 p.m.**
353-355

Chair:
John Manis, MD, Boston Children's Hospital, Boston, MA

Speakers:
John Manis, MD, Boston Children's Hospital, Boston, MA

Pre-Transplant Transfusion Strategies in Alloimmunized Patients with Sickle Cell Disease

Marianne Yee, MD, MSc, Emory University, Atlanta, GA

Procurement of Blood for Highly Alloimmunized Patients

Patricia Shi, MD, Seattle Children's Hospital, Seattle, WA

Immune-Mediated Transfusion Reactions in Sickle Cell Disease: A Practical Approach

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Education Spotlight Sessions: Current Perspectives on Evolving Classification of Myeloid and Lymphoid Neoplasms

Sunday **4:30 p.m. – 5:45 p.m.**
391-392

Chair:
Amy DeZern, MD, MHS, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Speakers:
Sanam Loghavi, MD, MD Anderson Cancer Center, Houston, TX

Myeloid Updates

Laurence de Leval, MD, PhD, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland

Lymphoid Updates

MONDAY

Education Program: Advances in Management of Vascular Anomalies

Monday **10:30 a.m. – 11:45 a.m.**
220-222

Chair:
Kiersten Ricci, MD, Cincinnati Children's Hospital and Medical Center & University of Cincinnati Medical School, Cincinnati, **OH**

Speakers:
Bryan Sisk, MD, MS, Washington University School of Medicine, St. Louis, MO

Vascular Anomalies: Understanding the Healthcare Experiences of Patients and Caregivers

Guillaume Canaud, MD, PhD, Hôpital Necker Enfants Malades, Paris, France

Targeted Therapies for PI3k/AKT/mTOR Pathway Disorders

Kiersten Ricci, MD, Cincinnati Children's Hospital and Medical Center & University of Cincinnati Medical School, Cincinnati, OH

Targeted Therapies for Vascular Anomalies with RAS/MAPK Pathway Pathogenic Variants

Education Program: Managing Iron Status Before and During Pregnancy: Protecting Mother and Fetus

Monday **10:30 a.m. – 11:45 a.m.**
Hall E

Chair:
Anat Gafter-Gvili, MD, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel

Speakers:
Malcolm Munro, MD, University of California Los Angeles, Los Angeles, CA

Heavy Menstrual Bleeding, Iron Deficiency, and Iron Deficiency Anemia: A Hidden Epidemic in Plain Sight

Michael Georgieff, MD, University of Minnesota, Minneapolis, MN

The Role of Iron in the Developing Brain

Anat Gafter-Gvili, MD, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel

Intravenous Iron Therapy to Prevent Perinatal Iron Deficiency

Education Program: The Golden Era of ALL Management: Rapid Advances Across the Age Spectrum non-CME

Monday **10:30 a.m. – 11:45 a.m.**
278-282

Chair:
Rachel Rau, MD, Seattle Children's Hospital & University of Washington, Seattle, WA

Speakers:
Rachel Rau, MD, Seattle Children's Hospital & University of Washington, Seattle, WA

Next Steps for Treatment of Pediatric ALL in the Era of Frontline Chemo-Immunotherapy

Yannis Valtis, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Acute Lymphoblastic Leukemia in Adolescents and Young Adults: Improving Outcomes Beyond the Use of Two Pediatric Regimens

Talha Badar, MD, Mayo Clinic, Jacksonville, FL

Older Adults Take the Lead: Revolutionizing B-cell ALL Treatment with Chemo-Sparing Approaches

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Education Program: The Heart and Brain in Older Patients with Sickle Cell Disease non-CME

Monday **10:30 a.m. – 11:45 a.m.**
243-245

Chair:
Samuel Wilson, MD, MSCR, University of North Carolina at Chapel Hill, Chapel Hill, NC

Speakers:
Thomas D'Humières, MD, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris (AP-HP) & Coordinating Referral Center for Sickle Cell Disease and Red Blood Cell Disorders, Créteil, France

Preventing a Broken Heart: Approaches to Cardiovascular Health in Adults with Sickle Cell Disease

Samuel Wilson, MD, MSCR, University of North Carolina at Chapel Hill, Chapel Hill, NC

Stroke in the Older Adult with Sickle Cell Disease

Stephanie Forte, MD, MSc, Centre hospitalier de l'Universite de Montreal (CHUM) and Centre de recherche du CHUM (CRCHUM), Montreal, Canada

Addressing Cognitive Changes in Patients with Sickle Cell Disease

Education Spotlight Sessions: Public Health & Hematology: Results and Lessons from the PEN-Plus Model of Care for Severe, Chronic Non-Communicable Diseases like Sickle Cell Disease in Resource-Poor Areas

Monday **10:30 a.m. – 11:45 a.m.**
295-296

Chair:
Julie Makani, MD, PhD, Muhimbili University, Dar es Salaam, Tanzania

Speakers:
Emily Wroe, MD, MPH, Center for Integration Science, Brigham & Women's Hospital & NCDI Poverty Network, Boston, MA

Introduction to the PEN-Plus SCD Model of Care and Outcomes From the First Years of Implementation

Jane Hankins, MD, MS, St. Jude Children's Research Hospital, Memphis, TN

Integrating Newborn Screening for SCD by CONSA, St Jude's Global Hematology and Ministries of Health into PEN-Plus in LMICs and Rural Settings

Education Spotlight Sessions: Rebooting the Immune System with Cellular Therapies

Monday **10:30 a.m. – 11:45 a.m.**
275-277

Chair:
Natalie Wuliji, DO, Fred Hutchinson Cancer Center, Seattle, WA

Speakers:
George Georges, MD, Feinberg School of Medicine, Northwestern University, Chicago, IL

Defining Immune Reset: Mechanisms, Immune Reconstitution, and Biomarkers from Auto-HCT and CAR T-cell Therapy

Natalie Wuliji, DO, Fred Hutchinson Cancer Center, Seattle, WA

Cellular Therapies for Severe Autoimmune Disease: From Case Series to Multicenter Trials and Hematologic Applications

Education Spotlight Sessions: Splenectomy in Membrane Disorders and Enzymopathies: Who, When and How?

Monday **10:30 a.m. – 11:45 a.m.**
391-392

Chair:
Melissa Rose, DO, Nationwide Children's & The Ohio State University, Columbus, OH

Speakers:
Scott Peslak, MD, PhD, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Indications and Timing of Splenectomy in Hereditary Hemolytic Anemia

Lawrence Wolfe, MD, Donald & Barbara Zucker School of Medicine at Hofstra, Hempstead, NY

Techniques for Splenectomy and Partial Splenectomy and Peri-splenectomy Care

Education Program: Chronic Lymphocytic Leukemia - From Clonal Evolution to Novel Therapies

Monday **2:45 p.m. – 4:00 p.m.**
271-273

Chair:
Catherine Coombs, MD, University of California Irvine, Orange, CA

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Speakers:

Clare Sun, MD, Memorial Sloan Kettering Cancer Center, New York, NY

A Clinical Perspective on Clonal Evolution in Chronic Lymphocytic Leukemia

Michael Hallek, MD, University of Cologne, Köln, Germany

First and Second-Line Therapy of Chronic Lymphocytic Leukemia

Catherine Coombs, MD, University of California Irvine, Orange, CA

Treatment of Relapsed or Refractory CLL and of Richter Transformation

Education Program: Diffuse Large B-cell Lymphoma

Monday **2:45 p.m. – 4:00 p.m.**
278-282

Chair:

Laurie H. Sehn, MD, BC Cancer Center for Lymphoid Cancer, Vancouver, Canada

Speakers:

Laurie H. Sehn, MD, BC Cancer Center for Lymphoid Cancer, Vancouver, Canada

Frontline Therapy of Diffuse Large B-Cell Lymphoma

Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Bispecific Antibodies and Cellular Therapies for Diffuse Large B-Cell Lymphoma

Christopher Melani, MD, National Institutes of Health, National Cancer Institute, Bethesda, MD

Novel Approaches for Diffuse Large B-Cell Lymphoma

Education Program: Improving Care of Patients with Sickle Cell Disease via Complement, Pain Control, and Trial Design

Monday **2:45 p.m. – 4:00 p.m.**
Hall E

Chair:

Satheesh Chonat, MD, Emory University School of Medicine, Atlanta, GA

Speakers:

Satheesh Chonat, MD, Emory University School of Medicine, Atlanta, GA

Complement Inhibition in Sickle Cell Disease

C. Patrick Carroll, MD, Johns Hopkins School of Medicine, Baltimore, MD

What's New in Pain Management in Sickle Cell Disease?

Julie Kanter, MD, University of Alabama Birmingham, Birmingham, AL

After the Fall: Trial Design, National and International, in the Modern Era of Sickle Cell Disease

Education Spotlight Sessions: Balancing Bleeding and Clotting: Extended VTE Treatment for Whom and at What Dose?

Monday **2:45 p.m. – 4:00 p.m.**
208-210

Chair:

Alok Khorana, MD, Cleveland Clinic, Cleveland, IL

Speakers:

Marc Rodger, MD, MSc, McGill University, Montreal, Canada

VTE: Who Should Continue Anticoagulants Long-Term?

Isabelle Mahe, MD, PhD, Paris Cité University, Assistance Publique Hôpitaux de Paris, Paris, France

Anticoagulant Dose Reduction (who, how, and when)?

Education Program: A Decade of Progress Towards Safer and More Broadly Applicable Allogeneic Stem Cell Transplantation

Monday **4:30 p.m. – 5:45 p.m.**
343-345

Chair:

Shernan Holtan, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Speakers:

Hany Elmariah, MD, MS, Stanford University, Stanford, CA

New Standards in GVHD Prophylaxis: Towards a Future Without GVHD

Mahasweta Gooptu, MD, Dana-Farber Cancer Institute, Boston, MA

Targeting Acute and Chronic GVHD with Effective New Therapies

Shernan Holtan, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Donor for All: Increasing Access and Improving Outcomes

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Education Program: Battle-Scarred Blood Cells: Hematologic Malignancies in Military Service Members

Monday 4:30 p.m. – 5:45 p.m.
278-282

Chair:
Christin DeStefano, MD, Uniformed Services University of the Health Sciences, Bethesda, MD

Speakers:
Christin DeStefano, MD, Uniformed Services University of the Health Sciences, Bethesda, MD

Mission-Critical Care: Approaching a Service Member or Veteran with a Hematologic Malignancy

Helen Ma, MD, MS, VA Long Beach Healthcare System, Long Beach, CA

Beyond the Uniform: Understanding B-cell Malignancy Risks in Military Personnel

Suman Kambhampati, MD, VA Medical Center, Kansas City, MO

From Service to Cells: Toxic Exposures, Myeloid Malignancies, and Search for Pragmatic Solutions for Veterans

Education Program: Don't Miss It! Methemoglobinemia: Inherited and Acquired

Monday 4:30 p.m. – 5:45 p.m.
293-294

Chair:
Jennifer Herrick, MD, Mayo Clinic, Rochester, MN

Speakers:
Jennifer Herrick, MD, Mayo Clinic, Rochester, MN

Laboratory Testing in Methemoglobinemia

Josef Prchal, MD, University of Utah and VA and Huntsman Cancer institute, Salt Lake City, UT

Inherited Methemoglobinemia: Not Only and Not Always Cyanosis. Different Pathophysiology, Different Mutated Genes, and Different Management

Noemi Roy, MD, Oxford University Hospitals NHS Foundation Trust & University of Oxford, Oxford, United Kingdom

Acquired Methemoglobinemia: Who, Why, and What to Do

Education Program: Multiple Myeloma: The Future is Now

Monday 4:30 p.m. – 5:45 p.m.
Hall E

Chair:
Craig Cole, MD, Karmanos Cancer Institute, Detroit, MI

Speakers:
Ajai Chari, MD, University of California San Francisco, San Francisco, CA

Bispecific Antibodies OR CAR-T in Early Relapse for Multiple Myeloma

Surbhi Sidana, MD, Stanford University, Palo Alto, CA

Treatment Sequencing After CAR-T Failure in Multiple Myeloma

Joshua Richter, MD, Tisch Cancer Institute, New York, NY

Maintenance Therapy for High-Risk Multiple Myeloma

Education Program: Neutropenia: Updates in Diagnosis, Treatment, and Supportive Care.

Monday 4:30 p.m. – 5:45 p.m.
275-277

Chair:
Helen Papadaki, MD, PhD, University of Crete School of Medicine, University Hospital of Heraklion, Heraklion, Crete, Greece

Speakers:
Helen Papadaki, MD, PhD, University of Crete School of Medicine, University Hospital of Heraklion, Heraklion, Crete, Greece

Diagnosis of Congenital and Acquired Neutropenia

Francesca Fioredda, MD, Giannina Gaslini Research Children's Hospital, Genova, Italy

Treatment of Neutropenia: Cytokines and Beyond

Julia Warren, MD, PhD, Children's Hospital of Philadelphia, Philadelphia, PA

Supportive Care for Patients with Chronic Neutropenia

Education Spotlight Sessions: Bispecific Antibody Therapy vs CAR T Therapy in Lymphoid Malignancies

Monday 4:30 p.m. – 5:45 p.m.
271-273

Chair:
Yvonne Efebera, MD, MPH, OhioHealth, Columbus, OH

Speakers:
Eden Biltibo, MD, MS, Vanderbilt Health, Nashville, TN

Bispecific Antibodies vs CAR T: Myeloma Perspective

Matthew Mei, MD, City of Hope, Duarte, CA

Bispecific Antibodies vs CAR T: Lymphoma Perspective

SPECIAL INTEREST SESSIONS AND STUDIOS

These sessions provide the opportunity for ASH's various communities to focus on specific topics of interest.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

FRIDAY

Training Program Directors' Workshop

Friday **9:00 a.m. – 12:00 p.m.**
Hilton Garden Inn - Magnolia

Chair:
Katherine Walsh, MD, Vanderbilt University Medical Center, Nashville, TN

Speakers:
Alissa Kleinhenz, MD, University of California in San Francisco, San Francisco, CA

Olufolake Egbujo (Adisa), MD, MSc, Alan Pearson Cancer Center, Centra, Lynchburg, VA & Novartis Pharmaceuticals Corporation, East Hanover, NJ

Supporting Fellows in their Pursuit of Research Funding and Career Placement

Andrew Srisuwananukorn, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Roni Shouval, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Artificial Intelligence Highlights for Program Directors

Lori Rosenstein, MD, Emplify by Gundersen Health, La Crosse, WI

Kenneth Cohen, MD, The University of Chicago, Chicago, IL

Insights and Experiences After One Year of Program Signaling

SATURDAY STUDIOS

ASH Studio, Hall D non-CME

8:00 a.m. – 8:25 a.m.	Treating Fairly Talks: Building Infrastructure for Systemic Change in Maternal Health Outcomes
9:00 a.m. – 9:25 a.m.	Treating Fairly Talks: Expanding Access to Therapies for Underserved Populations
11:00 a.m. – 11:25 a.m.	Treating Fairly Talks: Engaging American Indians and Alaska Native Populations in Community Interventions/Research
1:30 p.m. – 1:55 p.m.	Treating Fairly Talks: Leveraging AI on Our Path to More Inclusive Clinical Outcomes
3:30 p.m. – 3:55 p.m.	Treating Fairly Talks: Iron Deficiency Interventions in Low Resource Settings

ASH Wellness Studio, Hall D non-CME

9:05 a.m. – 9:15 a.m.	The Instant Calm
9:15 a.m. – 9:25 a.m.	Sip Yourself Sharp
11:05 a.m. – 11:15 a.m.	Quiet the Noise
11:20 a.m. – 11:30 a.m.	Reclaim Your Spark
11:35 a.m. – 11:45 a.m.	Own Your Time
1:35 p.m. – 1:45 p.m.	Eat for Energy
1:45 p.m. – 1:55 p.m.	Shake it Off
3:35 p.m. – 3:45 p.m.	Find Your Tribe
3:45 p.m. – 3:55 p.m.	The Instant Calm

Blood Journals Studio, Hall F non-CME

8:00 a.m. – 9:00 a.m.	ASH Poster Walk on Emerging Toxicities and Predictors in T-Cell–Redirecting Therapies Hosted by *Blood Immunology & Cellular Therapy*
9:05 a.m. – 9:30 a.m.	Meet the Journal Editors: *Blood Immunology & Cellular Therapy*
1:30 p.m. – 2:00 p.m.	Inside Peer Review at *Blood Advances*
3:30 p.m. – 4:30 p.m.	Blood Journals Club: Characteristics of Donor and Recipient Clonal Hematopoiesis in Non-myeloablative Transplant for Sickle Cell Disease

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

Treating Fairly Talks: Building Infrastructure for Systemic Change in Maternal Health Outcomes

non-CME

Saturday 8:00 a.m. – 8:25 a.m.
Hall D ASH Studio

Speaker:
Imo Akpan, MD, Columbia University Medical Center, New York, NY

Treating Fairly Talks: Expanding Access to Therapies for Underserved Populations

non-CME

Saturday 9:00 a.m. – 9:25 a.m.
Hall D ASH Studio

Speaker:
Ann-Kathrin Eisfeld, MD, Ohio State University Medical Center & The Ohio State University Wexner Medical Center, Columbus, OH

Meet the Journal Editors: *Blood Immunology & Cellular Therapy*

non-CME

Saturday 9:05 a.m. – 9:30 a.m.
Hall F Blood Journals Studio

Speaker:
Willem Fibbe, MD, PhD, Editor-in-Chief, *Blood Immunology & Cellular Therapy* & Leiden University Medical Center, Leiden, Netherlands

Caron Jacobson, MD, Deputy Editor, *Blood Immunology & Cellular Therapy* & Dana-Farber Cancer Institute, Boston, MA

Ancestry Origins in Personalized Medicine: Advancing Biological Discovery, Population-Representative Research Design, and Translational Validity in Hematology

Saturday 9:30 a.m. – 10:45 a.m.
220-222

Co-Chairs:
Ruemu Birhiray, MD, Hematology Oncology of Indiana & American Oncology Network & Indy Hematology Education & Marian University Tom and Julie Wood College of Osteopathic Medicine, Indianapolis, IN

Ari Melnick, MD, Josep Carreras Leukaemia Research Institute, Barcelona, Spain

Speakers:
Ambroise Wonkam, MD, PhD, Johns Hopkins University School of Medicine, Baltimore, MD

Leveraging our Common African Genomes to Improve Health Globally

Eimear Kenny, PhD, Icahn School of Medicine at Mount Sinai, New York, NY

Modeling Ancestry-Informed Bias in Hematology: Duffy-null Status and Other Genotypic Determinants

Ari Melnick, MD, Josep Carreras Leukaemia Research Institute, Barcelona, Spain

African Ancestry-Associated Mechanisms of Immune System Malignancies and Precision Therapies

QI Intensive - A Practical Guide to Quality Improvement in Hematology

Saturday 9:30 a.m. – 11:00 a.m.
293-294

Chair:
Michael Keng, MD, University of Virginia, Charlottesville, VA

Speakers:
Menaka Pai, MSc, MD, FRCPC, McMaster University, Hamilton, Canada

Understanding the Problem and Developing Measures within Quality Improvement

Michael Keng, MD, University of Virginia, Charlottesville, VA

Process Analysis Tools and Introduction to Data in Quality Improvement

Treating Fairly Talks: Engaging American Indians and Alaska Native Populations in Community Interventions/Research

non-CME

Saturday 11:00 a.m. – 11:25 a.m.
Hall D ASH Studio

Speaker:
Denise Dillard, PhD, MS, Washington State University, Spokane, WA

ASH Advocacy Network Lunch

Saturday 11:15 a.m. – 12:15 p.m.
Marriott Warehouse - Gravier A-F

Chair:
Bart Scott, MD, Fred Hutchinson Cancer Research Center, Seattle, WA

Speaker:
Francis Collins, MD, PhD, National Institutes of Health, Bethesda, MD

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Blood Presents: How to Get Published in a Peer Review Journal non-CME

Saturday 11:15 a.m. – 12:15 p.m.
252-254

Speaker:
Andrew Roberts, MBBS, PhD, Editor-in-Chief, *Blood,* Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

Treating Fairly Talks: Leveraging AI on Our Path to More Inclusive Clinical Outcomes non-CME

Saturday 1:30 p.m. – 1:55 p.m.
Hall D ASH Studio

Speaker:
Shakira Grant, MBBS, MSc, CROSS Global Research & Strategy, Research Triangle Park, Durham, NC

Inside Peer Review at *Blood Advances* non-CME

Saturday 1:30 p.m. – 2:00 p.m.
Hall F Blood Journals Studio

Speakers:
Steven Lane, MD, PhD, Associate Editor, *Blood Advances,* Royal Brisbane and Women's Hospital and QIMR Berghofer Medical Research Institute, Brisbane, Australia

Sarah O'Brien, MD, MSc, Associate Editor, *Blood Advances,* Nationwide Children's Hospital, Columbus, OH

Distinguished Abstract Achievement Award Ceremony

Saturday 2:00 p.m. – 3:00 p.m.
346-347

Moderator:
H. Leighton Grimes, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Treating Fairly Talks: Iron Deficiency Interventions in Low Resource Settings non-CME

Saturday 3:30 p.m. – 3:55 p.m.
Hall D ASH Studio

Speaker:
Ali Taher, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon

Blood Journals Club: Characteristics of Donor and Recipient Clonal Hematopoiesis in Non-myeloablative Transplant for Sickle Cell Disease non-CME

Saturday 3:30 p.m. – 4:30 p.m.
Hall F Blood Journals Studio

Co-Chairs:
Andrew Roberts, MBBS, PhD, Editor-in-Chief, *Blood,* Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

Anna Marneth, PhD, Radboud University Medical Center, Nijmegen, Netherlands

Speakers:
Lachelle Weeks, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Courtney Fitzhugh, MD, National Institutes of Health, Bethesda, MD

Fireside Chats on Innovation in a Changing Regulatory Landscape non-CME

Saturday 4:00 p.m. – 5:30 p.m.
293-294

Chair:
Jonathan Hoggatt, Moderna, Cambridge, MA

Speakers:
Tomas Ganz, MD, PhD, UCLA Medical School, Los Angeles, CA

John Quisel, JD, PhD, Disc Medicine, Boston, MA

Regulatory Environment

Meg Wood, MPH, NYBC Ventures, Boston

Philip DeSouza, MD, Newpath Partners, Boston, MA

Investor Perspective: The Changing Regulatory Landscape

Wilbur Lam, MD, PhD, Emory University, Atlanta, GA

Jeroen Roose, PhD, University of California–San Francisco, San Francisco, CA

NAMs in the New Regulatory Landscape

Hematology Inclusion Pathway (HIP) Oral Presentations on Classical Hematology

Saturday 6:00 p.m. – 8:00 p.m.
Hilton - Grand Ballroom C

Speakers:
Carmela Caringas, Rush Medical College, Chicago, IL

Patterns of Pain and Outcomes in Youth with Sickle Cell Disease

Danielle Cicka, MD, PhD, Washington University in St. Louis, St. Louis, MO

Assessing Disease-Modifying Therapy in Sickle Cell Disease: A Claims-Based Cohort Study

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Uchenna Maureen Amaechi, Howard University Hospital, Washington DC

Lung Cancer Incidence and Survival in Adults with Sickle Cell Disease: The Impact of Chronic Pulmonary Injury and Pulmonary Hypertension

Amber Smith, University of California--San Francisco, San Francisco, CA

Exploring the Practice Patterns and Comparative Effectiveness of Anticoagulation in Adults with Thrombotic Anti-Phospholipid Syndrome

Clement Ojo, UConn Health, Farmington, CT

The Role of Oxysterol Metabolism in Clonal Hematopoiesis

Corbin Azucenas, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Codanin-1 Deficiency Accelerates Erythroblast Cycling While Leading to Ineffective Erythropoiesis

Ajibike Lapite, MD, MPHTM, Texas Children's Hospital, Houston, TX

Mutational Landscape of Clonal Hematopoiesis in PLWH of African Ancestry

Nowah Afangbedji, PhD, Stanford University, Stanford, CA

Mutation-Agnostic HBB Gene Replacement Coupled to Erythroid-Selective Expansion Drives Functional Correction of β-Hemoglobinopathies

Zanshé Thompson, Ph.D., The Johns Hopkins University School of Medicine, Baltimore, MD

The High Mobility Group A1 Chromatin Regulator Induces Inflammatory Signals and Promotes Atherogenesis in Tet2 Mutant Clonal Hematopoiesis

Emily Villalpando, A.M., Boston Children's Hospital, Harvard University, Cambridge, MD

Unraveling Fetal Hemoglobin Regulation Through Multiplexed Base Editing in Primary Human Hematopoietic Cells

Hematology Inclusion Pathway (HIP) Oral Presentations on Health Outcomes

Saturday 6:00 p.m. – 8:00 p.m.
Hilton - Grand Ballroom D

Speakers:

Princess Della Tsivor, B.A, Warren Alpert Medical School of Brown University, Providence, RI

Hydroxyurea Significantly Improves Quality of Life for Children with Sickle Cell Disease in Angola: Results from the PUSHUP Trial

Cedrick Ofori, Meharry Medical College, Nashville, TN

Insufficient Neuroradiology Reports Limit Diagnosis and Longitudinal Assessment of Silent Cerebral Infarcts in Sickle Cell Anemia

Alec Seidman Sorsby, MD, Boston Medical Center, Boston University, Boston, MA

Rates of Thrombosis and Bleeding in Patients with Breast Cancer and Ductal Carcinoma in Situ Treated with Endocrine Therapy

Whitney Nichols, University of Cincinnati, Cincinnati Children's Medical Center, Cincinnati, OH

Evaluating the Effects of Neighborhood Gun Violence on Pain Among Children and Adolescents with Sickle Cell Disease

Andrew Bueno, MD, Beth Israel Deaconess Medical Center, Cambridge, MA

Engaging Artificial Intelligence for Accurate Prediction of Cancer-Associated Thrombosis

Chiamaka Nwachukwu, MBBS, Tulane University School of Medicine, New Orleans, LA

Planning Adolescent Transition in Healthcare for Sickle Cell (PATH-SC): Self-Efficacy, Transition Readiness and Preparation Among Nigerian Adolescents with Sickle Cell Disease.

Alador Bereketab, University of Ottawa, Faculty of Medicine, Ottawa, Canada

Racial Differences in Pregnancy-Associated Venous Thromboembolism in Ontario, Canada: A Population-Based Retrospective Cohort Study

Jennifer Afranie-Sakyi, MD, Yale School of Medicine, New Haven, CT

The Association of Pain, Silent Cerebral Infarcts and Neurocognition in Adults With SCD: The PAIN+SCAN Study

Eduarda Grinsztejn, MD, Weill Cornell Medicine, New York, NY

Thrombosis Risk Assessment in Transgender Women on Gender-Affirming Hormone Therapy

Rahul Reddy Tirumalareddy, MBBS, The University of Tennessee Health Science Center, Memphis, TN

Association Between Depressive Symptoms and Vaso-Occlusive Crisis Frequency in Adults with Sickle Cell Disease: A Retrospective Cohort Study

Hematology Inclusion Pathway (HIP) Oral Presentations on Malignant Hematology I

Saturday 6:00 p.m. – 8:00 p.m.
Hilton - Grand Ballroom A

Speakers:

Alexander Sanjurjo, BS, Columbia University Vagelos College of Physicians & Surgeons, New York, NY

Patient-Reported Outcomes in a Phase II Trial of Ruxolitinib and Pembrolizumab for Relapsed or Refractory Peripheral and Cutaneous T-cell Lymphomas

Mark Pusung, Knight Cancer Institute - Oregon Health & Science University, Portland, OR

Milestones and Challenges in Chronic Myeloid Leukemia

Ryan Mack, PhD, Loyola University Chicago, Chicago, IL

Evaluating Clinicopathologic and Spatial Determinants of HIV-Associated Lymphoma Outcomes in the Antiretroviral Therapy Era in Malawi

Gaelen Dwyer, MD, PhD, University of Michigan, Ann Arbor, MI

Adverse Social Drivers of Health are Associated with an Elevated Pre-Transplant Inflammatory Cytokine Profile and Intensive Care Admission Following Pediatric Hematopoietic Cell Transplantation

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Chinemerem Emeasoba, MD, University of Arkansas for Medical Sciences Fayetteville, Fayetteville, AR

Clinical Characteristics and Survival Outcomes in Intravascular Large B-Cell Lymphoma: A Population-Based Study Using the SEER Research Plus Database, 2010-2022

Jannaldo Nieves-Salva, University of Michigan, Ann Arbor, MI

Activating Mutations of the Condensate Organizer ZMIZ1 in Newly Defined ETP Leukemia

Briana Turner, Weill Cornell Medical College, New York, NY

Targeting Mutant Isocitrate Dehydrogenase Acute Myeloid Leukemias by Leveraging Fructose Metabolism

Franco Castillo Tokumori, MD, Weill Cornell Medicine, New York, NY

MPN Clonal Fitness: Measuring the Pathobiology of Myeloproliferative Neoplasms

Maria Leon-Camarena, MD, Emory University School of Medicine, Atlanta, GA

Impact of Race and HLA-Matching on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation

Amara Pang, Oregon Health & Science University, Portland, OR

Development of a Pre-Clinical Model of Systemic Mastocytosis with an Endogenous KIT Mutation

Hematology Inclusion Pathway (HIP) Oral Presentations on Malignant Hematology II

Saturday 6:00 p.m. – 8:00 p.m.
Hilton - Grand Ballroom B

Speakers:

Janet Chukwu, Liberty University College of Osteopathic Medicine, Lynchburg, VA

Assessing the Safety and Efficacy of BCMA CAR T-Cell Therapy for Relapsed or Refractory Myeloma in Patients With Renal Failure

Qierra Brockman, PhD, University of Colorado Anschutz Medical Campus Aurora, CO

Epigenetic Reprogramming of Anti-Tumor Immunity by Clonal Hematopoiesis

Mark Pusung, Knight Cancer Institute - Oregon Health & Science University, Portland, OR

ABS26-12905 Dysregulation of Ubiquitination-Related Genes is Associated With BCR-ABL1 Kinase- Independent Resistance and Progression in Chronic Myeloid Leukemia

Yu-Han Chen, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Clinical Features and Outcomes of Myeloproliferative Neoplasm Patients with MPL Mutations

Evani Patel, MD, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA

Differences in Myelofibrosis Care Between Academic and Community Centres: A Retrospective Cohort Analysis

Jether Amos Espinosa, BA, MPhil, Yale, New Haven, CT

RBM15::MKL1 Maintains WTAP Recruitment and Blocks Megakaryocytic Differentiation Independent of the RBM15 SPOC Domain

Briandy Fernandez Marrero, The University of Texas at El Paso, El Paso, TX

G0S2 is a Novel Unfolded Protein Response (UPR)-Induced Negative Feedback Effector That Suppresses Autophagy and Limits Stress Adaptation in Myeloid Leukemia

Daniela Ortiz Chavez, University of Colorado Anschutz Medical Campus, Aurora, CO

Integrated Multi-Omics Reveals a Non-Canonical Role for CDK1-Dependent Protein Synthesis in AML Survival

Jessica Diarra, Stanford University School of Medicine, Stanford, CA

CXCR4 Signaling Marks a Less-Suppressive, Regenerative Treg Phenotype in the Bone Marrow with Implications for Allo-HSCT

Mwanasha Merrill, MD, University of California--San Francisco, San Francisco, CA

Cell Free DNA for Lymphoma Diagnosis in Sub-Saharan Africa

Allison O. Taylor, MD, MS, Massachusetts General Hospital, Mass General Brigham Cancer Institute, Cambridge, MA

Relationship Between Sociodemographic Factors, Conditioning Intensity and Survival in Myeloid Malignancy Transplant Recipients: A Single Center Study

Hematology Inclusion Pathway (HIP) Reception

Saturday 8:00 p.m. – 9:00 p.m.
Hilton - Chemin Royale

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SUNDAY

SUNDAY STUDIOS

ASH Studio, Hall D non-CME

8:00 a.m. – 8:25 a.m.	Treating Fairly Talks: Leveraging AI on Our Path to More Inclusive Clinical Outcomes
9:00 a.m. – 9:25 a.m.	MedEd Talks: Interactive Teaching Methods
11:00 a.m. – 11:25 a.m.	Treating Fairly Talks: Expanding Access to Therapies for Underserved Populations
12:00 p.m. – 12:25 p.m.	MedEd Talks: Leadership Skills and Styles in Medical Education
1:30 p.m. – 1:55 p.m.	Treating Fairly Talks: What is "Normal?" Updating Absolute Neutrophil Count Reference Ranges by Duffy Status
4:00 p.m. – 4:25 p.m.	Treating Fairly Talks: Building Infrastructure for Systemic Change in Maternal Health Outcomes

ASH Wellness Studio, Hall D non-CME

9:05 a.m. – 9:15 a.m.	Sip Yourself Sharp
9:15 a.m. – 9:25 a.m.	Reclaim Your Spark
11:05 a.m. – 11:15 a.m.	Own Your Time
11:20 a.m. – 11:30 a.m.	Quiet the Noise
11:35 a.m. – 11:45 a.m.	Shake it Off
4:05 p.m. – 4:15 p.m.	Eat For Energy
4:15 p.m. – 4:25 p.m.	The Instant Calm

Blood Journals Studio, Hall F non-CME

8:00 a.m. – 9:00 a.m.	ASH Poster Walk on New Developments in Targeted Therapies for Myeloid Malignancies Hosted by *Blood Neoplasia*
9:05 a.m. – 9:30 a.m.	Meet the Journal Editors: *Blood Neoplasia*
11:15 a.m. – 12:15 p.m.	ASH Poster Walk on Innovations in Hemostasis and Thrombosis Clinical Research Design Hosted by *Blood Vessels, Thrombosis & Hemostasis*
4:00 p.m. – 4:30 p.m.	Meet the Journal Editors: *Blood Vessels, Thrombosis & Hemostasis*

Medical Educators' Symposium

Sunday 7:00 a.m. – 9:00 a.m.
Marriott Warehouse - Cypress I-II

Chair:
Reshma Ramlal, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Speakers:
Torsten Haferlach, MD, PhD, Munich Leukemia Laboratory, Munich, Germany

General Session 1: How to Use AI for Curriculum Development

Alice Ma, MD, University of North Carolina School of Medicine, Chapel Hill, NC

General Session 2: Educator Wellness

Manpreet Kochhar, MD, Brown University, Providence, RI

General Session 3: MEI Project Presentation

Scott Moerdler, MD, Rutgers Cancer Institute, New Brunswick, NJ

Breakout 1: Best AI and Social Media Tools to Support Instruction

Rakhi Naik, MD, MHS, Johns Hopkins University, Baltimore, MD

Breakout 2: Fostering Critical Thinking and a Feedback Culture

Oluwatoyosi Onwuemene, MD, MS, Duke University & Veterans Health Administration, Durham, NC

Breakout 3: Time Management for Educators

Rima Jubran, MD, MPH, Children's Hospital Los Angeles, Los Angeles, CA

Breakout 4: Creating Engaging Environments for Learners

Treating Fairly Talks: Leveraging AI on Our Path to More Inclusive Clinical Outcomes

Sunday 8:00 a.m. – 8:25 a.m.
Hall D ASH Studio

Speaker:
Shakira Grant, MBBS, MSc, CROSS Global Research & Strategy, Research Triangle Park, Durham, NC

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

MedEd Talks: Interactive Teaching Methods

non-CME

Sunday **9:00 a.m. – 9:25 a.m.**
Hall D ASH Studio

Speaker:
Joanna Pierro, DO, Staten Island University Hospital - Northwell Health, Staten Island, NY

Meet the Journal Editors: *Blood Neoplasia*

non-CME

Sunday **9:05 a.m. – 9:30 a.m.**
Hall F Blood Journals Studio

Speakers:
Maria Figueroa, MD, Deputy Editor, *Blood Neoplasia*, University of Miami Miller School of Medicine, Miami, FL

Early Faculty Career Development Session

Sunday **9:30 a.m. – 11:00 a.m.**
293-294

Chair:
Annie Im, MD, University of Pittsburgh & UPMC Hillman Cancer Center, Pittsburgh, PA

Speakers:
Kamal Menghrajani, MD, Harvard Medical School & Mass General Brigham Cancer Institute, Boston, MA

Nina Shah, MD, AstraZeneca, San Francisco, CA

How to Pursue Non-Traditional Academic Careers

Julie Panepinto, MD, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

Jonathan Licht, MD, Van Andel Institute, Grand Rapids, MI

Diversifying Funding

Jane Churpek, MD, MS, The University of Wisconsin-Madison, Madison, WI

Michaela Liedtke, MD, Stanford University Cancer Center, Stanford, CA

Ifeyinwa Osunkwo, MD, Novo Nordisk, Plainsboro, NJ

Rahma Warsame, MD, Mayo Clinic, Rochester, MN

Tackling Common Obstacles

From Real-World Evidence to Real-World Impact: Translating Multiple Myeloma Data into Clinical Practice

non-CME

Sunday **9:30 a.m. – 11:00 a.m.**
265-268

Chair:
Saad Usmani, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Speakers:
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN

International Myeloma Working Group (IMWG) Perspective: From Multinational Real-World Data to Global Myeloma Guidelines

Shaji Kumar, MD, Mayo Clinic, Rochester, MN

ASH Research Collaborative Multiple Myeloma Research Network: Building Actionable Evidence at Scale

Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL

United States Experience: Real-World Evidence from U.S. Practice: Treatment Patterns, Outcomes, and Quality Improvement

Kimmo Porkka, University of Helsinki, Helsinki, Finland

Europe/Asia Perspective: Real-World Evidence from Diverse Health Care Systems: Treatment Patterns, Outcomes, and Quality Improvement (Part 1)

Wee-Joo Chng, National University of Singapore, Clementi, Singapore

Europe/Asia Perspective: Real-World Evidence from Diverse Health Care Systems: Treatment Patterns, Outcomes, and Quality Improvement (Part 2)

Treating Fairly Talks: Expanding Access to Therapies for Underserved Populations

Sunday **11:00 a.m. – 11:25 a.m.**
Hall D ASH Studio

Speaker:
Ann-Kathrin Eisfeld, MD, Ohio State University Medical Center & The Ohio State University Wexner Medical Center, Columbus, OH

LBGTQIA+ Community Networking Brunch

Sunday **11:00 a.m. – 12:30 p.m.**
Marriott Warehouse - Cypress I-II

ASH Clinicians in Practice Lunch - Beyond Bandwidth: Improving Workflow Efficiency in Clinical Practice through Clinical Collaborations and Artificial Intelligence

Sunday **11:15 a.m. – 12:30 p.m.**
Marriott Warehouse - Gravier C-F

Chair:
Mary-Elizabeth Percival, MD, Fred Hutchinson Cancer Center, Seattle, WA

Speakers:
Kylee Martens, MD, Oregon Health & Science University, Portland, OR

Partnering with Primary Care to Eliminate Inefficiencies

Camila Masias, MD, Baptist Health Medical Group, Miami, FL

Development of Clinical Collaborations with Advanced Practice Providers to Create Efficiencies

Aziz Nazha, MD, Thomas Jefferson University, Philadelphia, PA

AI: Artificial Intelligence as a Tool to Streamline Practice Workflows

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Showcasing a Decade of Discoveries in *Blood Advances* non-CME

Sunday **11:15 a.m. – 12:15 p.m.**
252-254

Chair:
Robert Negrin, MD, President, American Society of Hematology, Founding Editor, *Blood Advances* & Stanford University, Stanford, CA

Speakers:
Catherine M. Bollard, MD, Editor-in-Chief, *Blood Advances* & George Washington University, Washington, DC

Andrew S. Weyrich, PhD, Deputy Editor, *Blood Advances* & Oklahoma Medical Research Foundation, Oklahoma City, OK

Treating Fairly Rounds Lunch

Sunday **11:30 a.m. – 12:30 p.m.**
Marriott Warehouse - Gravier AB

Co-Chairs:
Urshila Durani, MD, MPH, Mayo Clinic, Rochester, MN

Srinivas Devarakonda, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Speakers:
Deirdra Terrell, PhD, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Amar Kelkar, MD, MPH, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA

Challenges and Opportunities with Healthcare Reform

MedEd Talks: Leadership Skills and Styles in Medical Education non-CME

Sunday **12:00 p.m. – 12:25 p.m.**
Hall D ASH Studio

Speaker:
Leslie Kersun, Children's Hospital of Philadelphia, Philadelphia, PA

Treating Fairly Talks: What is "Normal?" Updating Absolute Neutrophil Count Reference Ranges by Duffy Status

Sunday **1:30 p.m. – 1:55 p.m.**
Hall D ASH Studio

Speaker:
Lauren Merz, MD, MSc, University of Michigan, Ann Arbor, MI

Simulcast of Awards and Plenary Scientific Session

Sunday **1:30 p.m. – 4:00 p.m.**
Two locations: 208-210 & New Orleans Theatre C

Meet the Journal Editors: *Blood Vessels, Thrombosis & Hemostasis* non-CME

Sunday **4:00 p.m. – 4:30 p.m.**
Hall F Blood Journals Studio

Speakers:
Keith R. McCrae, MD, Editor-in-Chief, *Blood Vessels, Thrombosis & Hemostasis* & Cleveland Clinic, Cleveland, OH

Karin Hoffmeister, MD, Deputy Editor, *Blood Vessels, Thrombosis & Hemostasis* & Versiti Blood Research Institute, Milwaukee, WI

Scott Cameron, MD, PhD, Associate Editor, *Blood Vessels, Thrombosis & Hemostasis* & Cleveland Clinic, Cleveland, OH

Treating Fairly Talks: Building Infrastructure for Systemic Change in Maternal Health Outcomes

Sunday **4:00 p.m. – 4:25 p.m.**
Hall D ASH Studio

Speaker:
Imo Akpan, MD, Columbia University Medical Center, New York, NY

Real-World Data Applications in Sickle Cell Disease Trial Design non-CME

Sunday **4:30 p.m. – 6:00 p.m.**
243-245

Chair:
Charles Abrams, MD, Penn Medicine, Philadelphia, PA

Speakers:
Mike Callaghan, MD, Agios Pharmaceuticals, Cambridge, MA

Using the SCD Data Hub as a Contemporaneous Control Arm in a Clinical Trial

Keith Marsolo, PhD, Duke University, Durham, NC

EHR to Evidence: Defining Acute Sickle Cell Pain as a Real-World Data Endpoint

Jeremy Rupon, MD, PhD, Pfizer Inc, Philadelphia, PA

Simulating Placebo Control Arms Using Real-World Registry Data in Sickle Cell Disease Trials

Tina Hernandez-Boussard, PhD, MPH, MS, Stanford University, Stanford, CA

Real World Registry Controls Versus Synthetic Data: Safeguarding Validity in Trial Design

The AI Colleague: Promise, Peril, and Practice in Hematology non-CME

Sunday **4:30 p.m. – 6:00 p.m.**
393-396

Chair:
Roni Shouval, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Speakers:
Andrew Srisuwananukorn, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Practical Generative AI Tools for Clinicians and Investigators

Jan-Niklas Eckardt, MD, Else Kroener Fresenius Center for Digital Health, TUD Dresden University of Technology & University Hospital Dresden, Dresden, Germany

Multi-Agent AI systems

Vanessa Kennedy, MD, Stanford University, Palo Alto, CA

Limitations and Risks of Generative AI

MONDAY

Back to Business Breakfast non-CME

Monday 7:30 a.m. – 9:00 a.m.
Marriott Warehouse - Gravier ABC

Chair:
Jonathan Hoggatt, PhD, Moderna, Cambridge, MA

MONDAY STUDIOS

ASH Studio, Hall D non-CME

8:00 a.m. – 8:25 a.m.	Treating Fairly Talks: What is "Normal?" Updating Absolute Neutrophil Count Reference Ranges by Duffy Status
10:00 a.m. – 10:25 a.m.	Treating Fairly Talks: Engaging American Indians and Alaska Native Populations in Community Interventions/Research
12:00 p.m. – 12:25 p.m.	MedEd Talks: Giving Feedback and Remediation for UME/GME
1:00 p.m. – 1:25 p.m.	Treating Fairly Talks: Iron Deficiency Interventions in Low Resource Settings

ASH Wellness Studio, Hall D non-CME

10:05 a.m. – 10:15 a.m.	Sip Yourself Sharp
10:15 a.m. – 10:25 a.m.	Own Your Time
12:05 p.m. – 12:15 p.m.	Eat For Energy
12:20 p.m. – 12:30 p.m.	Quiet the Noise
12:35 p.m. – 12:45 p.m.	Shake it Off
2:35 p.m. – 2:45 p.m.	The Instant Calm

Blood Journals Studio, Hall F non-CME

8:00 a.m. – 9:00 a.m.	ASH Poster Walk on Beyond Acute Vaso-Occlusion: Emerging Mechanisms and Phenotypes of Chronic Pain in Sickle Cell Disease Hosted by *Blood Red Cells & Iron*
10:00 a.m. – 10:30 a.m.	Meet the Journal Editors: *Blood Red Cells & Iron*
12:15 p.m. – 1:15 p.m.	ASH Poster Walk on Leukemia in Latin America: Outcomes and Access to Diagnostics and Therapies Hosted by *Blood Global Hematology*
1:15 p.m. – 1:30 p.m.	Meet the Journal Editors: *Blood Global Hematology*

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Treating Fairly Talks: What is "Normal?" Updating Absolute Neutrophil Count Reference Ranges by Duffy Status

Monday 8:00 a.m. – 8:25 a.m.
Hall D ASH Studio

Speaker:
Lauren Merz, MD, MSc, University of Michigan, Ann Arbor, MI

Treating Fairly Talks: Engaging American Indians and Alaska Native Populations in Community Interventions/Research

Monday 10:00 a.m. – 10:25 a.m.
Hall D ASH Studio

Speaker:
Denise Dillard, PhD, MS, Washington State University, Spokane, WA

Meet the Journal Editors: *Blood Red Cells & Iron*

non-CME

Monday 10:00 a.m. – 10:30 a.m.
Hall F Blood Journals Studio

Speakers:
Patrick Gallagher, MD, Editor-in-Chief, *Blood Red Cells & Iron* & Nationwide Children's Hospital & Ohio State University, Columbus, OH

Laura Silvestri, PhD, Deputy Editor, *Blood Red Cells & Iron* & San Raffaele Scientific Institute & Vita-Salute University, Milan, Italy

ASH-FDA Joint Symposium on Newly Approved Therapies 1

Monday 10:30 a.m. – 12:00 p.m.
343-345

Clinical Practice Guidelines on the Treatment of Light-Chain Amyloidosis

Monday 10:30 a.m. – 12:00 p.m.
293-294

Chair:
Vishal Kukreti, MD, Princess Margaret Cancer Centre, Toronto, Canada

Speakers:
Vaishali Sanchorawala, MD, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, MA

Front-Line Therapy for Transplant-Eligible AL Amyloidosis

Timothy Schmidt, MD, University of Wisconsin Carbone Cancer Center, Madison, WI

Relapsed and Refractory AL Amyloidosis

Manisha Bhutani, MD, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC

How Deep Is Deep Enough? Response-Guided ASCT Decisions in AL Amyloidosis

MedEd Talks: Giving Feedback and Remediation for UME/GME non-CME

Monday 12:00 p.m. – 12:25 p.m.
Hall D ASH Studio

Speaker:
Alice Ma, MD, University of North Carolina School of Medicine, Chapel Hill, NC

Celebrating Diverse Voices: Enriching Hematology Lunch

Monday 12:00 p.m. – 1:30 p.m.
Marriott Warehouse - Cypress I-II

Chair:
Noha Soror, MD, OU Health Stephenson Cancer Center, Oklahoma City, OK

Speaker:
Chancellor Donald, MD, Tulane University School of Medicine, New Orleans, LA

Treating Fairly Talks: Iron Deficiency Interventions in Low Resource Settings

Monday 1:00 p.m. – 1:25 p.m.
Hall D ASH Studio

Speaker:
Ali Taher, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon

Meet the Journal Editors: *Blood Global Hematology* non-CME

Monday 1:15 p.m. – 1:30 p.m.
Hall F Blood Journals Studio

Speaker:
Jorge Cortes, MD, Editor-in-Chief, *Blood Global Hematology* & University of Alabama at Birmingham, Birmingham, AL

ASH-FDA Joint Symposium on Newly Approved Therapies 2

Monday 2:45 p.m. – 4:15 p.m.
343-345

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Clinical Practice Guidelines on the Treatment of Iron Deficiency with or without Anemia

Monday **2:45 p.m. – 4:15 p.m.**
293-294

Chair:
Jacquelyn Powers, MD, Baylor College of Medicine & Texas Children's Hospital, Houston, TX

Speakers:
Thomas Deloughery, MD, Oregon Health & Science University, Portland, OR

Severe Anemia, Chronic Blood Loss, or Inflammation, Oh My! Recommendations For the Treatment of Adults with Iron Deficiency

Amanda Jacobson-Kelly, MD, MSc, Nationwide Children's Hospital & The Ohio State University College of Medicine, Columbus, OH

Indications and Approach to Iron Replacement Therapies in Children with Iron Deficiency

Jori May, MD, University of Alabama, Birmingham, AL

Menstruating and Pregnant Populations with Iron Deficiency and Iron Deficiency Anemia: Outcomes of Oral Versus Intravenous Iron Therapy

The Predicament of Patients in Prison: A Hematology Perspective

Monday **2:45 p.m. – 4:15 p.m.**
295-296

Chair:
Alan Mast, MD, PhD, Versiti Blood Research Institute, Milwaukee, WI

Speakers:
Shira Shavit, MD, University of California–San Francisco, San Francisco, CA

Anjali Niyogi, MD, MPH, Tulane University School of Medicine, New Orleans, LA

Subject Matter Experts

Michael DeBaun, MD, MPH, Vanderbilt University School of Medicine, Nashville, TN

Hematologists

Ian Cazenave, Formerly Incarcerated Transitions (FIT) Clinic, New Orleans, LA

Lived Experience Expert Representative

The Future of Clinical Endpoints in Sickle Cell Disease non-CME

Monday **4:30 p.m. – 6:00 p.m.**
220-222

Chair:
Alexis Thompson, MD, MPH, Children's Hospital of Philadelphia, Philadelphia, PA

Speaker:
Karina Yazdanbakhsh, PhD, New York Blood Center Enterprises, Rye, NY & New York Blood Center, New York, NY

Setting the Stage: Progress and/or Current Landscape of SCD Endpoints

Panelists:
Melissa Creary, PhD, University of Michigan School of Public Health, Ann Arbor, MI

Nicole Verdun, MD, Formerly of U.S. Food and Drug Administration, Washington, DC

Julie Panepinto, MD, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

Ted Love, MD, Biotechnology Innovation Organization (BIO), Washington, DC

Ronisha Edwards-Elliot, PhD, Northern Illinois University, Dekalb, IL

Karina Yazdanbakhsh, PhD, New York Blood Center Enterprises, Rye, NY & New York Blood Center, New York, NY

ASH Networking Reception for the Hemostasis and Thrombosis Community

Monday **6:00 p.m. – 7:30 p.m.**
Rivergate Terrace

ASH Networking Reception for the Sickle Cell Disease Community

Monday **6:00 p.m. – 8:00 p.m.**
215-216

Women in Hematology Networking Dinner Event

Monday **7:30 p.m. – 9:00 p.m.**
Hilton - St. Charles Ballroom

Moderator:
Brittany Ragon, MD, Atrium Health Levine Cancer Institute & Wake Forest University School of Medicine, Charlotte, NC

Speakers:
Hetty Carraway, MD, MBA, Cleveland Clinic, Cleveland, OH

Leadership: Authority Without Penalty

Adele Fielding, MBBS PhD, Centre for Blood Research, University of York, York, United Kingdom

Influence: Voice, Credibility, and Impact

Monica Guzman, PhD, Weill Cornell Medicine, New York, NY

Mid-Career: Expansion Versus Stagnation

Oluwatoyosi Onwuemene, MD, MS, Duke University & Veterans Health Administration, Durham, NC

Difficult Conversations: Respect Under Tension



©2026. All rights reserved. Unless otherwise indicated, all trademarks are owned by SELLAS Life Sciences Group, Inc. or licensed for its use. US-GPS-26-01 10/26

SELLAS
LIFE SCIENCES GROUP

TRAINEE ACTIVITIES

ASH provides a variety of high-quality educational, career-development, and networking opportunities to help trainees make the most of their meeting experience.

The following activities have been identified as most relevant to the unique interests of undergraduates, medical and graduate students, residents, and fellows.

These activities are open only to individuals with a blue trainee badge or by invitation.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

ASH-a-Palooza non-CME

Friday	**12:00 p.m. – 5:00 p.m. Generations Hall (located at 310 Andrew Higgins Blvd, within walking distance to convention center)**

Co-Chairs:

Hetty Carraway, MD, MBA, Cleveland Clinic, Cleveland, OH

Nicholas Lee, MD, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

Designed for undergraduates, medical and graduate students, residents, and fellows, ASH-a-Palooza provides a variety of opportunities for trainees attending the ASH annual meeting. This event is only open to annual meeting attendees with a blue trainee badge. Doors open at 11:30 a.m., and lunch is available at 11:45 a.m.

ASH Talks: These sessions are 18- to 20-minute presentations, similar to a TED Talk, with dynamic speakers presenting timely topics.

Blood Drops: These sessions are 10-minute career development presentations designed to provide short bursts of learning. Each micro-learning session will be held twice in a row and will allow the audience to move easily between each presentation.

Blood Buddies: In-person trainees will have the opportunity to meet with leaders in the field! Trainees can sign up for a one-on-one Blood Buddy 10-minute mentoring session with a faculty member.

Blood Booths: Trainees will have the opportunity to explore interactive booths at ASH-a-Palooza. Chat with peers, take part in live training sessions, learn from experts, explore ASH opportunities, and more!

Trainee Welcome Reception: This informal social event immediately follows ASH-a-Palooza for in-person attendees. The reception provides the opportunity for undergraduates, medical and graduate students, residents, and fellows (DO, MD, and PhD) to network and celebrate with their peers.

ASH-a-Palooza Begins: Lunch and Networking! non-CME

Friday	**12:00 p.m. – 12:40 p.m. Generations Hall**

Blood Booths non-CME

Friday	**12:00 p.m. – 12:40 p.m. Generations Hall - Courtyard**

International Trainee Welcome non-CME

Friday	**12:00 p.m. – 12:40 p.m.. Hilton Garden Inn-GardenGrille**

Main Stage: Welcome Address & Opening Festivities non-CME

Friday	**12:45 p.m. – 1:05 p.m. Generations Hall - Main Stage**

Distinguished Lecture: ASH Talk #1 - Finding Strength in Setbacks non-CME

Friday	**1:05 p.m. – 1:25 p.m. Generations Hall - Main Stage**

Co-Chairs:

Hetty Carraway, MD, MBA, Cleveland Clinic, Cleveland, OH

Nicholas Lee, MD, National Heart, Lung, and Blood Institutes, National Institutes of Health, Bethesda, MD

Speaker:

Leonido Luznik, MD, Baylor College of Medicine, Houston, TX

Blood Buddies non-CME

Friday	**1:35 p.m. – 3:55 p.m. Generations Hall - Upper Level**

Adult Clinical Classical Hematology

Michael Auerbach, MD, Center for Cancer and Blood Disorders Baltimore, Georgetown University School of Medicine, Washington, DC

Alexander Boucher, MD, University of Minnesota, Minneapolis, MN

Payal Desai, MD, Levine Cancer Atrium Health, Wake Forest University, Charlotte, NC

Nicoletta Machin, DO, MS, University of Pittsburgh, Pittsburgh, PA

Katherine Walsh, MD, Vanderbilt University Medical Center, Nashville, TN

Ted Wun, MD, University of California, Davis School of Medicine, Sacramento, CA

Adult Clinical Malignant Hematology

Anita D'Souza, MD, Medical College of Wisconsin, Milwaukee, WI

Elizabeth Griffiths, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Adam Kittai, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Lekha Mikkilineni, MD, MA, Stanford University School of Medicine, Stanford, CA

Raymond Thertulien, MD, PhD, Novant Health Weisiger Cancer Institute, Charlotte, NC

Douglas Tremblay, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Artificial Intelligence - Future of Hematology

Alfred Lee, MD, PhD, Mass General Brigham, Boston, MA

Aziz Nazha, MD, Thomas Jefferson University Hospital, Philadelphia, PA

Sandeep Raj, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Career Pathways [Federal Agencies]

Valentina Baez Sosa, MD, National Heart, Lung and Blood Institute, Bethesda, MD

Daphne Friedman, MD, Durham VA and Duke University Medical Centers, Durham, NC

Career Pathways [Industry]

Michael Boyiadzis, MD, Oncoverity, Pittsburg, PA

Nina Shah, MD, AstraZeneca, San Francisco, CA

Aric Parnes, MD, Vertex Pharmaceuticals Incorporated, Boston, MA

Hemostasis & Thrombosis

Ariela Marshall, MD, University of Minnesota, Minneapolis, MN

Jordan Schaefer, MD, MSc, University of Michigan, Ann Arbor, MI

Brian Branchford, MD, Versiti Blood Research Institute, Milwaukee, WI

Inclusion Pathways

Ash Alpert, MD, Yale Cancer Center, New Haven, CT

Jennifer Cooperrider, MD, University of Chicago, Chicago, IL

International Medical Graduates

Maya Abdallah, MD, Boston Medical Center, Boston, MA

Sergei Nekhai, PhD, Howard University, Washington, DC

Priyanka Pophali, MD, UW Health l Carbone Cancer Center, Madison, WI

Narendranath Epperla, MD, MS, FACP, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Medical Education

Kyle Mendonça, MD, CancerCare Manitoba & University of Manitoba, Winnipeg, Canada

Mary Jo Lechowicz, MD, Emory University, Atlanta, GA

J. Christian Barrett, MD, Virginia Commonwealth University, Richmond, VA

Robert Stern, MD, Dana-Farber Cancer Institute, Boston, MA

John Molina, MD, MEd, Cleveland Clinic, Cleveland, OH

Pediatric Clinical Classical Hematology

Julie Jaffray, MD, Rady Children's Hospital, San Diego, CA

Akshat Jain, MD, MPH, Loma Linda University School of Medicine, Loma Linda, CA

Jacquelyn Powers, MD, MS, Texas Children's Hospital, Houston, TX

Meghan Drayton Jackson, DO, MBOE, Riley Children's Hospital, Indiana University, Indianapolis, IN

Luke Smart, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Pediatric Clinical Malignant Hematology

Saro Armenian, MD, MPH, City of Hope Cancer Care and Research, Duarte, CA

Hiroto Inaba, MD. PHD, St. Jude Children's Research Hospital, Memphis, TN

Leslie Kersun, Children's Hospital of Philadelphia, Philadelphia, PA

Leidy Isenalumhe, MD, MS, Moffitt Cancer Center, Tampa, FL

PhD/Lab

Martin Rivas, PhD, MS, University of Miami, Miami, FL

Florian Scherer, MD, PhD, Freiburg University Medical Center, Freiburg, Germany

Ze Zheng, PhD, Medical College of Wisconsin & Versiti Blood Research Institute, Milwaukee, WI

Sherine Elsawa, PhD, University of New Hampshire, Durham, NH

Quality Improvement & Health Services/Outcomes

Menaka Pai, MSc, MD, FRCPC, McMaster University, Ontario, Canada

Jori May, MD, University of Alabama at Birmingham, Birmingham, AL

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Transplant & Cellular Therapy - Pediatric and Adult

Rayne Rouce, MD, Texas Children's Hospital, Houston, TX

Yvonne Efebera, MD, MPH, OhioHealth, Columbus, OH

Nirali Shah, MD, MHSc, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

Annie Im, MD, University of Pittsburgh & UPMC Hillman Cancer Center, Pittsburgh, PA

Urshila Durani, MD, MPH, Mayo Clinic, Rochester, NY

Blood Drop: Tips for Success non-CME

Friday **1:35 p.m. – 2:05 p.m.**
Generations Hall - Main Level

Adult Classical Hematology Career Track

Rakhi Naik, MD, MHS, Johns Hopkins University, Baltimore, MD

Awards for Early and Mid-Career Investigators [Scholar Award]

Martin Rivas, PhD, MS, University of Miami, Miami, FL

Awards for Medical/Graduate Students [HIP Medical Student Award]

Sacha Belinda Mapombo Choupa, MHS, Meharry Medical College, Nashville, TN

Clinical Investigator Career Track [Clinical Research Training Institute]

Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Clinician-Educator [Medical Education) Career Track [Medical Educators Institute]

Kyle Mendonça, MD, CancerCare Manitoba & University of Manitoba, Winnipeg, Canada

Community Practice Career Track

Raymond Thertulien, MD, PhD, Novant Health, Charlotte, NC

Industry Career Track

Michael Boyiadzis, MD, Oncoverity, Pittsburgh, PA

Pediatric Malignant Career Track

TBD

Research (PhD/Lab) Career Track [Translational Research Training in Hematology]

Florian Scherer, MD, PhD, Freiburg University Medical Center, Freiburg, Germany

Transplant and Cellular Therapy Career Track [Pediatrics]

Rayne Rouce, MD, Texas Children's Hospital, Houston, TX

Distinguished Lecture: ASH Talk #2 - Becoming a Leader in Hematology non-CME

Friday **2:15 p.m. – 2:35 p.m.**
Generations Hall - Main Stage

Co-Chairs:

Hetty Carraway, MD, MBA, Cleveland Clinic, Cleveland, OH

Nicholas Lee, MD, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

Speakers:

Nancy Berliner, MD, Brigham and Women's Hospital, Boston, MA

Navneet Majhail, MD, Sarah Cannon Cancer Network at Johnston-Willis, Nashville, TN

Blood Booths non-CME

Friday **2:35 p.m. – 4:15 p.m.**
Generations Hall - Courtyard

Blood Drops: Tips for Success non-CME

Friday **2:45 p.m. – 3:15 p.m.**
Generations Hall - Main Level

Adult Malignant Hematology Career Track

TBD

Awards for Early and Mid-Career Investigators [Research Training Award for Fellows]

Jennifer Cooperrider, MD, University of Chicago, Chicago, IL

Awards for Medical/Graduate Students [Graduate Hematology Award]

Ruchi Patel, PhD, University of Pennsylvania, Philadelphia, PA

Clinical Investigator Career Track

Valentina Baez Sosa, MD, National Heart, Lung and Blood Institute, Bethesda, MD

Clinician-Educator (Medical Education) Career Track

Mary Jo Lechowicz, MD, Emory University, Atlanta, GA

Community Practice Career Track

Michael Auerbach, MD, Center for Cancer and Blood Disorders Baltimore, Georgetown University, Washington, DC

Industry Career Track

Aric Parnes, MD, Vertex Pharmaceuticals Incorporated, Boston, MA

Pediatric Classical Hematology Career Track

Julie Jaffray, MD, Rady Children's Hospital, San Diego, CA

Research (PhD/Lab) Career Track

Sherine Elsawa, PhD, University of New Hampshire, Durham, NH

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Transplant and Cellular Therapy Career Track [Adult]

Yvonne Efebera, MD, MPH, OhioHealth, Columbus, OH

Blood Drops: How To Talks non-CME

Friday **3:25 p.m. – 3:55 p.m.**
Generations Hall - Main Level

Choosing YOU While Building a Career

Ariela Marshall, MD, University of Minnesota, Minneapolis, MN

Dos & Don'ts of Grant Writing

Sergei Nekhai, PhD, Howard University, Washington, DC

How to Build a Mentorship Team

Elizabeth Griffiths, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

How to Get Your Dream Job as a Basic/Translational Scientist

Ze Zheng, PhD, Medical College of Wisconsin & Versiti Blood Research Institute, Milwaukee, WI

How to Review and Negotiate a Clinical Investigator Job Offer

Ted Wun, MD, University of California, Davis School of Medicine, Sacramento, CA

Main Stage: Hearts of Hematology non-CME

Friday **4:40 p.m. – 4:50 p.m.**
Generations Hall-Main Stage

Speaker:
Rushad Patell, MD, Beth Israel Deaconess Medical Center, Boston, MA

Main Stage: Closing Remarks non-CME

Friday **4:50 p.m. – 5:00 p.m.**
Generations Hall - Main Stage

Trainee Welcome Reception non-CME

Friday **5:00 p.m. – 7:00 p.m.**
Generations Hall (located at 310 Andrew Higgins Blvd, within walking distance to convention center)

SATURDAY

Career Development Lunch non-CME

Saturday **11:15 a.m. – 12:15 p.m.**
Hilton - St. Charles Ballroom

This session provides an opportunity for trainees to meet with leaders in hematology in small groups to discuss careers in the wide array of practice areas within hematology, including basic, clinical, and translational research; PhD careers; careers in industry settings; and careers in community and clinical practice.

There are multiple tables dedicated to each career area and one faculty member at each table leading the discussion. A boxed lunch is provided. This is a first-come, first-served event that is only offered in person.

Chair:
Adam Kittai, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Administrative Careers in Hematology

Jennifer Woyach, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Leidy Isenalumhe, MD, MS, Moffitt Cancer Center, Tampa, FL

John Leonard, MD, NYU Langone, New York, NY

Adult BMT/Cellular Therapy

Luis Batista, PhD, University of Utah, Salt Lake City, UT

Sumithira Vasu, MBBS, MD, The Ohio State University, Columbus, OH

Humberto Martinez-Cordero, MD, MSc, Instituto Nacional de Cancerología of Colombia, Bogotá, Colombia

Cesar Rodriguez Valdes, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Adult Clinical Classical Hematology

Ibrahim Idris, MBBS, MPH, Aminu Kano Teaching Hospital, Kano, Nigeria

Pantep Angchaisuksiri, MD, Ramathibodi Hospital, Bangok, Thailand

Adult Clinical Malignant Hematology

Adam Duvall, MD, MPH, University of Chicago, Chicago, IL

Björn Chapuy, MD, Charite, University Medicine Berlin, Berlin, Germany

Harinder Gill, MBBS, MD, The University of Hong Kong, Hong Kong

Amy DeZern, MD, MHS, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Community Practice

Srikanth Nagalla, MBBS, Miami Cancer Institute, Miami, FL

Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN

Geriatric Hematology

Ashley Rosko, MD, The Ohio State University, Columbus, OH

Heidi Klepin, MD, Wake Forest University School of Medicine, Winston Salem, NC

Government Careers

Carrie Diamond, MD, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

Cindy Roy, PhD, National Institutes of Health, Bethesda, MD

Daphne Friedman, MD, Durham VA Health Care System, Durham, NC

Hematology-Focused Fellowship Training Program

Ana Antun, MD, Emory University, Atlanta, GA

David Garcia, MD, University of Washington, Seattle, WA

Layla Van Doren, MD, MBA, University of California, San Francisco, San Francisco, CA

International Graduate Hematology

Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Navneet Majhail, MD, Sarah Cannon Cancer Network, Nashville, TN

Paola Ghione, MD, MS, Memorial Sloan Kettering Cancer Center, New York, NY

Nikhil Munshi, MD, Boston VA Healthcare System, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA

International Opportunities in Hematology

Mathijs Sanders, MSc, PhD, Erasmus MC Cancer Institute, Rotterdam, Netherlands

Antonija Jurak Begonja, PhD, University of Rijeka, Rijeka, Croatia

Felicitas R Thol, MD, Hannover Medical School, Hannover, Germany

Laboratory and Translational Hematology

Shannon Elf, PhD, University of Utah, Salt Lake City, UT

Francesca Cottini, MD, The Ohio State University, Columbus, OH

Esther Obeng, MD, PhD, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine & Emory University, Atlanta, GA

MD in Industry Careers

Parameswaran Hari, MD, MBBS, Medical College of Wisconsin, Brookfield, WI

Rafael Bejar, MD, PhD, University of California San Diego, La Jolla, CA

Angela Smith, MD, Syndax Pharmaceuticals, Minneapolis, MN

Medical & Bio Informatics and AI

Andrew Hantel, MD, MPH, Dana-Farber Cancer Institute, Boston, MA

Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York City, NY

Ash Alpert, MD, Yale Cancer Center, New Haven, CT

Medical Educators in Hematology

Audrey Sigmund, MD, The Ohio State University, Columbus, OH

Nisha Joseph, MD, Winship Cancer Institute, Emory University, Louisville, GA

Hannah Levavi, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Pediatric BMT/Cellular Therapy

Alexander Ngwube, MD, Baylor College of Medicine & Texas Children's Hospital, Houston, TX

Kevin McNerney, MD, MSc, Lurie Children's Hospital, Chicago, IL

Rajinder Bajwa, MBBS, MD, Nationwide Children's Hospital, Columbus, OH

Pediatric Classical Hematology

Alexander Boucher, MD, University of Minnesota, Minneapolis, MN

Omar Niss, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Robert Liem, MD, Lurie Children's Hospital, Chicago, OH

Alice Taylor, MD, MBBS, BSc, Great Ormond Street Hospital, London, United Kingdom

Pediatric Hematology/Oncology

Alexandra Power-Hays, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Susan Creary, MD, Nationwide Children's Hospital Research Institute, Columbus, OH

Amanda Sankar, MD, Nationwide Children's Hospital, Columbus, OH

PhD Careers

Yi Zheng, PhD, Cincinnati Children's Hospital, Cincinnati, OH

Brian Walker, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, MD

Courtney Jones, PhD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

PhD in Industry Careers

Katy Gray, PhD, Johnson & Johnson, Bridgewater, NJ

Women in Hematology

Jennifer Crombie, MD, Dana Farber Cancer Institute, Boston, MA

Women's Health

Henny Billett, MD, Montefiore-Einstein Medical Center, Bronx, NY

Bethany Samuelson Bannow, MD, Cleveland Clinic Foundation, Cleveland, OH

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SUNDAY

Trainee Didactic Session: Giving a Scientific Presentation non-CME

Sunday 11:15 a.m. – 12:15 p.m.
260-262

Co-Chairs:

John Molina, MD, MEd, Cleveland Clinic, Cleveland, OH

Lindsay Wilde, MD, Sidney Kimmel Comprehensive Cancer Center at Jefferson Health, Philadelphia, PA

Speakers:

Julia Maxson, PhD, Oregon Health & Science University, Portland, OR

Thomas Deloughery, MD, Oregon Health & Science University, Portland, OR

Giving a Scientific Presentation

Trainee Didactic Session: How to Transition from Academia to Industry or Community Practice non-CME

Sunday 11:15 a.m. – 12:15 p.m.
265-268

Co-Chairs:

John Molina, MD, MEd, Cleveland Clinic, Cleveland, OH

Lindsay Wilde, MD, Sidney Kimmel Comprehensive Cancer Center at Jefferson Health, Philadelphia, PA

Speakers:

Angela Smith, MD, Syndax Pharmaceuticals, Minneapolis, MN

Transitioning From Academia to Industry

Loretta Nastoupil, MD, Mercy CommonSpirit & Mercy Hospital, CommonSpirit Medical Oncology, Durango, CO

Transitioning From Academia to Community Practice

MONDAY

Trainee Didactic Session: How to Transition from Trainee to Faculty non-CME

Monday 12:15 p.m. – 1:15 p.m.
260-262

Co-Chairs:

John Molina, MD, MEd, Cleveland Clinic, Cleveland, OH

Lindsay Wilde, MD, Sidney Kimmel Comprehensive Cancer Center at Jefferson Health, Philadelphia, PA

Speakers:

Anna Marneth, PhD, Radboud University Medical Center, Nijmegen, Netherlands

Katelyn Sadler, PhD, University of Texas at Dallas, Richardson, TX

How to Transition from Trainee to Faculty

Trainee Didactic Session: Mentoring and Being Mentored non-CME

Monday 12:15 p.m. – 1:15 p.m.
265-268

Co-Chairs:

John Molina, MD, MEd, Cleveland Clinic, Cleveland, OH

Lindsay Wilde, MD, Sidney Kimmel Comprehensive Cancer Center at Jefferson Health, Philadelphia, PA

Speakers:

Andres Gomez-De Leon, MD, The Autonomous University of Nuevo León, Nuevo León, Mexico

Adam Cuker, MD, MS, University of Pennsylvania, Philadelphia, PA

Mentoring and Being Mentored

2026 SCIENTIFIC CATEGORIES

For the 68th ASH Annual Meeting, abstracts were submitted in 77 different scientific categories in 9 larger topics. For your ease in finding the oral and poster abstracts on topics of interest to you, the abstract program has been organized by category number. Oral Abstract Sessions titles begin with the category number and name. They are listed in the Program-at-a-Glance by date, time, and then by category number. The In-Person and Virtual Poster Hall is arranged by date and then by category number.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited

100s - Red Cell Physiology and Disorders

100s - Red Cell Physiology and Disorders

101 Red Cells and Erythropoiesis, Excluding Iron

102 Iron Homeostasis and Biology in Physiological and Pathological Conditions

112 Thalassemia and Globin Gene Regulation

113 Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational

114 Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological

200s - Leukocytes, Inflammation and Immunology

201 Granulocytes, Monocytes, and Macrophages

203 Lymphocytes and Acquired or Congenital Immunodeficiency Disorders

300s - Hemostasis, Thrombosis and Vascular Wall Biology

301 Platelets and Megakaryocytes: Basic and Translational

311 Disorders of Platelet Number or Function: Clinical and Epidemiological

321 Coagulation and Fibrinolysis: Basic and Translational

322 Hemophilia A and B: Clinical and Epidemiological

323 Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological

330 Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational

331 Thrombotic Microangiopathies/ Thrombocytopenias: Clinical and Epidemiological

332 Thrombosis and Anticoagulation: Clinical and Epidemiological

400s - Transfusion Medicine

401 Blood Transfusion

500s - Hematopoiesis

501 Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational

503 Clonal Hematopoiesis, Aging, and Inflammation

506 Bone Marrow Microenvironment

508 Bone Marrow Failure: Acquired

509 Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital

600s - Hematologic Malignancy

602 Myeloid Oncogenesis: Basic

603 Lymphoid Oncogenesis: Basic

604 Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms

605 Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms

612 Acute Lymphoblastic Leukemias: Clinical and Epidemiological

613 Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation

614 Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis

615 Acute Myeloid Leukemias: Clinical and Epidemiological

616 Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies

617 Acute Myeloid Leukemias: Commercially Available Therapies

618 Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis

619 Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment

621 Lymphomas: Translational – Molecular and Genetic

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

622 Lymphomas: Translational – Non-Genetic

623 Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological

624 Hodgkin Lymphomas: Clinical and Epidemiological

625 T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological

626 Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials

627 Aggressive Lymphomas: Targeted and Pharmacologic Therapies

628 Aggressive Lymphomas: Cellular Therapies

629 Aggressive Lymphomas, Non-Cellular Immunotherapy including Bispecific Antibodies

631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational

632 Chronic Myeloid Leukemia: Clinical and Epidemiological

634 Myeloproliferative Syndromes: Clinical and Epidemiological

636 Myelodysplastic Syndromes: Basic and Translational

637 Myelodysplastic Syndromes: Clinical and Epidemiological

641 Chronic Lymphocytic Leukemia: Basic and Translational

642 Chronic Lymphocytic Leukemia: Clinical and Epidemiological

651 Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational

652 MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological

653 Multiple Myeloma: Clinical and Epidemiological

654 Multiple Myeloma: Pharmacologic Therapies

655 Multiple Myeloma: Cellular Therapies

656 Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, including Minimal Residual Disease

700s - Transplantation and Adoptive Cell Therapies

701 Experimental Transplantation: Basic and Translational

702 CAR-T Cell Therapies: Basic and Translational

703 Cellular Immunotherapies other than CAR-T Cells: Basic and Translational

704 Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities

711 Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products

721 Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities

722 Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution

723 Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence

732 Allogeneic Transplantation: Disease Response and Comparative Treatment Studies

800s - Gene Therapies, Chemical Biology, and Emerging Diagnostics

801 Gene Therapies

802 Chemical Biology and Experimental Therapeutics

803 Emerging Tools, Techniques, and Artificial Intelligence in Hematology

900s - Health Services, Quality Improvement, and Outcomes Research

900 Health Services and Quality Improvement: Hemoglobinopathies

901 Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies

902 Health Services and Quality Improvement: Lymphoid Malignancies

903 Health Services and Quality Improvement: Myeloid Malignancies

904 Outcomes Research: Hemoglobinopathies

905 Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies

906 Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders

907 Outcomes Research: Plasma Cell Disorders

908 Outcomes Research: Myeloid Malignancies

909 Medical Education and Workforce Development

ORAL ABSTRACT SESSIONS

The Oral Abstract Sessions will be held Saturday, December 12, through Monday, December 14. Each abstract presentation will be followed immediately by a question-and-answer period with the presenter. The Plenary Scientific Session will be held Sunday, December 13, from 2:00–4:00 p.m. The Oral Abstract Sessions are not offered for CME credit.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

9:30 a.m. – 11:00 a.m. Oral Abstract Sessions non-CME

112. Thalassemia and Globin Gene Regulation: Advances Across the Thalassemia Spectrum: Novel Targets and Therapeutics (7–12)
243-245

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological - Natural history (13–18)
252-254

201. Granulocytes, Monocytes, and Macrophages: Novel Therapeutic Targets in Histiocytosis and Hyperinflammation (19–24)
291-292

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Bench to Bedside: Practical Applications in ITP (25–30)
217-219

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Refining Risk in Cancer-Associated Thrombosis: From Circulating Biomarkers to Population Outcomes (31–36)
208-210

508. Bone Marrow Failure: Acquired: The Science Behind the Clinic (37–42)
295-296

603. Lymphoid Oncogenesis: Basic: Epigenetic and Transcriptional Deregulation (43–48)
275-277

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Integrated Omics Approaches for Precision Medicine in Acute Lymphoblastic Leukemia (49–54)
265-268

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Novel Combination Regimens for Fit and Less-fit AML Patients (55–60)
Great Hall BC

617. Acute Myeloid Leukemias: Commercially Available Therapies: Rewriting the AML Playbook: Precision, Intensification, and New Therapeutic Frontiers (61–66)
Great Hall AD

621. Lymphomas: Translational – Molecular and Genetic: Genomics and Liquid Biopsy in Lymphoma: Tumor Biology to Clinical Monitoring (67–72)
New Orleans Theatre A

627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Novel Combinations Move Beyond Chemotherapy (73–78)
New Orleans Theatre C

629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: Response-Adapted Strategies in Aggressive Lymphomas (79–84)
New Orleans Theatre B

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: CALR and Friends: Adventures in MPN! (85–90)
R02-R05

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Biomarkers, Resistance, and the Molecular Frontier (91–96)
Hall B

636. Myelodysplastic Syndromes: Basic and Translational: Multi-Modal Mapping of Clonal Evolution and Microenvironmental Remodeling in MDS and Leukemic Progression (97–102)
Hall C

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches for Patients with Relapsed/Refractory CLL, Richter Transformation, and Hypogammaglobulinemia (103–108)
260-262

654. Multiple Myeloma: Pharmacologic Therapies (109–114)
La Nouvelle A-B

655. Multiple Myeloma: Cellular Therapies: CART in Myeloma: Racing Towards a Cure (115–120)
Hall E

701. Experimental Transplantation: Basic and Translational: Emerging Biology to Translational Innovation II (121–126)
353-355

702. CAR-T Cell Therapies: Basic and Translational (127–132)
343-345

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Conditioning the Outcome: Optimizing Transplantation in Acute Leukemia (133–138)
388-390

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: From Cells to Code: AI and the Next Generation of Hematologic Diagnostics (139–144)
393-396

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Beyond Efficacy - Quality of Life, Patient Reported Outcomes and Social Determinants of Health (145–150)
271-273

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

907. Outcomes Research: Plasma Cell Disorders - Beyond Disease Control: Supportive Care, Survivorship, and Patient-Centered Outcomes in Multiple Myeloma (151–156)
La Nouvelle C

12:00 p.m. – 1:30 p.m. Oral Abstract Sessions non-CME

401. Blood Transfusion: Advancing Transfusion Medicine - From Precision Blood Component Therapy to Blood Substitutes (157–162)
220-222

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Is Chemo-immunotherapy Ready for Retirement? Bispecific and CELMoD-Based Frontline Regimens in Follicular Lymphoma (163–168)
278-282

904. Outcomes Research: Hemoglobinopathies: Health Systems, Care Delivery, and Real-World Outcomes in Sickle Cell Disease (169–174)
243-245

2:00 p.m. – 3:30 p.m. Oral Abstract Sessions non-CME

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: The Tip of the Iceberg - How Do We Spot and Stop Organ Damage in Sickle Cell Disease? (175–180)
243-245

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological (181–186)
208-210

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: New Frontiers in Thrombosis: FXI Inhibition, Intervention, and Long-term Outcomes (187–192)
217-219

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Mechanisms in Hematopoietic Stem Cell Regulation, Development, and Regeneration (193–198)
291-292

503. Clonal Hematopoiesis, Aging, and Inflammation: Evolution, Interactions, and Interception (199–204)
Hall E

506. Bone Marrow Microenvironment (205–210)
295-296

602. Myeloid Oncogenesis: Basic (211–216)
R06-R09

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Integrating Genomic and Functional Approaches to Uncover Mechanisms of Pathogenesis and Treatment Resistance in B-ALL (217–222)
265-268

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis (223–228)
Hall C

622. Lymphomas: Translational: Non-Genetic – Lymphoma Landscapes: Spatial Biology of Tumor States and Immune Niches (229–234)
New Orleans Theatre B

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Mapping the Post-BTK Inhibitor Landscape: Cellular Therapy, Novel Combinations, and Genomic Insights in B-Cell Lymphomas (235–240)
New Orleans Theatre A

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Emerging Therapies and Approaches in MPN (241–246)
Hall B

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Novel Therapeutic Strategies and Prognostic Stratification in MDS and MDS/MPN (247–252)
Great Hall BC

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Improving Outcomes for Relapsed/Refractory CLL/SLL (253–258)
271-273

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Clinical Trials for Plasma Cell Dyscrasias and Related Disorders (259–264)
278-282

654. Multiple Myeloma: Pharmacologic Therapies: Novel Approaches in Relapsed Myeloma: Immunotherapies and Small Molecules (265–270)
La Nouvelle A-B

655. Multiple Myeloma: Cellular Therapies: Efficacy Meets Safety: Optimizing CART in MM (271–276)
La Nouvelle C

702. CAR-T Cell Therapies: Basic and Translational: Engineering CAR T-cells for Improved Persistence, Activity, and Tumor Control (277–282)
343-345

703. Cellular Immunotherapies Other Than CAR-T Cells: Basic and Translational: Expanding the Garage: Advancements in Non-T Cell CAR Platforms and Optimization Strategies (283–288)
353-355

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Building a Better Transplant: Refining the PTCy Platform and Beyond (289–294)
388-390

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: From Algorithms to the Clinic: AI and Molecular Innovation in Hematology (295–300)
393-396

900. Health Services and Quality Improvement: Hemoglobinopathies - Emerging Clinical, Treatment, and Health Services Considerations Across Different Stages of Sickle Cell Care (301–306)
252-254

902. Health Services and Quality Improvement: Lymphoid Malignancies: CAR-T Cell Therapy (307–312)
260-262

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders - Beyond Response: Toxicity, Infection, and Late Events After Novel Therapies (313–318)
New Orleans Theatre C

908. Outcomes Research: Myeloid Malignancies: Beyond Biology: Social, Environment, and Healthcare Determinants of Outcomes in Myeloid Malignancies (319–324)
Great Hall AD

4:00 p.m. – 5:30 p.m. Oral Abstract Sessions non-CME

101. Red Cells and Erythropoiesis, Excluding Iron: Internal and External Drivers of Erythroid Development (325–330)
291-292

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological - Therapeutics (331–336)
243-245

322. Hemophilia A and B: Clinical and Epidemiological: Transforming Hemophilia Care: Long-term Outcomes, Treatment Transitions, and Innovation (337–342)
208-210

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational (343–348)
217-219

508. Bone Marrow Failure: Acquired: Clinical Data on PNH and SAA Therapeutics (349–354)
295-296

602. Myeloid Oncogenesis: Basic: Transcriptional and Epigenetic Dependencies (355–360)
R02-R05

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms - Resistance Mechanisms and New Therapeutic Vulnerabilities in AML (361–366)
Hall B

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Molecular Vulnerabilities and Therapeutic Resistance (367–372)
271-273

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Relapsed/Refractory Acute Lymphoblastic Leukemia: From Novel CAR T-cell Constructs to Real-World Experience in B-ALL, and an Investigational Agent in T-cell ALL (373–378)
265-268

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Decoding AML Resistance: Cell States, Immune Niches, and Therapeutic Vulnerabilities (379–384)
Great Hall BC

619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Measures for Measures: New Tools and New Uses for MRD in AML (385–390)
Great Hall AD

621. Lymphomas: Translational – Molecular and Genetic: From Tumor Evolution to Therapeutic Targets: Integrated Genomic and Microenvironmental Insights in B-Cell Lymphomas (391–396)
New Orleans Theatre B

622. Lymphomas: Translational – Non-Genetic: Shaping Lymphoma Fate: Oncogenic Programs, Stromal Support, and Immune Failure (397–402)
New Orleans Theatre A

627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Novel Study Designs and New Immunotherapy Approaches (403–408)
New Orleans Theatre C

634. Myeloproliferative Syndromes: Clinical and Epidemiological: MF and SM: Emerging Targets and Treatment Strategies (409–414)
Hall C

653. Multiple Myeloma: Clinical and Epidemiological: Optimizing Outcomes for Multiple Myeloma, Young and Old (415–420)
La Nouvelle A-B

654. Multiple Myeloma: Pharmacologic Therapies: The March of Immunotherapy (421–426)
La Nouvelle C

702. CAR-T Cell Therapies: Basic and Translational: Overcoming Resistance and Escape in CAR-T Cell Therapy (427–432)
343-345

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations from Bench to Bedside (433–438)
391-392

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: HCT Under Stress: Acute Toxicities and Organ Injury (439–444)
388-390

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Allogeneic Transplantation Outcomes: Lymphoid Malignancies, Pediatric Malignancies, and Donor Factors (445–450)
278-282

802. Chemical Biology and Experimental Therapeutics: Leveraging Chemical Biology for Therapeutic Discovery (451–456)
353-355

902. Health Services and Quality Improvement: Lymphoid Malignancies: Geriatrics, Palliative, and End of Life Care (457–462)
260-262

SUNDAY

9:30 a.m. – 11:00 a.m. Oral Abstract Sessions non-CME

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advancing Sickle Cell Disease Care on All Fronts (463–468)
252-254

301. Platelets and Megakaryocytes: Basic and Translational: Megakaryocytes and Platelets from Development to Defense (469–474)
208-210

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis and Hemorrhage in Hematologic Malignancy: From CAR T-Cells to Clonal Hematopoiesis (475–480)
217-219

503. Clonal Hematopoiesis, Aging, and Inflammation: Forces Shaping Clonal Selection (481–486)
291-292

603. Lymphoid Oncogenesis: Basic: Metabolic and Immune Mechanisms (487–492)
260-262

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Prognostic and Predictive Factors in AML and BPDCN (493–498)
Hall B

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Emerging Clinically Relevant Biomarkers in AML (499–504)
Great Hall BC

621. Lymphomas: Translational – Molecular and Genetic (505–510)
275-277

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Emerging Targeted Therapies in NK/T-Cell Lymphomas and HLH: From Epigenetic Modulation to JAK Signaling (511–516)
New Orleans Theatre C

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Evaluation of Newly-Diagnosed DLBCL Patients (517–522)
New Orleans Theatre B

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Combining Forces Against Myelofibrosis (523–528)
R02-R05

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Novel Targeted Agents and Combination Regimens in CMML, MDS, and MDS/MPN Overlap Neoplasms: Emerging Clinical Trial Data (529–534)
Hall C

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Studies in Previously Untreated CLL/SLL (535–540)
New Orleans Theatre A

653. Multiple Myeloma: Clinical and Epidemiological: Optimizing Sequencing and Toxicity Management With Novel Myeloma Therapies (541–546)
La Nouvelle A-B

656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: The Evolving Landscape of Risk Definition in Multiple Myeloma (547–552)
La Nouvelle C

702. CAR-T Cell Therapies: Basic and Translational: Next-Generation CAR T-cell Therapy Strategies for AML (553–558)
Great Hall AD

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities (559–564)
343-345

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Advances in GVHD Prophylaxis and Immune Reconstitution after Allogeneic HCT (565–570)
388-390

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Predicting and Preventing Post-transplant Relapse and GvHD: Minimal Residual Disease, Immune Dynamics, and Biomarkers (571–576)
353-355

900. Health Services and Quality Improvement: Hemoglobinopathies: Improving How Sickle Cell Care is Organized, Implemented, and Delivered Across Healthcare Settings (577–582)
243-245

902. Health Services and Quality Improvement: Lymphoid Malignancies: Monitoring, Demographics, and Access to Care (583–588)
271-273

12:00 p.m. – 1:30 p.m. Oral Abstract Sessions non-CME

101. Red Cells and Erythropoiesis, Excluding Iron: Programming Erythropoiesis: From Chromatin Architecture to Red Cell Fate (589–594)
291-292

321. Coagulation and Fibrinolysis: Basic and Translational: Right Protein, Right Place: Compartmentalized Coagulation in Development, Vasculature, and Organ Injury (595–600)
220-222

322. Hemophilia A and B: Clinical and Epidemiological: Precision Hemophilia Care: Bleeding Prediction and Overcoming Inhibitors (601–606)
217-219

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Mechanistic Insights and Therapeutic Strategies (607–612)
295-296

628. Aggressive Lymphomas: Cellular Therapies: Optimizing Every Step of the CAR T-Cell Journey in Large B-Cell Lymphoma (613–618)
New Orleans Theatre C

629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: Clinical Trials in Untreated and Relapsed/Refractory LBCL, Including CNS Lymphoma (619–624)
New Orleans Theatre B

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: Tracking MRD in Blood and Marrow of Multiple Myeloma Patients (625–630)
La Nouvelle A-B

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Hemoglobinopathies, Fungus, and Deceased Donor HPCs, Oh My! (631–636)
243-245

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Decoding Cytopenias (637–642)
208-210

907. Outcomes Research: Plasma Cell Disorders: T-Cell–Redirecting Therapies in Multiple Myeloma: Treatment Optimization and Emerging Toxicities (643–648)
La Nouvelle C

909. Medical Education and Workforce Development: Shaping the Future: From AI to Wellbeing and the Hematology Workforce (649–654)
293-294

2:00 p.m. – 4:00 p.m. **Plenary Scientific Session** non-CME

Hall E

Simulcast of Awards and Plenary Scientific Session
Two locations: 208-210 & New Orleans Theatre C

4:30 p.m. – 6:00 p.m. **Oral Abstract Sessions** non-CME

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Strategies and Modulation of Anti-Tumor Responses (655–660)
260-262

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies - Novel Combinations with Menin, FLT3 and BCL2 Inhibitors (661–666)
Hall B

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Genetic Heterogeneity and Functional Vulnerabilities in AML (667–672)
Great Hall BC

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Triple S: MPN Goes Spatial, Selective and to the Cell Surface! (673–678)
Hall C

641. Chronic Lymphocytic Leukemia: Basic and Translational: Resolving Complexity of CLL and Richter Transformation (679–684)
265-268

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Optimizing T-cell Redirected Therapy for Myeloma and Related Conditions (685–690)
La Nouvelle C

656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: Immune and Microenvironment Drivers of Treatment Outcomes in Multiple Myeloma (691–696)
La Nouvelle A-B

701. Experimental Transplantation: Basic and Translational: Emerging Biology to Translational Innovation I (697–702)
343-345

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Next-Generation CAR T-Cell Therapy in Lymphoma: In Vivo Engineering and Beyond (703–708)
New Orleans Theatre B

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Long-term Follow-up After Allogeneic Hematopoietic Cell Transplantation (709–714)
388-390

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Allogeneic Transplantation for Myeloid Malignancies: Timing, Donors, and Disease Control (715–720)
Great Hall AD

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: From Iron to Immunity: Real-World Outcomes in Classical Hematology (721–726)
252-254

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders - Outcomes Across the Age Spectrum: Assessment, Tolerability, and Survivorship (727–732)
278-282

908. Outcomes Research: Myeloid Malignancies: From Patient Voice to Clinical Impact: PROs and Real-World Outcomes in an Evolving Digital Era (733–738)
R06-R09

MONDAY

10:30 a.m. – 12:00 p.m. **Oral Abstract Sessions** non-CME

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: End-organ Dysfunction in Sickle Cell Disease: From Risk Prediction to Therapeutic Innovation (739–744)
252-254

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

201. Granulocytes, Monocytes, and Macrophages: Decoding Neutrophil and Macrophage Biology: Novel Insights into Congenital Neutropenia Defects, Inflammation, and Leukemia Immunology (745–750)
291-292

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Reshaping the Research Frontier in ITP: Targeted Therapeutics and Validation of the ITP Diagnosis (751–756)
217-219

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Cell-Intrinsic and Niche-Mediated Mechanisms of Drug Resistance in AML (757–762)
Great Hall BC

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: New Genomic and Immunologic Insights (764–890)
265-268

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Optimizing Treatment Decisions for Acute Myeloid Leukemia in Pediatric and AYA Patients (769–774)
R02-R05

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Novel Immunotherapeutic Approaches to AML (775–780)
Hall C

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Finite vs. Forever: Redefining Treatment Duration in Relapsed/Refractory Waldenstrom's Macroglobulinemia and Marginal Zone Lymphoma (781–786)
New Orleans Theatre B

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Precision Approaches in NK/T-Cell Lymphoma and CTCL: Optimizing Therapy and Predicting Outcomes (787–792)
New Orleans Theatre A

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials (793–798)
New Orleans Theatre C

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: New Drugs, New Paradigms in CML (799–804)
R06-R09

637. Myelodysplastic Syndromes: Clinical and Epidemiological (805–810)
Great Hall AD

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Initial CLL Treatment Strategies with Targeted Agent Combinations and MRD-guidance (811–816)
271-273

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Transcriptional and Epigenetic Control of MM (817–822)
La Nouvelle A-B

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Advancing Treatment Strategies in AL Amyloidosis (823–828)
260-262

702. CAR T-cell Therapies: Basic and Translational: Engineering CAR-T Cell Fitness, Persistence, and Safety (829–834)
353-355

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution (835–840)
388-390

907. Outcomes Research: Plasma Cell Disorders: Real-World Efficacy of Immunotherapy (841–846)
La Nouvelle C

908. Outcomes Research: Myeloid Malignancies: Advancing Precision and Value-Based Care in AML: Real-World Evidence Across the Disease Continuum (847–852)
Hall B

2:45 p.m. – 4:15 p.m. Oral Abstract Sessions non-CME

102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Iron at the Crossroads: Physiology, Pathology, Including Pregnancy (853–858)
291-292

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Red Cell Rescue: Novel Approaches in Sickle Cell Disease (859–864)
243-245

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Immune Dysregulation and Clinical Translation (865–870)
R06-R09

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: New Therapeutics in ITP and Chemotherapy-Induced Thrombocytopenia (871–876)
217-219

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological (877–882)
220-222

602. Myeloid Oncogenesis: Basic: Rewiring Chromatin, Metabolism, and Immunity in Myeloid Neoplasms (883–888)
R02-R05

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Clinical, Genomic, and Social Predictors of Outcomes (763–894)
265-268

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Venetoclax-based Therapy and AML Risk (895–900)
Great Hall AD

617. Acute Myeloid Leukemias: Commercially Available Therapies: Molecularly Targeted Combinations in AML (901–906)
Great Hall BC

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Cellular and Immune Therapies in T-Cell and NK-Cell Malignancies (907–912)
New Orleans Theatre B

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: From Trials to Reality: Real-World Evidence in Large B-cell Lymphoma (913–918)
New Orleans Theatre C

629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: T-cell Engagers and ADC Combinations and Long-Term Outcomes of Trials in Relapsed/Refractory LBCL (919–924)
New Orleans Theatre A

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Molecular Insights and New Approaches in MPNs (925–930)
Hall B

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myeloma Genomics (931–936)
La Nouvelle A-B

653. Multiple Myeloma: Clinical and Epidemiological: Evolving Population-Level Outcomes and Trends (937–942)
La Nouvelle C

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence (943–948)
353-355

801. Gene Therapies: Beyond Transplant: The Expanding Role of Gene Therapy in Hematology (949–954)
388-390

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: AI at the Bedside: From Prediction to Therapeutic Decisions (955–960)
393-396

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: H and T on the Rocks: Real-World Hemostasis and Thrombosis (961–966)
252-254

907. Outcomes Research: Plasma Cell Disorders: Beyond Response Rates: T-cell Engagement in the Real World (967–972)
260-262

908. Outcomes Research: Myeloid Malignancies: Mind the (Molecular) Gap: From Testing to Trials, Across Race and Place (973–978)
Hall C

4:30 p.m. – 6:00 p.m. Oral Abstract Sessions (non-CME)

101. Red Cells and Erythropoiesis, Excluding Iron: How to Make a Red Cell: Remodeling, Enucleation, Signaling, and Resilience (979–984)
291-292

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: T and NK Cell Development and Anti-Tumor Functions (985–990)
R06-R09

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms (991–996)
Hall B

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Frontline Therapy in Acute Lymphoblastic Leukemia: At the Crossroads of Chemotherapy, Immunotherapy, and Targeted Therapy Across the Age Spectrum (997–1002)
265-268

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Chemotherapy and Transplantation (1003–1008)
Great Hall BC

617. Acute Myeloid Leukemias: Commercially Available Therapies (1009–1014)
Great Hall AD

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - From Cytotoxic to Selective: The BTK Inhibitor Revolution in The Frontline Treatment of Mantle Cell Lymphoma (1015–1020)
New Orleans Theatre B

624. Hodgkin Lymphomas: Clinical and Epidemiological: Precision, Prognostication, and Paradigm Shifts (1021–1026)
New Orleans Theatre C

628. Aggressive Lymphomas: Cellular Therapies: Novel CAR-T Constructs, Durability, and Long-Term Outcomes (1027–1032)
New Orleans Theatre A

634. Myeloproliferative Syndromes: Clinical and Epidemiological: ET and PV: Moving Beyond Conventional Therapy (1033–1038)
Hall C

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myeloma Basic and Translational Research (1039–1044)
La Nouvelle C

653. Multiple Myeloma: Clinical and Epidemiological: Differentiating Multiple Myeloma(s): A Path to Cure (1045–1050)
La Nouvelle A-B

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Early Innovation of Immune Effector Cell Therapies (1051–1056)
388-390

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prophylaxis-Clinical and Translational Aspects (1057–1062)
353-355

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Emerging Technologies for Molecular Classification, Monitoring, and Modelling (1063–1068)
393-396

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: A World of Bleeding and Clotting (1069–1074)
217-219

903. Health Services and Quality Improvement: Myeloid Malignancies: JAKPOT! Improving Care Quality from Pre-hab, Sleep, and Home Transfusions to Pall-care, Costs, and JAK Testing (1075–1080)
R02-R05

904. Outcomes Research: Hemoglobinopathies: Therapeutic Innovation and Clinical Outcomes in Hemoglobinopathies (1081–1086)
252-254

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Platelets in Practice: Outcomes Across ITP, TTP, and TMA (1087–1092)
243-245

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Assessing Real World Effectiveness and Toxicity of Immune and Cellular Therapies (1093–1098)
260-262


blood® Journals Portfolio


Your Home for Hematology

Visit the *Blood* Journals Studio in the Poster Hall
















bloodjournals.org

POSTER PRESENTATIONS

The Poster Hall will be open for in-person and Virtual attendees. The Poster Hall is located in the Ernest N. Morial Convention Center, Hall F. Presenters will stand beside their posters during the evening Presentation times. Virtual poster presentations will be shared via a brief PowerPoint presentation with accompanying audio. The Virtual Poster Hall will allow attendees to browse a new set of posters starting at 8:00 a.m. (Central time) each day, as well as access posters from previous days on the virtual platform.

Poster Sessions are not offered for CME credit.

The Poster Hall hours are as follows:

Saturday (posters 1099 – 2858)
8:00 a.m. – 7:30 p.m.

Sunday (posters 2859 – 4618)
8:00 a.m. – 8:00 p.m.

Monday (posters 4619 – 6377)
8:00 a.m. – 8:00 p.m.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY,
DECEMBER 12, 2026

8:00 a.m. – 7:30 p.m. **Poster Session I – Viewing** non-CME

5:30 p.m. – 7:30 p.m. **Poster Session I – Presentations** non-CME

Hall F

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I (1099 - 1121)
102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster I (1122 - 1134)
112. Thalassemia and Globin Gene Regulation: Poster I (1135 - 1139)
113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I (1140 - 1155)
114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster I (1156 - 1194)
201. Granulocytes, Monocytes, and Macrophages: Poster I (1195 - 1215)
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I (1216 - 1229)
301. Platelets and Megakaryocytes: Basic and Translational: Poster I (1230 - 1238)
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I (1239 - 1264)
321. Coagulation and Fibrinolysis: Basic and Translational: Poster I (1265 - 1271)
322. Hemophilia A and B: Clinical and Epidemiological: Poster I (1272 - 1287)
323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster I (1288 - 1301)
330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster I (1302 - 1312)
331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster I (1313 - 1324)
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I (1325 - 1345)
401. Blood Transfusion: Poster I (1346 - 1353)
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I (1354 - 1366)
503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I (1367 - 1380)
506. Bone Marrow Microenvironment: Poster I (1381 - 1389)
508. Bone Marrow Failure: Acquired: Poster I (1390 - 1412)
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I (1413 - 1427)
602. Myeloid Oncogenesis: Basic: Poster I (1428 - 1453)
603. Lymphoid Oncogenesis: Basic: Poster I (1454 - 1466)
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I (1467 - 1498)
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I (1499 - 1516)
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I (1517 - 1536)
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I (1537 - 1560)
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster I (1561 - 1575)
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I (1576 - 1624)
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I (1625 - 1641)

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I (1642 - 1670)

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I (1671 - 1718)

619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster I (1719 - 1726)

621. Lymphomas: Translational: Molecular and Genetic: Poster I (1727 - 1755)

622. Lymphomas: Translational – Non-Genetic: Poster I (1756 - 1774)

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I (1775 - 1817)

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I (1818 - 1829)

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I (1830 - 1856)

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster I (1857 - 1884)

627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster I (1885 - 1910)

628. Aggressive Lymphomas: Cellular Therapies: Poster I (1911 - 1930)

629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: Poster I (1931 - 1957)

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I (1958 - 1979)

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I (1980 - 1998)

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I (1999 - 2052)

636. Myelodysplastic Syndromes: Basic and Translational: Poster I (2053 - 2064)

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I (2065 - 2097)

641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I (2098 - 2108)

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I (2109 - 2147)

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I (2148 - 2183)

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I (2184 - 2202)

653. Multiple Myeloma: Clinical and Epidemiological: Poster I (2203 - 2240)

654. Multiple Myeloma: Pharmacologic Therapies: Poster I (2241 - 2267)

655. Multiple Myeloma: Cellular Therapies: Poster I (2268 - 2287)

656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: Poster I (2288 - 2315)

701. Experimental Transplantation: Basic and Translational: Poster I (2316 - 2331)

702. CAR-T Cell Therapies: Basic and Translational: Poster I (2332 - 2376)

703. Cellular Immunotherapies Other Than CAR-T Cells: Basic and Translational: Poster I (2377 - 2388)

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I (2389 - 2416)

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I (2417 - 2427)

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I (2428 - 2460)

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I (2461 - 2491)

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I (2492 - 2516)

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I (2517 - 2539)

801. Gene Therapies: Poster I (2540 - 2552)

802. Chemical Biology and Experimental Therapeutics: Harnessing Chemical Biology to Reveal Therapeutic Vulnerabilities: Poster I (2553 - 2559)

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I (2560 - 2591)

900. Health Services and Quality Improvement: Hemoglobinopathies: Poster I (2592 - 2605)

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I (2606 - 2623)

902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I (2624 - 2652)

903. Health Services and Quality Improvement: Myeloid Malignancies: Poster I (2653 - 2664)

904. Outcomes Research: Hemoglobinopathies: Poster I (2665 - 2679)

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster I (2680 - 2707)

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I (2708 - 2774)

907. Outcomes Research: Plasma Cell Disorders: Poster I (2775 - 2808)

908. Outcomes Research: Myeloid Malignancies: Poster I (2809 - 2846)

909. Medical Education and Workforce Development: Poster I (2847 - 2858)

SUNDAY, DECEMBER 13, 2026

8:00 a.m. – 8:00 p.m. **Poster Session II – Viewing** non-CME

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

6:00 p.m. – 8:00 p.m. Poster Session II – Presentations non-CME

Hall F

101. Red Cells and Erythropoiesis, Excluding Iron: Poster II (2859 - 2880)
102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster II (2881 - 2894)
112. Thalassemia and Globin Gene Regulation: Poster II (2895 - 2899)
113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster II (2900 - 2915)
114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster II (2916 - 2956)
201. Granulocytes, Monocytes, and Macrophages: Poster II (2957 - 2976)
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II (2977 - 2991)
301. Platelets and Megakaryocytes: Basic and Translational: Poster II (2992 - 2999)
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II (3000 - 3026)
321. Coagulation and Fibrinolysis: Basic and Translational: Poster II (3027 - 3033)
322. Hemophilia A and B: Clinical and Epidemiological: Poster II (3034 - 3049)
323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster II (3050 - 3062)
330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster II (3063 - 3074)
331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster II (3075 - 3085)
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II (3086 - 3110)
401. Blood Transfusion: Poster II (3111 - 3119)
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II (3120 - 3130)
503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II (3131 - 3146)
506. Bone Marrow Microenvironment: Poster II (3147 - 3155)
508. Bone Marrow Failure: Acquired: Poster II (3156 - 3178)
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II (3179 - 3192)
602. Myeloid Oncogenesis: Basic: Poster II (3193 - 3218)
603. Lymphoid Oncogenesis: Basic: Poster II (3219 - 3232)
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II (3233 - 3263)
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II (3264 - 3280)
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II (3281 - 3300)
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II (3301 - 3322)
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster II (3323 - 3337)
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II (3338 - 3384)
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II (3385 - 3402)
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II (3403 - 3431)
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II (3432 - 3479)
619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster II (3480 - 3487)
621. Lymphomas: Translational – Molecular and Genetic: Poster II (3488 - 3516)
622. Lymphomas: Translational – Non-Genetic: Poster II (3517 - 3534)
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II (3535 - 3580)
624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II (3581 - 3592)
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II (3593 - 3619)
626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster II (3620 - 3647)
627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster II (3648 - 3673)
628. Aggressive Lymphomas: Cellular Therapies: Poster II (3674 - 3693)
629. Aggressive Lymphomas, Non-Cellular Immunotherapy including Bispecific Antibodies: Poster II (3694 - 3720)
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II (3721 - 3742)
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II (3743 - 3761)
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II (3762 - 3816)
636. Myelodysplastic Syndromes: Basic and Translational: Poster II (3817 - 3828)
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II (3829 - 3861)
641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II (3862 - 3872)
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II (3873 - 3912)
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II (3913 - 3949)
652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II (3950 - 3968)
653. Multiple Myeloma: Clinical and Epidemiological: Poster II (3969 - 4007)
654. Multiple Myeloma: Pharmacologic Therapies: Poster II (4008 - 4034)
655. Multiple Myeloma: Cellular Therapies: Poster II (4035 - 4054)

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, including Minimal Residual Disease: Poster II (4055 - 4081)

701. Experimental Transplantation: Basic and Translational: Poster II (4082 - 4097)

702. CAR-T Cell Therapies: Basic and Translational: Poster II (4098 - 4142)

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster II (4143 - 4153)

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II (4154 - 4182)

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II (4183 - 4192)

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II (4193 - 4226)

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II (4227 - 4255)

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II (4256 - 4279)

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II (4280 - 4302)

801. Gene Therapies: Poster II (4303 - 4316)

802. Chemical Biology and Experimental Therapeutics: Poster II (4317 - 4322)

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II (4323 - 4356)

900. Health Services and Quality Improvement: Hemoglobinopathies: Poster II (4357 - 4370)

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II (4371 - 4388)

902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II (4389 - 4417)

903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II (4418 - 4431)

904. Outcomes Research: Hemoglobinopathies: Poster II (4432 - 4445)

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II (4446 - 4473)

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II (4474 - 4534)

907. Outcomes Research: Plasma Cell Disorders: Poster II (4535 - 4568)

908. Outcomes Research: Myeloid Malignancies: Poster II (4569 - 4607)

909. Medical Education and Workforce Development: Poster II (4608 - 4618)

MONDAY, DECEMBER 14, 2026

8:00 a.m. – 8:00 p.m. **Poster Session III – Viewing** non-CME

6:00 p.m. – 8:00 p.m. **Poster Session III – Presentations** non-CME

Hall F

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III (4619 - 4640)

102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster III (4641 - 4653)

112. Thalassemia and Globin Gene Regulation: Poster III (4654 - 4658)

113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster III (4659 - 4674)

114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Poster III (4675 - 4717)

201. Granulocytes, Monocytes, and Macrophages: Poster III (4718 - 4738)

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III (4739 - 4752)

301. Platelets and Megakaryocytes: Basic and Translational: Poster III (4753 - 4761)

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III (4762 - 4787)

321. Coagulation and Fibrinolysis: Basic and Translational: Poster III (4788 - 4795)

322. Hemophilia A and B: Clinical and Epidemiological: Poster III (4796 - 4811)

323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster III (4812 - 4824)

330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster III (4825 - 4836)

331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster III (4837 - 4847)

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III (4848 - 4870)

401. Blood Transfusion: Poster III (4871 - 4878)

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III (4879 - 4891)

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster III (4892 - 4906)

506. Bone Marrow Microenvironment: Poster III (4907 - 4915)

508. Bone Marrow Failure: Acquired: Poster III (4916 - 4938)

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III (4939 - 4952)

602. Myeloid Oncogenesis: Basic: Poster III (4953 - 4978)

603. Lymphoid Oncogenesis: Basic: Poster III (4979 - 4992)

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III (4993 - 5023)

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III (5024 - 5041)

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III (5042 - 5061)

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III (5062 - 5082)

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster III (5083 - 5098)

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III (5099 - 5145)

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III (5146 - 5163)

617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III (5164 - 5192)

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III (5193 - 5240)

619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster III (5241 - 5247)

621. Lymphomas: Translational – Molecular and Genetic: Poster III (5248 - 5277)

622. Lymphomas: Translational – Non-Genetic: Poster III (5278 - 5295)

623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III (5296 - 5340)

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster III (5341 - 5351)

625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III (5352 - 5378)

626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster III (5379 - 5406)

627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster III (5407 - 5432)

628. Aggressive Lymphomas: Cellular Therapies: Poster III (5433 - 5453)

629. Aggressive Lymphomas, Non-Cellular Immunotherapy including Bispecific Antibodies: Poster III (5454 - 5480)

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III (5481 - 5503)

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III (5504 - 5522)

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III (5523 - 5576)

636. Myelodysplastic Syndromes: Basic and Translational: Poster III (5577 - 5588)

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III (5589 - 5622)

641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster III (5623 - 5632)

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III (5633 - 5674)

651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III (5675 - 5710)

652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III (5711 - 5729)

653. Multiple Myeloma: Clinical and Epidemiological: Poster III (5730 - 5767)

654. Multiple Myeloma: Pharmacologic Therapies: Poster III (5768 - 5795)

655. Multiple Myeloma: Cellular Therapies: Poster III (5796 - 5814)

656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, including Minimal Residual Disease: Poster III (5815 - 5842)

701. Experimental Transplantation: Basic and Translational: Poster III (5843 - 5858)

702. CAR-T Cell Therapies: Basic and Translational: Poster III (5859 - 5904)

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster III (5905 - 5915)

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III (5916 - 5944)

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III (5945 - 5954)

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III (5955 - 5988)

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III (5989 - 6017)

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III (6018 - 6040)

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III (6041 - 6063)

801. Gene Therapies: Poster III (6064 - 6078)

802. Chemical Biology and Experimental Therapeutics: Poster III (6079 - 6085)

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III (6086 - 6120)

900. Health Services and Quality Improvement: Hemoglobinopathies: Poster III (6121 - 6134)

901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III (6135 - 6151)

902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III (6152 - 6180)

903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III (6181 - 6193)

904. Outcomes Research: Hemoglobinopathies: Poster III (6194 - 6207)

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III (6208 - 6235)

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III (6236 - 6291)

907. Outcomes Research: Plasma Cell Disorders: Poster III (6292 - 6325)

908. Outcomes Research: Myeloid Malignancies: Poster III (6326 - 6365)

909. Medical Education and Workforce Development: Poster III (6366 - 6377)



CELEBRATING 10 YEARS OF

blood advances®

Pick up a special 10th anniversary print issue at the ASH booth.

bloodadvances.org

American Society of Hematology

Helping hematologists conquer blood diseases worldwide

SATELLITE SYMPOSIA

These symposia will take place on Friday, December 11, 2026, preceding the ASH annual meeting. ASH appreciates its corporate and nonprofit partners for their participation in this program. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs.

Satellite Symposia are not CME-accredited through ASH and are planned solely by the sponsoring organizations. Each symposium lists a contact person for accreditation information. An ASH meeting badge is not needed to attend these symposia.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

FRIDAY MORNING SYMPOSIA:
7:00 A.M. – 10:00 A.M.

A Hematologist's Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond

Friday **7:00 a.m. – 10:00 a.m.**
Hall C

This program is supported by Agios Pharmaceuticals, Inc., Beam Therapeutics, Genetix Biotherapeutics and Novo Nordisk Inc.

Chair:
Sophie Lanzkron, MD, MHS, Thomas Jefferson University, Philadelphia, PA

Speakers:
Haydar Frangoul, MD, MS, The Children's Hospital at TriStar Centennial, Nashville, TN

Madhav Vissa, MD, UCSF Benioff Children's Hospitals, San Francisco, CA

Tami John, MD, Stanford University, Palo Alto, CA

Contact: Carolyn Ciaramella
cciaramella@medscapelive.com

Anti-BCMA Bispecific Antibodies in Multiple Myeloma: From Biology to Real-World Implementation

Friday **7:00 a.m. – 10:00 a.m.**
Great Hall AD

This program is supported by a grant from the International Academy for Clinical Hematology (IACH).

Co-Chairs:
Mohamad Mohty, MD, PhD, Saint-Antoine Research Center & Sorbonne Université, Paris, France

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain

Speakers:
Nizar Bahlis, MD, University of Calgary, Calgary, Canada

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain

Mohamad Mohty, MD, PhD, Saint-Antoine Research Center & Sorbonne Université, Paris, France

Salomon Manier, MD, PhD, Hospital Center University De Lille, Lille, France

Karthik Ramasamy, MD PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Elena Zamagni, MD, PhD, Istituto Di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy

Douglas Sborov, MD, MS, University of Utah, Salt Lake City, UT

Contact: Amnon Ron
amnon@iach.org

B-Cell–Directed Therapies in Immune Thrombocytopenia: Real-World Practice

Friday **7:00 a.m. – 10:00 a.m.**
R06-R09

This program is supported by an educational grant from Novartis.

Chair:
David Kuter, MD, DPhil, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Speakers:
Ronak Mistry, DO, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Cindy Neunert, MD, Columbia University Medical Center, New York, NY

Contact: Sylvia Ehle
sehle@mlieducation.org

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Breaking News: Launching Bispecific Antibodies for Multiple Myeloma in Community Practice

Friday **7:00 a.m. – 10:00 a.m.**
Hall B

This program is supported by Johnson & Johnson and Regeneron Pharmaceuticals, Inc.

Chair:
Ajay Nooka, MD, MPH, Winship Cancer Institute of Emory University, Atlanta, GA

Speakers:
Caitlin Costello, MD, UC San Diego, La Jolla, CA

Beth Faiman, PhD, MSN, APN-BC, AOCN®, TCTCN®, FAAN, FAPO, Cleveland Clinic Taussig Cancer Institute, Cleveland, IL

Jeffrey Matous, MD, Colorado Blood Cancer Institute, Denver, CO

Contact: Carolyn Ciaramella
cciaramella@medscapelive.com

Consensus or Controversy? Documenting And Discussing Investigators' Approaches to the Management of Patients with Chronic Lymphocytic Leukemia

Friday **7:00 a.m. – 10:00 a.m.**
Sheraton - Napoleon Ballroom CD

This program is supported by AstraZeneca Pharmaceuticals LP, BeOne, and Lilly.

Chair:
Shazia Nakhoda, MD, Fox Chase Cancer Center, Philadelphia, PA

Speakers:
Talha Munir, MBBS, MRCP, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Toby Eyre, MBChB, DipMedEd, MRCP, MD, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX

Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Center and University of Washington, Seattle, WA

Contact: Sylvia Eriksen
meetings@researchtopractice.com

Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review

Friday **7:00 a.m. – 10:00 a.m.**
Sheraton - Napoleon Ballroom AB

This program is supported by Astellas, Rigel Pharmaceuticals Inc, AbbVie Inc, Daiichi Sankyo Inc, Kura Oncology Inc, and Taiho Oncology Inc.

Chair:
Amir Fathi, MD, Massachusetts General Hospital & Harvard Medical School, Boston, MA

Speakers:
Stéphane de Botton, MD, PhD, Gustave Roussy Cancer Center, Villejuif, France

Andrew H. Wei, MBBS, PhD, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

Courtney DiNardo, MD, MSCE, The University of Texas MD Anderson Cancer Center, Houston, TX

Harry Erba, MD, PhD, Duke University School of Medicine, Durham, NC

Contact: Sylvia Eriksen
meetings@researchtopractice.com

From Controversies to Consensus in Paroxysmal Nocturnal Hemoglobinuria: Developing IPIG Guidelines

Friday **7:00 a.m. – 10:00 a.m.**
R02-R05

This program is supported by educational grants from Alexion, Regeneron, Roche and Sobi.

Co-Chairs:
Rodrigo Calado, MD, PhD, Hospital das Clínicas de Ribeirão Preto, São Paulo, Brazil

Phillip Scheinberg, MD, PhD, Hospital A Beneficência Portuguesa de São Paulo, São Paulo, Brazil

Speakers:
Neal Young, MD, NIH, Bethesda, MD

Britta Höchsmann, Ulm University Institute of Transfusion Medicine, Ulm, Germany

Richard Kelly, MBChB, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Jens Panse, MD, University Hospital RWTH, Aachen, Germany

Rosario Notaro, MD, Instituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO), Florence, Italy

Contact: Dawn McKnight
dmcknight@kmgnet.com

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

MDS in Practice: Navigating Complex Decisions Across the Disease Spectrum

Friday **7:00 a.m. – 10:00 a.m.**
208-210

This program is supported by the Myelodysplastic Syndromes Foundation, Inc. in partnership with AKH Inc., Advancing Knowledge in Healthcare.

Co-Chairs:

Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA

Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Speakers:

Rafael Bejar, MD, PhD, University of California San Diego, La Jolla, CA

Maria Diez-Campelo, MD, PhD, Salamanca University Hospital, Salamanca, Spain

Lionel Ades, MD, PhD, Hôpital Saint-Louis, Paris, France

Valeria Santini, MD, AOU Careggi-University of Florence, Florence, Italy

Michael Savona, MD, Vanderbilt University Medical Center, Nashville, TN

Lewis Silverman, MD, Icahn School of Medicine, New York, NY

Contact: Victor Gonzalez
vgonzalez@mds-foundation.org

Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs

Friday **7:00 a.m. – 10:00 a.m.**
Hilton - Grand Ballroom CD

This program is supported by independent educational grants from AbbVie, AstraZeneca, Bristol Myers Squibb, CellCentric, and Johnson & Johnson. This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Multiple Myeloma.

Chair:

Sagar Lonial, MD, FACP, Winship Cancer Institute, Atlanta, GA

Speakers:

Nisha Joseph, MD, Winship Cancer Institute, Atlanta, GA

Binod Dhakal, MD, MS, Medical College of Wisconsin, Milwaukee, WI

Contact: Grayson Baldy
grayson.baldy@peerview.com

FRIDAY EARLY AFTERNOON SYMPOSIA:
11:00 A.M. – 2:00 P.M.

A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We're Going

Friday **11:00 a.m. – 2:00 p.m.**
Sheraton - Napoleon Ballroom AB

This program is supported by AstraZeneca Pharmaceuticals LP, and Bristol Myers Squibb.

Chair:

Peter Voorhees, MD, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, NC

Speakers:

Shambavi Richard, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Sarah Larson, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA

Thomas Martin, MD, Helen Diller Family Comprehensive Cancer Center, UCSF Medical Center, San Francisco, CA

Contact: Sylvia Eriksen
meetings@researchtopractice.com

Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together

Friday **11:00 a.m. – 2:00 p.m.**
Hall C

This program is supported by Alexion Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., and Johnson & Johnson.

Speakers:

Suzanne Lentzsch, MD, PhD, Columbia University Medical Center, New York, NY

Morie Gertz, MD, Mayo Clinic, Rochester, MN

Pedro Vianna, MD, Harvard Medical School, Boston, MA

Contact: Carolyn Ciaramella
cciaramella@medscapelive.com

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation

Friday **11:00 a.m. – 2:00 p.m.**
Hilton - Grand Ballroom CD

This program is supported by an independent educational grant from AstraZeneca. This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.

Chair:
Nicola Göekbuget, MD, University Hospital, Frankfurt, Germany

Speakers:
Ibrahim Aldoss, MD, City of Hope, Duarte, CA

Bijal Shah, MD, MS, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Contact: Grayson Baldy
grayson.baldy@peerview.com

Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review

Friday **11:00 a.m. – 2:00 p.m.**
Sheraton - Napoleon Ballroom CD

This program is supported by AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Genmab US Inc.

Chair:
Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN

Speakers:
Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Chan Cheah, MBBS, DMSc, Sir Charles Gairdner Hospital, Perth, Australia

Nancy Bartlett, MD, Washington University School of Medicine, St Louis, MO

Contact: Sylvia Eriksen
meetings@researchtopractice.com

Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum

Friday **11:00 a.m. – 2:00 p.m.**
R02-R05

This program is supported by an educational grant from Genmab. This activity is provided by PRIME Education.

Speakers:
Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, MA

Shelby Sullivan, PharmD, PRIME Education, LLC, New York, NY

Yasmin Karimi, MD, University of Michigan, Ann Arbor, MI

Contact: Eryn Litvinas
e.litvinas@primeinc.org

CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation

Friday **11:00 a.m. – 2:00 p.m.**
243-245

This program is supported by Bristol Myers Squibb. Provided by Clinical Care Options, LLC. dba Decera Clinical Education.

Chair:
Michael Bishop, MD, University of Chicago, Chicago, IL

Speakers:
Jeremy S. Abramson, MD, Harvard Medical School, Cambridge, MA

Caron Jacobson, MD, MMSc, Harvard Medical School, Cambridge MA,

Michael Jain, MD, PhD, Moffitt Cancer Center, Tampa, FL

Tanya Siddiqi, MD, City of Hope, Irvine, CA

Contact: Ishana Fleurant
Ifleurant@clinicaloptions.com

Cases and Conversations: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies

Friday **11:00 a.m. – 2:00 p.m.**
La Nouvelle A-B

This program is supported by educational grants from AbbVie and Menarini Stemline.

Chair:
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:
Andrew Lane, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Gary Schiller, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA

Contact: Physicians' Education Resource, LLC
onc-info@gotoper.com

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies

Friday **11:00 a.m. – 2:00 p.m.**
208-210

This program is supported by AstraZeneca, BeOne Medicines, and Lilly. Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with CLL Society.

Chair:
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:
Brian Koffman, MDCM, CLL Society, Claremont, CA

Jennifer Woyach, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Meghan Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Ishana Fleurant
Ifleurant@clinicaloptions.com

CML Treatment Continuum: Optimizing Therapy Selection, Molecular Monitoring, And Long-Term Quality of Life

Friday **11:00 a.m. – 2:00 p.m.**
Great Hall BC

This program is supported by Enliven Therapeutics Inc. and Novartis Pharmaceuticals Corporation. Developed through a strategic collaboration between H. Jean Khoury CML Consortium and Medscape Oncology.

Chair:
Kendra Sweet, MD, MS, Moffitt Cancer Center, Tampa, FL

Speakers:
Ehab Atallah, MD, Medical College of Wisconsin, Milwaukee, WI

Michael Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Carolyn Ciaramella
cciaramella@medscapelive.com

Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making

Friday **11:00 a.m. – 2:00 p.m.**
343-345

This program is supported by Servier Pharmaceuticals, LLC.

Chair:
Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA

Speakers:
Uma Borate, MBBS, MSc, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Curtis Lachowiez, MD, OHSU Knight Cancer Institute, Portland, OR

Contact: Greg Maheu
gmaheu@paradigmmc.com

Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease

Friday **11:00 a.m. – 2:00 p.m.**
265-268

This program is supported by Blueprint Medicines, a Sanofi company. Provided by Clinical Care Options, LLC. dba Decera Clinical Education.

Chair:
Daniel DeAngelo, MD, PhD, Harvard Medical School, Boston, MA

Speakers:
James McCloskey, MD, HMH John Theurer Cancer Center Lymphoma Hackensack, Hackensack, NJ

Brian Chernak, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Ishana Fleurant
Ifleurant@clinicaloptions.com

Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care

Friday **11:00 a.m. – 2:00 p.m.**
Great Hall AD

This program is supported by educational grants from Rigel Pharmaceuticals, Inc., Syndax Pharmaceuticals, and Taiho Oncology, Inc.

Chair:
Naval Daver, MD, MD Anderson Cancer Center, Houston, TX

Speakers:
Gail Roboz, MD, Weill Cornell Medicine, New York, NY

Amer Zeidan, MD, Yale Cancer Center, New Haven, CT

Richard Dillon, MD, King's College London, London, United Kingdom

Contact: Physicians' Education Resource, LLC
onc-info@gotoper.com

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Medical Crossfire®: Redefining DLBCL — How Biomarker- and Mechanism-Driven Strategies Are Reshaping Management Across the Disease Continuum

Friday **11:00 a.m. – 2:00 p.m.**
La Nouvelle C

This program is supported by educational grants from ADC Therapeutics; AstraZeneca Pharmaceuticals; and Lyell Immunopharma.

Speakers:

Jason Westin, MD, MS, FACP, FASCO, The University of Texas MD Anderson Cancer Center, Houston, TX

Lori Leslie, MD, Hackensack University Medical Center, Hackensack, NJ

Matthew Lunning, DO, FACP, University of Nebraska Medical Center, Omaha, NE

Contact: Physicians' Education Resource, LLC
onc-info@gotoper.com

Medical Crossfire®: Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies

Friday **11:00 a.m. – 2:00 p.m.**
393-396

This program is supported by an educational grant from Sanofi Genzyme.

Speakers:

Krina K. Patel, MD, MSc, The University of Texas MD Anderson Cancer Center, Houston, TX

Jesús Berdeja, MD, Tennessee Oncology, Nashville, TN

Rahul Banerjee, MD, Fred Hutchinson Cancer Center, Seattle, WA

Borja Puertas, MD, PhD, Universidad de Salamanca, Salamanca, Spain

Contact: Physicians' Education Resource, LLC
onc-info@gotoper.com

Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies

Friday **11:00 a.m. – 2:00 p.m.**
Hilton - Grand Ballroom AB

This program is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly. This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.

Chair:

Martin Dreyling, MD, PhD, LMU University Hospital, Munich, Germany

Speakers:

Kami Maddocks, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Christine Ryan, MD, Dana-Farber Cancer Institute, Boston, MA

Contact: Grayson Baldy
grayson.baldy@peerview.com

Show Me the Data™: Emerging Evidence and Evolving Clinical Practice in Essential Thrombocythemia and Polycythemia Vera

Friday **11:00 a.m. – 2:00 p.m.**
R06-R09

This program is supported by an educational grant from PharmaEssentia.

Chair:

Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY

Speakers:

Pankit Vachhani, MD, University of Alabama at Birmingham, Birmingham, AL

Jeanne Palmer, MD, Mayo Clinic, Phoenix, AZ

Contact: Physicians' Education Resource, LLC
onc-info@gotoper.com

The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care

Friday **11:00 a.m. – 2:00 p.m.**
217-219

This program is supported by an independent educational grant from Bristol Myers Squibb.

Chair:

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston

Speakers:

James Berenson, MD, Berenson Cancer Center, West Hollywood, CA

Luciano J. Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL

Contact: Andrea Mathis
amathis@glc.healthcare

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Transforming Care for Newly-Diagnosed Multiple Myeloma: Integrating Evidence-Based Innovation into Community Practice

Friday **11:00 a.m. – 2:00 p.m.**
Hall B

This program is supported by Sanofi.

Chair:
Ola Landgren, MD, PhD, University of Miami, Miami

Speakers:
Noopur Raje, MD, Mass General Brigham Cancer Institute, Boston, MA

Sikander Ailawadhi, MD, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL

Contact: Carolyn Ciaramella
cciaramella@medscapelive.com

FRIDAY LATE AFTERNOON SYMPOSIA:
3:00 P.M. –6:00 P.M.

A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We're Going

Friday **3:00 p.m. – 6:00 p.m.**
Sheraton - Napoleon Ballroom CD

This program is supported by GSK, Bristol Myers Squibb, Geron Corporation, Incyte Corporation, Karyopharm Therapeutics, and Novartis.

Chair:
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa

Speakers:
Francesco Passamonti, MD, University of Milan, Milan, Italy

Ruben Mesa, MD, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte, NC

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY

Contact: Sylvia Eriksen
meetings@researchtopractice.com

Acknowledging the Rare: Navigating Diagnostic and Therapeutic Complexities in Rare Hematologic Disorders

Friday **3:00 p.m. – 6:00 p.m.**
Hall B

This program is supported by Recordati Rare Diseases.

Chair:
Srikanth Nagalla, MBBS, Miami Cancer Institute, Miami

Speakers:
Ilene Weitz, MD, University of Southern California, Los Angeles, CA

Frits van Rhee, MD, PhD, University of Arkansas for Medical Sciences, Little Rock, AR

Howard Liebman, MD, University of Southern California, Los Angeles, CA

Contact: Carolyn Ciaramella
cciaramella@medscapelive.com

Cases and Conversations: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms

Friday **3:00 p.m. – 6:00 p.m.**
R06-R09

This program is supported by educational grants from Geron Corporation, GSK, and PharmaEssentia.

Speakers:
Jennifer O'Sullivan, MB Bch BAO, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Gabriela Hobbs, MD, Mass General Brigham Cancer Institute, Boston, MA

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY

Contact: Physicians' Education Resource, LLC
onc-info@gotoper.com

Evidence at Every Step: Applying the Latest CAR T-Cell Data Across the NHL Care Continuum

Friday **3:00 p.m. – 6:00 p.m.**
R02-R05

This program is supported by an educational grant from Novartis Pharmaceuticals Corporation. This activity is provided by PRIME Education.

Chair:
Peter Riedell, MD, University of Chicago, Chicago, IL

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Speakers:
Daniel Landsburg, MD, University of Pennsylvania, Philadelphia, PA

Shelby Sullivan, PharmD, PRIME Education, LLC, New York, NY

Contact: Eryn Litvinas
e.litvinas@primeinc.org

FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment

Friday **3:00 p.m. – 6:00 p.m.**
Hilton - Grand Ballroom CD

This program is supported by an independent educational grant from AstraZeneca. This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, HealthTree Foundation for Chronic Lymphocytic Leukemia.

Chair:
Matthew S Davids, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA

Speakers:
Nicole Lamanna, MD, New York-Presbyterian & Columbia University Medical Center, New York, NY

Lydia Scarfò, MD, Università Vita-Salute San Raffaele, Milan, Italy

Contact: Grayson Baldy
grayson.baldy@peerview.com

Hemophilia at the Crossroads: New Evidence for Individualized Care

Friday **3:00 p.m. – 6:00 p.m.**
Great Hall BC

This program is supported by Sanofi.

Chair:
Steven Pipe, MD, University of Michigan, Ann Arbor, MI

Speakers:
Maissaa Janbain, MD, Louisiana Center for Bleeding & Clotting Disorders, New Orleans, LA

Allison Wheeler, MD, MSCI, Washington Center for Bleeding Disorders, Seattle, WA

Contact: Carolyn Ciaramella
cciaramella@medscapelive.com

Immune Therapy for Myeloma: From CAR T and T-Cell Engagers to Community Care

Friday **3:00 p.m. – 6:00 p.m.**
343-345

This program is supported by Legend Biotech, Kite Gilead, Johnson & Johnson and Bristol Myers Squibb.

Co-Chairs:
Marco Davila, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Renier Brentjens, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Speakers:
Danai Dima, MD, Fred Hutchinson Cancer Center, Seattle, WA

Hamza Hassan, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA

Maximilian Merz, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Hemn Mohammadpour, DVM, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Jens Hillengass, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Ehsan Malek, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Contact: Ashley Snowden
ashley.snowden@roswellpark.org

ITP at a Crossroads: Closing Knowledge Gaps in Pathophysiology, Treatment Selection, and Patient-Centred Care

Friday **3:00 p.m. – 6:00 p.m.**
217-219

This program is supported by Sanofi.

Chair:
Sandhya Panch, MD, Fred Hutchinson Cancer Center, Seattle

Speakers:
Hanny Al-Samkari, MD, Harvard Medical School, Boston, MA

Gerald Soff, MD, University of Miami Health System, Miami, FL

Contact: George Vuturo
gvuturo@affinityced.com

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Live Hot Seat™: Advancing Precision Care in Acute Myeloid Leukemia With the Integration of Menin Inhibitors

Friday **3:00 p.m. – 6:00 p.m.**
393-396

This program is supported by educational grants from Janssen and Kura Oncology.

Chair:
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Speakers:
Jessica Altman, MD, Northwestern University, Chicago, IL

Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY

Contact: Physicians' Education Resource, LLC
onc-info@gotoper.com

Live Tumor Board: Advancing Clinical Competence in Primary CNS Lymphoma — Navigating Molecular Pathways and Emerging Therapies

Friday **3:00 p.m. – 6:00 p.m.**
La Nouvelle C

This program is supported by an educational grant from Deciphera Pharmaceuticals.

Speakers:
Christopher D'Angelo, MD, University of Nebraska Medical Center, Omaha, NE

Christian Grommes, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Ashley Sumrall, MD, FACP, FASCO, Advocate Health, Charlotte, NC

Contact: Physicians' Education Resource, LLC
onc-info@gotoper.com

MDS in the Modern Era: Getting Ahead of the 8-Ball

Friday **3:00 p.m. – 6:00 p.m.**
Hall C

This program is supported by Bristol Myers Squibb, Geron Corporation, and OrcaBio.

Chair:
Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:
Caspian Oliai, MD, University of California Los Angeles, Los Angeles, CA

David Sallman, MD, Moffitt Cancer Center, Tampa, FL

Contact: Carolyn Ciaramella
cciaramella@medscapelive.com

Medical Crossfire®: Strategic Sequencing in ALL — From Asparaginase to Cellular Therapy in an MRD-Driven Era

Friday **3:00 p.m. – 6:00 p.m.**
La Nouvelle A-B

This program is supported by educational grants from Amgen, Autolus Therapeutics, and Jazz Pharmaceuticals.

Chair:
Hagop Kantarjian, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Speakers:
Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Sumit Gupta, MD, PhD, FRCPC, The Hospital for Sick Children, Toronto, Canada

Aaron Logan, MD, PhD, MPhil, University of California, San Francisco, San Francisco, CA

Claire Roddie, MBChB, PhD, University College London (UCL Cancer Institute), London, United Kingdom

Contact: Physicians' Education Resource, LLC
onc-info@gotoper.com

Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice

Friday **3:00 p.m. – 6:00 p.m.**
243-245

This program is supported by AstraZeneca, Johnson & Johnson, and Sanofi. Provided by National Comprehensive Cancer Network in collaboration with Decera Clinical Education.

Chair:
Carol Huff, MD, Johns Hopkins University, Baltimore, MD

Speakers:
Larry Anderson, MD, PhD, UT Southwestern Medical Center, Dallas, TX

Rachid Baz, MD, Moffitt Cancer Center, Tampa, FL

Contact: Ishana Fleurant
lfleurant@clinicaloptions.com

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions

Friday **3:00 p.m. – 6:00 p.m.**
265-268

This program is supported by AstraZeneca and Genmab. Provided by Clinical Care Options, LLC. dba Decera Clinical Education.

Chair:
Matthew Matasar, MD, Rutgers Cancer Institute, New Brunswick, NJ

Speaker:
Tycel Phillips, MD, FASCO, Rutgers Cancer Institute, New Brunswick, NJ

Contact: Ishana Fleurant
Ifleurant@clinicaloptions.com

Quadruplet Therapy in NDMM: Interpreting the Data, Applying the Evidence

Friday **3:00 p.m. – 6:00 p.m.**
208-210

This program is supported by an educational grant from Sanofi. This activity is provided by Answers in CME.

Speakers:
Amrita Krishnan, MD, FACP, Director of Judy and Bernard Briskin Center for Multiple Myeloma, Irvine, CA

Adriana Rossi, MD, Icahn School of Medicine, Mount Sinai Hospital, New York, NY

Contact: Kaitlyn Bell
kaitlyn.bell@answersincme.com

The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care

Friday **3:00 p.m. – 6:00 p.m.**
Hilton - Grand Ballroom AB

This program is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc. This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.

Chair:
Prof. Dr. Max Topp, MD, Universitätsklinikum Würzburg, Würzburg, Germany

Speakers:
Sameh Gaballa, MD, H. Lee Moffitt Cancer Center, Tampa, FL

Elizabeth Brem, MD, University of California, Irvine, Orange, CA

Contact: Grayson Baldy
grayson.baldy@peerview.com

FRIDAY EVENING SYMPOSIA:
7:00 P.M. –10:00 P.M.

Accelerating CARs for Lymphoma: Expert Workshops on CAR-T Standards, Sequencing, and Emerging Cellular Therapy Platforms

Friday **7:00 p.m. – 10:00 p.m.**
Hilton - Grand Ballroom AB

This program is supported by educational grants from Caribou Biosciences, Inc., Kite, A Gilead Company, Legend Biotech, and Miltenyi Biomedicine. This CME/MOC/EBAH/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Non-Hodgkin Lymphoma.

Chair:
Sairah Ahmed, MD, The University of Texas MD Anderson Cancer Center, Houston

Speakers:
Nirav Shah, MD, MS, Medical College of Wisconsin, Milwaukee, WI

Sunita Dwivedy Nasta, MD, MS, Hospital of the University of Pennsylvania, Philadelphia, PA

Contact: Grayson Baldy
grayson.baldy@peerview.com

Addressing Community Oncologists' Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies in Multiple Myeloma – What Clinicians Want To Know

Friday **7:00 p.m. – 10:00 p.m.**
Sheraton - Napoleon Ballroom CD

This program is supported by GSK and from Genentech, a member of the Roche Group.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Chair:
Natalie Callander, MD, University of Wisconsin Carbone Cancer Center, Madison, WI

Speakers:
Suzanne Trudel, MD, Alexandra Hospital, Athens, Greece

Meletios-Athanasios (Thanos) Dimopoulos, MD, Alexandra Hospital, Athens, Greece

Adam Cohen, MD, University of Pennsylvania, Philadelphia, PA

Contact: Sylvia Eriksen
meetings@researchtopractice.com

Addressing Community Oncologists' Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know

Friday **7:00 p.m. – 10:00 p.m.**
Sheraton - Napoleon Ballroom AB

This program is supported by ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, and Incyte Corporation.

Chair:
Sonali Smith, MD, FASCO, The University of Chicago, Chicago, IL

Speakers:
Mark Hoffmann, MD, The University of Kansas Cancer Center, Kansas City, KS

Brad Kahl, MD, Washington University School of Medicine, St Louis, MO

Paolo Caimi, MD, University Hospitals Seidman Cancer Center, Cleveland, IL

Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Contact: Sylvia Eriksen
meetings@researchtopractice.com

Advancing the DLBCL Paradigm: Sequencing Bispecifics in Optimizing Patient Care

Friday **7:00 p.m. – 10:00 p.m.**
Great Hall BC

This program is supported by F. Hoffmann-La Roche Ltd.

Chair:
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

Speakers:
Haifaa Abdulhaq, Clinical Professor, University of California, San Francisco, Fresno, CA

Michael Dickinson, MBBS (Hons), DMedSci FRACP, FRCPA, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, Australia

Contact: Carolyn Ciaramella
cciaramella@medscapelive.com

Cases and Conversations: Endothelial Injury, Complement, and TA-TMA After Allogeneic Stem Cell Transplant

Friday **7:00 p.m. – 10:00 p.m.**
La Nouvelle C

This program is supported by an educational grant from Omeros Corporation.

Speakers:
Michelle Schoettler, MD, Emory University School of Medicine, Atlanta, GA

Alessandro Rambaldi, MD, University of Milan, Milan, Italy

Jeffrey Laurence, MD, Weill Cornell Medicine, New York, NY

Contact: Physicians' Education Resource, LLC
onc-info@gotoper.com

Cases and Conversations: Sequencing Strategies in Relapsed and Refractory CLL

Friday **7:00 p.m. – 10:00 p.m.**
La Nouvelle A-B

This program is supported by educational grants from Lilly; Nurix Therapeutics, Inc.; and Genentech, a member of the Roche Group.

Chair:
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA

Speakers:
Seema Bhat, MD, The James Outpatient Care, Columbus, OH

Jeff Sharman, MD, US Oncology, Eugene, OR

Contact: Physicians' Education Resource, LLC
onc-info@gotoper.com

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Clinical Turning Points: Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis

Friday **7:00 p.m. – 10:00 p.m.**
Hall C

This program is supported by Blueprint Medicines, a Sanofi company and Cogent Biosciences, Inc.

Chair:
Tracy George, MD, University of Utah, Salt Lake City, UT

Speakers:
Lindsay Rein, MD, Duke University Health System, Durham, NC

Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA

Contact: Carolyn Ciaramella
cciaramella@medscapelive.com

From Evidence to Action in MPN: Transforming Challenges to Opportunities in PV and ET Patients

Friday **7:00 p.m. – 10:00 p.m.**
208-210

This program is supported by an independent educational grant from Merck & Co., Inc., Rahway, NJ USA. This activity is provided by Answers in CME.

Speakers:
Jennifer Vaughn, MD, MSPH, The Ohio State University, Columbus, OH

Brady Stein, MD, Northwestern University Feinberg School of Medicine, Chicago, IL

Contact: Kaitlyn Bell
kaitlyn.bell@answersincme.com

Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia

Friday **7:00 p.m. – 10:00 p.m.**
343-345

This program is supported by Servier Pharmaceuticals, LLC.

Chair:
Stephen Hunger, MD, Children's Hospital of Philadelphia, Philadelphia, PA

Speakers:
Seth Karol, MD, MSCI, St. Jude Children's Research Hospital, Memphis, TN

Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA

Contact: Greg Maheu
gmaheu@paradigmmc.com

12-14 Dec 2026 Saturday–Monday

CLINICAL TRIAL SHOWCASES

Clinical Trial Showcases as of October 14, 2026.

Check the mobile app for an updated list of Clinical Trial Showcases.

Clinical Trial Showcases are 15-minute presentations that provide an overview of the sponsoring company's clinical trials. Presenting companies can be commercial companies, non-profit organizations, or contract/clinical research organizations. Sessions are non-CME and solely promotional in nature.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

Advancing Research in Hemophilia A and von Willebrand Disease

Saturday 1:30 p.m. – 1:45 p.m.
Hall J, Theater 1

Sponsored by Genentech, a Member of the Roche Group

For in-person participants only

Speakers:
Dan Hart, BSc, MBChB, FRCP, FRCPath, PhD, Roche

HARBOR: A Global Phase 2/3 Clinical Trial Evaluating Elenestinib in Patients with Indolent Systemic Mastocytosis

Saturday 1:30 p.m. – 1:45 p.m.
Hall J, Theater 3

Sponsored by Sanofi

For in-person participants only

Speakers:
Robyn Scherber, MD, MPH, Sanofi

Javier Munoz-Gonzalez, PhD, Sanofi

Fitusiran ATLAS-KIDS Clinical Trial

Saturday 1:45 p.m. – 2:00 p.m.
Hall J, Theater 3

Sponsored by Sanofi

For in-person participants only

Speakers:
Marek Demissie, MD, PhD, Sanofi

LUNA 4 - Early Multi-Immune Modulation with Rilzabrutinib in Patients with Primary ITP After First-Line Treatment Failure: A Phase 3b Study

Saturday 3:30 p.m. – 3:45 p.m.
Hall J, Theater 3

Sponsored by Sanofi

For in-person participants only

Speakers:
Maria Belen Rodriguez, MD, Sanofi

LUMINA 3 –A Phase 3, Two Arm Study, Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Warm Autoimmune Hemolytic Anemia (wAIHA)

Saturday 3:45 p.m. – 4:00 p.m.
Hall J, Theater 3

Sponsored by Sanofi

For in-person participants only

Speakers:
Maria Belen Rodriguez, MD, Sanofi

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SUNDAY

Evaluating Osivelotor in Sickle Cell Disease: The Phase 3 DREAM Trial

Sunday **4:15 p.m. – 4:30 p.m.**
Hall J, Theater 5

Sponsored by Pfizer

For in-person participants only

Speakers:
Geoffrey Allen, MD, Pfizer

MONDAY

Closing the Evidence Gap in Hemophilia: Marstacimab Phase 3 Clinical Trial in Mild to Moderate Hemophilia and the MARVL-US Real-World Study

Monday **10:00 a.m. – 10:15 a.m.**
Hall J, Theater 5

Sponsored by Pfizer Inc.

For in-person participants only

Speakers:
Jasmine Healy, PhD, Pfizer Inc.

Carlos Estevez, MD, Pfizer Inc.

Phase 2 and 3 Placebo-Controlled and Long-Term Extension Study of Rilzabrutinib in Adults with iCVID to Evaluate Efficacy, Safety, and Tolerability

Monday **10:00 a.m. – 10:15 a.m.**
Hall J, Theater 3

Sponsored by Sanofi

For in-person participants only

Speakers:
Joyce Talavera, MD, Sanofi

Sutimlimab in Adults With Chronic ITP: An Upcoming Phase 3 Clinical Trial

Monday **10:00 a.m.- 10:15 a.m.**
Hall J, Theater 1

Sponsored by Recordati UK Ltd.

For in-person participants only

Speaker:
Enrico Minnella, MD, PhD, Recordati UK Ltd.

LIBRA – A Randomized Placebo-Controlled Study Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Sickle-Cell Disease (SCD)

Monday **10:15 a.m. – 10:30 a.m.**
Hall J, Theater 3

Sponsored by Sanofi

For in-person participants only

Speakers:
Mohammad Abdelgawwad, MD, PhD, Sanofi

COMPANY SHOWCASES

Company Showcases as of October 14, 2026.

Check the mobile app for an updated list of Company Showcases

Company Showcases are 15-minute presentations that provide an overview of the company's products, services, or mission-based initiatives services for a company, nonprofit organization, or contract/clinical research organization. Sessions are non-CME and solely promotional in nature.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

From Subjectivity to Precision: Hybrid AI-Powered Bone Marrow Smear Analysis in Myelodysplastic Syndrome

Saturday 1:30 p.m. – 1:45 p.m.
Hall J, Theater 5

Sponsored by aetherAI Co., Ltd.

For in-person participants only

Speakers:

Joe Yeh, MD, PhD Candidate, aetherAI Co., Ltd.

Discover the Organization of Cell Surface Proteins to Uncover Mechanisms behind Hematological Disease

Saturday 3:30 p.m. – 3:45 p.m.
Hall J, Theater 5

Sponsored by Pixelgen Technologies

For in-person participants only

Speakers:

Michael Förster, PhD, Pixelgen Technologies

SUNDAY

A New Standard in MRD Assessment: ARUP CLARISPECT™ Supports Highly Sensitive Detection for Rare Residual Malignant Populations

Sunday 4:15 p.m. – 4:30 p.m.
Hall J, Theater 3

Sponsored by ARUP Laboratories

For in-person participants only

Speakers:

Madhu Menon, MD, PhD, FACP, FASCP, ARUP Laboratories

David Ng, MD, FCAP, ARUP Laboratories

AbbVie In Oncology

Sunday 4:15 p.m. – 4:30 p.m.
Hall J, Theater 1

Sponsored by AbbVie

For in-person participants only

Speakers:

Svetlana Kobina, MD, PhD, AbbVie

Eilean Therapeutics. Targeting Escape Mutations in Hematological Cancers with First and Best in Class Medicines

Sunday 4:15 p.m. – 4:30 p.m.
Hall J, Theater 4

Sponsored by Eilean Therapeutics LLC

For in-person participants only

Speakers:

Iain Dukes, DPhil, Eilean Therapeutics LLC

INDUSTRY FORUMS

Industry Forums as of October 14, 2026.

Check the mobile app for an updated list of Industry Forums.

Industry Forums are developed by sponsoring companies with interactive discussions on topics focused on educational resources for the diagnosis and treatment of hematologic diseases, improvements or quality in health care, patient support services and/or treatment resources. Discussions feature various perspectives and roles including health care providers, company representatives, patients, caretakers, and patient advocates. Sessions are non-CME and solely promotional in nature.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

Myth vs Mast Cell: Would You Recognize Systemic Mastocytosis? Patient and Clinician Perspectives on Diagnosis, Disease Burden, and Unmet Need

Saturday 8:00 a.m. – 9:00 a.m.
295-296

Sponsored by Cogent Biosciences

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

This session will include perspectives from patients living with systemic mastocytosis

Speakers:

Jennifer Nicoloro-SantaBarbara, MD, Brigham and Women's Hospital, Harvard Medical School

Lindsay Rein, MD, Duke University

Nathan Boggs, MD, PhD, Uniformed Services University

Navigating PV with MIMRYLO: A Patient-Centered Clinical Conversation

Saturday 8:00 a.m. – 9:00 a.m.
288-290

Sponsored by Takeda

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

This session will include a patient perspective

Speakers:

Ramon Tiu, MD, Takeda

Who Wants to Design a Better Sickle Cell Trial

Saturday 8:00 a.m. – 9:00 a.m.
293-294

Sponsored by Pfizer

For in-person participants only

This session will include a perspective from a patient advocate

Speakers:

Nirmish Shah, MD, Duke University

Onye Ononogbu, PharmD, MPH, BCOP, UT Health Houston

Cassandra Trimnell, Sickle Cell 101

INDUSTRY THEATERS

Industry Theaters as of October 14, 2026.

Check the mobile app for an updated list of Industry Theaters.

Industry Theaters are presentations developed by sponsoring companies that highlight medical devices, medical technology, non-FDA-approved pharmaceutical products, investigational products or devices in pipeline or clinical trial phases, and patient treatment resources. Sessions are non-CME and solely promotional in nature.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SUNDAY

Beyond Bone Marrow: Integrating Circulating Plasma Cell Enumeration and Genomic Profiling into Multiple Myeloma Disease Assessment

Sunday **8:00 a.m. – 9:00 a.m.**
Hall J, Theater 5

Sponsored by Menarini Silicon Biosystems

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Bevan Tandon, MD, Menarini Silicon Biosystems

Zoltan Simandi, Menarini Silicon Biosystems

C. Michael Osborne, MS, CGC, Menarini Silicon Biosystems

When Pediatric Care Ends, What Comes Next for Patients with PROS and Lymphatic Malformations?

Sunday **8:00 a.m. – 9:00 a.m.**
Hall J, Theater 1

Sponsored by Novartis Pharmaceuticals Corporation

For in-person participants only

This session will include perspective from a patient advocate

Speakers:
Jochen Rössler, MD, Novartis Pharmaceuticals Corporation

Nydia Caro, MD, MBA, Novartis Pharmaceuticals Corporation

Lauren Beauregard, CLOVES

MONDAY

Advancing Care in Primary Central Nervous System Lymphoma: Evolving Treatment Approaches

Monday **8:00 a.m. – 9:00 a.m.**
288-290

Sponsored by Deciphera – A Member of ONO Pharma

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Charles Psoinos, MD, MS, MBA, Deciphera – A Member of ONO Pharma

Beyond BCMA: Investigating GPRC5D CAR T Therapy in RRMM

Monday **8:00 a.m. – 9:00 a.m.**
Hall J, Theater 5

Sponsored by Bristol Myers Squibb

For in-person participants only

Speakers:
Jaclyn Davis, MD, Bristol Myers Squibb

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Hemolysis in Sickle Cell Disease (SCD): Connecting Biology, Clinical Outcomes, and the Lived Experience

Monday **8:00 a.m. – 9:00 a.m.**
Hall J, Theater 6

Sponsored by Agios Pharmaceuticals

For in-person participants only

This session will include a perspective from a patient living with sickle cell disease

Speakers:

Sarah Gheuens, MD, PhD, Agios Pharmaceuticals

Mike Callaghan, MD, Agios Pharmaceuticals

Integrated Innovation in Cell Therapy: From Manufacturing to Clinical Development

Monday **8:00 a.m. – 9:00 a.m.**
Hall J, Theater 4

Sponsored by Miltenyi Biomedicine

For in-person participants only

Speakers:

Boris Engels, PhD, Miltenyi Biomedicine

Dirk Redlich, PhD, Miltenyi Biomedicine

Tobias Kampfenkel, MD, MHBS, Miltenyi Biomedicine

Anna Wijatyk, MD, Miltenyi Biomedicine

Building the Evidence: Novo Nordisk's Investigational Clinical Development in Sickle Cell Disease and Thalassemia

Monday **12:15 p.m. – 1:15 p.m.**
Hall J, Theater 6

Sponsored by Novo Nordisk Healthcare AG

For in-person participants only

Speakers:

F. Leila Jerome Clay, MD, MCTS, Novo Nordisk Healthcare AG

Richard Addo, MD, PhD, MBA, Novo Nordisk Healthcare AG

Vinay Babu, MD, Novo Nordisk Healthcare AG

PRODUCT THEATERS

Product Theaters as of October 14, 2026.

Check the mobile app for an updated list of Product Theaters.

Product Theaters feature exhibitor presentations on the clinical benefit or scientific research relating to the development of an approved pharmaceutical product and may include information on new uses, combinations, or therapies for the approved product. Sessions are non-CME and solely promotional in nature.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

SATURDAY

A Therapy for Adults with RRMM After a PI and an Immunomodulatory Agent

Saturday 11:30 a.m. – 12:30 p.m.
Hall J, Theater 1

Sponsored by Johnson & Johnson

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Tonya Le Blanc, PhD, Johnson & Johnson

Discover A New Oral-Based Regimen for First Relapse Myeloma

Saturday 11:30 a.m. – 12:30 p.m.
Hall J, Theater 6

Sponsored by Bristol Myers Squibb

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Brian Engelhardt, MD, MSci, Bristol Myers Squibb

Insights into a RRMM Patient and Care Partner Journey: Clinical Evidence for a BCMA-Directed Therapy

Saturday 11:30 a.m. – 12:30 p.m.
Hall J, Theater 3

Sponsored by Pfizer Inc.

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

This session will include perspectives from a patient and caregiver

Speakers:
David Hughes, PharmD, BCOP, MPH, Pfizer Inc.

The Only BTKi Approved in 1L CLL/SLL and 1L MCL

Saturday 11:30 a.m. – 12:30 p.m.
Hall J, Theater 5

Sponsored by AstraZeneca

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Anthony Mato, MD, AstraZeneca

Understanding Time off Treatment with an All-Oral, Fixed-Duration Regimen: Perspective of a Patient with Previously Untreated CLL

Saturday 11:30 a.m. – 12:30 p.m.
Hall J, Theater 2

Sponsored by AbbVie

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Allison Allan, MSN, AGNP-BC, BSN, RN, AbbVie

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

WAYRILZ Real World Cases & Patient Experience

Saturday **11:30 a.m. – 12:30 p.m.**
Hall J, Theater 4

Sponsored by Sanofi

For in-person participants only

This session will include a patient perspective

Speakers:
Alex Kareotes, MBA, Sanofi
David Farber, PharmD, Sanofi

SUNDAY

Changing the ET Conversation: A New Paradigm in ET Management

Sunday **8:00 a.m. – 9:00 a.m.**
Hall J, Theater 4

Sponsored by PharmaEssentia

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Sam Lin, MBA, MPH, PharmaEssentia
Stephanie Goldbaum, MD, PharmaEssentia

DARZALEX FASPRO® + VRd: A Clinical Foundation from the CEPHEUS and PERSEUS Trials

Sunday **8:00 a.m. – 9:00 a.m.**
291-292

Sponsored by Johnson & Johnson

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Wasiulla Khan, PhD, Johnson & Johnson

Gene Addition Therapy in Sickle Cell Disease: Connecting Clinical Outcomes with the Patient Journey

Sunday **8:00 a.m. – 9:00 a.m.**
Hall J, Theater 3

Sponsored by Genetix Biotherapeutics

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Anjulika Chawla, MD, Genetix Biotherapeutics

Learn About A Frontline Treatment Option in Peripheral T-Cell Lymphoma

Sunday **8:00 a.m. – 9:00 a.m.**
288-290

Sponsored by Pfizer

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speaker:
Richa Shah, PharmD, Pfizer

Let's Talk About Hemophilia Management Today

Sunday **8:00 a.m. – 9:00 a.m.**
Hall J, Theater 2

Sponsored by Novo Nordisk Inc.

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

This session will include a patient perspective

Speakers:
Barbara Mische, Novo Nordisk Inc.
Emily Waters, PhD, Novo Nordisk Inc.
Michael Wessel, Novo Nordisk Inc.

Ph+ CML-CP: A Nilotinib Treatment Option

Sunday **8:00 a.m. – 9:00 a.m.**
Hall J, Theater 6

Sponsored by Azurity Pharmaceuticals, Inc.

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Karen Tumaneng, PhD, Azurity Pharmaceuticals, Inc.

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

A BCMA-Directed Bispecific for the Treatment of Patients with R/R Multiple Myeloma After At Least 4 Prior Lines of Treatment

Sunday **11:30 a.m. – 12:30 p.m.**
Hall J, Theater 1

Sponsored by Regeneron

For in-person participants only

Speakers:
Tito Roccia, MD, Regeneron

Challenging the Status Quo in Thalassemia Management: Hear Patient Perspectives and Discover an Oral Treatment Option from Agios Pharmaceuticals

Sunday **11:30 a.m. – 12:30 p.m.**
Hall J, Theater 4

Sponsored by Agios Pharmaceuticals

For in-person participants only

This session will include perspectives from patients living with thalassemia

Speakers:
Keely Gilroy, PhD, Agios Pharmaceuticals

Lauren Czapla, APN, Agios Pharmaceuticals

First-in-Class Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Sunday **11:30 a.m. – 12:30 p.m.**
Hall J, Theater 5

Sponsored by Johnson & Johnson

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Ibrahim Saber, MD, Johnson & Johnson

From Data to Decisions: Advancing Patient Care in 2L+ Follicular Lymphoma and R/R DLBCL

Sunday **11:30 a.m. – 12:30 p.m.**
Hall J, Theater 6

Sponsored by Incyte

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Peg Squier, MD, PhD, Incyte

Real-World Management of Hemophilia A and B: Clinical Cases with Rebalancing and Factor Replacement Therapies

Sunday **11:30 a.m. – 12:30 p.m.**
Hall J, Theater 3

Sponsored by Sanofi

For in-person participants only

This session will include perspectives from patients living with Hemophilia A and B

Speakers:
Dina Issa, PharmD, Sanofi

See How Jaypirca® (pirtobrutinib) is Sparking More Possibilities

Sunday **11:30 a.m. – 12:30 p.m.**
Hall J, Theater 2

Sponsored by Eli Lilly and Company

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
John Pagel, MD, Eli Lilly and Company

Sarang Abhyankar, MD, MS, Eli Lilly and Company

MONDAY

7-Year Follow-up of the POLARIX Study

Monday **8:00 a.m. – 9:00 a.m.**
Hall J, Theater 3

Sponsored by Genentech

Speakers:
Matthew Sugidono, PharmD, Genentech

HYMPAVZI (marstacimab-hncq): Expanding Possibilities in Hemophilia Management and Case-Based Treatment Considerations

Monday **8:00 a.m. – 9:00 a.m.**
Hall J, Theater 2

Sponsored by Pfizer

This presentation is intended for U.S.-based registered meeting attendees

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

For in-person participants only

Speakers:
Carlos Estevez, MD, Pfizer

Anu Gupta, PharmD, Pfizer

Jennifer Schumacher, PhD, Pfizer

The APP Perspective: Building Confidence with DARZALEX Faspro®

Monday 8:00 a.m. – 9:00 a.m.
291-292

Sponsored by Johnson & Johnson

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Brandon Shank, PharmD, MPH, Johnson & Johnson

Understanding the Evolving Treatment Landscape of Relapsed/Refractory NPM1-mutated AML

Monday 8:00 a.m. – 9:00 a.m.
Hall J, Theater 1

Sponsored by Syndax Pharmaceuticals

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Craig Freyer, PharmD, BCOP, Syndax Pharmaceuticals

Beyond a Single Biomarker: NGS Solutions for Hematologic Malignancies MRD Research

Monday 12:15 p.m. – 1:15 p.m.
Hall J, Theater 4

Sponsored by Thermo Fisher Scientific

For in-person participants only

Speakers:
Sophie Rozenzhak, PhD, Thermo Fisher Scientific

Chris Allen, BSc (Hon), Thermo Fisher Scientific

Expanding Community Therapy Options in Relapsed or Refractory Multiple Myeloma: A BCMA-Targeted Option

Monday 12:15 p.m. – 1:15 p.m.
Hall J, Theater 3

Sponsored by GSK

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

Speakers:
Peter Barth, MD, GSK

Indolent Mastocytosis: Evolving Perspectives on Treatment and Patient Impact

Monday 12:15 p.m. – 1:15 p.m.
Hall J, Theater 5

Sponsored by Blueprint Medicines, a Sanofi Company

This presentation is intended for U.S.-based registered meeting attendees

For in-person participants only

This session will include a patient perspective

Speakers:
Amber King, PharmD, BCOP, Blueprint Medicines, a Sanofi Company

OMISIRGE®: Challenging Conventional Thinking About Time to Transplant and Patient Outcomes in Hematological Conditions with a Novel Cell Therapy Donor Source

Monday 12:15 p.m. – 1:15 p.m.
Hall J, Theater 1

Sponsored by Gamida Cell

This presentation is intended for U.S.-based registered meeting attendees

Speakers:
Ronit Simantov, MD, Gamida Cell

Unlocking the Potential for a Bispecific Antibody in 2L+ FL and 3L+ DLBCL

Monday 12:15 p.m. – 1:15 p.m.
Hall J, Theater 2

Sponsored by Genmab/AbbVie

This presentation is intended for U.S.-based registered meeting attendees
For in-person participants only

Speakers:
Felipe Marques Gonçalves, MD, MBA, Genmab

EXHIBITORS

Participating Exhibitors as of October 15, 2026

Exhibitors

Company Name	Booth Number
AbbVie	1613
Accessia Health	2618
Acrotech Biopharma	2320
Actinium Pharmaceuticals	2932
Adaptive Biotechnologies Corporation	3629
ADC Therapeutics	2529
AdventHealth Research Institute	855
Advocate Health	122
aetherAI	805
Agilent Technologies	306
Agios Pharmaceuticals	929
Alaska Native Medical Center	2517
Allucent	707
Alnylam Pharmaceuticals	2313
American Association for Cancer Research	2413
American Porphyria Foundation	2922
American Society for Transplantation and Cellular Therapy (ASTCT)	2521
American Society of Clinical Oncology (ASCO)	2721
American Society of Hematology (ASH)	1429
American Society of Pediatric Hematology Oncology (ASPHO)	2912
Amgen	3438
Amyloidosis Foundation	2920
Amyloidosis Support Groups	2916
Aplastic Anemia and MDS International Foundation, Inc.	2225
AplusA	2957
Aptitude Health	2516
argenx	2312
Arima Genomics	2959
ARUP Laboratories	2422
Asahi Kasei Therapeutics	2547
Ascentage Pharma	1957
Association for Value-Based Cancer Care	2615

Association of Cancer Care Centers	2620
Association of PAs in Oncology	2825
Astellas Pharma US, Inc.	3512
AstraZeneca	1339
Autolus	2839
Azurity Pharmaceuticals, Inc	3355
Beam Therapeutics	2628
Beckman Coulter Life Sciences	1919
BeOne Medicines USA, Inc.	421
Binaytara	2823
Binding Site, Inc.	2212
Biocytogen	401
Biogen	2934
BioTNS Co., Ltd.	2549
Blood Cancer United	2323
Blue Spark Technologies, Inc.	2419
Bluprint Oncology - Powered by Petauri	823
BostonGene	947
Brand Institute, Inc.	958
Brazilian Association of Hematology, Hemotherapy and Cell Therapy	2821
Bristol Myers Squibb	1313
Cancer Research And Biostatistics (CRAB)	2619
Cardinal Health	1857
Caris Life Sciences	3057
CellCentric, Ltd.	301, 305
Cerba Research	600
Cerus Corporation	2122
Chiesi Global Rare Diseases	348
Children's Health System of Texas	2614
Children's Hospital of Philadelphia	2221
CIBMTR (Center for International Blood & Marrow Transplant Research)	2519
Citius Oncology	3255
City of Hope	3423
Cleveland Clinic Cancer Institute	131
CLL Society	2914
Cogent Biosciences	3812
College of American Pathologists	2716
Conexiant	706
Cooley's Anemia Foundation	2712
CorMedix Therapeutics	2420
Covaris, Inc.	123
CTI	2215

Cure HHT	2715
Current Health	801
Cycle Pharmaceuticals Ltd.	922
Cytek Biosciences Inc.	323
Cytoart, Inc.	151
Daiichi Sankyo	1939
Damora Therapeutics	1157, 1159
DAVA Oncology	2412
Decera Clinical	2123
Deciphera Pharmaceuticals	3731
Dendrite Clinical Systems Ltd.	2646
Diamond Blackfan Anemia Canada	2815
Diamond Blackfan Anemia Foundation Inc.	2813
Doximity	2657
DREN Bio	1154
Eilean Therapeutics	2451
Einstein Hospital Israelita	825
Electra Therapeutics	2357
Eli Lilly and Company	1039
Elsevier	248
EmeritusDX	2759
Emmes	804
Enable Injections	2258
Enliven Therapeutics	557
Eppendorf North America	129
Eurofins Viracor	125
European Hematology Association	422
European School of Haematology (ESH)	2725
Flatiron Health, Inc.	723
Fortrea	2512
Foundation for Sickle Cell Disease Research	2533
Foundation for the Accreditation of Cellular Therapy	2612
Foundation Medicine	2222
Fred Hutchinson Cancer Center	2319
Gamida Cell	2633
GenCART, Inc.	2757
Genentech	439
Genetix Biotherapeutics	3653
Genetron Health	504
Genmab	3229
Genomic Testing Cooperative	3157
Geron Corporation	1929

Gilead and Kite Oncology	729
Global Action Network for Sickle Cell & Other Inherited Blood Disorders	2617
Global Learning Collaborative	204
GSK	1739
Halia Therapeutics	457
Hangzhou Tigermed Consulting Co. LTD	1055
Harvest Integrated Research Organization Corp.	2159
Haymarket Oncology	2219
HCU Network America	2723
HealthTree Foundation	2924
Hospital Information Services for Jehovah's Witnesses	2717
Ichnos Glenmark Innovation	2317
Imaging Endpoints II, LLC	2112
Immunome, Inc.	1059
ImpriMed, Inc.	226
Incyte Corporation	1113
Incyte Corporation, Inc	228
Inizio	2728
Intermountain Health	148
International Myeloma Foundation	2416
International Myeloma Society	2613
Invivoscribe, Inc.	3523
INVIVYD	3753
Ipsen Biopharmaceuticals	3247
IQVIA Biotech	2023
IQVIA Laboratories	2021
Jazz Pharmaceuticals	3429
John Theurer Cancer Center	2015
Johnson & Johnson	2913
Kapadi, Inc.	601
Karius	404
Karyopharm Therapeutics Inc.	939
KCAS Bio	2648
Korean Society of Hematology (KSH)	2722
Kura Oncology	2229
Kyowa Kirin, Inc.	1947
Lee Health	956
Legend Biotech	2329
Lunaphore	700
Machaon Diagnostics, Inc.	604
Manning Family Children's	2718
Mantle Cell Lymphoma Alliance	2820

MaxCyte Inc.	205
McGraw Hill	201
Med Learning Group	1255, 3613
Mednet	405
Medpace Inc.	222
Medscape Oncology & Hematology	3239
Menarini Silicon Biosystems	223
Menarini Stemline	229
Merck	2639
MERIT	800
Mesoblast Inc	955
Miltenyi Biomedicine GmbH	3213
MIMO Biosciences S.L.	1057
Mission Bio	3056
MJH Life Sciences	1757
Moffitt Cancer Center	3623
Mohawk Valley Health System	2650
Moleculin Biotech, Inc	249
myTomorrows	807
Natera	3455
National Blood Clot Alliance	2621
National Comprehensive Cancer Network (NCCN)	2513
NCODA	2714
NeoGenomics	239
nference	2553
NMDP	2518
Northside Hospital	2314
Northwell Health	2624
Novartis	2339
Novo Nordisk Healthcare AG	913
NURIX	3446
Ochsner Health	701
Ohio State's Comprehensive Cancer Center–James Cancer Hospital & Solove Research Institute	2539
OHSU Knight Cancer Institute	2523
Omeros Corporation	1647
Ontada	2059
Open Health	505
OpenEvidence	132
Oracle	2013
Orca Bio	2029
Ossium Health, Inc.	904

Oxford Nanopore Technologies	954
Ozette Technologies, Inc	606
Parexel	2457
Penn Medicine	130
Perceptive Imaging	704
Pfizer	2039
PharmaEssentia Corporation	3739
PharmaNutra SpA (SiderAL)	2629
Pierre Fabre Pharmaceuticals	2847, 2851
Pixelgen Technologies	507
Platelet Disorder Support Association	2623
Precision for Medicine	2018
Predicine	407
Predicta Biosciences	128
Primum Health	300
PSI CRO	2421
Quest Diagnostics	2119
Quetzal Therapeutics	2856
QuidelOrtho	500
Randox Laboratories Ltd	400
Rapid Novor Inc.	605
Rarity Bioscience	616
Recordati Rare Diseases	415, 417
Regeneron	1229
Rigel Pharmaceuticals	613
Roswell Park Comprehensive Cancer Center	2557
RTI Catalyze	2817
Rutgers Cancer Institute/RWJBarnabas Health	1923
Sabrina Memorial Foundation	2814
Sanguina, Inc.	705
Sanofi	2939
Sarah Cannon Research Institute	2316
Sebia	232
Secura Bio Inc.	347
SELLAS Life Sciences Group, Inc.	138
Servier Pharmaceuticals LLC	2733
Shwachman Diamond Syndrome Foundation Inc.	2918
Sickle Cell Disease Association of America, Inc.	2822
Siemens Healthineers	900
Silence Therapeutics	454
Siteman Cancer Center	2625
Sobi VEXAS	146

SOBI, Inc	339
Society of Hematologic Oncology	2525
St. Jude Children's Research Hospital	2824
STEMCELL Technologies	2116
Sumitomo Pharma America	3725
Sutter Health	2216
Syndax Pharmaceuticals, Inc.	3539
Syneos Health	1913
Taiho Oncology Commercial	713
Takeda	739
Team Telomere	2713
Tectonic Therapeutic	2652
Telios Pharma, Inc.	2124
Tempus	2120
Tethis S.p.A.	304
The Blood Project	2616
The Hematology Society of Taiwan	517
The Japanese Society of Hematology	2724
The MDS Foundation, Inc.	2515
Theradex Oncology	657
Therakos LLC	2259
ThermoFisher	1129
Turkish Society of Hematology	2719
UF Health Cancer Institute	2622
United Porphyrias Association	2812
University of Cincinnati Cancer Center	149
UPMC Hillman Cancer Center	200
UT MD Anderson	2857
UVA Health	2818
UVA Health University Physicians Group	2816
Vaniam Group	755
Vertex Pharmaceuticals Inc.	1639
Veterans Health Administration	2819
Waters Biosciences	2351
West Virginia University Medicine	2720
Wolters Kluwer	2551
Worldwide Clinical Trials	2113
Wuhan Kindstar Medical Laboratory Limited Company	2218
X4 Pharmaceuticals	2213
Xspray Pharma AB	2522

FIGHT 4 HEMATOLOGY

ASH® is fighting for hematology in the face of executive orders and other federal actions that threaten research and, ultimately, the care of patients.

1. ADVOCATE

Protect access to care, support research funding, and protect the critical federal health care workforce.



2. SHARE

Share how executive orders and federal cuts have impacted hematology research, patient care, and treatment.



3. AMPLIFY

Use your voice on social media to spread awareness and support for the #Fight4Hematology!



4. DONATE

Contribute to the ASH Foundation to support additional ASH Awards to help ensure that hematologists can continue their vital research without interruption.



Together, we can drive meaningful change!

Learn More
hematology.org/Fight4Hematology

BROWSE BY DISEASE


AS OF 10/24/2026

The ASH annual meeting features sessions on every area of hematology. For attendees focused on a particular disease, we have assembled an index of oral sessions that will cover the chosen disease, listed by date and time. This Index does not represent all available sessions; not every disease is represented here, and not all sessions are disease-specific. Check the virtual meeting platform and the meeting mobile app to search for sessions by the full list of keywords.

DISEASE	PAGE
Bleeding and Clotting	161
Bone Marrow Failure Syndrome	165
Genetic Disorders	167
Hemoglobinopathies	169
Immunology	171
Lymphoid Malignancies	175
Metabolic Disorders	184
Myeloid Malignancies	185

ASH® Self-Assessment Program, Ninth Edition

With 49 chapters and 254 multiple-choice questions, ASH-SAP is designed for self-directed learning and review with case studies containing key points, graphics, animation, and a glossary. Earn up to 45 hours of CME credit and/or ABIM MOC credit through a series of six test modules.



ASH® Q&A Bank

New feature included free of charge with the Ninth Edition

A complimentary self-guided ASH Q&A Bank app that provides more than 300 additional practice questions and multiple practice tests.*

**Contents of the ASH Q&A Bank app are not CME accredited*

Get your copy at ASH Store in ASH Central or online at hematology.org/store

ACCME ACCREDITED

45 CME credits

ABIM CME MOC ACCREDITED

45 ABIM Medical Knowledge Points

BLEEDING AND CLOTTING

Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	B-Cell–Directed Therapies in Immune Thrombocytopenia: Real-World Practice	Satellite Symposia	R06-R09	CME
Friday	3:00–6:00 p.m.	Acknowledging the Rare: Navigating Diagnostic and Therapeutic Complexities in Rare Hematologic Disorders	Satellite Symposia	Hall B	CME
Friday	3:00–6:00 p.m.	Hemophilia at the Crossroads: New Evidence for Individualized Care	Satellite Symposia	Great Hall BC	CME
Friday	3:00–6:00 p.m.	ITP at a Crossroads: Closing Knowledge Gaps in Pathophysiology, Treatment Selection, and Patient-Centered Care	Satellite Symposia	217-219	CME
Friday	3:00–6:00 p.m.	Scientific Workshop on Interplay between Coagulation and Malignancy	Scientific Workshops	295-296	
Saturday	8:00–9:00 a.m.	How I Treat: Heavy Menstrual Bleeding in Women with Bleeding Disorders	How I Treat	Hilton - Canal	CME
Saturday	8:00–9:00 a.m.	How I Treat: Refractory ITP Unresponsive to Steroids and Thrombopoietin Agonists	How I Treat	Hilton - Commerce	CME
Saturday	8:00–9:00 a.m.	aIIbß3: One Receptor, Two Drugs, and the Long Road of Translational Platelet Biology	Meet the Scientist	Hilton - Parish	
Saturday	9:30–11:00 a.m.	311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Bench to Bedside: Practical Applications in ITP	Oral Abstract Session	217-219	
Saturday	9:30–11:00 a.m.	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Refining Risk in Cancer-Associated Thrombosis: From Circulating Biomarkers to Population Outcomes	Oral Abstract Session	208-210	
Saturday	11:30 a.m.–12:30 p.m.	WAYRILZ Real World Cases & Patient Experience	Interact with Industry	Hall J Theater 4	
Saturday	12:00–1:30 p.m.	401. Blood Transfusion: Advancing Transfusion Medicine - From Precision Blood Component Therapy to Blood Substitutes	Oral Abstract Session	220-222	
Saturday	1:30–1:45 p.m.	Advancing Research in Hemophilia A and von Willebrand Disease	Interact with Industry	Hall J Theater 1	
Saturday	1:45–2:00 p.m.	Fitusiran ATLAS-KIDS Clinical Trial	Interact with Industry	Hall J Theater 3	
Saturday	2:00–3:15 p.m.	The Unusual Bleed: Cracking the Code of Platelet and Rare Bleeding Disorders	Education Program	220-222	CME
Saturday	2:00–3:15 p.m.	Lab-Grown Red Blood Cells: From Scalable Manufacturing to Clinical Translation	Scientific Symposia	391-392	CME
Saturday	2:00–3:30 p.m.	331. Thrombotic Microangiopathies/ Thrombocytopenias: Clinical and Epidemiological	Oral Abstract Session	208-210	
Saturday	2:00–3:30 p.m.	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: New Frontiers in Thrombosis: FXI Inhibition, Intervention, and Long-term Outcomes	Oral Abstract Session	217-219	
Saturday	3:30–3:45 p.m.	LUNA 4 - Early Multi-Immune Modulation with Rilzabrutinib in Patients with Primary ITP After First-Line Treatment Failure: A Phase 3b Study	Interact with Industry	Hall J Theater 3	
Saturday	3:45–4:00 p.m.	LUMINA 3 – A Phase 3, Two Arm Study, Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Warm Autoimmune Hemolytic Anemia (wAIHA)	Interact with Industry	Hall J Theater 3	
Saturday	4:00–5:15 p.m.	The Big Clot Problem	Education Program	Hall E	CME
Saturday	4:00–5:15 p.m.	Cutting-Edge Insights into Pro-Thrombotic Anti-Platelet Factor 4-Associated Disorders	Scientific Program	220-222	
Saturday	4:00–5:30 p.m.	322. Hemophilia A and B: Clinical and Epidemiological: Transforming Hemophilia Care: Long-term Outcomes, Treatment Transitions, and Innovation	Oral Abstract Session	208-210	
Saturday	4:00–5:30 p.m.	330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational	Oral Abstract Session	217-219	

Day	Time	Session Title	Program	Location	CME
Sunday	8:00–9:00 a.m.	How I Treat: TTP in the Caplacizumab Era	How I Treat	Hilton - Commerce	CME
Sunday	8:00–9:00 a.m.	Let's Talk About Hemophilia Management Today	Interact with Industry	Hall J Theater 2	
Sunday	9:30–11:00 a.m.	301. Platelets and Megakaryocytes: Basic and Translational: Megakaryocytes and Platelets from Development to Defense	Oral Abstract Session	208-210	
Sunday	9:30–11:00 a.m.	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis and Hemorrhage in Hematologic Malignancy: From CAR T-Cells to Clonal Hematopoiesis	Oral Abstract Session	217-219	
Sunday	9:30–11:00 a.m.	How Clots Form and Fall Apart: From Engineered Vessels to Targeted Therapies	Scientific Program	220-222	
Sunday	11:15 a.m.–12:15 p.m.	ASH Poster Walk on Innovations in Hemostasis and Thrombosis Clinical Research Design Hosted by Blood Vessels, Thrombosis & Hemostasis	ASH Poster Walks	Hall F Blood Journals Studio	
Sunday	11:30 a.m.–12:30 p.m.	Real-World Management of Hemophilia A and B: Clinical Cases with Rebalancing and Factor Replacement Therapies	Interact with Industry	Hall J Theater 3	
Sunday	12:00–1:30 p.m.	321. Coagulation and Fibrinolysis: Basic and Translational: Right Protein, Right Place: Compartmentalized Coagulation in Development, Vasculature, and Organ Injury	Oral Abstract Session	220-222	
Sunday	12:00–1:30 p.m.	322. Hemophilia A and B: Clinical and Epidemiological: Precision Hemophilia Care: Bleeding Prediction and Overcoming Inhibitors	Oral Abstract Session	217-219	
Sunday	12:00–1:30 p.m.	901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Decoding Cytopenias	Oral Abstract Session	208-210	
Sunday	4:30–5:45 p.m.	From Mutations to Manifestations: Connecting Clonal Hematopoiesis (CH) and Thrombosis	Education Program	208-210	
Sunday	4:30–5:45 p.m.	Built to Clot, Built to Break: Structural Control of Hemostasis and Fibrinolysis	Scientific Program	220-222	CME
Sunday	4:30–5:45 p.m.	Rethinking Antiplatelet Strategies: Selective Blockade, Broad-Acting Drugs, and Beyond	Scientific Program	217-219	
Sunday	4:30–5:45 p.m.	Sticky Situations: Glycans in Classical and Malignant Hematopoiesis	Scientific Spotlight Sessions	288-290	CME
Sunday	4:30–6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: From Iron to Immunity: Real-World Outcomes in Classical Hematology	Oral Abstract Session	252-254	
Monday	10:00–10:15 a.m.	Closing the Evidence Gap in Hemophilia: Marstacimab Phase 3 Clinical Trial in Mild to Moderate Hemophilia and the MARVL-US Real-World Study	Interact with Industry	Hall J Theater 5	
Monday	10:00–10:15 a.m.	Sutimlimab in Adults With Chronic ITP: An Upcoming Phase 3 Clinical Trial	Interact with Industry	Hall J Theater 1	
Monday	10:15–10:30 a.m.	LIBRA – A Randomized Placebo-Controlled Study Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Sickle-Cell Disease (SCD)	Interact with Industry	Hall J Theater 3	
Monday	10:30–11:45 a.m.	Advances in Management of Vascular Anomalies	Education Program	220-222	CME
Monday	10:30–11:45 a.m.	Splenectomy in Membrane Disorders and Enzymopathies: Who, When and How?	Education Spotlight Sessions	391-392	CME
Monday	10:30–11:45 a.m.	Unlocking Blood Disorders: Targeting Genetics to Identify Early Phenotypes	Scientific Program	208-210	
Monday	10:30 a.m.–12:00 p.m.	201. Granulocytes, Monocytes, and Macrophages: Decoding Neutrophil and Macrophage Biology: Novel Insights into Congenital Neutropenia Defects, Inflammation, and Leukemia Immunology	Oral Abstract Session	291-292	
Monday	10:30 a.m.–12:00 p.m.	311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Reshaping the Research Frontier in ITP: Targeted Therapeutics and Validation of the ITP Diagnosis	Oral Abstract Session	217-219	
Monday	2:45–4:00 p.m.	Balancing Bleeding and Clotting: Extended VTE Treatment for Whom and at What Dose?	Education Spotlight Sessions	208-210	CME


All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Day	Time	Session Title	Program	Location	CME
Monday	2:45–4:15 p.m.	203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Immune Dysregulation and Clinical Translation	Oral Abstract Session	R06-R09	
Monday	2:45–4:15 p.m.	311. Disorders of Platelet Number or Function: Clinical and Epidemiological: New Therapeutics in ITP and Chemotherapy-Induced Thrombocytopenia	Oral Abstract Session	217-219	
Monday	2:45–4:15 p.m.	323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological	Oral Abstract Session	220-222	
Monday	2:45–4:15 p.m.	801. Gene Therapies: Beyond Transplant: The Expanding Role of Gene Therapy in Hematology	Oral Abstract Session	388-390	
Monday	2:45–4:15 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: AI at the Bedside: From Prediction to Therapeutic Decisions	Oral Abstract Session	393-396	
Monday	2:45–4:15 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: H and T on the Rocks: Real-World Hemostasis and Thrombosis	Oral Abstract Session	252-254	
Monday	4:30–6:00 p.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: ET and PV: Moving Beyond Conventional Therapy	Oral Abstract Session	Hall C	
Monday	4:30–6:00 p.m.	901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: A World of Bleeding and Clotting	Oral Abstract Session	217-219	
Monday	4:30–6:00 p.m.	904. Outcomes Research: Hemoglobinopathies: Therapeutic Innovation and Clinical Outcomes in Hemoglobinopathies	Oral Abstract Session	252-254	
Monday	4:30–6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Platelets in Practice: Outcomes Across ITP, TTP, and TMA	Oral Abstract Session	243-245	
Monday	4:30–6:00 p.m.	Special Symposium on the Basic Science of Hemostasis and Thrombosis (SSBSHT)	Scientific Symposia	208-210	CME
Monday	2:45–4:15 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Antithrombotic Roulette: Balancing Risk, Cost, and Care	Oral Abstract Session	W304ABCD	
Monday	4:30–6:00 p.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Drivers and Mast Cells and Blasts, Oh My! - Insights and Treatments for MPNs and Mastocytosis.	Oral Abstract Session	West Hall D2	
Monday	4:30–6:00 p.m.	801. Gene Therapies: Technological Developments in Gene Therapy	Oral Abstract Session	Sunburst Room (W340)	
Monday	4:30–6:00 p.m.	901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Risk Assessment, and Care Optimization, and AI, Oh my! The Spectrum of Quality in Classical Hematology	Oral Abstract Session	W308	
Monday	4:30–6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Bleeding, Barriers, and Bridging the Gaps	Oral Abstract Session	W307	
Monday	4:30–6:00 p.m.	Special Symposium on the Basic Science in Hemostasis and Thrombosis	Scientific Program	Valencia Room W415D	

Hematology 2026

The Hematology 2026 Education Program is Available Now

EARN UP TO **88** CME/MOC CREDITS



FREE digital access for ASH Members and Annual Meeting attendees!

Purchase print edition now at the ASH Store: hematology.org/store

ACCME ACCREDITED

ABIM CME MOC ACCREDITED

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ASH designates this journal-based CME activity for a maximum of 88 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Visit **ashpublications.org/hematology** to learn more

BONE MARROW FAILURE SYNDROME

Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	From Controversies to Consensus in Paroxysmal Nocturnal Hemoglobinuria: Developing IPIG Guidelines	Satellite Symposia	R02-R05	CME
Friday	7:00–10:00 a.m.	MDS in Practice: Navigating Complex Decisions Across the Disease Spectrum	Satellite Symposia	208-210	CME
Friday	3:00–6:00 p.m.	Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure	Scientific Workshops	278-282	
Friday	7:00–10:00 p.m.	Cases and Conversations: Endothelial Injury, Complement, and TA-TMA After Allogeneic Stem Cell Transplant	Satellite Symposia	La Nouvelle C	CME
Saturday	9:30–11:00 a.m.	508. Bone Marrow Failure: Acquired: The Science Behind the Clinic	Oral Abstract Session	295-296	
Saturday	4:00–5:30 p.m.	101. Red Cells and Erythropoiesis, Excluding Iron: Internal and External Drivers of Erythroid Development	Oral Abstract Session	291-292	
Saturday	4:00–5:30 p.m.	508. Bone Marrow Failure: Acquired: Clinical Data on PNH and SAA Therapeutics	Oral Abstract Session	295-296	
Sunday	8:00–9:00 a.m.	From Ribosomes to Risk Stratification: Decoding Inherited Bone Marrow Failure and Its Path to Leukemia	Meet the Scientist	Hilton - Magazine	CME
Sunday	9:30–10:45 a.m.	Through Space and Time: Spatiotemporal Organization of Haematopoiesis in Health and Disease	Scientific Program	295-296	CME
Sunday	9:30–11:00 a.m.	503. Clonal Hematopoiesis, Aging, and Inflammation: Forces Shaping Clonal Selection	Oral Abstract Session	291-292	
Sunday	9:30–11:00 a.m.	637. Myelodysplastic Syndromes: Clinical and Epidemiological: Novel Targeted Agents and Combination Regimens in CMML, MDS, and MDS/MPN Overlap Neoplasms: Emerging Clinical Trial Data	Oral Abstract Session	Hall C	
Sunday	12:00–1:30 p.m.	101. Red Cells and Erythropoiesis, Excluding Iron: Programming Erythropoiesis: From Chromatin Architecture to Red Cell Fate	Oral Abstract Session	291-292	
Sunday	12:00–1:30 p.m.	509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Mechanistic Insights and Therapeutic Strategies	Oral Abstract Session	295-296	
Sunday	12:00–1:30 p.m.	901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Decoding Cytopenias	Oral Abstract Session	208-210	
Sunday	4:30–5:45 p.m.	Are We There Yet? Improving Outcomes in MDS	Education Program	R02-R05	CME
Sunday	4:30–5:45 p.m.	Understanding and Targeting Metabolism in Erythrocyte Development and Disorders	Scientific Program	291-292	CME
Monday	10:30–11:45 a.m.	Unlocking Blood Disorders: Targeting Genetics to Identify Early Phenotypes	Scientific Program	208-210	
Monday	10:30 a.m.–12:00 p.m.	637. Myelodysplastic Syndromes: Clinical and Epidemiological	Oral Abstract Session	Great Hall AD	
Monday	10:30 a.m.–12:00 p.m.	702. CAR T-cell Therapies: Basic and Translational: Engineering CAR-T Cell Fitness, Persistence, and Safety	Oral Abstract Session	353-355	
Monday	12:15–1:15 p.m.	OMISIRGE®: Challenging Conventional Thinking About Time To Transplant And Patient Outcomes In Hematological Conditions With A Novel Cell Therapy Donor Source	Interact with Industry	Hall J Theater 1	
Monday	2:45–4:15 p.m.	723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence	Oral Abstract Session	353-355	
Monday	4:30–5:45 p.m.	Neutropenia: Updates in Diagnosis, Treatment, and Supportive Care.	Education Program	275-277	CME

Day	Time	Session Title	Program	Location	CME
Monday	4:30–5:45 p.m.	The Great Escape- Immune Evasions in Bone Marrow Failure	Scientific Program	295-296	CME
Monday	4:30–6:00 p.m.	903. Health Services and Quality Improvement: Myeloid Malignancies: JAKPOT! Improving Care Quality from Pre-hab, Sleep, and Home Transfusions to Pall-care, Costs, and JAK Testing	Oral Abstract Session	R02-R05	

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

GENETIC DISORDERS

Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	A Hematologist's Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond	Satellite Symposia	Hall C	CME
Saturday	8:00–9:00 a.m.	How I Treat: Heavy Menstrual Bleeding in Women with Bleeding Disorders	How I Treat	Hilton - Canal	CME
Saturday	8:00–9:00 a.m.	aIIbß3: One Receptor, Two Drugs, and the Long Road of Translational Platelet Biology	Meet the Scientist	Hilton - Parish	
Saturday	9:30–11:00 a.m.	508. Bone Marrow Failure: Acquired: The Science Behind the Clinic	Oral Abstract Session	295-296	
Saturday	9:30–11:00 a.m.	603. Lymphoid Oncogenesis: Basic: Epigenetic and Transcriptional Deregulation	Oral Abstract Session	275-277	
Saturday	2:00–3:15 p.m.	The Unusual Bleed: Cracking the Code of Platelet and Rare Bleeding Disorders	Education Program	220-222	CME
Saturday	2:00–3:15 p.m.	Lab-Grown Red Blood Cells: From Scalable Manufacturing to Clinical Translation	Scientific Symposia	391-392	CME
Saturday	2:00–3:30 p.m.	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: The Tip of the Iceberg - How Do We Spot and Stop Organ Damage in Sickle Cell Disease?	Oral Abstract Session	243-245	
Saturday	4:00–5:30 p.m.	101. Red Cells and Erythropoiesis, Excluding Iron: Internal and External Drivers of Erythroid Development	Oral Abstract Session	291-292	
Saturday	4:00–5:30 p.m.	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological - Therapeutics	Oral Abstract Session	243-245	
Saturday	4:00–5:30 p.m.	322. Hemophilia A and B: Clinical and Epidemiological: Transforming Hemophilia Care: Long-term Outcomes, Treatment Transitions, and Innovation	Oral Abstract Session	208-210	
Saturday	4:00–5:30 p.m.	602. Myeloid Oncogenesis: Basic: Transcriptional and Epigenetic Dependencies	Oral Abstract Session	R02-R05	
Sunday	8:00–9:00 a.m.	Gene Addition Therapy in Sickle Cell Disease: Connecting Clinical Outcomes With the Patient Journey	Interact with Industry	Hall J Theater 3	
Sunday	8:00–9:00 a.m.	When Pediatric Care Ends, What Comes Next for Patients With PROS and Lymphatic Malformations?	Interact with Industry	Hall J Theater 1	
Sunday	9:30–11:00 a.m.	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advancing Sickle Cell Disease Care on All Fronts	Oral Abstract Session	252-254	
Sunday	9:30–11:00 a.m.	503. Clonal Hematopoiesis, Aging, and Inflammation: Forces Shaping Clonal Selection	Oral Abstract Session	291-292	
Sunday	9:30–11:00 a.m.	900. Health Services and Quality Improvement: Hemoglobinopathies: Improving How Sickle Cell Care is Organized, Implemented, and Delivered Across Healthcare Settings	Oral Abstract Session	243-245	
Sunday	12:00–1:30 p.m.	101. Red Cells and Erythropoiesis, Excluding Iron: Programming Erythropoiesis: From Chromatin Architecture to Red Cell Fate	Oral Abstract Session	291-292	
Sunday	12:00–1:30 p.m.	321. Coagulation and Fibrinolysis: Basic and Translational: Right Protein, Right Place: Compartmentalized Coagulation in Development, Vasculature, and Organ Injury	Oral Abstract Session	220-222	
Sunday	12:00–1:30 p.m.	509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Mechanistic Insights and Therapeutic Strategies	Oral Abstract Session	295-296	

Day	Time	Session Title	Program	Location	CME
Sunday	4:30–5:45 p.m.	Hemolysis Beyond Globin: Managing Inherited RBC Membrane and Enzyme Disorders	Education Program	275-277	CME
Sunday	4:30–5:45 p.m.	Understanding and Targeting Metabolism in Erythrocyte Development and Disorders	Scientific Program	291-292	CME
Monday	8:00–9:00 a.m.	HYMPAVZI (marstacimab-hncq): Expanding Possibilities in Hemophilia Management and Case-Based Treatment Considerations	Interact with Industry	Hall J Theater 2	
Monday	10:00–10:15 a.m.	Closing the Evidence Gap in Hemophilia: Marstacimab Phase 3 Clinical Trial in Mild to Moderate Hemophilia and the MARVL-US Real-World Study	Interact with Industry	Hall J Theater 5	
Monday	10:00–10:15 a.m.	Phase 2 and 3 Placebo-Controlled and Long-Term Extension Study of Rilzabrutinib in Adults with iCVID to Evaluate Efficacy, Safety, and Tolerability	Interact with Industry	Hall J Theater 3	
Monday	10:15–10:30 a.m.	LIBRA – A Randomized Placebo-Controlled Study Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Sickle-Cell Disease (SCD)	Interact with Industry	Hall J Theater 3	
Monday	10:30–11:45 a.m.	Advances in Management of Vascular Anomalies	Education Program	220-222	CME
Monday	10:30–11:45 a.m.	Splenectomy in Membrane Disorders and Enzymopathies: Who, When and How?	Education Spotlight Sessions	391-392	CME
Monday	10:30–11:45 a.m.	Unlocking Blood Disorders: Targeting Genetics to Identify Early Phenotypes	Scientific Program	208-210	
Monday	10:30 a.m.–12:00 p.m.	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: End-organ Dysfunction in Sickle Cell Disease: From Risk Prediction to Therapeutic Innovation	Oral Abstract Session	252-254	
Monday	10:30 a.m.–12:00 p.m.	201. Granulocytes, Monocytes, and Macrophages: Decoding Neutrophil and Macrophage Biology: Novel Insights into Congenital Neutropenia Defects, Inflammation, and Leukemia Immunology	Oral Abstract Session	291-292	
Monday	2:45–4:15 p.m.	102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Iron at the Crossroads: Physiology, Pathology, Including Pregnancy	Oral Abstract Session	291-292	
Monday	2:45–4:15 p.m.	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Red Cell Rescue: Novel Approaches in Sickle Cell Disease	Oral Abstract Session	243-245	
Monday	2:45–4:15 p.m.	323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological	Oral Abstract Session	220-222	
Monday	2:45–4:15 p.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Molecular Insights and New Approaches in MPNs	Oral Abstract Session	Hall B	
Monday	2:45–4:15 p.m.	801. Gene Therapies: Beyond Transplant: The Expanding Role of Gene Therapy in Hematology	Oral Abstract Session	388-390	
Monday	4:30–5:45 p.m.	Don't Miss It! Methemoglobinemia: Inherited and Acquired	Education Program	293-294	CME
Monday	4:30–6:00 p.m.	101. Red Cells and Erythropoiesis, Excluding Iron: How to Make a Red Cell: Remodeling, Enucleation, Signaling, and Resilience	Oral Abstract Session	291-292	
Monday	4:30–6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Platelets in Practice: Outcomes Across ITP, TTP, and TMA	Oral Abstract Session	243-245	
Monday	4:30–6:00 p.m.	Special Symposium on the Basic Science of Hemostasis and Thrombosis (SSBSHT)	Scientific Symposia	208-210	CME
Tuesday	9:45–11:15 a.m.	Presidential Symposium	Marquee Sessions	Hall E	

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

HEMOGLOBINOPATHIES

Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	A Hematologist's Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond	Satellite Symposia	Hall C	CME
Friday	3:00–6:00 p.m.	Scientific Workshop on Mechanism-Driven Biomarkers in Sickle Cell Disease	Scientific Workshops	293-294	
Saturday	8:00–9:00 a.m.	Who Wants to Design a Better Sickle Cell Trial	Interact with Industry	293-294	
Saturday	9:30–11:00 a.m.	112. Thalassemia and Globin Gene Regulation: Advances Across the Thalassemia Spectrum: Novel Targets and Therapeutics	Oral Abstract Session	243-245	
Saturday	9:30–11:00 a.m.	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological - Natural history	Oral Abstract Session	252-254	
Saturday	11:15 a.m.–12:15 p.m.	Career Development Lunch	Trainee Activities and Services	Hilton - St. Charles Ballroom	
Saturday	12:00–1:30 p.m.	401. Blood Transfusion: Advancing Transfusion Medicine - From Precision Blood Component Therapy to Blood Substitutes	Oral Abstract Session	220-222	
Saturday	12:00–1:30 p.m.	904. Outcomes Research: Hemoglobinopathies: Health Systems, Care Delivery, and Real-World Outcomes in Sickle Cell Disease	Oral Abstract Session	243-245	
Saturday	2:00–3:15 p.m.	Lab-Grown Red Blood Cells: From Scalable Manufacturing to Clinical Translation	Scientific Symposia	391-392	CME
Saturday	2:00–3:30 p.m.	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: The Tip of the Iceberg - How Do We Spot and Stop Organ Damage in Sickle Cell Disease?	Oral Abstract Session	243-245	
Saturday	2:00–3:30 p.m.	900. Health Services and Quality Improvement: Hemoglobinopathies - Emerging Clinical, Treatment, and Health Services Considerations Across Different Stages of Sickle Cell Care	Oral Abstract Session	252-254	
Saturday	4:00–5:15 p.m.	Longer Lives, New Challenges: Managing Thalassemia in 2026	Education Program	252-254	CME
Saturday	4:00–5:30 p.m.	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological - Therapeutics	Oral Abstract Session	243-245	
Saturday	4:00–5:30 p.m.	711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations from Bench to Bedside	Oral Abstract Session	391-392	
Sunday	9:30–11:00 a.m.	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advancing Sickle Cell Disease Care on All Fronts	Oral Abstract Session	252-254	
Sunday	9:30–11:00 a.m.	900. Health Services and Quality Improvement: Hemoglobinopathies: Improving How Sickle Cell Care is Organized, Implemented, and Delivered Across Healthcare Settings	Oral Abstract Session	243-245	
Sunday	9:30–11:00 a.m.	How Clots Form and Fall Apart: From Engineered Vessels to Targeted Therapies	Scientific Program	220-222	
Sunday	12:00–1:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Hemoglobinopathies, Fungus, and Deceased Donor HPCs, Oh My!	Oral Abstract Session	243-245	
Sunday	12:00–1:30 p.m.	909. Medical Education and Workforce Development: Shaping the Future: From AI to Wellbeing and the Hematology Workforce	Oral Abstract Session	293-294	
Sunday	4:15–4:30 p.m.	Evaluating Osivelotor in Sickle Cell Disease: The Phase 3 DREAM Trial	Interact with Industry	Hall J Theater 5	
Sunday	4:30–5:45 p.m.	Hemolysis Beyond Globin: Managing Inherited RBC Membrane and Enzyme Disorders	Education Program	275-277	CME

Day	Time	Session Title	Program	Location	CME
Sunday	4:30–5:45 p.m.	Tailored Transfusion Strategies for Alloimmunized Patients	Education Program	353-355	CME
Sunday	4:30–5:45 p.m.	Understanding and Targeting Metabolism in Erythrocyte Development and Disorders	Scientific Program	291-292	CME
Sunday	4:30–6:00 p.m.	Real-World Data Applications in Sickle Cell Disease Trial Design	Special-Interest Sessions	243-245	
Monday	8:00–9:00 a.m.	ASH Poster Walk on Beyond Acute Vaso-Occlusion: Emerging Mechanisms and Phenotypes of Chronic Pain in Sickle Cell Disease Hosted by Blood Red Cells & Iron	ASH Poster Walks	Hall F Blood Journals Studio	
Monday	10:15–10:30 a.m.	LIBRA – A Randomized Placebo-Controlled Study Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Sickle-Cell Disease (SCD)	Interact with Industry	Hall J Theater 3	
Monday	10:30–11:45 a.m.	The Heart and Brain in Older Patients with Sickle Cell Disease	Education Program	243-245	
Monday	10:30–11:45 a.m.	Public Health & Hematology: Results and Lessons from the PEN-Plus Model of Care for Severe, Chronic Non-Communicable Diseases like Sickle Cell Disease in Resource-Poor Areas	Education Spotlight Sessions	295-296	CME
Monday	10:30–11:45 a.m.	Splenectomy in Membrane Disorders and Enzymopathies: Who, When and How?	Education Spotlight Sessions	391-392	CME
Monday	10:30 a.m.–12:00 p.m.	114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: End-organ Dysfunction in Sickle Cell Disease: From Risk Prediction to Therapeutic Innovation	Oral Abstract Session	252-254	
Monday	12:15–1:15 p.m.	Building the Evidence: Novo Nordisk's Investigational Clinical Development in Sickle Cell Disease and Thalassemia	Interact with Industry	Hall J Theater 6	
Monday	2:45–4:00 p.m.	Improving Care of Patients with Sickle Cell Disease via Complement, Pain Control, and Trial Design	Education Program	Hall E	CME
Monday	2:45–4:15 p.m.	102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Iron at the Crossroads: Physiology, Pathology, Including Pregnancy	Oral Abstract Session	291-292	
Monday	2:45–4:15 p.m.	113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Red Cell Rescue: Novel Approaches in Sickle Cell Disease	Oral Abstract Session	243-245	
Monday	2:45–4:15 p.m.	626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: From Trials to Reality: Real-World Evidence in Large B-cell Lymphoma	Oral Abstract Session	New Orleans Theatre C	
Monday	2:45–4:15 p.m.	801. Gene Therapies: Beyond Transplant: The Expanding Role of Gene Therapy in Hematology	Oral Abstract Session	388-390	
Monday	2:45–4:15 p.m.	The Predicament of Patients in Prison: A Hematology Perspective	Special-Interest Sessions	295-296	CME
Monday	4:30–5:45 p.m.	Don't Miss It! Methemoglobinemia: Inherited and Acquired	Education Program	293-294	CME
Monday	4:30–5:45 p.m.	Iron Homeostasis Across the Lifespan in Health and Disease	Scientific Program	288-290	CME
Monday	4:30–6:00 p.m.	904. Outcomes Research: Hemoglobinopathies: Therapeutic Innovation and Clinical Outcomes in Hemoglobinopathies	Oral Abstract Session	252-254	
Monday	4:30–6:00 p.m.	The Future of Clinical Endpoints in Sickle Cell Disease	Special-Interest Sessions	220-222	

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

IMMUNOLOGY

Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	B-Cell–Directed Therapies in Immune Thrombocytopenia: Real-World Practice	Satellite Symposia	R06-R09	CME
Friday	11:00 a.m.–2:00 p.m.	Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease	Satellite Symposia	265-268	CME
Friday	3:00–6:00 p.m.	ITP at a Crossroads: Closing Knowledge Gaps in Pathophysiology, Treatment Selection, and Patient-Centered Care	Satellite Symposia	217-219	CME
Friday	7:00–10:00 p.m.	Addressing Community Oncologists' Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies in Multiple Myeloma – What Clinicians Want To Know	Satellite Symposia	Sheraton - Napoleon Ballroom CD	CME
Saturday	9:30–11:00 a.m.	201. Granulocytes, Monocytes, and Macrophages: Novel Therapeutic Targets in Histiocytosis and Hyperinflammation	Oral Abstract Session	291-292	
Saturday	9:30–11:00 a.m.	311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Bench to Bedside: Practical Applications in ITP	Oral Abstract Session	217-219	
Saturday	9:30–11:00 a.m.	508. Bone Marrow Failure: Acquired: The Science Behind the Clinic	Oral Abstract Session	295-296	
Saturday	9:30–11:00 a.m.	701. Experimental Transplantation: Basic and Translational: Emerging Biology to Translational Innovation II	Oral Abstract Session	353-355	
Saturday	9:30–11:00 a.m.	702. CAR-T Cell Therapies: Basic and Translational	Oral Abstract Session	343-345	
Saturday	9:30–11:00 a.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Beyond Efficacy - Quality of Life, Patient Reported Outcomes and Social Determinants of Health	Oral Abstract Session	271-273	
Saturday	11:30 a.m.–12:30 p.m.	WAYRILZ (rilzabrutinib) Real World Cases & Patient Experience	Interact with Industry	Hall J Theater 4	
Saturday	2:00–3:15 p.m.	In Vivo Gene Modification Approaches for Classical and Malignant Hematologic Disorders	Scientific Symposia	275-277	
Saturday	2:00–3:15 p.m.	Lab-Grown Red Blood Cells: From Scalable Manufacturing to Clinical Translation	Scientific Symposia	391-392	CME
Saturday	2:00–3:15 p.m.	Single-Cell and Spatial Genomics Redefining the Immune Cell Landscape in AML/MDS	Scientific Symposia	288-290	CME
Saturday	2:00–3:30 p.m.	501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Mechanisms in Hematopoietic Stem Cell Regulation, Development, and Regeneration	Oral Abstract Session	291-292	
Saturday	2:00–3:30 p.m.	703. Cellular Immunotherapies Other Than CAR-T Cells: Basic and Translational: Expanding the Garage: Advancements in Non-T Cell CAR Platforms and Optimization Strategies	Oral Abstract Session	353-355	
Saturday	3:30–3:45 p.m.	Discover the Organization of Cell Surface Proteins to Uncover Mechanisms Behind Hematological Disease	Interact with Industry	Hall J Theater 5	
Saturday	3:30–3:45 p.m.	LUNA 4 - Early Multi-Immune Modulation with Rilzabrutinib in Patients with Primary ITP After First-Line Treatment Failure: A Phase 3b Study	Interact with Industry	Hall J Theater 3	
Saturday	3:45–4:00 p.m.	LUMINA 3 – A Phase 3, Two Arm Study, Assessing Efficacy, and Safety of Rilzabrutinib in Participants with Warm Autoimmune Hemolytic Anemia (wAIHA)	Interact with Industry	Hall J Theater 3	
Saturday	4:00–5:15 p.m.	Cutting-Edge Insights into Pro-Thrombotic Anti-Platelet Factor 4-Associated Disorders	Scientific Program	220-222	
Saturday	4:00–5:15 p.m.	T Resident Memory Cells (Trm) in Health, Disease, and Therapeutics	Scientific Program	275-277	CME

Day	Time	Session Title	Program	Location	CME
Saturday	4:00–5:30 p.m.	330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational	Oral Abstract Session	217-219	
Saturday	4:00–5:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: HCT Under Stress: Acute Toxicities and Organ Injury	Oral Abstract Session	388-390	
Sunday	8:00–9:00 a.m.	Engineering Tolerance: CAR-Tregs and the New Era of Cell Therapy for Autoimmunity	Meet the Scientist	Hilton - Fulton	CME
Sunday	9:30–10:45 a.m.	Power Sharing: Transplantation and Cellular Therapy in Autoimmunity	Scientific Program	Hall E	
Sunday	9:30–10:45 a.m.	Through Space and Time: Spatiotemporal Organization of Haematopoiesis in Health and Disease	Scientific Program	295-296	CME
Sunday	9:30–10:45 a.m.	Designing Microbiome-Directed Interventional Trials in Hematologic Malignancies	Scientific Symposia	288-290	CME
Sunday	9:30–11:00 a.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Advances in GVHD Prophylaxis and Immune Reconstitution after Allogeneic HCT	Oral Abstract Session	388-390	
Sunday	9:30–11:00 a.m.	723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Predicting and Preventing Post-transplant Relapse and GvHD: Minimal Residual Disease, Immune Dynamics, and Biomarkers	Oral Abstract Session	353-355	
Sunday	12:00–1:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Hemoglobinopathies, Fungus, and Deceased Donor HPCs, Oh My!	Oral Abstract Session	243-245	
Sunday	12:00–1:30 p.m.	901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Decoding Cytopenias	Oral Abstract Session	208-210	
Sunday	12:30–1:30 p.m.	ASH-EHA Joint Symposium: Novel Approaches to Cell Engineering in Hematopoietic Cell Transplantation	Marquee Sessions	Hall E	CME
Sunday	4:30–5:45 p.m.	A New Treatment Paradigm for Follicular Lymphoma	Education Program	New Orleans Theatre A	CME
Sunday	4:30–5:45 p.m.	Driving CARs Safely- Preventing and Managing Intermediate and Long-Term CAR-T Toxicity	Education Program	New Orleans Theatre C	
Sunday	4:30–5:45 p.m.	Hemolysis Beyond Globin: Managing Inherited RBC Membrane and Enzyme Disorders	Education Program	275-277	CME
Sunday	4:30–5:45 p.m.	Tailored Transfusion Strategies for Alloimmunized Patients	Education Program	353-355	CME
Sunday	4:30–5:45 p.m.	Built to Clot, Built to Break: Structural Control of Hemostasis and Fibrinolysis	Scientific Program	220-222	CME
Sunday	4:30–5:45 p.m.	Decoding Macrophage Diversity in Lymphomas: Spatial Insights and Immunotherapeutic Implications	Scientific Spotlight Sessions	271-273	CME
Sunday	4:30–5:45 p.m.	Sticky Situations: Glycans in Classical and Malignant Hematopoiesis	Scientific Spotlight Sessions	288-290	CME
Sunday	4:30–6:00 p.m.	701. Experimental Transplantation: Basic and Translational: Emerging Biology to Translational Innovation I	Oral Abstract Session	343-345	
Sunday	4:30–6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: From Iron to Immunity: Real-World Outcomes in Classical Hematology	Oral Abstract Session	252-254	
Monday	8:00–9:00 a.m.	Integrated Innovation in Cell Therapy: From Manufacturing to Clinical Development	Interact with Industry	Hall J Theater 4	
Monday	10:00–10:15 a.m.	Phase 2 and 3 Placebo-Controlled and Long-Term Extension Study of Rilzabrutinib in Adults with iCVID to Evaluate Efficacy, Safety, and Tolerability	Interact with Industry	Hall J Theater 3	

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Day	Time	Session Title	Program	Location	CME
Monday	10:30–11:45 a.m.	Rebooting the Immune System with Cellular Therapies	Education Spotlight Sessions	275-277	CME
Monday	10:30–11:45 a.m.	Splenectomy in Membrane Disorders and Enzymopathies: Who, When and How?	Education Spotlight Sessions	391-392	CME
Monday	10:30 a.m.–12:00 p.m.	201. Granulocytes, Monocytes, and Macrophages: Decoding Neutrophil and Macrophage Biology: Novel Insights into Congenital Neutropenia Defects, Inflammation, and Leukemia Immunology	Oral Abstract Session	291-292	
Monday	10:30 a.m.–12:00 p.m.	311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Reshaping the Research Frontier in ITP: Targeted Therapeutics and Validation of the ITP Diagnosis	Oral Abstract Session	217-219	
Monday	10:30 a.m.–12:00 p.m.	626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials	Oral Abstract Session	New Orleans Theatre C	
Monday	10:30 a.m.–12:00 p.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution	Oral Abstract Session	388-390	
Monday	2:45–4:00 p.m.	Balancing the Blood: Immune Control of Stem Cell Fidelity	Scientific Program	275-277	CME
Monday	2:45–4:15 p.m.	203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Immune Dysregulation and Clinical Translation	Oral Abstract Session	R06-R09	
Monday	4:30–5:45 p.m.	A Decade of Progress Towards Safer and More Broadly Applicable Allogeneic Stem Cell Transplantation	Education Program	343-345	CME
Monday	4:30–5:45 p.m.	Neutropenia: Updates in Diagnosis, Treatment, and Supportive Care.	Education Program	275-277	CME
Monday	4:30–5:45 p.m.	The Great Escape- Immune Evasions in Bone Marrow Failure	Scientific Program	295-296	CME
Monday	4:30–6:00 p.m.	203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: T and NK Cell Development and Anti-Tumor Functions	Oral Abstract Session	R06-R09	
Monday	4:30–6:00 p.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prophylaxis-Clinical and Translational Aspects	Oral Abstract Session	353-355	
Monday	4:30–6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Platelets in Practice: Outcomes Across ITP, TTP, and TMA	Oral Abstract Session	243-245	
Tuesday	9:45–11:15 a.m.	Presidential Symposium	Marquee Sessions	Hall E	

A LEGACY OF LEADERSHIP!

Celebrating Dr. Mohandas Narla for 50 Years of ASH annual meeting attendance!



Dr. Mohandas Narla
2024 ASH President,
2020 Wallace H. Coulter Award for Lifetime Achievement in Hematology recipient

#ASH26

LYMPHOID MALIGNANCIES

Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	Anti-BCMA Bispecific Antibodies in Multiple Myeloma: From Biology to Real-World Implementation	Satellite Symposia	Great Hall AD	CME
Friday	7:00–10:00 a.m.	Breaking News: Launching Bispecific Antibodies for Multiple Myeloma in Community Practice	Satellite Symposia	Hall B	CME
Friday	7:00–10:00 a.m.	Consensus or Controversy? Documenting And Discussing Investigators' Approaches to the Management of Patients with Chronic Lymphocytic Leukemia	Satellite Symposia	Sheraton - Napoleon Ballroom CD	CME
Friday	7:00–10:00 a.m.	Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs	Satellite Symposia	Hilton - Grand Ballroom CD	CME
Friday	11:00 a.m.–2:00 p.m.	Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together	Satellite Symposia	Hall C	CME
Friday	11:00 a.m.–2:00 p.m.	Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation	Satellite Symposia	Hilton - Grand Ballroom CD	CME
Friday	11:00 a.m.–2:00 p.m.	Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review	Satellite Symposia	Sheraton - Napoleon Ballroom CD	CME
Friday	11:00 a.m.–2:00 p.m.	Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum	Satellite Symposia	R02-R05	CME
Friday	11:00 a.m.–2:00 p.m.	CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation	Satellite Symposia	243-245	CME
Friday	11:00 a.m.–2:00 p.m.	CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies	Satellite Symposia	208-210	CME
Friday	11:00 a.m.–2:00 p.m.	Medical Crossfire®: Redefining DLBCL — How Biomarker- and Mechanism-Driven Strategies Are Reshaping Management Across the Disease Continuum	Satellite Symposia	La Nouvelle C	CME
Friday	11:00 a.m.–2:00 p.m.	Medical Crossfire®: Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies	Satellite Symposia	393-396	CME
Friday	11:00 a.m.–2:00 p.m.	Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies	Satellite Symposia	Hilton - Grand Ballroom AB	CME
Friday	11:00 a.m.–2:00 p.m.	Transforming Care for Newly-Diagnosed Multiple Myeloma: Integrating Evidence-Based Innovation into Community Practice	Satellite Symposia	Hall B	CME
Friday	3:00–6:00 p.m.	Evidence at Every Step: Applying the Latest CAR T-Cell Data Across the NHL Care Continuum	Satellite Symposia	R02-R05	CME
Friday	3:00–6:00 p.m.	FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment	Satellite Symposia	Hilton - Grand Ballroom CD	CME
Friday	3:00–6:00 p.m.	Immune Therapy for Myeloma: From CAR T and T-Cell Engagers to Community Care	Satellite Symposia	343-345	CME
Friday	3:00–6:00 p.m.	Live Tumor Board: Advancing Clinical Competence in Primary CNS Lymphoma — Navigating Molecular Pathways and Emerging Therapies	Satellite Symposia	La Nouvelle C	CME
Friday	3:00–6:00 p.m.	Medical Crossfire®: Strategic Sequencing in ALL — From Asparaginase to Cellular Therapy in an MRD-Driven Era	Satellite Symposia	La Nouvelle A-B	CME
Friday	3:00–6:00 p.m.	Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice	Satellite Symposia	243-245	CME
Friday	3:00–6:00 p.m.	Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions	Satellite Symposia	265-268	CME
Friday	3:00–6:00 p.m.	Quadruplet Therapy in NDMM: Interpreting the Data, Applying the Evidence	Satellite Symposia	208-210	CME

Day	Time	Session Title	Program	Location	CME
Friday	3:00–6:00 p.m.	The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care	Satellite Symposia	Hilton - Grand Ballroom AB	CME
Friday	3:00–6:00 p.m.	Scientific Workshop on Clonal Evolution in Chronic Lymphocytic Leukemia: Mechanisms of Resistance, Disease Progression and Measurable Residual Disease-Based Monitoring	Scientific Workshops	288-290	
Friday	3:00–6:00 p.m.	Scientific Workshop on Emerging Technologies and Innovations in Diagnostic Hematology	Scientific Workshops	252-254	
Friday	3:00–6:00 p.m.	Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Discovery to Patients	Scientific Workshops	275-277	
Friday	3:00–6:00 p.m.	Scientific Workshop on New Frontiers in T-Cell Acute Lymphoblastic Leukemia Biology: Metabolism, Genomics, and Microenvironment	Scientific Workshops	260-262	
Friday	3:00–6:00 p.m.	Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies	Scientific Workshops	291-292	
Friday	7:00–10:00 p.m.	Addressing Community Oncologists' Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies in Multiple Myeloma – What Clinicians Want To Know	Satellite Symposia	Sheraton - Napoleon Ballroom CD	CME
Friday	7:00–10:00 p.m.	Addressing Community Oncologists' Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know	Satellite Symposia	Sheraton - Napoleon Ballroom AB	CME
Friday	7:00–10:00 p.m.	Advancing the DLBCL Paradigm: Sequencing Bispecifics in Optimizing Patient Care	Satellite Symposia	Great Hall BC	CME
Friday	7:00–10:00 p.m.	Cases and Conversations: Sequencing Strategies in Relapsed and Refractory CLL	Satellite Symposia	La Nouvelle A-B	CME
Friday	7:00–10:00 p.m.	Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia	Satellite Symposia	343-345	CME
Saturday	8:00–9:00 a.m.	ASH Poster Walk on Emerging Toxicities and Predictors in T-Cell–Redirecting Therapies Hosted by Blood Immunology & Cellular Therapy	ASH Poster Walks	Hall F Blood Journals Studio	
Saturday	8:00–9:00 a.m.	From Splicing Mutations to Cancer Neoantigens: A Decade of Targeting RNA Biology in Leukemia	Meet the Scientist	Hilton - Fulton	
Saturday	9:30–10:45 a.m.	Navigating the Treatment Landscape of CNS Lymphomas	Education Program	278-282	CME
Saturday	9:30–10:45 a.m.	Optimizing Patient Care: Practicing Bloodless Medicine	Education Program	391-392	CME
Saturday	9:30–10:45 a.m.	Back to the Future: Using Old and New Tools to Move the Field of Plasma Cell Research Forward	Scientific Program	288-290	CME
Saturday	9:30–10:45 a.m.	Ancestry Origins in Personalized Medicine: Advancing Biological Discovery, Population-Representative Research Design, and Translational Validity in Hematology	Special-Interest Sessions	220-222	CME
Saturday	9:30–11:00 a.m.	201. Granulocytes, Monocytes, and Macrophages: Novel Therapeutic Targets in Histiocytosis and Hyperinflammation	Oral Abstract Session	291-292	
Saturday	9:30–11:00 a.m.	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Refining Risk in Cancer-Associated Thrombosis: From Circulating Biomarkers to Population Outcomes	Oral Abstract Session	208-210	
Saturday	9:30–11:00 a.m.	603. Lymphoid Oncogenesis: Basic: Epigenetic and Transcriptional Deregulation	Oral Abstract Session	275-277	
Saturday	9:30–11:00 a.m.	614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Integrated Omics Approaches for Precision Medicine in Acute Lymphoblastic Leukemia	Oral Abstract Session	265-268	
Saturday	9:30–11:00 a.m.	621. Lymphomas: Translational – Molecular and Genetic: Genomics and Liquid Biopsy in Lymphoma: Tumor Biology to Clinical Monitoring	Oral Abstract Session	New Orleans Theatre A	

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Day	Time	Session Title	Program	Location	CME
Saturday	9:30–11:00 a.m.	627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Novel Combinations Move Beyond Chemotherapy	Oral Abstract Session	New Orleans Theatre C	
Saturday	9:30–11:00 a.m.	629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: Response-Adapted Strategies in Aggressive Lymphomas	Oral Abstract Session	New Orleans Theatre B	
Saturday	9:30–11:00 a.m.	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches for Patients with Relapsed/Refractory CLL, Richter Transformation, and Hypogammaglobulinemia	Oral Abstract Session	260-262	
Saturday	9:30–11:00 a.m.	654. Multiple Myeloma: Pharmacologic Therapies	Oral Abstract Session	La Nouvelle A-B	
Saturday	9:30–11:00 a.m.	655. Multiple Myeloma: Cellular Therapies: CART in Myeloma: Racing Towards a Cure	Oral Abstract Session	Hall E	
Saturday	9:30–11:00 a.m.	702. CAR-T Cell Therapies: Basic and Translational	Oral Abstract Session	343-345	
Saturday	9:30–11:00 a.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: From Cells to Code: AI and the Next Generation of Hematologic Diagnostics	Oral Abstract Session	393-396	
Saturday	9:30–11:00 a.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Beyond Efficacy - Quality of Life, Patient Reported Outcomes and Social Determinants of Health	Oral Abstract Session	271-273	
Saturday	9:30–11:00 a.m.	907. Outcomes Research: Plasma Cell Disorders - Beyond Disease Control: Supportive Care, Survivorship, and Patient-Centered Outcomes in Multiple Myeloma	Oral Abstract Session	La Nouvelle C	
Saturday	11:15 a.m.–12:15 p.m.	Career Development Lunch	Trainee Activities and Services	Hilton - St. Charles Ballroom	
Saturday	11:30 a.m.–12:30 p.m.	A Therapy for Adults with RRMM After a PI and an Immunomodulatory Agent	Interact with Industry	Hall J Theater 1	
Saturday	11:30 a.m.–12:30 p.m.	Discover A New Oral-Based Regimen for First Relapse Myeloma	Interact with Industry	Hall J Theater 6	
Saturday	11:30 a.m.–12:30 p.m.	The Only BTKi Approved in 1L CLL/SLL and 1L MCL	Interact with Industry	Hall J Theater 5	
Saturday	12:00–1:30 p.m.	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Is Chemo-immunotherapy Ready for Retirement? Bispecific and CELMoD-Based Frontline Regimens in Follicular Lymphoma	Oral Abstract Session	278-282	
Saturday	12:30–1:30 p.m.	Ham-Wasserman Lecture	Marquee Sessions	Hall E	CME
Saturday	2:00–3:30 p.m.	503. Clonal Hematopoiesis, Aging, and Inflammation: Evolution, Interactions, and Interception	Oral Abstract Session	Hall E	
Saturday	2:00–3:30 p.m.	614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Integrating Genomic and Functional Approaches to Uncover Mechanisms of Pathogenesis and Treatment Resistance in B-ALL	Oral Abstract Session	265-268	
Saturday	2:00–3:30 p.m.	622. Lymphomas: Translational: Non-Genetic – Lymphoma Landscapes: Spatial Biology of Tumor States and Immune Niches	Oral Abstract Session	New Orleans Theatre B	
Saturday	2:00–3:30 p.m.	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Mapping the Post-BTK Inhibitor Landscape: Cellular Therapy, Novel Combinations, and Genomic Insights in B-Cell Lymphomas	Oral Abstract Session	New Orleans Theatre A	
Saturday	2:00–3:30 p.m.	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Improving Outcomes for Relapsed/ Refractory CLL/SLL	Oral Abstract Session	271-273	
Saturday	2:00–3:30 p.m.	652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Clinical Trials for Plasma Cell Dyscrasias and Related Disorders	Oral Abstract Session	278-282	

Day	Time	Session Title	Program	Location	CME
Saturday	2:00–3:30 p.m.	654. Multiple Myeloma: Pharmacologic Therapies: Novel Approaches in Relapsed Myeloma: Immunotherapies and Small Molecules	Oral Abstract Session	La Nouvelle A-B	
Saturday	2:00–3:30 p.m.	655. Multiple Myeloma: Cellular Therapies: Efficacy Meets Safety: Optimizing CART in MM	Oral Abstract Session	La Nouvelle C	
Saturday	2:00–3:30 p.m.	702. CAR-T Cell Therapies: Basic and Translational: Engineering CAR T-cells for Improved Persistence, Activity, and Tumor Control	Oral Abstract Session	343-345	
Saturday	2:00–3:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Building a Better Transplant: Refining the PTCy Platform and Beyond	Oral Abstract Session	388-390	
Saturday	2:00–3:30 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: From Algorithms to the Clinic: AI and Molecular Innovation in Hematology	Oral Abstract Session	393-396	
Saturday	2:00–3:30 p.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: CAR-T Cell Therapy	Oral Abstract Session	260-262	
Saturday	2:00–3:30 p.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders - Beyond Response: Toxicity, Infection, and Late Events After Novel Therapies	Oral Abstract Session	New Orleans Theatre C	
Saturday	3:30–3:45 p.m.	Discover the Organization of Cell Surface Proteins to Uncover Mechanisms Behind Hematological Disease	Interact with Industry	Hall J Theater 5	
Saturday	4:00–5:30 p.m.	605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Molecular Vulnerabilities and Therapeutic Resistance	Oral Abstract Session	271-273	
Saturday	4:00–5:30 p.m.	613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Relapsed/ Refractory Acute Lymphoblastic Leukemia: From Novel CAR T-cell Constructs to Real-World Experience in B-ALL, and an Investigational Agent in T-cell ALL	Oral Abstract Session	265-268	
Saturday	4:00–5:30 p.m.	621. Lymphomas: Translational – Molecular and Genetic: From Tumor Evolution to Therapeutic Targets: Integrated Genomic and Microenvironmental Insights in B-Cell Lymphomas	Oral Abstract Session	New Orleans Theatre B	
Saturday	4:00–5:30 p.m.	622. Lymphomas: Translational – Non-Genetic: Shaping Lymphoma Fate: Oncogenic Programs, Stromal Support, and Immune Failure	Oral Abstract Session	New Orleans Theatre A	
Saturday	4:00–5:30 p.m.	627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Novel Study Designs and New Immunotherapy Approaches	Oral Abstract Session	New Orleans Theatre C	
Saturday	4:00–5:30 p.m.	653. Multiple Myeloma: Clinical and Epidemiological: Optimizing Outcomes for Multiple Myeloma, Young and Old	Oral Abstract Session	La Nouvelle A-B	
Saturday	4:00–5:30 p.m.	654. Multiple Myeloma: Pharmacologic Therapies: The March of Immunotherapy	Oral Abstract Session	La Nouvelle C	
Saturday	4:00–5:30 p.m.	702. CAR-T Cell Therapies: Basic and Translational: Overcoming Resistance and Escape in CAR-T Cell Therapy	Oral Abstract Session	343-345	
Saturday	4:00–5:30 p.m.	711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations from Bench to Bedside	Oral Abstract Session	391-392	
Saturday	4:00–5:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: HCT Under Stress: Acute Toxicities and Organ Injury	Oral Abstract Session	388-390	
Saturday	4:00–5:30 p.m.	732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Allogeneic Transplantation Outcomes: Lymphoid Malignancies, Pediatric Malignancies, and Donor Factors	Oral Abstract Session	278-282	
Saturday	4:00–5:30 p.m.	802. Chemical Biology and Experimental Therapeutics: Leveraging Chemical Biology for Therapeutic Discovery	Oral Abstract Session	353-355	
Saturday	4:00–5:30 p.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: Geriatrics, Palliative, and End of Life Care	Oral Abstract Session	260-262	

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Day	Time	Session Title	Program	Location	CME
Saturday	4:00–5:35 p.m.	JOINT SESSION - New Horizons in RNA Biology in Myeloid Development and Malignancy	Scientific Program	288-290	
Sunday	8:00–9:00 a.m.	Beyond Bone Marrow: Integrating Circulating Plasma Cell Enumeration and Genomic Profiling into Multiple Myeloma Disease Assessment	Interact with Industry	Hall J Theater 5	
Sunday	8:00–9:00 a.m.	DARZALEX FASPRO® + VRd: A Clinical Foundation from the CEPHEUS and PERSEUS Trials	Interact with Industry	291-292	
Sunday	8:00–9:00 a.m.	Learn About A Frontline Treatment Option in Peripheral T-Cell Lymphoma	Interact with Industry	288-290	
Sunday	9:30–10:45 a.m.	Advancing Personalized Care in Classic Hodgkin Lymphoma	Education Program	278-282	CME
Sunday	9:30–10:45 a.m.	AI Models of Cell State for the Design of Next-Generation T Cell Therapies	Scientific Symposia	393-396	
Sunday	9:30–10:45 a.m.	Designing Microbiome-Directed Interventional Trials in Hematologic Malignancies	Scientific Symposia	288-290	CME
Sunday	9:30–11:00 a.m.	332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis and Hemorrhage in Hematologic Malignancy: From CAR T-Cells to Clonal Hematopoiesis	Oral Abstract Session	217-219	
Sunday	9:30–11:00 a.m.	603. Lymphoid Oncogenesis: Basic: Metabolic and Immune Mechanisms	Oral Abstract Session	260-262	
Sunday	9:30–11:00 a.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Emerging Clinically Relevant Biomarkers in AML	Oral Abstract Session	Great Hall BC	
Sunday	9:30–11:00 a.m.	621. Lymphomas: Translational – Molecular and Genetic	Oral Abstract Session	275-277	
Sunday	9:30–11:00 a.m.	625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Emerging Targeted Therapies in NK/T-Cell Lymphomas and HLH: From Epigenetic Modulation to JAK Signaling	Oral Abstract Session	New Orleans Theatre C	
Sunday	9:30–11:00 a.m.	626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Evaluation of Newly-Diagnosed DLBCL Patients	Oral Abstract Session	New Orleans Theatre B	
Sunday	9:30–11:00 a.m.	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Studies in Previously Untreated CLL/SLL	Oral Abstract Session	New Orleans Theatre A	
Sunday	9:30–11:00 a.m.	653. Multiple Myeloma: Clinical and Epidemiological: Optimizing Sequencing and Toxicity Management With Novel Myeloma Therapies	Oral Abstract Session	La Nouvelle A-B	
Sunday	9:30–11:00 a.m.	656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: The Evolving Landscape of Risk Definition in Multiple Myeloma	Oral Abstract Session	La Nouvelle C	
Sunday	9:30–11:00 a.m.	702. CAR-T Cell Therapies: Basic and Translational: Next-Generation CAR T-cell Therapy Strategies for AML	Oral Abstract Session	Great Hall AD	
Sunday	9:30–11:00 a.m.	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities	Oral Abstract Session	343-345	
Sunday	9:30–11:00 a.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Advances in GVHD Prophylaxis and Immune Reconstitution after Allogeneic HCT	Oral Abstract Session	388-390	
Sunday	9:30–11:00 a.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: Monitoring, Demographics, and Access to Care	Oral Abstract Session	271-273	
Sunday	9:30–11:00 a.m.	From Real-World Evidence to Real-World Impact: Translating Multiple Myeloma Data into Clinical Practice	Special-Interest Sessions	265-268	
Sunday	9:30–11:05 a.m.	JOINT SESSION - Bridging the Gap: Research and Clinical Implications of Emerging Technologies in Hematology	Scientific Program	391-392	CME
Sunday	11:30 a.m.–12:30 p.m.	A BCMA-Directed Bispecific for the Treatment of Patients with R/R Multiple Myeloma After At Least 4 Prior Lines of Treatment	Interact with Industry	Hall J Theater 1	

Day	Time	Session Title	Program	Location	CME
Sunday	11:30 a.m.–12:30 p.m.	First-in-Class Treatment for Patients with Relapsed or Refractory Multiple Myeloma	Interact with Industry	Hall J Theater 5	
Sunday	11:30 a.m.–12:30 p.m.	From Data to Decisions: Advancing Patient Care in 2L+ Follicular Lymphoma and R/R DLBCL	Interact with Industry	Hall J Theater 6	
Sunday	11:30 a.m.–12:30 p.m.	See How Jaypirca® (pirtobrutinib) is Sparking More Possibilities	Interact with Industry	Hall J Theater 2	
Sunday	12:00–1:30 p.m.	628. Aggressive Lymphomas: Cellular Therapies: Optimizing Every Step of the CAR T-Cell Journey in Large B-Cell Lymphoma	Oral Abstract Session	New Orleans Theatre C	
Sunday	12:00–1:30 p.m.	629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: Clinical Trials in Untreated and Relapsed/Refractory LBCL, Including CNS Lymphoma	Oral Abstract Session	New Orleans Theatre B	
Sunday	12:00–1:30 p.m.	656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: Tracking MRD in Blood and Marrow of Multiple Myeloma Patients	Oral Abstract Session	La Nouvelle A-B	
Sunday	12:00–1:30 p.m.	907. Outcomes Research: Plasma Cell Disorders: T-Cell–Redirecting Therapies in Multiple Myeloma: Treatment Optimization and Emerging Toxicities	Oral Abstract Session	La Nouvelle C	
Sunday	4:15–4:30 p.m.	A New Standard in MRD Assessment: ARUP CLARISPECT(TM) Supports Highly Sensitive Detection for Rare Residual Malignant Populations	Interact with Industry	Hall J Theater 3	
Sunday	4:15–4:30 p.m.	Eilean Therapeutics. Targeting Escape Mutations in Hematological Cancers with First and Best in Class Medicines	Interact with Industry	Hall J Theater 4	
Sunday	4:30–5:45 p.m.	A New Treatment Paradigm for Follicular Lymphoma	Education Program	New Orleans Theatre A	CME
Sunday	4:30–5:45 p.m.	Driving CARs Safely- Preventing and Managing Intermediate and Long-Term CAR-T Toxicity	Education Program	New Orleans Theatre C	
Sunday	4:30–5:45 p.m.	Current Perspectives on Evolving Classification of Myeloid and Lymphoid Neoplasms	Education Spotlight Sessions	391-392	CME
Sunday	4:30–5:45 p.m.	Decoding Macrophage Diversity in Lymphomas: Spatial Insights and Immunotherapeutic Implications	Scientific Spotlight Sessions	271-273	CME
Sunday	4:30–6:00 p.m.	605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Strategies and Modulation of Anti-Tumor Responses	Oral Abstract Session	260-262	
Sunday	4:30–6:00 p.m.	616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies - Novel Combinations with Menin, FLT3 and BCL2 Inhibitors	Oral Abstract Session	Hall B	
Sunday	4:30–6:00 p.m.	641. Chronic Lymphocytic Leukemia: Basic and Translational: Resolving Complexity of CLL and Richter Transformation	Oral Abstract Session	265-268	
Sunday	4:30–6:00 p.m.	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Optimizing T-cell Redirected Therapy for Myeloma and Related Conditions	Oral Abstract Session	La Nouvelle C	
Sunday	4:30–6:00 p.m.	656. Multiple Myeloma: Biomarkers in Diagnosis, Prognosis, and Treatment Outcome, Including Minimal Residual Disease: Immune and Microenvironment Drivers of Treatment Outcomes in Multiple Myeloma	Oral Abstract Session	La Nouvelle A-B	
Sunday	4:30–6:00 p.m.	701. Experimental Transplantation: Basic and Translational: Emerging Biology to Translational Innovation I	Oral Abstract Session	343-345	
Sunday	4:30–6:00 p.m.	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Next-Generation CAR T-Cell Therapy in Lymphoma: In Vivo Engineering and Beyond	Oral Abstract Session	New Orleans Theatre B	
Sunday	4:30–6:00 p.m.	723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Long-term Follow-up After Allogeneic Hematopoietic Cell Transplantation	Oral Abstract Session	388-390	
Sunday	4:30–6:00 p.m.	732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Allogeneic Transplantation for Myeloid Malignancies: Timing, Donors, and Disease Control	Oral Abstract Session	Great Hall AD	

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Day	Time	Session Title	Program	Location	CME
Sunday	4:30–6:00 p.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders - Outcomes Across the Age Spectrum: Assessment, Tolerability, and Survivorship	Oral Abstract Session	278-282	
Monday	8:00–9:00 a.m.	7-Year Follow-up of the POLARIX Study	Interact with Industry	Hall J Theater 3	
Monday	8:00–9:00 a.m.	Advancing Care in Primary Central Nervous System Lymphoma: Evolving Treatment Approaches	Interact with Industry	288-290	
Monday	8:00–9:00 a.m.	Beyond BCMA: Investigating GPRC5D CAR T Therapy in RRMM	Interact with Industry	Hall J Theater 5	
Monday	8:00–9:00 a.m.	Integrated Innovation in Cell Therapy: From Manufacturing to Clinical Development	Interact with Industry	Hall J Theater 4	
Monday	8:00–9:00 a.m.	The APP Perspective: Building Confidence With DARZALEX Faspro®	Interact with Industry	291-292	
Monday	9:00–10:00 a.m.	Announcement of Awards: J. Evan Sadler Award for Mentorship, Bernard Forget Award for Mentorship, and E. Donnall Thomas Lecture and Prize	Marquee Sessions	Hall E	
Monday	10:30–11:45 a.m.	The Golden Era of ALL Management: Rapid Advances Across the Age Spectrum	Education Program	278-282	
Monday	10:30–11:45 a.m.	Illuminating the Dark Corners in the Genomes of Lymphoid Neoplasms	Scientific Spotlight Sessions	288-290	CME
Monday	10:30 –12:00 p.m.	612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: New Genomic and Immunologic Insights	Oral Abstract Session	265-268	
Monday	10:30 –12:00 p.m.	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Finite vs. Forever: Redefining Treatment Duration in Relapsed/Refractory Waldenstrom's Macroglobulinemia and Marginal Zone Lymphoma	Oral Abstract Session	New Orleans Theatre B	
Monday	10:30 –12:00 p.m.	625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Precision Approaches in NK/T-Cell Lymphoma and CTCL: Optimizing Therapy and Predicting Outcomes	Oral Abstract Session	New Orleans Theatre A	
Monday	10:30 –12:00 p.m.	626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials	Oral Abstract Session	New Orleans Theatre C	
Monday	10:30 –12:00 p.m.	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Initial CLL Treatment Strategies with Targeted Agent Combinations and MRD-guidance	Oral Abstract Session	271-273	
Monday	10:30 –12:00 p.m.	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Transcriptional and Epigenetic Control of MM	Oral Abstract Session	La Nouvelle A-B	
Monday	10:30–12:00 p.m.	652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Advancing Treatment Strategies in AL Amyloidosis	Oral Abstract Session	260-262	
Monday	10:30–12:00 p.m.	702. CAR T-cell Therapies: Basic and Translational: Engineering CAR-T Cell Fitness, Persistence, and Safety	Oral Abstract Session	353-355	
Monday	10:30–12:00 p.m.	907. Outcomes Research: Plasma Cell Disorders: Real-World Efficacy of Immunotherapy	Oral Abstract Session	La Nouvelle C	
Monday	10:30 –12:00 p.m.	Clinical Practice Guidelines on the Treatment of Light-Chain Amyloidosis	Special-Interest Sessions	293-294	CME
Monday	12:15–1:15 p.m.	ASH Poster Walk on Leukemia in Latin America: Outcomes and Access to Diagnostics and Therapies Hosted by Blood Global Hematology	ASH Poster Walks	Hall F Blood Journals Studio	
Monday	12:15–1:15 p.m.	Beyond a Single Biomarker: NGS Solutions for Hematologic Malignancies MRD Research	Interact with Industry	Hall J Theater 4	
Monday	12:15–1:15 p.m.	Expanding Community Therapy Options in Relapsed or Refractory Multiple Myeloma: A BCMA-Targeted Option	Interact with Industry	Hall J Theater 3	
Monday	12:15–1:15 p.m.	OMISIRGE®: Challenging Conventional Thinking About Time To Transplant And Patient Outcomes In Hematological Conditions With A Novel Cell Therapy Donor Source	Interact with Industry	Hall J Theater 1	

Day	Time	Session Title	Program	Location	CME
Monday	12:15–1:15 p.m.	Unlocking the Potential for a Bispecific Antibody in 2L+ FL and 3L+ DLBCL	Interact with Industry	Hall J Theater 2	
Monday	1:15–1:30 p.m.	Meet the Journal Editors: Blood Global Hematology	Blood Journals Studio	Hall F Blood Journals Studio	
Monday	1:30–2:30 p.m.	Ernest Beutler Lecture and Prize	Marquee Sessions	Hall E	CME
Monday	2:45–4:00 p.m.	Chronic Lymphocytic Leukemia - From Clonal Evolution to Novel Therapies	Education Program	271-273	CME
Monday	2:45–4:00 p.m.	Diffuse Large B-cell Lymphoma	Education Program	278-282	CME
Monday	2:45–4:00 p.m.	Balancing the Blood: Immune Control of Stem Cell Fidelity	Scientific Program	275-277	CME
Monday	2:45–4:00 p.m.	Greasy Situations: Unraveling Lipid-Mediated Therapy Resistance	Scientific Spotlight Sessions	288-290	CME
Monday	2:45–4:15 p.m.	203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Immune Dysregulation and Clinical Translation	Oral Abstract Session	R06-R09	
Monday	2:45–4:15 p.m.	612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Clinical, Genomic, and Social Predictors of Outcomes	Oral Abstract Session	265-268	
Monday	2:45–4:15 p.m.	625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Cellular and Immune Therapies in T-Cell and NK-Cell Malignancies	Oral Abstract Session	New Orleans Theatre B	
Monday	2:45–4:15 p.m.	626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: From Trials to Reality: Real-World Evidence in Large B-cell Lymphoma	Oral Abstract Session	New Orleans Theatre C	
Monday	2:45–4:15 p.m.	629. Aggressive Lymphomas, Non-Cellular Immunotherapy Including Bispecific Antibodies: T-cell Engagers and ADC Combinations and Long-Term Outcomes of Trials in Relapsed/Refractory LBCL	Oral Abstract Session	New Orleans Theatre A	
Monday	2:45–4:15 p.m.	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myeloma Genomics	Oral Abstract Session	La Nouvelle A-B	
Monday	2:45–4:15 p.m.	653. Multiple Myeloma: Clinical and Epidemiological: Evolving Population-Level Outcomes and Trends	Oral Abstract Session	La Nouvelle C	
Monday	2:45–4:15 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: AI at the Bedside: From Prediction to Therapeutic Decisions	Oral Abstract Session	393-396	
Monday	2:45–4:15 p.m.	907. Outcomes Research: Plasma Cell Disorders: Beyond Response Rates: T-cell Engagement in the Real World	Oral Abstract Session	260-262	
Monday	2:45–4:15 p.m.	908. Outcomes Research: Myeloid Malignancies: Mind the (Molecular) Gap: From Testing to Trials, Across Race and Place	Oral Abstract Session	Hall C	
Monday	4:30–5:45 p.m.	Battle-Scarred Blood Cells: Hematologic Malignancies in Military Service Members	Education Program	278-282	CME
Monday	4:30–5:45 p.m.	Multiple Myeloma: The Future is Now	Education Program	Hall E	CME
Monday	4:30–5:45 p.m.	Bispecific Antibody Therapy vs CAR T Therapy in Lymphoid Malignancies	Education Spotlight Sessions	271-273	CME
Monday	4:30–6:00 p.m.	613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Frontline Therapy in Acute Lymphoblastic Leukemia: At the Crossroads of Chemotherapy, Immunotherapy, and Targeted Therapy Across the Age Spectrum	Oral Abstract Session	265-268	
Monday	4:30–6:00 p.m.	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - From Cytotoxic to Selective: The BTK Inhibitor Revolution in The Frontline Treatment of Mantle Cell Lymphoma	Oral Abstract Session	New Orleans Theatre B	
Monday	4:30–6:00 p.m.	624. Hodgkin Lymphomas: Clinical and Epidemiological: Precision, Prognostication, and Paradigm Shifts	Oral Abstract Session	New Orleans Theatre C	

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Day	Time	Session Title	Program	Location	CME
Monday	4:30–6:00 p.m.	628. Aggressive Lymphomas: Cellular Therapies: Novel CAR-T Constructs, Durability, and Long-Term Outcomes	Oral Abstract Session	New Orleans Theatre A	
Monday	4:30–6:00 p.m.	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myeloma Basic and Translational Research	Oral Abstract Session	La Nouvelle C	
Monday	4:30–6:00 p.m.	653. Multiple Myeloma: Clinical and Epidemiological: Differentiating Multiple Myeloma(s): A Path to Cure	Oral Abstract Session	La Nouvelle A-B	
Monday	4:30–6:00 p.m.	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Early Innovation of Immune Effector Cell Therapies	Oral Abstract Session	388-390	
Monday	4:30–6:00 p.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prophylaxis-Clinical and Translational Aspects	Oral Abstract Session	353-355	
Monday	4:30–6:00 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Emerging Technologies for Molecular Classification, Monitoring, and Modelling	Oral Abstract Session	393-396	
Monday	4:30–6:00 p.m.	903. Health Services and Quality Improvement: Myeloid Malignancies: JAKPOT! Improving Care Quality from Pre-hab, Sleep, and Home Transfusions to Pall-care, Costs, and JAK Testing	Oral Abstract Session	R02-R05	
Monday	4:30–6:00 p.m.	906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Assessing Real World Effectiveness and Toxicity of Immune and Cellular Therapies	Oral Abstract Session	260-262	

METABOLIC DISORDERS

Day	Time	Session Title	Program	Location	CME
Friday	3:00–6:00 p.m.	Acute Hepatic Porphyria: Bridging Gaps for Better Diagnosis and Management	Interact with Industry	Hyatt - Plaza Int'l HIJK	CME
Saturday	9:30–10:45 a.m.	Iron and Heme Metabolism and Its Considerations in Understanding Pathophysiology and Therapy	Scientific Program	Hyatt - Regency Ballroom OPQ	
Saturday	9:30–11:00 a.m.	631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Precision targeting in MPN	Oral Abstract Session	W414AB	
Saturday	12:00–1:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients	Oral Abstract Session	W331	
Saturday	4:00–5:30 p.m.	801. Gene Therapies: Advances in Gene Therapy for Blood Disorders	Oral Abstract Session	Chapin Theater (W320)	
Saturday	4:00–5:30 p.m.	ASH Clinical Practice Guidelines on Diagnosis of Iron Deficiency with and without Anemia	Special-Interest Sessions	Hyatt - Regency Ballroom OPQ	CME
Sunday	9:30–11:00 a.m.	301. Platelets and Megakaryocytes: Basic and Translational: Platelets in thromboinflammatory disorders	Oral Abstract Session	W304EFGH	
Sunday	9:30–11:00 a.m.	330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Platelets, leukocytes, and endothelium in thrombotic and vascular disease	Oral Abstract Session	W307	
Sunday	12:00–1:30 p.m.	102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Erythropoiesis, Inflammation and Hematologic Recovery: The Iron and Heme Drama Unfolds	Oral Abstract Session	W311EFGH	
Sunday	12:00–1:30 p.m.	901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Closing the Quality Gap: Women's Health and Rapid Testing	Oral Abstract Session	W304ABCD	
Monday	10:30 a.m.–12:00 p.m.	112. Thalassemia and Globin Gene Regulation: Murine models and a clinical approach to reduce toxicity, modulate hemoglobin F and improve outcomes in thalassemia	Oral Abstract Session	W311ABCD	
Monday	2:45–4:00 p.m.	Biology-Based Management of Iron Toxicity and Overload in Hematology Practice	Education Program	Hyatt - Regency Ballroom OPQ	CME
Monday	4:30–6:00 p.m.	905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Bleeding, Barriers, and Bridging the Gaps	Oral Abstract Session	W307	

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

MYELOID MALIGNANCIES

Day	Time	Session Title	Program	Location	CME
Friday	7:00–10:00 a.m.	Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review	Satellite Symposia	Sheraton - Napoleon Ballroom AB	CME
Friday	7:00–10:00 a.m.	MDS in Practice: Navigating Complex Decisions Across the Disease Spectrum	Satellite Symposia	208-210	CME
Friday	11:00 a.m.–2:00 p.m.	A Case-Based Exploration of CAR T-Cell Therapy in Multiple Myeloma – Where We Are, Where We're Going	Satellite Symposia	Sheraton - Napoleon Ballroom AB	CME
Friday	11:00 a.m.–2:00 p.m.	Cases and Conversations: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies	Satellite Symposia	La Nouvelle A-B	CME
Friday	11:00 a.m.–2:00 p.m.	CML Treatment Continuum: Optimizing Therapy Selection, Molecular Monitoring, And Long-Term Quality of Life	Satellite Symposia	Great Hall BC	CME
Friday	11:00 a.m.–2:00 p.m.	Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making	Satellite Symposia	343-345	CME
Friday	11:00 a.m.–2:00 p.m.	Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care	Satellite Symposia	Great Hall AD	CME
Friday	11:00 a.m.–2:00 p.m.	Show Me the Data™: Emerging Evidence and Evolving Clinical Practice in Essential Thrombocythemia and Polycythemia Vera	Satellite Symposia	R06-R09	CME
Friday	2:00–6:00 p.m.	Scientific Workshop on Myeloid Development	Satellite Symposia	220-222	
Friday	3:00–6:00 p.m.	A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We're Going	Satellite Symposia	Sheraton - Napoleon Ballroom CD	CME
Friday	3:00–6:00 p.m.	Cases and Conversations: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms	Satellite Symposia	R06-R09	CME
Friday	3:00–6:00 p.m.	Live Hot Seat™: Advancing Precision Care in Acute Myeloid Leukemia With the Integration of Menin Inhibitors	Satellite Symposia	393-396	CME
Friday	3:00–6:00 p.m.	MDS in the Modern Era: Getting Ahead of the 8-Ball	Satellite Symposia	Hall C	CME
Friday	3:00–6:00 p.m.	Scientific Workshop on Emerging Technologies and Innovations in Diagnostic Hematology	Scientific Workshops	252-254	
Friday	3:00–6:00 p.m.	Scientific Workshop on Mitochondria and Metabolism in Blood Cancer - From Discovery to Patients	Scientific Workshops	275-277	
Friday	3:00–6:00 p.m.	Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies	Scientific Workshops	291-292	
Friday	7:00–10:00 p.m.	Cases and Conversations: Endothelial Injury, Complement, and TA-TMA After Allogeneic Stem Cell Transplant	Satellite Symposia	La Nouvelle C	CME
Friday	7:00–10:00 p.m.	From Evidence to Action in MPN: Transforming Challenges to Opportunities in PV and ET Patients	Satellite Symposia	208-210	CME
Saturday	8:00–9:00 a.m.	ASH Poster Walk on Emerging Toxicities and Predictors in T-Cell–Redirecting Therapies Hosted by Blood Immunology & Cellular Therapy	ASH Poster Walks	Hall F Blood Journals Studio	
Saturday	8:00–9:00 a.m.	Myth vs Mast Cell: Would You Recognize Systemic Mastocytosis? Patient and Clinician Perspectives on Diagnosis, Disease Burden, and Unmet Need	Interact with Industry	295-296	
Saturday	8:00–9:00 a.m.	Navigating PV with MIMRYLO: A Patient-Centered Clinical Conversation	Interact with Industry	288-290	
Saturday	8:00–9:00 a.m.	From Splicing Mutations to Cancer Neoantigens: A Decade of Targeting RNA Biology in Leukemia	Meet the Scientist	Hilton - Fulton	
Saturday	9:30–10:45 a.m.	Addressing Resistance and Progression in Myeloproliferative Diseases	Education Program	R06-R09	CME
Saturday	9:30–10:45 a.m.	Optimizing Patient Care: Practicing Bloodless Medicine	Education Program	391-392	CME
Saturday	9:30–11:00 a.m.	201. Granulocytes, Monocytes, and Macrophages: Novel Therapeutic Targets in Histiocytosis and Hyperinflammation	Oral Abstract Session	291-292	

Day	Time	Session Title	Program	Location	CME
Saturday	9:30–11:00 a.m.	508. Bone Marrow Failure: Acquired: The Science Behind the Clinic	Oral Abstract Session	295-296	
Saturday	9:30–11:00 a.m.	603. Lymphoid Oncogenesis: Basic: Epigenetic and Transcriptional Deregulation	Oral Abstract Session	275-277	
Saturday	9:30–11:00 a.m.	614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Integrated Omics Approaches for Precision Medicine in Acute Lymphoblastic Leukemia	Oral Abstract Session	265-268	
Saturday	9:30–11:00 a.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Novel Combination Regimens for Fit and Less-fit AML Patients	Oral Abstract Session	Great Hall BC	
Saturday	9:30–11:00 a.m.	617. Acute Myeloid Leukemias: Commercially Available Therapies: Rewriting the AML Playbook: Precision, Intensification, and New Therapeutic Frontiers	Oral Abstract Session	Great Hall AD	
Saturday	9:30–11:00 a.m.	631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: CALR and Friends: Adventures in MPN!	Oral Abstract Session	R02-R05	
Saturday	9:30–11:00 a.m.	632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Biomarkers, Resistance, and the Molecular Frontier	Oral Abstract Session	Hall B	
Saturday	9:30–11:00 a.m.	636. Myelodysplastic Syndromes: Basic and Translational: Multi-Modal Mapping of Clonal Evolution and Microenvironmental Remodeling in MDS and Leukemic Progression	Oral Abstract Session	Hall C	
Saturday	9:30–11:00 a.m.	702. CAR-T Cell Therapies: Basic and Translational	Oral Abstract Session	343-345	
Saturday	9:30–11:00 a.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Conditioning the Outcome: Optimizing Transplantation in Acute Leukemia	Oral Abstract Session	388-390	
Saturday	9:30–11:00 a.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: From Cells to Code: AI and the Next Generation of Hematologic Diagnostics	Oral Abstract Session	393-396	
Saturday	11:15 .–12:15 p.m.	Career Development Lunch	Trainee Activities and Services	Hilton - St. Charles Ballroom	
Saturday	12:00–1:30 p.m.	401. Blood Transfusion: Advancing Transfusion Medicine - From Precision Blood Component Therapy to Blood Substitutes	Oral Abstract Session	220-222	
Saturday	1:30–1:45 p.m.	HARBOR: A Global Phase 2/3 Clinical Trial Evaluating Elenestinib in Patients with Indolent Systemic Mastocytosis	Interact with Industry	Hall J Theater 3	
Saturday	2:00–3:15 p.m.	Targeted Therapies for AML: Bulls Eye!	Education Program	R02-R05	CME
Saturday	2:00–3:15 p.m.	Single-Cell and Spatial Genomics Redefining the Immune Cell Landscape in AML/MDS	Scientific Symposia	288-290	CME
Saturday	2:00–3:30 p.m.	501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Mechanisms in Hematopoietic Stem Cell Regulation, Development, and Regeneration	Oral Abstract Session	291-292	
Saturday	2:00–3:30 p.m.	503. Clonal Hematopoiesis, Aging, and Inflammation: Evolution, Interactions, and Interception	Oral Abstract Session	Hall E	
Saturday	2:00–3:30 p.m.	506. Bone Marrow Microenvironment	Oral Abstract Session	295-296	
Saturday	2:00–3:30 p.m.	602. Myeloid Oncogenesis: Basic	Oral Abstract Session	R06-R09	
Saturday	2:00–3:30 p.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis	Oral Abstract Session	Hall C	
Saturday	2:00–3:30 p.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Emerging Therapies and Approaches in MPN	Oral Abstract Session	Hall B	
Saturday	2:00–3:30 p.m.	637. Myelodysplastic Syndromes: Clinical and Epidemiological: Novel Therapeutic Strategies and Prognostic Stratification in MDS and MDS/MPN	Oral Abstract Session	Great Hall BC	
Saturday	2:00–3:30 p.m.	702. CAR-T Cell Therapies: Basic and Translational: Engineering CAR T-cells for Improved Persistence, Activity, and Tumor Control	Oral Abstract Session	343-345	

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Day	Time	Session Title	Program	Location	CME
Saturday	2:00–3:30 p.m.	703. Cellular Immunotherapies Other Than CAR-T Cells: Basic and Translational: Expanding the Garage: Advancements in Non-T Cell CAR Platforms and Optimization Strategies	Oral Abstract Session	353-355	
Saturday	2:00–3:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Building a Better Transplant: Refining the PTCy Platform and Beyond	Oral Abstract Session	388-390	
Saturday	2:00–3:30 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: From Algorithms to the Clinic: AI and Molecular Innovation in Hematology	Oral Abstract Session	393-396	
Saturday	2:00–3:30 p.m.	908. Outcomes Research: Myeloid Malignancies: Beyond Biology: Social, Environment, and Healthcare Determinants of Outcomes in Myeloid Malignancies	Oral Abstract Session	Great Hall AD	
Saturday	3:30–3:45 p.m.	Discover the Organization of Cell Surface Proteins to Uncover Mechanisms behind Hematological Disease	Interact with Industry	Hall J Theater 5	
Saturday	4:00–5:15 p.m.	Persistent Challenges in Managing Chronic Myelogenous Leukemia	Education Program	R06-R09	CME
Saturday	4:00–5:30 p.m.	602. Myeloid Oncogenesis: Basic: Transcriptional and Epigenetic Dependencies	Oral Abstract Session	R02-R05	
Saturday	4:00–5:30 p.m.	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms - Resistance Mechanisms and New Therapeutic Vulnerabilities in AML	Oral Abstract Session	Hall B	
Saturday	4:00–5:30 p.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Decoding AML Resistance: Cell States, Immune Niches, and Therapeutic Vulnerabilities	Oral Abstract Session	Great Hall BC	
Saturday	4:00–5:30 p.m.	619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Measures for Measures: New Tools and New Uses for MRD in AML	Oral Abstract Session	Great Hall AD	
Saturday	4:00–5:30 p.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: MF and SM: Emerging Targets and Treatment Strategies	Oral Abstract Session	Hall C	
Saturday	4:00–5:30 p.m.	654. Multiple Myeloma: Pharmacologic Therapies: The March of Immunotherapy	Oral Abstract Session	La Nouvelle C	
Saturday	4:00–5:30 p.m.	702. CAR-T Cell Therapies: Basic and Translational: Overcoming Resistance and Escape in CAR-T Cell Therapy	Oral Abstract Session	343-345	
Saturday	4:00–5:30 p.m.	711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations from Bench to Bedside	Oral Abstract Session	391-392	
Saturday	4:00–5:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: HCT Under Stress: Acute Toxicities and Organ Injury	Oral Abstract Session	388-390	
Saturday	4:00–5:30 p.m.	732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Allogeneic Transplantation Outcomes: Lymphoid Malignancies, Pediatric Malignancies, and Donor Factors	Oral Abstract Session	278-282	
Saturday	4:00–5:30 p.m.	802. Chemical Biology and Experimental Therapeutics: Leveraging Chemical Biology for Therapeutic Discovery	Oral Abstract Session	353-355	
Saturday	4:00–5:30 p.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: Geriatrics, Palliative, and End of Life Care	Oral Abstract Session	260-262	
Saturday	4:00–5:35 p.m.	JOINT SESSION - New Horizons in RNA Biology in Myeloid Development and Malignancy	Scientific Program	288-290	
Sunday	8:00–9:00 a.m.	ASH Poster Walk on New Developments in Targeted Therapies for Myeloid Malignancies Hosted by Blood Neoplasia	ASH Poster Walks	Hall F Blood Journals Studio	
Sunday	8:00–9:00 a.m.	How I Treat: MPN	How I Treat	Hilton - Jackson	CME
Sunday	8:00–9:00 a.m.	Ph+ CML-CP: A Nilotinib Treatment Option	Interact with Industry	Hall J Theater 6	

Day	Time	Session Title	Program	Location	CME
Sunday	9:30–10:45 a.m.	Innovations in the Detection and Characterization of Chemoresistant Cells in AML: From Molecular MRD to Molecular Resistance Mechanisms	Scientific Program	R06-R09	CME
Sunday	9:30–10:45 a.m.	Designing Microbiome-Directed Interventional Trials in Hematologic Malignancies	Scientific Symposia	288-290	CME
Sunday	9:30–11:00 a.m.	301. Platelets and Megakaryocytes: Basic and Translational: Megakaryocytes and Platelets from Development to Defense	Oral Abstract Session	208-210	
Sunday	9:30–11:00 a.m.	503. Clonal Hematopoiesis, Aging, and Inflammation: Forces Shaping Clonal Selection	Oral Abstract Session	291-292	
Sunday	9:30–11:00 a.m.	603. Lymphoid Oncogenesis: Basic: Metabolic and Immune Mechanisms	Oral Abstract Session	260-262	
Sunday	9:30–11:00 a.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Prognostic and Predictive Factors in AML and BPDCN	Oral Abstract Session	Hall B	
Sunday	9:30–11:00 a.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Emerging Clinically Relevant Biomarkers in AML	Oral Abstract Session	Great Hall BC	
Sunday	9:30–11:00 a.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Combining Forces Against Myelofibrosis	Oral Abstract Session	R02-R05	
Sunday	9:30–11:00 a.m.	637. Myelodysplastic Syndromes: Clinical and Epidemiological: Novel Targeted Agents and Combination Regimens in CMML, MDS, and MDS/MPN Overlap Neoplasms: Emerging Clinical Trial Data	Oral Abstract Session	Hall C	
Sunday	9:30–11:00 a.m.	702. CAR-T Cell Therapies: Basic and Translational: Next-Generation CAR T-cell Therapy Strategies for AML	Oral Abstract Session	Great Hall AD	
Sunday	9:30–11:00 a.m.	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities	Oral Abstract Session	343-345	
Sunday	9:30–11:00 a.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Advances in GVHD Prophylaxis and Immune Reconstitution after Allogeneic HCT	Oral Abstract Session	388-390	
Sunday	9:30–11:00 a.m.	723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Predicting and Preventing Post-transplant Relapse and GvHD: Minimal Residual Disease, Immune Dynamics, and Biomarkers	Oral Abstract Session	353-355	
Sunday	9:30–11:00 a.m.	902. Health Services and Quality Improvement: Lymphoid Malignancies: Monitoring, Demographics, and Access to Care	Oral Abstract Session	271-273	
Sunday	9:30–11:05 a.m.	JOINT SESSION - Bridging the Gap: Research and Clinical Implications of Emerging Technologies in Hematology	Scientific Program	391-392	CME
Sunday	12:00–1:30 p.m.	509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Mechanistic Insights and Therapeutic Strategies	Oral Abstract Session	295-296	
Sunday	12:00–1:30 p.m.	721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Hemoglobinopathies, Fungus, and Deceased Donor HPCs, Oh My!	Oral Abstract Session	243-245	
Sunday	12:00–1:30 p.m.	901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Decoding Cytopenias	Oral Abstract Session	208-210	
Sunday	4:15–4:30 p.m.	Eilean Therapeutics. Targeting Escape Mutations in Hematological Cancers with First and Best in Class Medicines	Interact with Industry	Hall J Theater 4	
Sunday	4:30–5:45 p.m.	Are We There Yet? Improving Outcomes in MDS	Education Program	R02-R05	CME
Sunday	4:30–5:45 p.m.	Building Hematology Capacity Globally	Education Program	293-294	CME
Sunday	4:30–5:45 p.m.	Driving CARs Safely- Preventing and Managing Intermediate and Long-Term CAR-T Toxicity	Education Program	New Orleans Theatre C	
Sunday	4:30–5:45 p.m.	From Mutations to Manifestations: Connecting Clonal Hematopoiesis (CH) and Thrombosis	Education Program	208-210	
Sunday	4:30–5:45 p.m.	Innovations in the Treatment of Pediatric AML	Education Program	Hall E	CME
Sunday	4:30–5:45 p.m.	Current Perspectives on Evolving Classification of Myeloid and Lymphoid Neoplasms	Education Spotlight Sessions	391-392	CME

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Day	Time	Session Title	Program	Location	CME
Sunday	4:30–5:45 p.m.	Sticky Situations: Glycans in Classical and Malignant Hematopoiesis	Scientific Spotlight Sessions	288-290	CME
Sunday	4:30–6:00 p.m.	605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Strategies and Modulation of Anti-Tumor Responses	Oral Abstract Session	260-262	
Sunday	4:30–6:00 p.m.	616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies - Novel Combinations with Menin, FLT3 and BCL2 Inhibitors	Oral Abstract Session	Hall B	
Sunday	4:30–6:00 p.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Genetic Heterogeneity and Functional Vulnerabilities in AML	Oral Abstract Session	Great Hall BC	
Sunday	4:30–6:00 p.m.	631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Triple S: MPN Goes Spatial, Selective and to the Cell Surface!	Oral Abstract Session	Hall C	
Sunday	4:30–6:00 p.m.	701. Experimental Transplantation: Basic and Translational: Emerging Biology to Translational Innovation I	Oral Abstract Session	343-345	
Sunday	4:30–6:00 p.m.	723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Long-term Follow-up After Allogeneic Hematopoietic Cell Transplantation	Oral Abstract Session	388-390	
Sunday	4:30–6:00 p.m.	732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Allogeneic Transplantation for Myeloid Malignancies: Timing, Donors, and Disease Control	Oral Abstract Session	Great Hall AD	
Sunday	4:30–6:00 p.m.	908. Outcomes Research: Myeloid Malignancies: From Patient Voice to Clinical Impact: PROs and Real-World Outcomes in an Evolving Digital Era	Oral Abstract Session	R06-R09	
Monday	8:00–9:00 a.m.	Understanding the Evolving Treatment Landscape of Relapsed/Refractory NPM1-mutated AML	Interact with Industry	Hall J Theater 1	
Monday	10:30 –12:00 p.m.	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Cell-Intrinsic and Niche-Mediated Mechanisms of Drug Resistance in AML	Oral Abstract Session	Great Hall BC	
Monday	10:30 –12:00 p.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Optimizing Treatment Decisions for Acute Myeloid Leukemia in Pediatric and AYA Patients	Oral Abstract Session	R02-R05	
Monday	10:30 –12:00 p.m.	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Novel Immunotherapeutic Approaches to AML	Oral Abstract Session	Hall C	
Monday	10:30 –12:00 p.m.	632. Chronic Myeloid Leukemia: Clinical and Epidemiological: New Drugs, New Paradigms in CML	Oral Abstract Session	R06-R09	
Monday	10:30 –12:00 p.m.	637. Myelodysplastic Syndromes: Clinical and Epidemiological	Oral Abstract Session	Great Hall AD	
Monday	10:30 –12:00 p.m.	702. CAR T-cell Therapies: Basic and Translational: Engineering CAR-T Cell Fitness, Persistence, and Safety	Oral Abstract Session	353-355	
Monday	10:30 –12:00 p.m.	908. Outcomes Research: Myeloid Malignancies: Advancing Precision and Value-Based Care in AML: Real-World Evidence Across the Disease Continuum	Oral Abstract Session	Hall B	
Monday	12:15–1:15 p.m.	ASH Poster Walk on Leukemia in Latin America: Outcomes and Access to Diagnostics and Therapies Hosted by Blood Global Hematology	ASH Poster Walks	Hall F Blood Journals Studio	
Monday	12:15–1:15 p.m.	Beyond a Single Biomarker: NGS Solutions for Hematologic Malignancies MRD Research	Interact with Industry	Hall J Theater 4	
Monday	12:15–1:15 p.m.	OMISIRGE®: Challenging Conventional Thinking About Time To Transplant And Patient Outcomes In Hematological Conditions With A Novel Cell Therapy Donor Source	Interact with Industry	Hall J Theater 1	
Monday	1:15–1:30 p.m.	Meet the Journal Editors: Blood Global Hematology	Blood Journals Studio	Hall F Blood Journals Studio	
Monday	2:45–4:00 p.m.	Greasy Situations: Unraveling Lipid-Mediated Therapy Resistance	Scientific Spotlight Sessions	288-290	CME

Day	Time	Session Title	Program	Location	CME
Monday	2:45–4:15 p.m.	203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Immune Dysregulation and Clinical Translation	Oral Abstract Session	R06-R09	
Monday	2:45–4:15 p.m.	602. Myeloid Oncogenesis: Basic: Rewiring Chromatin, Metabolism, and Immunity in Myeloid Neoplasms	Oral Abstract Session	R02-R05	
Monday	2:45–4:15 p.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Venetoclax-based Therapy and AML Risk	Oral Abstract Session	Great Hall AD	
Monday	2:45–4:15 p.m.	617. Acute Myeloid Leukemias: Commercially Available Therapies: Molecularly Targeted Combinations in AML	Oral Abstract Session	Great Hall BC	
Monday	2:45–4:15 p.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Molecular Insights and New Approaches in MPNs	Oral Abstract Session	Hall B	
Monday	2:45–4:15 p.m.	723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence	Oral Abstract Session	353-355	
Monday	2:45–4:15 p.m.	908. Outcomes Research: Myeloid Malignancies: Mind the (Molecular) Gap: From Testing to Trials, Across Race and Place	Oral Abstract Session	Hall C	
Monday	4:30–5:45 p.m.	Battle-Scarred Blood Cells: Hematologic Malignancies in Military Service Members	Education Program	278-282	CME
Monday	4:30–5:45 p.m.	Iron Homeostasis Across the Lifespan in Health and Disease	Scientific Program	288-290	CME
Monday	4:30–6:00 p.m.	203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: T and NK Cell Development and Anti-Tumor Functions	Oral Abstract Session	R06-R09	
Monday	4:30–6:00 p.m.	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms	Oral Abstract Session	Hall B	
Monday	4:30–6:00 p.m.	615. Acute Myeloid Leukemias: Clinical and Epidemiological: Chemotherapy and Transplantation	Oral Abstract Session	Great Hall BC	
Monday	4:30–6:00 p.m.	617. Acute Myeloid Leukemias: Commercially Available Therapies	Oral Abstract Session	Great Hall AD	
Monday	4:30–6:00 p.m.	634. Myeloproliferative Syndromes: Clinical and Epidemiological: ET and PV: Moving Beyond Conventional Therapy	Oral Abstract Session	Hall C	
Monday	4:30–6:00 p.m.	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myeloma Basic and Translational Research	Oral Abstract Session	La Nouvelle C	
Monday	4:30–6:00 p.m.	704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Early Innovation of Immune Effector Cell Therapies	Oral Abstract Session	388-390	
Monday	4:30–6:00 p.m.	722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prophylaxis-Clinical and Translational Aspects	Oral Abstract Session	353-355	
Monday	4:30–6:00 p.m.	803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Emerging Technologies for Molecular Classification, Monitoring, and Modelling	Oral Abstract Session	393-396	
Monday	4:30–6:00 p.m.	903. Health Services and Quality Improvement: Myeloid Malignancies: JAKPOT! Improving Care Quality from Pre-hab, Sleep, and Home Transfusions to Pall-care, Costs, and JAK Testing	Oral Abstract Session	R02-R05	

All events take place in the Ernest N. Morial Convention Center unless indicated otherwise. All times are in Central time. Duplication/recording is prohibited.

Serious adverse reactions occurred in 74% of patients who received LYNOZYFIC. Serious adverse reactions that occurred in >5% of patients included cytokine release syndrome (27%), pneumonia (13%), COVID-19 (7%), and acute kidney injury (5%). Fatal adverse reactions occurred in 7% of patients, and included sepsis (3.4%), chronic kidney disease (0.9%), pneumonia (0.9%), tumor lysis syndrome (0.9%), and encephalopathy (0.9%).

Permanent discontinuation of LYNOZYFIC due to adverse reactions occurred in 16% of patients. Adverse reactions leading to discontinuation that occurred in at least 2 patients included sepsis, pneumonia, and encephalopathy.

Dosage interruptions or delays of LYNOZYFIC due to adverse reactions occurred in 74% of patients. Adverse reactions which required a dosage interruption or delay in >10% of patients included neutropenia (29%), upper respiratory tract infection (18%), pneumonia (15%), and COVID-19 infection (11%).

The most common adverse reactions (≥20%) were musculoskeletal pain, cytokine release syndrome, cough, upper respiratory tract infection, diarrhea, fatigue, pneumonia, nausea, headache, and dyspnea. The most common Grade 3 to 4 laboratory abnormalities (≥30%) were decreased lymphocyte count, decreased neutrophil count, decreased hemoglobin, and decreased white blood cell count.

Table 7 summarizes the adverse reactions in LINKER-MM1.

Table 7: Adverse Reactions (≥10%) in Patients With Relapsed or Refractory Multiple Myeloma Who Received LYNOZYFIC in LINKER-MM1

Adverse Reaction	LYNOZYFIC (N=117)	
	All Grades (%)	Grade 3 or 4 (%)
Musculoskeletal and connective tissue disorders		
Musculoskeletal pain*	53	3.4#
Immune system disorders		
Cytokine release syndrome	46	0.9#
Hypogammaglobulinemia	13	0.9#
Respiratory, thoracic and mediastinal disorders		
Cough*	39	0
Dyspnea*	21	0.9#
Nasal congestion	16	0
Infections and infestations		
Upper respiratory tract infection*	35	6#
Pneumonia[a±]	28	21
COVID-19	17	5
Urinary tract infections*	16	8#
Sepsis	10	6
Gastrointestinal disorders		
Diarrhea	35	1.7#
Nausea	23	0
Vomiting	19	0
Constipation	17	0
General disorders and administration site conditions		
Fatigue*	34	0
Edema*	19	0.9#
Pyrexia	17	0
Nervous system disorders		
Headache*	22	0.9#
Encephalopathy[±,b]	18	3.4
Sensory Neuropathy*	13	0.9
Metabolism and nutrition disorders		
Decreased appetite	15	0.9#
Skin and subcutaneous tissue disorders		
Rash[c]	15	1.7#
Psychiatric disorders		
Insomnia	13	0
Vascular disorders		
Hypertension	10	4.3#

*Includes other related terms.
#Only Grade 3 adverse reactions occurred.
±Includes fatal outcome.
[a]Pneumonia includes atypical pneumonia, COVID-19 pneumonia, PJP, pneumonia, pneumonia cytomegaloviral, pneumonia fungal, pneumonia influenzal, and pneumonia viral.
[b]Encephalopathy includes agitation, amnesia, cognitive disorder, confusional state, delirium, depressed level of consciousness, encephalopathy (including hyperammonemic and toxic encephalopathy), irritability, lethargy, memory impairment, mental status changes, somnolence, and excludes ICANS.
[c]Rash includes dermatitis acneiform, dermatitis contact, drug eruption, erythema, rash, rash erythematous, rash maculo-papular, rash pruritic, and stasis dermatitis.

Clinically significant adverse reactions that occurred in <10% of patients treated with LYNOZYFIC included IRR, motor dysfunction, febrile neutropenia, ICANS, CMV infection, and PML.

Table 8: Select Laboratory Abnormalities (≥5% for Grade 3 or 4) That Worsened From Baseline in Patients With Multiple Myeloma Treated With LYNOZYFIC in LINKER-MM1

Laboratory Abnormality[a]	LYNOZYFIC (N=117)[b]	
	All Grades (%)	Grade 3 or 4 (%)
Hematology		
Lymphocyte count decreased	97	92
Hemoglobin decreased	72	42
Platelet count decreased	64	19
White blood cell count decreased	63	31
Neutrophil count decreased	62	47
Chemistry		
Aspartate aminotransferase increased	61	10

Table 8: Select Laboratory Abnormalities (≥5% for Grade 3 or 4) That Worsened From Baseline in Patients With Multiple Myeloma Treated With LYNOZYFIC in LINKER-MM1 *(continued)*

Laboratory Abnormality[a]	LYNOZYFIC (N=117)[b]	
	All Grades (%)	Grade 3 or 4 (%)
Phosphorus decreased	55	24
Creatinine increased	47	7
Alanine aminotransferase increased	46	6

[a]Laboratory tests were graded according to NCI-CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) Version 5.0.
[b]The denominator used to calculate the rate varied from 106 to 117 based on the number of patients with a baseline value and at least one post-treatment value.

7 DRUG INTERACTIONS

7.1 Effects of LYNOZYFIC on Other Drugs

Certain CYP substrates

Monitor for toxicity unless otherwise recommended in the Prescribing Information of certain CYP substrates where minimal changes in the concentration may lead to serious adverse reactions when used concomitantly with LYNOZYFIC.

Linvoseltamab-gcpt causes the release of cytokines *[see Clinical Pharmacology (12.2)]* that may suppress cytochrome P450 (CYP) enzyme activity. Concomitant use with LYNOZYFIC increases CYP substrate exposure which may increase the risk of adverse reactions related to these substrates. Increased CYP substrate exposure is more likely to occur from initiation of the LYNOZYFIC step-up dosing schedule up to 14 days after the first 200 mg dose, and during and after CRS *[see Warnings and Precautions (5.1)]*.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on the mechanism of action, LYNOZYFIC may cause fetal harm when administered to a pregnant woman *[see Clinical Pharmacology (12.1)]*. There are no available data on the use of LYNOZYFIC in pregnant women to evaluate for a drug associated risk. No animal reproductive or developmental toxicity studies have been conducted with LYNOZYFIC.

Linvoseltamab-gcpt causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance. In addition, based on the finding of B-cell depletion in non-pregnant animals, linvoseltamab-gcpt can cause B-cell lymphocytopenia in infants exposed to linvoseltamab-gcpt in-utero. Human immunoglobulin (IgG) is known to cross the placenta after the first trimester of pregnancy; therefore, linvoseltamab-gcpt has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus.

LYNOZYFIC is associated with hypogammaglobulinemia, therefore, assessment of immunoglobulin levels in newborns of mothers treated with LYNOZYFIC should be considered.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

8.2 Lactation

Risk Summary

There are no data on the presence of linvoseltamab-gcpt in human milk, the effects on the breastfed child, or the effects on milk production. Maternal IgG is known to be present in human milk.

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with LYNOZYFIC and for 3 months after the last dose.

8.3 Females and Males of Reproductive Potential

LYNOZYFIC may cause fetal harm when administered to a pregnant woman *[see Use in Specific Populations (8.1)]*.

Pregnancy Testing

Verify the pregnancy status of females of reproductive potential prior to initiating treatment with LYNOZYFIC.

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of LYNOZYFIC.

8.4 Pediatric Use

The safety and effectiveness of LYNOZYFIC have not been established in pediatric patients.

8.5 Geriatric Use

Of the 117 patients with relapsed or refractory multiple myeloma who received LYNOZYFIC, 42 (36%) of patients were 65 to 74 years of age and 31 (26%) were 75 years of age and older [see Clinical Studies (14)]. No overall differences in safety or effectiveness were observed in patients 65 years of age and older, including patients 75 years of age and older, when compared with younger patients.

12 CLINICAL PHARMACOLOGY

12.6 Immunogenicity

The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the study described below with the incidence of anti-drug antibodies in other studies, including those of linvoseltamab-gcpt.

During treatment in LINKER-MM1 (evaluated through 30 months) *[see Clinical Studies (14)]*, 1% (2/192) of LYNOZYFIC-treated patients developed anti-linvoseltamab-gcpt antibodies. Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of linvoseltamab products is unknown.

REGENERON®

Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591)
©2025 Regeneron Pharmaceuticals, Inc. All rights reserved. US.LYN.25.05.0004 07/25

LYNOZYFIC™ (linvoseltamab-gcpt) injection, for intravenous use
Brief Summary of Prescribing Information

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY, INCLUDING IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME

- **Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LYNOZYFIC. Initiate treatment with LYNOZYFIC step-up dosing to reduce the risk of CRS. Manage CRS, withhold LYNOZYFIC until CRS resolves, and modify the next dose or permanently discontinue based on severity *[see Dosage and Administration (2.2, 2.4, 2.5) and Warnings and Precautions (5.1)]*.**
- **Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), including serious or life-threatening reactions, can occur in patients receiving LYNOZYFIC. Monitor patients for signs or symptoms of neurologic toxicity, including ICANS during treatment. Manage neurologic toxicity, including ICANS, withhold LYNOZYFIC until neurologic toxicity, including ICANS resolves, and modify the next dose or permanently discontinue based on severity *[see Dosage and Administration (2.2, 2.4, 2.5) and Warnings and Precautions (5.2)]*.**
- **Because of the risk of CRS and neurologic toxicity, including ICANS, LYNOZYFIC is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the LYNOZYFIC REMS *[see Warnings and Precautions (5.3)]*.**

1 INDICATIONS AND USAGE

LYNOZYFIC is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

This indication is approved under accelerated approval based on response rate and durability of response *[see Clinical Studies (14)]*. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Cytokine Release Syndrome (CRS)

LYNOZYFIC can cause cytokine release syndrome (CRS), which can be serious or life-threatening.

In LINKER-MM1, CRS occurred in 46% (54/117) of patients who received LYNOZYFIC at the recommended dose, with Grade 1 CRS occurring in 35% (41/117) of patients, Grade 2 in 10% (12/117), and Grade 3 in 0.9% (1/117) *[see Adverse Reactions (6.1)]*. Thirty-eight percent (45/117) of patients had CRS following step-up dose 1, including 1 patient who experienced Grade 3 CRS; 8% (9/117) had an initial CRS event following a subsequent dose. Seventeen percent (19/113) of patients developed CRS after step-up dose 2, 10% (11/111) developed CRS after the first full 200 mg dose of LYNOZYFIC, and 3.6% (4/110) developed CRS after the second full dose. Recurrent CRS occurred in 20% (23/117) of patients. The median time to onset of CRS from the end of infusion was 11 (range: -1 to 184) hours after the most recent dose with a median duration of 15 (range: 1 to 76) hours.

Clinical signs and symptoms of CRS included, but were not limited to pyrexia, chills, hypoxia, tachycardia, and hypotension.

Administer pretreatment medications and initiate therapy according to LYNOZYFIC step-up dosing to reduce the incidence and severity of CRS *[see Dosage and Administration (2.2) and Dosage and Administration (2.3)]*.

Monitor patients for signs and symptoms of CRS after infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur.

At the first sign of CRS, immediately evaluate patients for hospitalization, manage per current practice guidelines, and administer supportive care; withhold LYNOZYFIC until CRS resolves and modify the next dose or permanently discontinue LYNOZYFIC based on severity *[see Dosage and Administration (2.5)]*.

Infusion Related Reactions

Infusion-related reactions (IRR) may be clinically indistinguishable from manifestations of CRS. In the patients who were treated with the recommended step-up dosing regimen and pretreatment medications *[see Dosage and Administration (2.2) and Dosage and Administration (2.3)]*, the rate of IRR was 9% [11/117 including Grade 2 IRR (4.3%) and Grade 3 IRR (1.7%)]. For IRR, interrupt or slow the rate of infusion or permanently discontinue LYNOZYFIC based on severity of reaction *[see Dosage and Administration (2.5)]*.

LYNOZYFIC is available only through a restricted program under a REMS *[see Warnings and Precautions (5.3)]*.

5.2 Neurologic Toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome

LYNOZYFIC can cause serious or life-threatening neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS) *[see Adverse Reactions (6.1)]*.

In LINKER-MM1, neurologic toxicity occurred in 54% of patients, with Grade 3 or 4 neurologic toxicity occurring in 8% at the recommended dose *[see Adverse Reactions (6.1)]*. Neurologic toxicities included ICANS, depressed level of consciousness, encephalopathy, and toxic encephalopathy.

ICANS occurred in 8% of patients who received LYNOZYFIC with the recommended dosing regimen, including Grade 3 events in 2.6%. Most patients experienced ICANS following step-up dose 1 (5%). Two patients (1.8%) experienced initial ICANS following step-up dose 2 and one patient developed the first occurrence of ICANS following a subsequent full dose of LYNOZYFIC. Recurrent ICANS occurred in one patient. The median time to onset of ICANS was 1 (range: 1 to 4) day after the most recent dose with a median duration of 2 (range: 1 to 11) days. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS.

The most common clinical signs and symptoms of ICANS are confusion, depressed level of consciousness, and lethargy. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate the patient; provide supportive therapy and consider further management per current practice guidelines. Withhold LYNOZYFIC until ICANS resolves and modify the next dose or permanently discontinue LYNOZYFIC based on severity *[see Dosage and Administration (2.5)]*. Counsel patients to seek immediate medical attention should signs or symptoms of neurologic toxicity occur at any time.

Due to the potential for neurologic toxicity, including ICANS, patients receiving LYNOZYFIC are at risk of confusion and depressed consciousness. Advise patients to refrain from driving, or operating heavy or potentially dangerous machinery, for 48 hours after completion of each of the step-up doses *[see Dosage and Administration (2.2)]* and in the event of new onset of any neurological symptoms, until symptoms resolve.

LYNOZYFIC is available only through a restricted program under a REMS *[see Warnings and Precautions (5.3)]*.

5.3 LYNOZYFIC REMS

LYNOZYFIC is available only through a restricted program under a REMS called the LYNOZYFIC REMS because of the risks of CRS and neurologic toxicity, including ICANS *[see Warnings and Precautions (5.1, 5.2)]*.

Notable requirements of the LYNOZYFIC REMS include the following:

- Prescribers must be certified with the program by enrolling and completing training.
- Prescribers must counsel patients receiving LYNOZYFIC about the risk of CRS and neurologic toxicity, including ICANS, and provide patients with LYNOZYFIC Patient Wallet Card.
- Pharmacies and healthcare settings that dispense LYNOZYFIC must be certified with the LYNOZYFIC REMS program and must verify prescribers are certified through the LYNOZYFIC REMS program.
- Wholesalers and distributors must only distribute LYNOZYFIC to certified pharmacies or healthcare settings.

Further information about the LYNOZYFIC REMS program is available at LynozyficREMS.com or by telephone at 1-855-212-6391.

5.4 Infections

LYNOZYFIC can cause serious, life-threatening, or fatal infections. In patients who received LYNOZYFIC at the recommended dose in LINKER-MM1, serious infections, including opportunistic infections, occurred in 42% of patients, with Grade 3 or 4 infections in 38% and fatal infections in 4% *[see Adverse Reactions (6.1)]*. The most common serious infection reported (≥10%) were pneumonia and sepsis. Two cases of progressive multifocal leukoencephalopathy (PML) occurred in patients receiving LYNOZYFIC.

Monitor patients for signs and symptoms of infection and immunoglobulin levels prior to and during treatment with LYNOZYFIC and treat appropriately. Administer prophylactic antimicrobials, antibiotics, antifungals, antivirals, vaccines, and subcutaneous or intravenous immunoglobulin (IVIG) according to guidelines, including prophylaxis for PJP and herpesviruses *[see Dosage and Administration (2.3)]*.

Withhold LYNOZYFIC or consider permanent discontinuation of LYNOZYFIC based on severity of the infection *[see Dosage and Administration (2.5)]*.

5.5 Neutropenia

LYNOZYFIC can cause neutropenia and febrile neutropenia.

In patients who received LYNOZYFIC at the recommended dose in LINKER-MM1, decreased neutrophil count occurred in 62% of patients with Grade 3 or 4 decreased neutrophil count in 47%. Febrile neutropenia occurred in 8% of patients *[see Adverse Reactions (6.1)]*.

Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local guidelines. Monitor patients with neutropenia for signs of infection. Withhold LYNOZYFIC based on severity *[see Dosage and Administration (2.5)]*.

5.6 Hepatotoxicity

LYNOZYFIC can cause hepatotoxicity.

In LINKER-MM1, elevated ALT occurred in 46% of patients, with Grade 3 or 4 ALT elevation occurring in 6%; elevated AST occurred in 61% of patients, with Grade 3 or 4 AST elevation occurring in 10% of patients who received the recommended dose. Grade 3 or 4 total bilirubin elevations occurred in 1.7% of patients *[see Adverse Reactions (6.1)]*. Liver enzyme elevation can occur with or without concurrent CRS.

Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold LYNOZYFIC or consider permanent discontinuation of LYNOZYFIC based on severity *[see Dosage and Administration (2.5)]*.

5.7 Embryo-Fetal Toxicity

Based on its mechanism of action, LYNOZYFIC may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with LYNOZYFIC and for 3 months after the last dose *[see Use in Specific Populations (8.1, 8.3)]*.

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Cytokine Release Syndrome *[see Warnings and Precautions (5.1)]*
- Neurologic Toxicity, including Immune Effector Cell Associated Neurotoxicity Syndrome *[see Warnings and Precautions (5.2)]*
- Infections *[see Warnings and Precautions (5.4]*
- Neutropenia *[see Warnings and Precautions (5.5)]*
- Hepatotoxicity *[see Warnings and Precautions (5.6)]*

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Relapsed or Refractory Multiple Myeloma

The safety of LYNOZYFIC was evaluated in LINKER-MM1 *[see Clinical Studies (14)]*. Patients (n=117) received a single step-up dose of 5 mg on Day 1 and 25 mg on Day 8, and the first treatment dose of 200 mg on Day 15. Patients then received 200 mg intravenously once weekly from Week 4 to Week 13, followed by 200 mg every 2 weeks from Week 14. In the Phase 2 portion of the study, patients who achieved and maintained VGPR or better at or after Week 24 and received at least 17 doses of 200 mg were able to receive every 4-week dosing. The median duration of treatment was 47 weeks (range 1, 151); 55% of patients were exposed for 9 months or longer and 36% were exposed for 1 year or longer.

The median age of patients who received LYNOZYFIC was 70 years (range: 37 to 91 years); 55% were male; 71% were White, 17% were Black or African American, and 9% were Asian.

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions

Cytokine Release Syndrome (CRS): LYNOZYFIC can cause CRS, which can be serious or life-threatening. In LINKER-MM1, CRS occurred in 46% (54/117) of patients who received LYNOZYFIC at the recommended dose, with Grade 1 CRS occurring in 35% (41/117) of patients, Grade 2 in 10% (12/117), and Grade 3 in 0.9% (1/117). Thirty-eight percent (45/117) of patients had CRS following step-up dose 1, including 1 patient who experienced Grade 3 CRS; 8% (9/117) had an initial CRS event following a subsequent dose. Seventeen percent (19/113) of patients developed CRS after step-up dose 2, 10% (11/111) developed CRS after the first full 200-mg dose of LYNOZYFIC, and 3.6% (4/110) developed CRS after the second full dose. Recurrent CRS occurred in 20% (23/117) of patients. The median time to onset of CRS from the end of infusion was 11 (range: -1 to 184) hours after the most recent dose, with a median duration of 15 (range: 1 to 76) hours.

Clinical signs and symptoms of CRS included, but were not limited to pyrexia, chills, hypoxia, tachycardia, and hypotension. Administer pretreatment medications and initiate therapy according to LYNOZYFIC step-up dosing to reduce the incidence and severity of CRS. Monitor patients for signs and symptoms of CRS after infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur.

At the first sign of CRS, immediately evaluate patients for hospitalization, manage per current practice guidelines, and administer supportive care; withhold LYNOZYFIC until CRS resolves and modify the next dose or permanently discontinue LYNOZYFIC based on severity.

Infusion Related Reactions

Infusion-related reactions (IRR) may be clinically indistinguishable from manifestations of CRS. In the patients who were treated with the recommended step-up dosing regimen and pretreatment medications, the rate of IRR was 9% [11/117 including Grade 2 IRR (4.3%) and Grade 3 IRR (1.7%)]. For IRR, interrupt or slow the rate of infusion or permanently discontinue LYNOZYFIC based on severity of reaction.

Neurologic Toxicity, including Immune Effector Cell Associated Neurotoxicity Syndrome: LYNOZYFIC can cause serious or life-threatening neurologic toxicity, including ICANS. In LINKER-MM1, neurologic toxicity occurred in 54% of patients, with Grade 3 or 4 neurologic toxicity occurring in 8%, at the recommended dose. Neurologic toxicities included ICANS, depressed level of consciousness, encephalopathy, and toxic encephalopathy. ICANS occurred in 8% of patients who received LYNOZYFIC with the recommended dosing regimen, including Grade 3 events in 2.6%. Most patients experienced ICANS following step-up dose 1 (5%). Two patients (1.8%) experienced initial ICANS following step-up dose 2 and one patient developed the first occurrence of ICANS following a subsequent full dose of LYNOZYFIC. Recurrent ICANS occurred in one patient. The median time to onset of ICANS was 1 (range: 1 to 4) day after the most recent dose with a median duration of 2 (range: 1 to 11) days. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS.

The most common clinical signs and symptoms of ICANS are confusion, depressed level of consciousness, and lethargy. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate the patient; provide supportive therapy and consider further management per current practice guidelines. Withhold LYNOZYFIC until ICANS resolves and modify the next dose or permanently discontinue LYNOZYFIC based on severity. Counsel patients to seek immediate medical attention should signs or symptoms of neurologic toxicity, including ICANS occur at any time.

Due to the potential for neurologic toxicity, including ICANS, patients receiving LYNOZYFIC are at risk of confusion and depressed consciousness. Advise patients to refrain from driving, or operating heavy or potentially dangerous machinery, for 48 hours after completion of each of the step-up doses and in the event of new onset of any neurological symptoms, until symptoms resolve.

LYNOZYFIC REMS: LYNOZYFIC is available only through a restricted program under a REMS called the LYNOZYFIC REMS because of the risks of CRS and neurologic toxicity, including ICANS.

Infections: LYNOZYFIC can cause serious, life-threatening, or fatal infections. In patients who received LYNOZYFIC at the recommended dose in LINKER-MM1, serious infections, including opportunistic infections, occurred in 42% of patients, with Grade 3 or 4 infections in 38% and fatal infections in 4%. The most common serious infection reported (≥10%) were pneumonia and sepsis. Two cases of progressive multifocal leukoencephalopathy (PML) occurred in patients receiving LYNOZYFIC.

Monitor patients for signs and symptoms of infection and immunoglobulin levels prior to and during treatment with LYNOZYFIC and treat appropriately. Administer prophylactic antimicrobials, antibiotics, antifungals, antivirals, vaccines, and subcutaneous or intravenous immunoglobulin (IVIG) according to guidelines, including prophylaxis for PJP and herpesviruses. Withhold LYNOZYFIC or consider permanent discontinuation of LYNOZYFIC based on severity of the infection.

Neutropenia: LYNOZYFIC can cause neutropenia and febrile neutropenia. In patients who received LYNOZYFIC at the recommended dose in LINKER-MM1, decreased neutrophil count occurred in 62% of patients with Grade 3 or 4 decreased neutrophil count in 47%. Febrile neutropenia occurred in 8% of patients.

Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local guidelines. Monitor patients with neutropenia for signs of infection. Withhold LYNOZYFIC based on severity.

Hepatotoxicity: LYNOZYFIC can cause hepatotoxicity. In LINKER-MM1, elevated ALT occurred in 46% of patients, with Grade 3 or 4 ALT elevation occurring in 6%; elevated AST occurred in 61% of patients, with Grade 3 or 4 AST elevation occurring in 10% of patients who received the recommended dose. Grade 3 or 4 total bilirubin elevations occurred in 1.7% of patients. Liver enzyme elevation can occur with or without concurrent CRS.

Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold LYNOZYFIC or consider permanent discontinuation of LYNOZYFIC based on severity.

Embryo-Fetal Toxicity: Based on its mechanism of action, LYNOZYFIC may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with LYNOZYFIC and for 3 months after the last dose.

Adverse Reactions

The most common adverse reactions (≥20%) are musculoskeletal pain, cytokine release syndrome, cough, upper respiratory tract infection, diarrhea, fatigue, pneumonia, nausea, headache, and dyspnea. The most common Grade 3 or 4 laboratory abnormalities (≥30%) are decreased lymphocyte count, decreased neutrophil count, decreased hemoglobin, and decreased white blood cell count.

Use in Specific Populations

Lactation: Advise not to breastfeed.

Please see accompanying Brief Summary of Prescribing Information, including Boxed WARNING, for LYNOZYFIC on the following pages.

Reference: 1. LYNOZYFIC (linvoseltamab-gcpt) full U.S. prescribing information. Regeneron Pharmaceuticals, Inc.; 2025.

REGENERON

© 2025 Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Rd, Tarrytown, NY 10591
All rights reserved. US.LYN.25.10.0013 12/25

LYNOZYFIC™
(linvoseltamab-gcpt) Injection 5mg | 200mg

To explore an option for eligible patients with R/R multiple myeloma after at least 4 prior lines of treatment, visit Booth 1229 at the 68th ASH® Annual Meeting and Exposition.[1]

INDICATION AND USAGE

LYNOZYFIC is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY, including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME

- **Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LYNOZYFIC. Initiate treatment with LYNOZYFIC step-up dosing to reduce the risk of CRS. Manage CRS, withhold LYNOZYFIC until CRS resolves, and modify the next dose or permanently discontinue based on severity.**
- **Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS), including serious or life-threatening reactions, can occur in patients receiving LYNOZYFIC. Monitor patients for signs or symptoms of neurologic toxicity, including ICANS during treatment. Manage neurologic toxicity, including ICANS, withhold LYNOZYFIC until neurologic toxicity, including ICANS resolves, and modify the next dose or permanently discontinue based on severity.**
- **Because of the risk of CRS and neurologic toxicity, including ICANS, LYNOZYFIC is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the LYNOZYFIC REMS.**

R/R, relapsed/refractory.

Please see additional IMPORTANT SAFETY INFORMATION and accompanying Brief Summary of full Prescribing Information, including Boxed WARNING, for LYNOZYFIC on the following pages.